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Deutsche Zusammenfassung 
In der vorliegenden Dissertation sind die Ergebnisse von drei unabhängigen 
Forschungsprojekten zusammengefasst, die das übergeordnete Thema „Anwendung von 
unnatürlichen Strukturelementen zur Design und Synthese von bioaktiven Peptiden, 
Peptidomimetika und Biomakromolekülen“ umfassen. In den jeweiligen Projekten wurden 
nicht natürliche Strukturelemente für folgende Ziele in unterschiedlichen Biomolekülen 
eingebaut: 1. Zum molekularem Design von therapeutisch relevanten Wirkstoffen, 2. Zur 
Markierung für Strukturaufklärung, 3. Zur funktionalen Modifizierungen von 
Biomakromolekülen. Diese drei Themen wurden individuell bearbeitet und haben 
Gemeinsamkeiten in der generellen Strategie (Strukturierung in Design, Synthese und 
Aktivitätsuntersuchung) und der verwendeten Methoden zur Synthese (Peptid-
Festphasensynthese, „Click“-Chemie) und Charakterisierung (HPLC, Massen-Spektrometrie, 
Enzymassays).  
Projekt 1: Proteaseinhibitor mit einer Triazolgruppe im Peptid-Rückgrat 
Ein synthetischer Proteaseinhibitor mit einer Triazolgruppe im Peptid-Rückgrat wurde 
entwickelt und es wurde der Einfluss auf die Bioaktivität und proteolytische Stabilität durch 
diese Modifikation untersucht. Dazu wurde über rationales Design ein Inhibitor der humanen 
Neutrophil-Elastase (HNE), basierend auf dem Strukturgerüst der Sunflower Trypsin Inhibitor-
1 (SFTI-1) mit einer 1,4-disubstituierten Triazolgruppe als trans-Amidgruppen-Ersatz an der 
fiktiven proteolytischen Spaltungsposition (P1-P1‘ Position = „Scissile Bond“) neben weiteren 
Referenzpeptiden synthetisiert.  
Durch chromatographische und massenspektrometrische Analysen wurde mit dem 
synthetischen Inhibitor bzw. mit Vergleichspeptiden und deren Zielproteasen gezeigt, dass der 
Einbau einer 1,4-disubstituierten Triazolgruppe als unspaltbarer Ersatz der „Scissile Bond“ 
dient, was zu einer erhöhten Stabilität gegen die Proteolyse durch das Zielenzym führte. Bei 
24 stündiger Inkubation des synthetischen Inhibitors mit HNE konnte keine Spaltung an der 
entsprechenden Position nachgewiesen werden, wohingegen sein Ursprungspeptid bei 
gleicher Reaktionskondition mehr als 15 % abgebaut wurde. Gleiche Experimente mit der 
linearen Vorstufe des synthetischen Inhibitors zeigten proteolytische Spaltungen an 
alternativen Spaltungspostionen mit deutlich geringerer Reaktionsgeschwindigkeit als das 
entsprechende Ursprungspeptid, welches hauptsächlich an der „Scissile Bond“ gespalten 
wurde. 
Weiterhin wurde in Enzym-Inhibitions-Assays gezeigt, dass die Einführung der Triazolgruppe 
zu einer leichten Verschlechterung der Inhibitionskonstante im Vergleich zum 
Ursprungspeptid (von 144.48 nM auf 563.63 nM, Faktor 3.8) führte. Dieses Verhältnis von Ki 
der Inhibitoren mit und ohne Triazolgruppe an der fiktiven Spaltposition entspricht den 
ermittelten Werten von bisherigen, vergleichbaren Arbeiten[a] und ist deutlich besser als die 
Werte von ähnlichen Studien über Proteaseinhibitoren mit Prolin- oder Azitidin-Derivaten.[b] 
Daher wird vermutet, dass der Austausch der genannten Amid-Bindung durch eine 
Triazolgruppe als effektive Strategie zur Verbesserung der pharmakokinetischen 
Eigenschaften von proteolyseempfindlichen Proteaseinhibitoren angewendet werden kann. 
Die Strategie könnte von besonderem Nutzen zur Synthese von linearen Inhibitoren mit 
  
intrinsischer Empfindlichkeit gegen proteolytischen Verdau oder für die Herstellung von 
Inhibitoren aus hochaffinen Substraten sein. Allerdings benötigt die Studie noch weitere 
Untersuchungen mit zusätzlichen Modell-Peptiden und Zielproteasen um die Hypothese 
verallgemeinern zu können. 
Projekt 2: PHIP-aktive funktionale Peptide 
Zusammen mit der Arbeitsgruppe von Prof. Buntkowsky (TU Darmstadt) wurde eine 
systematische Studie über Parawasserstoff induzierte Polarisierung (parahydrogen-induced 
polarization, PHIP), die eine effektive Methode zur Verstärkung von NMR-Signalen darstellt, 
von funktionalen Peptiden durchgeführt. Dazu wurden drei unterschiedliche Alkinderivate 
Propargylglycin (Pra), 4-Pentinsäure und O-Propargyltyrosin (Tyr(O-propargyl)), die als 
Zielfunktionalitäten der homogen katalysierten Hydrierung und somit als 
Markierungsbausteine dienen, in das Grundgerüst vom monozyklischem SFTI-1 eingebaut. 
Über einfache in silico Modellierung bzw. Simulationen und vorläufige Experimente erwies 
sich der N-Terminus als am besten geeignet für den Einbau der PHIP-Markierungen. 
Anschließend wurde der Einfluss auf die Signalverstärkung und die Bioaktivität durch diese 
Modifizierung untersucht 
Aus den Ergebnissen von Vorarbeiten[c] wurde eine Hypothese erstellt, dass starke Elektronen-
Donatoren in räumlicher Nähe der zu hydrierenden ungesättigten Bindungen die 
Hydrierungseffizienz beeinträchtigen und dadurch zur Verschlechterung der PHIP-Aktivität 
führen. Dies wurde durch eine Reihe von PHIP-NMR-Experimenten bestätigt, da bei keinen 
der Pra markierten SFTI-Derivaten, bei denen nur eine Methyleneinheit zwischen 
Dreifachbindung und Peptid-Rückgrat vorhanden war, eine signifikante Signalverstärkung 
festgestellt werden konnte. Ähnliche Einschränkung der PHIP-Aktivität wurde auch bei einem 
SFTI-Derivat, was mit 4-Pentinsäure markiert wurde, beobachtet, obwohl der Baustein alleine 
eine extrem hohe intrinsische Signalverstärkung von Faktor 900 erwies. Dahingegen wurden 
hohe Signalverstärkungen um den Faktor 70 bei den SFTI-Derivaten mit Tyr(O-propargyl) als 
räumlich isolierte Markierung, selbst in wässrigen Lösungen, beobachtet.  
Ein weiterer Gegenstand der Studie war die Untersuchung des Einflusses von bestimmten 
Funktionalitäten im Peptid, die möglicherweise zur Vergiftung des Hydrierungskatalysators 
führen. Dazu wurden ausgewählte Funktionalitäten (Disulfidbrücke, freier Aminoterminus) 
durch alternative Gruppen ersetzt oder komplett entfernt. Jedoch führte die Einführung von 
1,5-disubstituiertem Triazol als Disulfidbrückenersatz und die Acylierung vom freien N-
Terminus zu keiner eindeutigen Verbesserung der PHIP-Aktivität. Daher wird vermutet, dass 
die Katalysatorvergiftung aus einem komplexen Zusammenspiel von mehreren Faktoren 
resultiert und somit nicht einer bestimmten funktionellen Gruppe zugeordnet werden kann. 
Interessanterweise führte die Einführung der PHIP-Markierung in das Gerüst von SFTI-1 zu 
keiner bzw. nur zu minimalen Verschlechterung der Inhibitionsaktivität gegen Trypsin (in 
einigen Fällen auch zu minimaler Verbesserung). Selbst bei Verwendung vom sterisch 
anspruchsvolleren Tyr(O-popargyl) als Markierung wurde keine merkliche Beeinträchtigung 
der Bioaktivität beobachtet, sodass alle synthetisierte PHIP markierte Inhibitoren eine 
hervorragende Inhibition gegen Trypsin im „Tight-binding Inhibitor“-Bereich aufwiesen. 
Dieses Ergebnis ist von besonderer Wichtigkeit für Folgestudien, die sich mit PHIP-
Experimenten an Enzym-Inhibitor-Komplexen beschäftigen und die zur Strukturaufklärung 
  
von komplexen Biomolekülen oder zur Mechanismenaufklärung von Bioprozessen dienen 
können. Die Ergebnisse dieses Teilprojektes sind bereits in einer Publikation veröffentlicht.[d] 
 
Projekt 3: Affinität gesteuerte chemische Ligation zur Multifunktionalisierung 
von biomolekularen Strukturgerüsten 
Die Affinität-gesteuerte Ligation als Strategie zur Synthese von komplexen biomolekularen 
Konjugaten wurde anhand von oligopeptidischen Modellsystemen und einem Proteingerüst, 
das aus einem Fc-Fragment eines IgG Antikörpers stammt, untersucht. Im Konzept der 
Affinität-gesteuerten Ligation werden die reaktiven Gruppen einer bioorthogonalen Reaktion 
durch nichtkovalent wechselwirkende Einheiten („Guiding Units“) in räumlicher Nähe 
vororientiert. Die Reaktion wird anschließend manuell durch einen „Trigger“ gestartet, sodass 
durch erhöhte lokale Konzentration der reaktiven Funktionalitäten eine Beschleunigung der 
Reaktionsgeschwindigkeit und Verbesserung der Selektivität zu erwarten ist. In der 
vorliegenden Arbeit wurden als „Guiding Units“ komplementäre α-helikale Peptide („Coiled 
Coil“ Peptide) und peptidische Nukleinsäuren („Peptide Nucleic Acid“ = PNA) verwendet. 
Als schaltbare bioorthogonale Reaktion wurde die Alkin-Nitron-Zykloaddition („Strain-
promoted Alkyne-Nitrone Cycloaddition“=SPANC) eingesetzt. Dazu wurde eine Bicyclononin- 
(BCN-) Einheit und eine Aldehydgruppe, die in situ zur reaktiven Nitron-Komponente 
umgesetzt wird, an den Aminotermini von komplementeren „Coiled Coil“-Peptiden mit 3 bzw. 
5 repetitiven Einheiten oder unterschiedlichen PNA-Oligomeren installiert. In einer Reihe von 
Testreaktionen mit unterschiedlichen Reaktionskonditionen wurde gezeigt, dass die Affinität-
gesteuerte SPANC zwischen diesen Modellpeptiden bzw. -PNAs einen signifikanten Vorteil 
bezüglich Reaktionskinetik und Selektivität gegenüber nicht-gesteuerten bzw. –geschalteten 
Konjugationen mit analogen Molekülen besitzen. Interessanterweise wurde bei den SPANC-
Reaktionen mit dem „Coiled Coil“-Peptiden mit 5 repetitiven Einheiten als „Guiding Unit“ ein 
besserer Reaktionsumsatz und eine erhöhte Reaktionsgeschwindigkeit als analoge Reaktion 
mit PNAs nachgewiesen. Daher wird vermutet, dass die Stärke der nicht kovalenten 
Wechselwirkungen in diesem Modelsystem keine primäre Rolle spielt. Während den 
Testreaktionen wurde eine unerwartete, bislang nicht beschriebene Nebenreaktion von 
SPANC-Reaktionen beobachtet, was zu einer Verschlechterung des Reaktionsumsatzes führte. 
Für Folgearbeiten muss daher eine Methode zur Unterdrückung dieser Nebenreaktion oder 
zur Isolation vom unerwünschten Nebenprodukt gefunden werden. 
Anschließend wurde die Konjugation von PNA-Oligomeren an das Fc-Gerüst durch Sortase A 
katalysierte Transpeptidierung untersucht. Das dabei entstandene Fc-PNA-Konjugat wurde in 
einem Folgeprojekt von Stephan Dickgießer (Arbeitskreis Kolmar, TU Darmstadt) als 
modulares Grundgerüst für die Herstellung von einem bioaktivem Bindermolekül verwendet, 
was mit einem nicht-peptidischen Binder gegen einem therapeutisch relevanten Zielrezeptor 
und einer Fluoreszenzmarkierung funktionalisiert wurde. Zusammen mit der Strategie der 
Affinität-gesteuerten Ligation, die eine selektive und effiziente Konjugation von mehreren 
Ligandeinheiten ermöglicht, dienen die Methoden, die in dieser Studie entwickelt und 
untersucht worden sind, als Grundlage für die Herstellung von komplexen, multivalenten 
Antikörper-Toxin-Konjugaten. 
  
Die Ergebnisse, die in der der vorliegenden Dissertation zusammengefasst sind, wurden in 
zwei wissenschaftlichen Publikationen veröffentlicht[d,e]. Sie können als Orientierungspunkte 
für nachfolgende Forschungen dienen, die die praktische Anwendung der jeweiligen Konzepte 
und Strategien im Blick haben werden. 
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The important thing is to think always that the stumbling way is the best way. 
If you possess this creed, it doesn’t matter where you stumble to as you can ultimately 
believe that the way you have chosen by yourself was the right one. 
 
Makoto Fujita (1957-) 
Chemist, Professor in Institute of Technology, Tokyo University 
 
重要な
ことは、たえず
「転んだ方が
ベスト」と思えること。
 
この信条さえあれば、自分がど
の道に転ぼ
うと、最後は
「自分
の選んだ
道は正しか
った」と思えるようになります。
 
藤田
 誠
  
C
h
e
m
-Statio
n化学者
へのショー
トインタビ
ュー
 
  
Danksagung 
Zunächst möchte ich an folgenden Personen meinen aufrichtigen Dank aussprechen: 
Als erstes bedanke ich mich selbstverständlich bei meinem Doktorvater Prof. Dr. Harald 
Kolmar für unzählige Unterstützungen, beginnend mit meiner Aufnahme als Doktorand und 
Mitarbeiter, Bereitstellung unterschiedlicher, interessanter Projekte und Gelegenheiten diese 
präsentieren zu dürfen, bis hin zur Beratung bei fachlichen und vor allem 
fächerübergreifenden Fragen. Einen herzlichen Dank dafür, dass ich überhaupt die Chance 
bekommen habe die Promotion anzufangen und bis zum Ende durchziehen zu können. 
Mein zweiter großer Dank geht an Dr. Olga Avrutina. Vielen Dank für die außerordentliche 
Sorgfalt und Geduld bei fachlichen Beratungen und vor allem bei der Korrektur von allen 
wissenschaftlichen Texten in Englisch, einschließlich der vorliegenden Arbeit. Ohne dich wäre 
keine von mir abgelegte Arbeit überhaupt verständlich gewesen. Ich weiß, dass in meinem 
Englisch noch ein großer Raum für Verbesserungen besteht, jedoch habe ich durch dich viele 
Grundlagen für das fachlich korrekte Schreiben erlernen können. 
Ein weiterer Dank geht an Prof. Dr. Gerd Buntkowsky für die Übernahme des Korreferats 
und der Bereitstellung eines sehr interessanten und gelungenen Kooperationsprojektes. 
Außerdem will ich mich dafür bedanken, dass ich einige Laborgeräte und Einrichtungen auch 
für weitere Projekte verwenden durfte. Bei meinen direkten Mitforschern aus dem 
Arbeitskreis Buntkowsky, Dr. Marco Körner, Grit Sauer und Dr. Daniel Tietze möchte ich 
mich für die angenehme und gelungene Zusammenarbeit bedanken. 
Ebenfalls bedanke ich mich für eine gelungene Kooperation bei Prof. Dr. Ulf Diederichsen 
aus der Georg-August-Universität Göttingen und den Mitarbeitern seines Arbeitskreises, Dr. 
Cornelia Panse und Stephen Middel, die einen Großteil der PNAs, die in dieser Arbeit 
verwendet worden sind, bereitgestellt haben.  
Bei Dr. Alesia Tietze bedanke ich mich für die externe MALDI-MS Messungen. 
Aus dem Arbeitskreis von Prof. Kolmar bedanke ich mich zuerst bei Stephan Dickgießer, für 
die unterhaltungsreiche Zusammenarbeit, Bereitstellung von einigen Ergebnissen für meine 
Arbeit und die gelungene Weiterführung von dem gemeinsamen Forschungsprojekt.  
Ebenfalls bedanke ich mich bei meinem Bench-Nachbarn Heiko Fittler für seine 
Hilfsbereitschaft und die spaßige Atmosphäre in unserem kleinen, aber angenehmen 
Peptidlabor. 
Bei meinen großen Vorgängern, Dr. Martin Empting und Michael Reinwarth bedanke ich 
mich dafür, dass sie mir alle wichtigen Grundlagen für einen Peptidchemiker beigebracht 
haben und bei Problemen stets entgegengekommen sind.  
Allen weiteren Mitarbeiter des Arbeitskreises von Prof. Kolmar möchte ich mich für 
zahlreiche Hilfestellungen und die angenehme Arbeitsatmosphäre bedanken. 
Meinen Eltern, Shinobu und Hideyuki Nasu und meinem Bruder Takumi Nasu bin ich sehr 
dankbar für die sowohl seelisch-moralische als auch finanzielle Unterstützung, die überhaupt 
mein Chemiestudium und die Promotion ermöglicht haben. 
Zuletzt bedanke ich mich bei Freunden und Bekannten aus meinem privaten Umfeld, die 
mich stets gut beraten und motiviert haben. Besonderen Dank an Tatsuya Shimizu., Masaru 
und Mikako Tanabe, Natsuko Takashima, Toshiyuki. Ohno, Takaomi Ichijou, Alexander 
und Martina Montag, Shohei Fujiwara und vielen weiteren Leuten. 
  
  
 
DOCTORAL THESIS DAICHI NASU TABLE OF CONTENTS 
 
  
Table of Contents 
1 Introduction ...................................................................................................................... 1 
1.1 Preface........................................................................................................................ 1 
1.2 Non-Natural Elements for Peptide-Based Molecular Design ....................................... 2 
1.2.1 Rational Drug Design ........................................................................................... 2 
1.2.2 Biomimetics with Non-Natural Structural Elements ............................................ 3 
1.2.3 Synthesis of Peptidomimetics and Peptide Analogs ............................................. 7 
1.3 Non-Natural Elements for Structural Investigations ................................................... 9 
1.3.1 Labels and Biomarkers for Diagnosis, Structural, and Mechanical Investigations 9 
1.3.2 NMR Hyperpolarization Techniques in Biochemistry ........................................... 9 
1.3.3 NMR PHIP Experiments with Biomolecules ....................................................... 11 
1.4 Non-Natural Elements for Bioorthogonal Conjugation ............................................. 13 
1.4.1 “Click” Chemistry ............................................................................................... 13 
1.4.2 Biocompatible Scaffolds for Drug Delivery and Oligomerization ....................... 17 
1.4.3 Affinity-Guided Reactions in Biochemistry ........................................................ 20 
1.5 Model Compounds and Test Systems ....................................................................... 21 
1.5.1 Trypsin-like Proteases and Related Serine Proteases ......................................... 21 
1.5.2 Sunflower Trypsin Inhibitor 1 ............................................................................ 24 
1.5.3 Heterodimeric Coiled Coils ................................................................................ 26 
1.5.4 Peptide Nucleic Acids ........................................................................................ 29 
2 Outline and Scope of Projects .......................................................................................... 33 
2.1 Protease Inhibitor with Triazolyl Backbone Mimic ................................................... 33 
2.1.1 Aims .................................................................................................................. 36 
2.2 PHIP-Active Functional Peptides ............................................................................... 36 
2.2.1 Aims .................................................................................................................. 38 
2.3 Affinity-Guided Chemical Ligation towards Multifunctionalization of Biomolecular 
Scaffolds .............................................................................................................................. 38 
2.3.1 Aims .................................................................................................................. 40 
3 Results and Discussion .................................................................................................... 45 
3.1 Protease Inhibitor with Triazolyl Backbone Mimic ................................................... 45 
3.1.1 Design and Synthesis ......................................................................................... 45 
3.1.2 Characterization and Evaluation of Activity ....................................................... 52 
3.1.3 Digest of Chapter 3.1 ......................................................................................... 59 
3.2 PHIP-Active Functional Peptides ............................................................................... 60 
3.2.1 Design and Synthesis ......................................................................................... 60 
3.2.2 Characterization and Evaluation of Activity ....................................................... 68 
3.2.3 Digest of Chapter 3.2 ......................................................................................... 74 
 
DOCTORAL THESIS DAICHI NASU TABLE OF CONTENTS 
 
 
3.3 Affinity-Guided Chemical Ligation towards Multifunctionalization of Biomolecular 
Scaffolds ............................................................................................................................. 76 
3.3.1 Design and Synthesis ........................................................................................ 76 
3.3.2 Characterization and Evaluation of Activity ...................................................... 93 
3.3.3 Digest of Chapter 3.3 ...................................................................................... 117 
4 Conclusion and Outlook ............................................................................................... 121 
4.1 Protease Inhibitor with Triazolyl Backbone Mimic ................................................. 121 
4.2 PHIP-Active Functional Peptides ............................................................................ 121 
4.3 Affinity-Guided Chemical Ligation towards Multifunctionalization of Biomolecular 
Scaffolds ........................................................................................................................... 122 
4.4 Closing Remarks .................................................................................................... 123 
5 Experimental Part ......................................................................................................... 125 
5.1 General .................................................................................................................. 125 
5.1.1 Reagents and Solvents .................................................................................... 125 
5.1.2 Analytical and Preparative Instruments .......................................................... 125 
5.1.3 Storage ........................................................................................................... 126 
5.2 Synthesis ................................................................................................................ 126 
5.2.1 General Procedure of Solid-Phase Peptide Synthesis....................................... 126 
5.2.2 General Procedure of Solid-Phase Synthesis of PNA-Peptide Hybrids ............. 129 
5.2.3 Synthesis of Protease Inhibitors ...................................................................... 130 
5.2.4 Synthesis of Modified Coiled Coil Guiding Units ............................................. 142 
5.2.5 Synthesis of Modified PNA Guiding Units ....................................................... 147 
5.3 Test Reactions ........................................................................................................ 156 
5.3.1 Proteolysis Experiments of Protease Inhibitors................................................ 156 
5.3.2 PHIP Experiments of SFTI Derivatives ............................................................ 157 
5.3.3 Strain-Promoted Cycloaddition and Nucleobase Cross-Conjugation ............... 158 
5.3.4 Psoralen Cross-Linkage ................................................................................... 164 
5.3.5 Sortase-Mediated Ligation .............................................................................. 165 
5.4 Enzyme Kinetic Assays ........................................................................................... 166 
5.4.1 Trypsin ............................................................................................................ 166 
5.4.2 Chymotrypsin .................................................................................................. 168 
5.4.3 Elastase ........................................................................................................... 168 
5.5 In Silico Modeling .................................................................................................. 169 
6 References .................................................................................................................... 171 
7 Appendix ...................................................................................................................... 179 
 
 
DOCTORAL THESIS DAICHI NASU INTRODUCTION 
 1 
1 Introduction 
1.1 Preface 
Engineering of natural compounds is used in drug discovery since decades. Bioactive products 
isolated from microorganisms, fungi, or plants often serve as lead compounds for synthetic or 
recombinantly produced therapeutics.[1] In the field of rational drug design, two approaches 
are of especial value, the installation of non-natural functional moieties into compounds of 
biological origin and the substitution of structural elements of biomolecules by non-biological 
surrogates.  
Depending on their chemical and biological characteristics, non-natural motifs can be of 
benefit in several application fields. Thus, they can modulate ligand-receptor binding, target 
specificity, ADMET (absorption, distribution, metabolism, excretion, and toxicity) and a 
number of other issues.[2] Moreover, they allow for the introduction of the de-novo functions 
such as labels, toxins or orthogonally addressable binding sites in biomolecules, thus 
converting them into potential agents for therapy, diagnostics, and structural or mechanistic 
investigations.  
Since a majority of biomolecules which are directly involved in the physiological processes are 
products of the cellular translation machinery, the chemical intervention is mostly preferred 
on post-translational level and relies on the chemistry of the amino acid building blocks. Till 
the end of 50s, only qualitative assessment of protein modification was possible due to the 
lack of sensitive and accurate methods to determine the precise amino acid composition, as 
well as efficient procedures to separate, purify, and characterize the modified products.[3] The 
development of advanced protein analytics, including radioactive labeling, automated amino 
acid analysis,[4] micro gel electrophoresis, X-ray crystallography, ESI and MALDI mass 
spectrometry, as well as ion-exchange and size-exclusion chromatography facilitated the 
characterization of modified proteins.[5]  
After the elaborated analytical base has been established, the research focus shifted towards 
the development of selective chemical transformations to obtain site-specific, pinpoint protein 
modifications. Starting with the labeling of the antigen-combining site of a rabbit anti-p-
azobenzenearsonate antibody with the p-azonylbenzenediazonium ion (Wofsey et al., 1962)[6] 
and the active-site labeling of chymotrypsin using TPCK (Schoellmann et al., 1963),[7] a large 
number of so-called affinity labeling reagents has been reported. However, this approach 
required detailed information on the structure and mechanism of the parent protein. 
Therefore, chemical conjugations using the side chains of amino acids followed, among them 
iodination of Tyr,[8] dicarbonyl conjugations to Arg,[9] or carboxymethylation of Cys by 
bromoacetate.[10] Unfortunately, due to the fact that amino acids are present in proteins in 
multiple copies this approach suffers from insufficient selectivity.[3] 
Two milestones have to be mentioned in view of the selective incorporation of non-natural 
elements in biomolecules. The first is the invention of “click” chemistry by Sharpless et al. in 
2001,[11] which describes a set of powerful, highly reliable, and selective reactions for rapid 
synthesis of desired compounds and combinatorial libraries. Although a number of 
transformations matching the criteria emphasized for “click” reactions has been already 
known, they were applied to modify biomolecules much later. Thus, within the recent ten 
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years, revision of “the last century” reactions towards biocompatible orthogonal ligations 
became a trend and resulted in molecular constructs with multiple functions or tailor-made 
characteristics. Details about “click” chemistry will be discussed in chapter 1.4.1. 
The second milestone was the development of the solid-phase peptide synthesis (SPPS) 
reported by Merrifield in 1963.[12] This epochal strategy facilitated, on the one hand, the 
access to highly pure synthetic peptides that can be used to model or mimic protein fragments 
or even proteins.[13] On the other hand, it enabled the preparation of peptides and 
peptidomimetics with pre-installed non-natural motifs for orthogonal conjugations or directly 
acting as labels. Even the installation of artificial elements in the backbone of the biopolymers 
became possible.[14] A large number of non-canonical amino acids and functional building 
blocks are to date commercially available as SPPS-compatible derivatives.  
With the keywords “click-chemistry”, “SPPS”, and “protein/peptide modification”, the 
research summarized in this work deals with synthetic biomolecules possessing non-natural 
structural elements for three applications: 
1. Molecular design of therapeutically relevant agents; 
2. Labels for structural investigations and diagnostics; 
3. Addressable sites for bioorthogonal conjugations. 
Each subject was elaborated as an individual project lacking direct interconnections, besides 
the philosophy and methodology of the used approach. In this chapter, the theoretical 
background of the concepts, strategies, and model components/systems discussed in the 
presented work are summarized. 
 
 
1.2 Non-Natural Elements for Peptide-Based Molecular Design 
1.2.1 Rational Drug Design 
Directed evolution and rational design are the two major strategies in the modern, target-
based pharmacology and drug discovery.[15] In contrast to directed evolution which is based 
on substance libraries comprising more than 107 randomized proteins and does not require 
detailed knowledge on the target,[16] in rational design novel molecules with defined functions 
are generated relying on the prediction of molecular behavior as a function of the structure by 
using physical or knowledge-based models.[17] Thus, more explicit information on structure 
and mechanism of the biomolecule is presumed. While the improvement of directed evolution 
strategy is strongly supported by the development of several high-throughput screening (HTS) 
techniques, the rational design made a rapid progress along with the rise of computational 
modeling and simulation methods. These are closely connected with powerful methods to 
analyze protein structure (e.g. X-ray crystallography, solid-state NMR, electron microscopy). 
Interestingly, the most popular trend in directed evolution, the pinpoint mutation of single 
protein domains, is based on the combination of amino acid randomization and structure- and 
knowledge-based drug design.  
One major advantage of the classic rational design strategy over random mutagenesis-based 
techniques is that the access to non-natural fragments in the target agent is much more 
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facilitated. While the scope of lead compounds found by directed evolution is often limited to 
peptides and proteins expressible in living cells, with the exception of glycoproteins and 
introduction of non-canonical amino acids by genetic code expansion, in rational design the 
rich arsenal of chemical transformations is available to manipulate molecules as long as the 
synthetic procedure is realistic and practicable. 
 
 
1.2.2 Biomimetics with Non-Natural Structural Elements 
How do non-natural structural elements tailor the properties of biomolecules? In this chapter, 
only the surrogates of the native functionalities of proteins and peptides are discussed; non-
natural elements acting as labels or giving the biomolecule a contrived function (e.g. toxins, 
carriers) will be addressed in chapter 1.3.1.  
Since the beginning of human history, mankind has taken benefits from mimicking biological 
systems. Starting from the macro-scaled objects, e.g. fluid systems for city planning or the 
“tunneling shield” technique for tunnel construction,[18] and followed by examples from the 
daily life as “hook and loop fasteners”[18-19] or medical bionics (implants, prosthetic devices), 
the interest to imitate biological motifs and to substitute them with artificial elements 
extended to the molecular level of peptidomimetics. These are rather short protein- or 
oligopeptide-like chains or small molecules designed to mimic natural peptides, proteins, or 
elements thereof in 3D space.[20] Peptidomimetics differ from canonical peptides by the 
backbone architecture as they can comprise non-α- or D-amino acids as well as bioisosteric 
groups.  
In some cases, regular peptides with special modifications in their side chains (peptide 
analogs) are also referred to as peptidomimetics. In general, peptidomimetics are designed to 
have similar biological effects as the original model peptides, but they often possess 
advantaged pharmacokinetic properties as enhanced resorption in physiological systems, 
higher stability against proteolytic degradation, in vivo distribution or even 
optimized/advanced pharmacodynamic characteristics.[20] Thus, mimicking peptides by small 
isosteric/isoelectronic groups is an important issue in the development of drug-like 
compounds.  
Peptidomimetics can be roughly classified in four types depending on their composition and 
the strategy of synthesis (Table 1).[21] Type-I peptidomimetics, also called pseudopeptides, are 
very similar to the original counterparts. Only pinpoint modifications of the backbone are 
performed while retaining the most functional groups to assure important contacts with the 
binding sites of the target protein. The modifications are restricted to only some motifs of the 
secondary structures as p-turns or β-hairpins. In general, for type-I peptidomimetics structure-
based design is used. Thus, a number of protease inhibitors were established as the structural 
mimics of the peptide bond in a transition state or product state for the enzyme-catalyzed 
reaction. Type-II peptidomimetics, also known as functional mimetics, are small non-peptidic 
molecules derived by molecular modeling, often in combination with high-throughput 
screening of chemical libraries. Type-II peptidomimetics have no or only limited structural 
similarity to the parental peptides and their classification as peptidomimetics has mainly 
historical reasons. In contrast, type-III peptidomimetics, also called topographical mimetics, 
possesses a novel scaffold, often unrelated to the parental peptide, but still retaining the 
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essential functional group for receptor binding. Hence, topographical mimetics are exclusively 
gained by structure-based design. Type-IV peptidomimetics or non-peptide peptidomimetics 
are constructed by the so-called Group Replacement Assisted Binding (GRAB) technique of 
drug design and they share structural and functional features of type-I peptidomimetics while 
bearing no obvious resemblance to a parent peptide or its isosters.[22] 
Table 1. Classification of peptidomimetics in four different types according their molecule class and 
design/synthesis route defined by Kharb et al.[21] 
Peptidomimetics Type-I Type-II Type-III Type-IV 
 
Synonym 
 
Pseudopeptides 
Functional 
mimetics 
Topographical 
mimetics 
Non-peptide 
mimetics 
 
Design/Synthesis 
 
Structure-based 
design 
Molecular 
modeling & HTS 
Structure-based 
design 
GRAB 
technique 
 
Molecule class 
 
Oligo-/poly-
pseudopeptides 
Small molecules Small molecules 
Small 
molecules 
 
Example 
 
Peptide-based 
protease 
inhibitors 
G-protein- 
coupled receptor 
antagonists 
Small molecule-
based protease 
inhibitors 
Piperidine 
inhibitors[22] 
A classic example for rational drug design using a natural peptide as starting point is the 
development of several integrin-like receptor agonists mimicking the Arg-Gly-Asp peptide 
motif (RGD motif). The RGD motif has been found in numerous extracellular proteins 
(vitronectin, collagen, or fibronectin), and plays an important role in intracellular recognition 
and adhesion.[23] Since several transmembrane proteins of the integrin super families were 
found to be overexpressed in diverse diseased cells,[24] they attracted attention as therapeutic 
and diagnostic targets. To that end, a number of approaches was developed, among them the 
structure-based design of selective small-molecule ligands.[25] In Table2, the structures and 
bioactivity of selected RGD peptidomimetics acting as GPIIb/IIIa (α2bβ3) receptor and the 
vitronectin (αvβ3) receptor inhibitors are listed. [26] As seen from Table 2, in the RGD mimetic 
1 (derived from the 3D structure of a cyclic RGD peptide) the essential structural elements of 
the original amino acid residues can still be recognized. Based on the structure of this lead 
compound, further highly specific receptor antagonists could be synthesized by simple 
modifications (RGD mimetic 2ab).[26] 
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Table 2. Chemical structure of native RGD motif and the synthetic peptidomimetics reported by Keenan et al. with 
corresponding inhibition constant Ki against GPIIb/IIIa (α2bβ3) receptor and the vitronectin (αvβ3) 
receptor.[26] 
 
A further example for drug design comprising a small organic molecule and using a short 
peptide as starting point for tuning is shown in Scheme 1. Captopril is a non-peptidic mimic 
of the bradykinin potentiating peptide (BPP5a). BPP5a, isolated from snake species like vipers 
and taipans, inhibits the natural angiotensin-converting enzymes (ACE) by competitive 
binding to the active site.[27] Though BPP5a regulates blood pressure, its resorption upon oral 
administration is not possible. However, its non-peptidic mimetic ensures easier uptake of the 
agent and leads to a higher in vivo stability.[28] Therefore, captopril became a commercially 
available therapeutic for treatment of hypertension. In the chemical structure of captopril, a 
construct resembling the amino acid sequence Ala-Pro can be found which is supposed to be 
the essential element for its bioactivity. These small molecule-based peptidomimetics can be 
classified to the type-III ones.[26] 
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Scheme 1. Amino acid sequence and chemical structure of A: ACE-binding substrate angiotensin I, B: its 
competitive inhibitor BPP5a, and C: its topographic mimetic captopril and the corresponding 3D structure 
depicted as stick with red = oxygen, blue = nitrogen, green = sulfur, and grey = carbon. Models derived 
from the crystal structure of angiotensin (PDB: 1N9V), ACE-BPP5a complex: (PDB: 4AA2), and ACE-
captopril complex (PDB: 4C2P). 
For some special therapeutically relevant targets, the similarity in topography of target-
binding regions is not sufficient for the selective binding of a peptidomimetic. In such cases, 
preserving the original scaffold of the model peptide can positively influence target 
recognition by electrostatic or non-polar interactions with the surface of target enzymes, or by 
enhancing the conformational rigidity upon intramolecular hydrogen bonding. Thus, the 
investigations towards the development of pseudopeptides and peptide analogs using 
therapeutically relevant model peptides as starting point has always been of high interest.[29]  
Often the rationale behind the replacement of a peptidic backbone element by a non-peptidic 
surrogate is to obtain conformationally constrained peptides which are often used to study the 
ligand-receptor interactions.[14a] Typical surrogates acting as mimics of amide bonds or 
dipeptide units with conformationally constrained architecture are shown in Scheme 2. N-
Substituted peptoids and depsipeptides bearing an ester bond instead of the amide one are 
peptide surrogates found in natural products. Along with D- and β-amino acids, they 
contribute to enhanced proteolytic stability and can also influence the peptide architecture. 
The ε-caprolactam[14b] and the 1,4-dusubtituted triazole are condensation products of two 
peptide fragments and act as conformationally constrained dipeptide mimics at the same time. 
The 1,2,3-triazole motif possessing topologic and electronic similarity to the original amide 
bond is preferentially used since the invention of efficient Cu(I)-catalyzed click reaction.[30] 
Valverde et al. recently reported the synthesis of a bombesin derivative, a protease-resistant 
gastrin-releasing peptide receptor antagonist, by introduction of a triazolyl backbone mimic 
with preserved affinity to its target receptor.[31] 
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Scheme 2. Commonly used amide surrogates. 
 
 
A “nonstandard peptide”[32] which belongs to 
cyclosporines and comprises several 
nonproteinogenic amino acids as well as non-
standard structural elements, is a prominent 
example for the Nature-derived peptide mimetics. 
Cyclosporine A (Figure 1) possesses a highly 
modified peptide scaffold including two various 
nonproteinogenic side chains, diverse 
N-methylated peptide bonds, a D-amino acid and a 
head-to-tail macrocyclization pattern. These 
structural elements contribute to the proteolytic 
stability, oral availability, membrane permeability, 
and highly specific receptor binding.[33] 
 
 
1.2.3 Synthesis of Peptidomimetics and Peptide Analogs 
Traditionally, peptidomimetics are synthesized chemically. In the case of small molecules, all 
methods of organic synthesis could be applied. For the pinpoint-modified oligo- or 
polypeptides a solid-phase approach utilizing non-canonical amino acids or non-natural 
building blocks in combination with in-solution chemistry is the standard procedure (Scheme 
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Figure 1. Cyclosporine A. 
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3A). Only in few special cases, peptidomimetics could be obtained from recombinantly 
produced peptide scaffolds via enzymatic reactions.[34]  
The installation of non-natural amino acids upon recombinant expression was enabled along 
with the development of the technique for genetic code expansion and became popular in the 
last decade. This strategy exploits the gap of the 64 codons-to-20-amino acids map by the 
introduction of an orthogonal pair of tRNA and aminoacyl tRNA synthetase in combination 
with the amber stop codon introduced in a gene of interest. That enabled the direct access to 
long-chain peptide analogs and alloproteins (Scheme 3B).[35] In addition, Suga and 
coworkers reported a so-called genetic code reprogramming technique which allowed a cell-
free translational synthesis of backbone-modified peptidomimetics.[32] A main advantage of 
this method based on specially screened, flexible ribozymes for RNA-aminoacylation 
(flexyzimes) is the fact that the installation of non-natural moieties is not limited to a single 
modification, making possible the synthesis of highly sophisticated, modified peptidomimetics 
as e.g. cyclosporine A (chapter 1.2.2 Figure 1). 
 
 
Scheme 3. Strategies towards peptidomimetics. A: Fmoc-SPPS and subsequent in-solution chemistry; B: 
recombinant expression via gene code expansion. Canonical amino acids are depicted as green balls. Non-
natural amino acids or building blocks are depicted as stars.  
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Since recombinant production of peptidomimetics is still limited due to the need of 
sophisticated equipment and optimized cells, as well as unpredictable efficacy, the 
conventional synthetic methods were chosen in the present study. 
 
 
1.3 Non-Natural Elements for Structural Investigations 
1.3.1 Labels and Biomarkers for Diagnosis, Structural, and Mechanical Investigations 
The installation of non-natural structural elements into peptides and proteins to bring a new 
function in the parent biomolecule is one of the basic strategies in biochemical/biomedical 
research. It can result in direct therapeutic effects (conjugation to antimicrobial or apoptosis-
inducing agents), promote enhanced target binding (oligomerization, immobilization, or 
multifunctionalization), or act as markers, making the biomolecule distinguishable from 
environment or other components. Being strongly dependent on the chosen analytical 
method, protein labeling can provide insights to the mechanisms of bioprocesses and structure 
of biomolecules, as well as to the distribution of diverse agents in physiological systems, etc. 
For instance, a fluorescent dye can act as label for direct or indirect visualization of cells, for 
protein structure analysis using fluorescence polarization techniques, for investigation of 
protein-protein interactions using fluorescence resonance energy transfer (FRET), or for 
quantification of diverse molecules in physiological systems by fluorescence spectroscopy. 
Radioisotope labels commonly bound to the biomolecule via DOTA or similar chelators, can 
be used for visualization of drug distribution and accumulation by single-photon emission 
computed tomography (SPECT) or positron emission tomography (PET).[36] In wide sense, 
selenomethionine (Sem) can also be categorized to labels for advanced structure elucidation 
by X-ray crystallography (indeed, Sem is a naturally existing amino acid).[37] Certain 
diagnostic labels possess also a therapeutic function, e.g. alpha-particle emitting isotopes 
(213Bi or 225Ac) for radioimmunotherapy[38] or near-infrared-activated photosensitizer 
(phthalocyanine derivatives) for photoimmunotherapy.[39] Isotope labeling of peptides and 
proteins is a popular technique in the field of protein structure elucidation via nuclear 
magnetic resonance spectroscopy (NMR),[40] whereby the most popular isotopic labels, 15N 
and 13C, are often incorporated via bacterial expression in proteins and chemically 
indistinguishable from the common isotopes of these elements.[41]  
 
 
1.3.2 NMR Hyperpolarization Techniques in Biochemistry 
Although NMR spectroscopy has become the most common method for structural analysis in 
organic chemistry and life science, the application of magnetic resonance-based methods to 
complicated biological systems still has limitations due to low inherent sensitivity leading to 
an insufficient signal-to-noise ratio (SNR) or poor resolution caused by the anisotropic nuclear 
interactions. To overcome these drawbacks, several techniques for protein NMR were 
developed. Thus, decoupling (e.g. magic-angle spinning) and recoupling of the spin 
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interactions in solid-state NMR (ssNMR) influence the chemical shift anisotropy, and isotope 
labeling using 13C, 15N, 19F, or 31P minimize the background noise.[40, 42]  
The NMR signals S (or the magnetization M) are proportional to the nuclear polarization P 
and the total number of nuclei N0 in an NMR sample 
 	 ∝   (1) 
and the polarization of an atomic nucleus with the quantum number I =   is dependent on 
the differences between the two energy state populations Nup and Ndown. These originate from 
the orientation of the magnetic moment µ of the nucleic spins to the external magnetic field 
B0 (parallel to field: µup, antiparallel to field: µdown).[43] 
  ≡ 



 (2) 
A small difference in the population of each energy level results in a weak polarization and, 
conclusively, to weak signals which is the case at thermal equilibrium. The population of the 
energy levels under thermal equilibrium can be described by the Boltzmann distribution: 
  = 	 ⁄ ∑ 	 ⁄ !"#$%"  (3) 
where Nm is the population of the nuclei in state m, kB is the Boltzmann constant, T is the 
temperature, and Em is the magnetic quantum energy of the state m given by the formula: 
 & = −( × * (4) 
By combination of the equations (2) – (4), it follows that P can be expressed as: 
  = +,-ℎ /01234 (5) 
and it becomes obvious that the NMR signal intensity is strongly dependent on the strength of 
the external magnetic field B0 and the temperature T.[43] Thus, the classical way to obtain 
intense signals in NMR experiments is the application of a stronger magnetic field, which can 
be accomplished by utilizing a larger magnet or by reduction of the temperature near to 
absolute zero. Thereby, the equal distribution of the nuclei in the energy states is rescinded 
and the sample is “hyperpolarized” (Figure 2).  
Since both strategies are associated with drawbacks in view of costs and application to 
biomolecular probes, more feasible methods for hyperpolarization were established.  
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Figure 2. Orientation of the nuclei at thermal equilibrium and in the hyperpolarized state. The magnetic field (B0) 
is directed vertically upwards. Figure modified from [44]. 
Hyperpolarization techniques using no “brute-force” approaches[45] were first reported in the 
1960s. They utilized transfer of the electron spins from optically pumped Rb atoms (ground-
state electron were pumped selectively to the ±  state via irradiation with circularly polarized 
laser light) to the nuclear spins of noble gases as 3He or 129Xe.[46] Another method used 
metastability exchange by the electron shell exchange of metastable atoms while collision 
with a ground-state noble gas atom.[47] Furthermore, the dynamic nuclear polarization (DNP) 
technique was invented 1978 by Abragam and Goldman, which uses the transfer of electronic 
spin polarization from free radicals added to the probe under microwave irradiation near the 
electron paramagnetic frequency to enhance the polarization of nuclear spins.[48] This method 
is now well-established and applied to the structure elucidation of several biomolecules in 
ssNMR and even in solution NMR analysis.[49] Nevertheless, DNP-enhanced NMR requires 
sophisticated equipments, high energy costs for cooling the probes, generation of a strong 
magnetic field, the microwave irradiation, and long polarization times.[50]  
In general, hyperpolarization of biomolecules opened the door for structural characterization 
of complex biomolecular analytes and investigation of biochemical processes via NMR or the 
magnetic resonance imaging (MRI). 
 
 
1.3.3 NMR PHIP Experiments with Biomolecules 
In 1986, Bowers and Weitekamp theoretically predicted that a strong nuclear spin 
polarization can be obtained upon homogeneously catalyzed addition of molecular 
parahydrogen (para-H2) to unsaturated hydrocarbons.[51] One year later, the same authors 
have experimentally confirmed their hypothesis.[52] Molecular hydrogen exists in two isomeric 
forms that differ in their nuclear spin conformation and the population of rotational states: 
molecular hydrogen with anti-symmetric nuclear states (para-H2) and hydrogen molecules 
with symmetric nuclear states (ortho- with an ortho-to-para ratio of 3:1 at ambient 
temperature. The thermodynamic equilibrium of the rotational and nuclear states is strongly 
dependent on the temperature, thus an enrichment of para-H2 can be accomplished at low 
temperature (e.g. by cooling with liquid nitrogen) and catalytically accelerated, for instance 
by charcoal.[53] Since para-H2 has due to its symmetric character an overall nuclear spin of 
zero, in the hydrogenation product exclusively the symmetry-matched nuclear spin energy 
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level becomes populated. This leads to significant deviation of the product spin system from 
that in a system at thermal equilibrium and, finally, to the observed signal enhancement (SE) 
and an antiphase doublet signal.[53]  
These characteristic signals can be explained by a simplified population model shown in 
Scheme 4: In an AX-type spin system at thermal equilibrium (Scheme 4A), four energy states 
αα, αβ, βα, and ββ are equally populated, where α and β are corresponding spin functions and 
the nuclear wave function of para-H2 is described as: 
 
 5 = √ 78 − 87 = 0 (6) 
Upon radiofrequency radiation in an NMR experiment four transitions shown in Scheme 4A 
yield the typical two-doublet signals centered at the corresponding chemical shift. If a 
catalytic hydrogenation of an unsaturated bond with para-H2 is performed inside the NMR 
magnet (experiment called PASADENA = Parahydrogen And Synthesis Allow Dramatically 
Enhanced Nuclear Alignment)[52, 54] and the para-H2 nuclei are transferred to into the AX-type 
spin system, the symmetry of the anti-aligned state of para-H2 abruptly breaks and induces a 
chemical distinction between the two hydrogen atoms. Hence, only the levels αβ and βα 
become populated and a large gap between the population numbers of each energy level 
arises resulting in an unusual, highly polarized pair of proton spins. The characteristic 
antiphase signals during the experiment are caused by the selective population transfer of the 
energy levels (Scheme 4B).  
. 
 
Scheme 4. Population models for an AX-type two-spin system and expected NMR signals in A: Standard NMR 
system (thermal equilibrium), B: during PASADENA experiment, C: during ALTADENA experiment. 
Expected NMR signals are numbered with corresponding nuclear spin transitions. Population numbers of 
spins are expressed as the width of red lines. Figure modified from [53]. 
When the catalytic hydrogenation of an unsaturated bond with para-H2 is performed outside 
the NMR magnet and subsequently transferred into the magnetic field under adiabatic 
condition (experiment called ALTADENA = Adiabatic Longitudinal Transport After 
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Dissociation Engenders Nuclear Alignment),[55] only one of the energy levels of αβ or βα will 
be populated leading to only two possible transitions during measurement, graphically shown 
in Scheme 4C. More detailed quantum mechanical explanations and models for these 
observations are omitted in the presented work and can be found in certain books and reviews 
on hyperpolarization methods.[53] Covering both experiments, PASADENA and ALTADENA, 
the term Parahydrogen-induced polarization (PHIP) was introduced.[56]  
Furthermore, a method closely related to PHIP, Signal Amplification By Reversible Exchange 
(SABRE), was described by Adams et al. 2009. It takes the advantage of the fact that in 
special cases a transient metal complexation of para-H2 together with the substrate of interest 
is sufficient to break the symmetry of para-H2, thus realizing a polarization transfer from the 
hydrogen molecule without direct hydrogenation, while the chemical structure of the analyte 
is kept unaltered.[57] Along with the already mentioned DNP, hyperpolarized Xenon biosensor 
(HP/Xe),[58] Chemically Induced Dynamic Nuclear Polarization (CIDNP),[59] PHIP and SABRE 
became well-established techniques for the signal enhancement in NMR experiments. A major 
advantage of PHIP NMR experiments is their feasibility with no need for sophisticated and 
expensive equipment.  
In contrast to DNP methods which have already gained recognition for the detection and the 
structural investigation of complicated biomolecules as e.g. membrane proteins, the 
application of para-H2-enhanced NMR techniques to bio-related targets is currently limited to 
a small number of small biomolecules: derivatives of glucose, barbituric acid, non-natural 
amino acids, and short oligopeptides.[60] The requirement of an unsaturated bond in the 
molecule of interest strongly narrows the spectrum of analytes. On the contrary, the 
development of SABRE enabled the signal enhancement provided by para-H2 for molecules 
without olefin or alkyne moieties. However, this technique utilizes a pyridine motif or a 
moiety with similar structural and electronic properties within the substrate to obtain 
successful hyperpolarization. Therefore, its application is hampered in case of complex 
biomolecules. For these reasons, the development of a viable PHIP label which could be easily 
installed in biomolecules and enables strong hyperpolarization without affecting bioactivity is 
in demand.[50b] 
 
 
1.4 Non-Natural Elements for Bioorthogonal Conjugation 
1.4.1 “Click” Chemistry 
According to the original definition given by Sharpless, a chemical reaction has to match the 
next criteria to be referred to as “click chemistry”: it has to be modular, wide in scope, regio- 
and stereospecific, high-yielding, generating no or only easily removable side products, 
performable in simple reaction conditions, with educts and starting materials being easily 
available, and solvents easily removable. Moreover, it must be compatible with atmospheric 
oxygen and aqueous conditions.[11] Along with the fact that the majority of the reactions 
matching the scope are bioorthogonal and compatible with biological systems, “click 
chemistry” finds wide application for the labeling of biomolecules and the generation of 
combinatorial chemical libraries for fragment-based drug screening.  
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Sharpless has classified three types of “click” reactions: 1) the nucleophilic opening of small, 
strained heterocyclic electrophiles (e.g. epoxides, azyridines, azyridinium, and episulfonium 
ions), 2) some special mild condensation reactions of carbonyl compounds (e.g. 1,3-dioxirane 
formation with 1,3-diols, oxime and hydrazone ligations using hydroxyamines and 
hydrazides, and Michael-type additions), 3) cycloadditions, especially reactions involving 
heteroatoms and 1,3-dipoles.[11] Few of these “click” reactions are listed in Scheme 5 whereby 
not all of the reactions do perfectly match the initial requirements of “click” chemistry. 
 
Scheme 5. Bioorthogonal conjugations referred to as “click” reactions. A,B: nucleophilic opening of epoxides; C: 
oxime ligation; D: sulfhydryl-maleimide conjugation; E: thiol-ene conjugation; F: traceless Staudinger 
ligation; G: CuAAC; H: SPAAC; I: tetrazine ligation. Most of the reaction schemes are simplified or 
generalized. 
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The benefit of these reactions is not limited to the assembly of functional fragments or the 
attachment of several organic or biomolecules to certain scaffolds. In some special cases, the 
linking motif generated during reaction can provide further functional properties itself, e.g. 
fluorescence, chemoluminescence, metal ion chelating functions, mimicry of protein structure 
elements with constrained conformations, or photo-cleavable linkage.[61]  
During the last decade, some of these reactions have been found to be especially attractive for 
the modification of biomolecules and were applied in biochemical and biomedical research, 
among them oxime ligation,[62] sulfhydryl-maleimide conjugation,[63] the traceless Staudinger 
ligation,[64] the inverse electron-demand Diels-Alder (DA) reaction using tetrazines,[65] and 
several variants of 1,3-dipolar cycloaddition.  
In general, the 1,3-dipolar cycloaddition between a 1,3-dipole (functional groups with four 
delocalized electrons in the π–system over three atoms as e.g. azides, diazoalkanes, 
nitrosoxides, or nitrones, Scheme 6) and a dipolarophile results in formation of a five-
membered ring as product. The most frequently used dipolarophile in biochemical research is 
the alkyne group due to its high stability in biological systems and its distinct orthogonal 
character.[66] 
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Scheme 6. Chemical structure of popular 1,3-dipoles classified depending on formal structure and central atom. 
For propargyl/allenyl anions both resonance structures are depicted. Scheme adapted from [67]. 
The diverse variants of 1,3-dipolar cycloadditions differ in the nature of the 1,3-dipoles and 
the way to overcome the high activation barrier (~25 kcal mol−1 for methyl azide and 
propyne) of the highly exothermic reaction.[68] As prototype of modern 1,3-dipolar 
cycloadditions, the alkyne-azide cycloaddition published by Huisgen et al. in 1961 can be 
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considered.[69] This non-catalyzed and non-regioselective reaction used thermal energy to 
overcome the activation barrier. Due to the harsh reaction conditions, the Huisgen 
cycloaddition itself was not compatible with sensitive biomolecules and had gone to oblivion 
for decades.  
Contrary, after the discovery of the Cu(I)-catalyzed variant of this reaction, called Cu(I)-
catalyzed alkyne-azide cycloaddition (CuAAC), in the beginning of 21st century 
(independently described by Meldal and Sharpless 2002)[70], it became one of the most 
valuable reactions for the covalent assembly of complex molecules in the repertoire of “click” 
chemistry. Even the term “click” reaction is frequently associated with it. CuAAC possesses 
many desirable features like high selectivity, bioorthogonality of educt functional groups and 
product triazole, high reliability, no need for elevated temperature; it is completely selective 
towards the formation of the 1,4-disubtituted regio isomer.[11, 30] Additionally to the Cu(I)-
catalyzed reaction, Ag(I)-catalyzed alkyne-azide cycloaddition (AgAAC)[71] towards selective 
formation of 1,4-triazoles and Ru(II)-catalyzed alkyne-azide cycloaddition (RuAAC)[72] 
selectively forming a 1,5-disubstituted triazole, are also reported, whereby the latter one 
requires elevated temperature or microwave irradiation and an oxygen- and water-free 
condition.[73] The simplified chemical equation of 1,3-dipolar cycloaddition between terminal 
alkynes and an azide is shown in Scheme 7A. 
 
Scheme 7. 1,3-Dipolar cycloaddition between A: terminal alkynes and azides; B: strain-promoted alkynes and an 
azide (top) or nitrone (bottom); C: a cyanobenzothiazol and a thiol. 
An interesting aspect of these reactions is the topologic and electronic similarity of the 
product, 1,2,3-triazole, with an amide bond.[30, 74] The heterocyclic linking unit can mimic 
peptide bonds, whereas the 1,4-disubstituted triazole can be used as conformationally 
constrained and hydrolytically stable surrogate for trans-peptides and the 1,5-disubtituted one 
as surrogate for a cis-peptides.[14a]  
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Nevertheless, the application of metal ion-catalyzed alkyne-azide cycloaddition in biological 
systems still has an unavoidable disadvantage which is caused by the metal ion itself.[75] On 
the one hand, the inherent cytotoxicity of transition metal ions hampers the in vivo 
application of the reactions and, on the other hand, the tendency to form stable complexes 
with both the reactants and products makes the isolation difficult. Thus, a metal-free click 
reaction was developed few years later by Bertozzi and coworkers where the alkyne 
dipolarophile is installed into a strained ring while using the ring tension to decrease the 
activation barrier (Scheme 7B).[75a] The reaction referred to as strain-promoted alkyne-azide 
cycloaddition (SPAAC) makes the 1,3-dipolar reaction possible in living cells and found 
application for in vivo labeling of several proteins.[76] But it has to be mentioned that the 
regioselectivity of the metal ion-catalyzed cycloaddition is lost.  
An arranged variant of SPAAC using in situ generated nitrones as 1,3-dipoles, strain-promoted 
alkyne-nitrone cycloaddition (SPANC), is also reported.[77] Moreover, a thiol-based 1,3-dipolar 
cycloaddition using 2-cyanobenzothiazole as dipolarophile and D-cysteine derivatives as 1,3-
dipole (Scheme 7C) was recently reported. This reaction was inspired by the natural 
regeneration pathway of luciferin in fireflies, and also has gathered attention, due to the 
inherent fluorescence or the bioluminescence emission of the resulting luciferin-like linker 
unit.[78]  
 
 
1.4.2 Biocompatible Scaffolds for Drug Delivery and Oligomerization 
An important area where bioorthogonal conjugations are frequently applied is the 
immobilization of functional ligands, peptides or small molecules, on solid surfaces as well as 
their loading to a biocompatible scaffold. Especially the latter approach has significance for 
the development of complex drugs with tailor-made functions and properties. As it is known 
from Nature, oligomerization of target-binding domains within a molecule or a molecular 
complex can lead to unexpected enhancements of the binding to a multimeric receptor. Thus, 
several natural antibodies form condensed oligomers as e.g. pentameric human IgM which is 
composed of five singular antibodies joined by certain peptidic linkers, or the IgG comprising 
a homodimer held together via disulfide bonds.[79] The non-linear connection between the 
number of paratopes and the epitope-binding ability is caused by the avidity (or functional 
affinity) effect and can be explained by thermodynamic and kinetic models.[80] Since the 
probability that multiple binding interactions simultaneously dissociate is low and the 
probability of re-association upon dissociation of one binding interaction is enhanced by the 
fixation of the second binding site, the binding constant of multivalent interaction is not a 
simple sum of the individual binding affinity constants Kn, but a multiple of it resulting in a 
cooperative effect and leading consequently to the beneficial entropic contribution to the 
overall free energy G.[81] In case of a polyvalent interaction with N individual receptor-ligand 
pairs, this can be derived from the following equation for the Gibbs free energy:  
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EH   (11) 
Kavid is the observed affinity caused by the polyvalent interaction, Gn - the free energy of an 
single interaction defined by the individual binding affinity constant Kn. From the perspective 
of kinetics, an elevated local concentration of the components (effective molarity) is provided 
upon the spatial proximity of the numerous binding sites, thus decreasing the probability and 
reaction rate of dissociation.[80] 
Analogous approaches towards the synthesis of artificial multivalent binders were investigated 
on various types of scaffolds, whereby the nature of the oligomerization scaffolds was also of 
high interest since it does not only define the number and spatial arrangement of the 
functional units, but also induced new properties. The range of molecules applicable for 
scaffold-based drug design is wide and includes inorganic materials like silsesquioxane-based 
nanoparticles,[82] organic materials like long-chained hydrocarbons[83] (Figure 3A) or 
dendrimers,[84] simple biomolecules like cyclic peptides or oligosaccharides,[85] and complex 
proteins as bovine serum albumin or monoclonal antibodies (mAbs).[86]  
An interesting approach for peptide conjugation on a cube-octametric silsequioxane (COSS) 
scaffold was reported by Hörner and Fabritz et al. (Figure 3B). [87] They demonstrated the 
successful loading of multiple copies of various functional peptides on a single COSS particle 
(2-8 copies depending on the size of the payloads) using oxime ligation.[87a] On the other 
hand, they examined the cell-penetrating character of the amino-functionalized COSS and 
succeeded in the targeted delivery of a cargo peptide into living cancer cells and even to their 
nuclei.[87b] 
As an example for peptide-based scaffold, the cyclic decapeptide developed by Mutter et al. 
should be mentioned.[13a] The scaffold molecule matches the concept of template assembled 
synthetic proteins (TASP)[13a] and the regioselectively addressable functionalized templates 
(RAFT).[88] Galbert et al. reported 2011 the one-pot synthesis of a highly sophisticated 
tetravalent and trifunctional bioconjugate based on this decapeptidic scaffold using three 
various bioorthogonal reactions: CuAAC, maleimide conjugation, and oxime ligation (Figure 
3C).[89] 
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Figure 3. Exemplary chosen biocompatible scaffolds with payloads. A: solanesol-derived multimerization scaffold 
loaded with functional peptides;[83] B: COSS scaffold for drug delivery or oligomerization;[87] C: TASP- 
and RAFT-based cyclic decapeptide scaffolds with three orthogonally conjugated ligands;[89] D: schematic 
depiction of homodimeric ADC on IgG base with site-specifically conjugated payloads. 
From the opposite perspective, the loading of small-molecule ligands onto larger biomolecular 
scaffolds as proteins is also a popular approach in scaffold-based drug design. Although small 
molecules and short peptide-based drugs often exhibit high in vitro bioactivity (target binding 
or toxicity), their application as pharmaceutical agent is strongly hampered by the 
inappropriate pharmacokinetical properties.[2b] Generally, the in vivo half-life of substances 
with a size below the cutoff for renal clearance (molecular weight cutoff: 48 kDa, size cutoff: 
10 nm) are very short (several minutes to few hours).[90] Combined with the fact that peptide-
based components can also undergo proteolytic degradation, a method to enhance their 
ADME properties was strongly desired. A strategy to couple the excellent bioactivity of small-
molecule drugs with the pharmacokinetic profile of mAbs can be considered in a novel class of 
pharmaceuticals referred to as antibody-drug conjugate (ADC).[86a, 91] ADCs are mAbs or 
fragments of antibodies covalently linked to bioactive payloads. In the first generation of 
ADCs, the intrinsic target-binding properties of the Ab paratopes were combined with 
cytotoxic payloads linked via a cleavable linker, whereby non-specific conjugation techniques 
through native residues as side chains of Lys or Cys were applied. This resulted in the 
heterogeneous mixture of ADCs with diverse numbers of payloads on a single mAB making 
the purification and characterization very difficult and influencing the pharmacokinetics of 
ADCs.[86a] Thus, in the next generation of ADCs, site-selective conjugation techniques through 
genetically or chemically engineered sites are used resulting in the homogeneous species with 
a controllable drug-to-antibody ratio (DAR). For site-selective transformation, bioorthogonal 
transformations like oxime ligation,[92] (Figure 3D) SPAAC,[93] or enzymatic reactions 
recognizing specific amino acid sequences are appropriated.[94] 
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1.4.3 Affinity-Guided Reactions in Biochemistry 
The concept of affinity-guided reactions rises from the field of coordination chemistry and is 
associated with the so-called “templated reactions”. The classical templated reaction 
comprises two or more coordination sites of a metal ion center giving the reactive groups a 
certain spatial pre-orientation (Scheme 8A). The close proximity provided by the non-
covalent binding leads to an increased local concentration of the reactive groups and, 
consequently, enhanced reaction rate and better selectivity.[95] As transition metal-catalyzed 
reactions can also be considered as non-stochiometrically templated, the majority of these 
reactions require the corresponding metal.[96]  
In biochemistry, the scope of “templated reactions” is extended towards the admission of 
every non-covalent interaction between biomolecules contributing to the spatial arrangement 
of reactive moieties and promoting the formation of a covalent linkage. Thus, enzyme-
catalyzed condensations with the reactive moieties of substrates brought in close proximity by 
the active site of the enzyme can also be regarded as “templated”. However, template-directed 
chemical ligation techniques are still useful for the site-specific labeling of target molecules or 
for fragment-based drug discovery. Hamachi and coworkers have developed the ligand-
directed tosyl (LDT) chemistry[97] and the affinity-guided DMAP (AGD) chemistry[98] for site-
specific protein labeling: in both strategies, labeling probes were selectively attached to a 
nucleophilic residue on the protein surface, whereby the selectivity is given by the spatial 
approximation of the electrophilic probe conjugated to the protein-binding ligand via a 
leaving group (Scheme 8B)  
 
Scheme 8. Sketch of exemplary chosen affinity-guided reactions. A: templated reaction in coordination chemistry. 
B: protein labeling by LDT chemistry. Lg = ligand, Nu = nucleophilic residue on protein surface. C: DNA-
templated NCL ligation of oligonucleotides. Template DNA is shown in blue. Helices shown in red are 
either terminally modified oligonucleotides or oligo-PNAs. 
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In the latter strategy, a carboxylic acid activator (AGD catalyst) is selectively attached to the 
nucleophile, and successive site-selective conjugation of a labeled acyl donor follows. Both 
approaches have found successful application for specific labeling of target cells in vivo.  
Furthermore, a method described by Rademann et al. as dynamic, template-assisted drug 
discovery has found application in fragment-based drug design.[99] In this strategy, two small-
molecule fragments binding two epitopes of a target protein with low affinity are covalently 
linked upon a fragment condensation after the non-covalent binding to their target sites has 
occurred. Several small-molecule enzyme inhibitors with high affinity and target specificities 
were identified and synthesized by this method. 
In the field of biochemically templated reactions, the non-covalent interactions for reactant 
pre-orientation are not limited to ligand-receptor (or substrate-enzyme) binding. Non-
covalent interactions between larger biomolecular subunits, among them the self-assembly of 
several protein subunits or the hybridization of a complementary oligonucleotide pair are of 
research interest as well. A large number of non-enzymatic techniques using DNA strands as a 
template are reported for the condensation of oligonucleotide fragments with native and non-
native linkers,[100] or for the multistep synthesis of small molecules (DNA-templated organic 
synthesis: DTS).[101] As an interesting example, a DNA-templated fragment ligation of peptide 
nucleic acids (PNAs) via native chemical ligation (NCL) during polymerase chain reaction 
(Scheme 8C)[102] and a surface labeling of quantum dots via DNA-instructed amino acyl 
transfer reaction was recently reported by Seitz and coworkers.[103] The high combinatorial 
diversity of oligonucleotides and the reliability of the sequence-specific hybridization make 
nucleic acid-templated ligations an interesting tool for the simultaneous attachment of diverse 
functionalities to a scaffold molecule. 
 
 
1.5 Model Compounds and Test Systems 
1.5.1 Trypsin-like Proteases and Related Serine Proteases 
Trypsin is an endopeptidase comprising 200 – 350 residues. Its natural function is the catalytic 
hydrolysis of nutritive peptides in the digestive system. Since the hydrolysis is supported by a 
catalytic triad within the active site possessing a serine residue which acts as a nucleophile 
and binds to the substrate during the reaction, it belongs to serine proteases. In Scheme 9, 
the mechanism of substrate hydrolysis by trypsin-like proteases is depicted.[104]  
The catalytic triad of trypsin-like proteases is composed of three amino acids in spatial 
proximity. Though the most common combination is His57, Asp102 (or Glu105, respectively), 
and Ser195, there are several other types of serine proteases with different amino acid 
combinations: the catalytic triads of cytomegalovirus proteases (His-His-Ser), or sedolisin 
(Asp-Glu-Ser).[105] Their mode of action relies on decreasing the activation energy barrier 
during the nucleophilic attack of the serine hydroxyl to the amide carbon of the substrate. To 
increase nucleophilicity of the alcohol group, a formal deprotonation via two further amino 
acids takes place. Under physiological pH, the carboxylic group of Asp102 (or Glu105, 
respectively) is deprotonated (pH optimum of trypsin: ~8), thus forming a hydrogen bond 
with the Npi-proton of His57. The shift of electron density leads to enhancement of the 
hydrogen bond from Nτ to the serine proton, which provides a formal deprotonation of the 
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serine side chain. The three-dimensional structure of the catalytic triad in bovine pancreas 
trypsin is depicted in Figure 4. 
 
 
Scheme 9. Mechanism of trypsin-catalyzed proteolysis. X, Y: side chains of a substrate peptide (X = 
Lys/Arg). Catalytic triad residues of trypsin are shown in grey. 
 
 
Figure 4. left: 3D computational model of trypsin in cartoon style. Residues forming the catalytic triad are shown 
as sticks, right: enlarged view of catalytic triad: red = oxygen, blue = nitrogen, cyan = carbon, grey = 
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hydrogen; hydrogen bonds are depicted as red, hashed lines. Model derived from crystal structure of 
bovine pancreas trypsin in co-complex with an inhibitor (PDB: 4ABJ). 
The catalytic cycle can be separated in two 
single reaction steps. During the first step, a 
transacylation of substrate peptide via 
nucleophilic attack of the activated serine to 
the peptide carboxylic group takes place 
while leading to the generation of 
tetrahedral oxyanion transition state, ts. The 
transition state is additionally stabilized by 
hydrogen bonds with Nα-protons of peptide 
groups of surrounding amino acid residues 
(Scheme 10). This stabilizing effect induces 
the shift of the chemical equilibrium towards 
formation of ts and, consequently, to 
acceleration of substrate conversion towards 
product formation.[105]  
The protonation of the Nα-group of the 
substrate leads to cleavage of an N-terminal 
peptide fragment while an O-acylated 
enzyme is formed. The ester bond is cleaved 
by alkaline ester hydrolysis and, 
simultaneously, the electron density flows back to Asp103 via His57. Thus the initial 
conformation is regenerated and the protease is ready for subsequent reaction cycles. 
The substrate specificity of serine proteases is mostly determined by the shape and charge of 
the primary specificity-site pocket inside the active site (S1 pocket). In case of trypsin, a 
deprotonated Asp189 at the bottom of the active site pocket binds to positively charged 
substrate residues and stipulates limited tolerance concerning substrate peptide residues. 
Taking into consideration the hydrophobic walls of the pocket, the residues bearing long 
aliphatic motifs of the side chains (Arg and Lys) are preferred as cleavage sites. Indeed, 
trypsin and trypsin-like proteases usually cleave non-terminal peptide bonds after these basic 
amino acids.  
The classification of serine proteases in the subfamilies is mainly based on their specificities 
against diverse target substrates. Thus, chymotrypsin (Figure 5, middle), a digestive enzyme 
of the pancreatic juice, preferably catalyzes the hydrolysis of peptide bonds after amino acids 
with large- to medium-size hydrophobic side chains (aromatics as Phe, Tyr, or Trp) belongs to 
chymotrypsin-like proteases. The mode of action of the catalytic triad is as same as for trypsin, 
whereby chymotrypsin possesses an S1 pocket with more hydrophobic cavity. Due to their 
well investigated structure and mechanism, established assays for characterization of 
bioactivity, certain homology with therapeutically relevant proteases, and availability, trypsin 
and chymotrypsin are popularly used as model enzymes in the fundamental research and drug 
discovery. 
Elastase-like proteases (Figure 5, right) possess a much smaller S1 pocket and preferably 
cleave peptide bonds after residues with small, hydrophobic side chains (Ala, Leu, or Val). 
The natural function of elastase is the breakup of an elastic fiber protein in the connective 
Scheme 10. Oxyanion stabilization and substrate 
selectivity towards positively charge amino acid
in the active site of trypsin. Hydrogen bonds are 
depicted as dashed lines. Substrate-binding 
pocket of active site is shown in dark grey. 
Polypeptide chain of trypsin is shown in light 
grey. 
 
DOCTORAL THESIS DAICHI NASU INTRODUCTION 
 
 24
tissue (elastin). Elastases are of therapeutic interest since neutrophil elastase is involved in 
inflammations caused by immunological response. [106] 
 
Figure 5. 3D computational models of trypsin (left), chymotrypsin (middle), and elastase (right). Residues of the 
catalytic triad are depicted in yellow stick model. Models are derived from the respective crystal structures 
(PDB 4ABJ, 1T7C, 3Q76). 
Competitive inhibitors against serine proteases require two important features. First, they 
must possess similarity with the cleavage site of the substrate peptide to get high affinity to 
the active site of enzyme. Second, they must imitate the tetrahedral transition state of 
substrate while binding to the enzyme without subsequent cleavage of the peptide bond.[107] A 
vast number of natural trypsin inhibitors are found in animals (Kunitz-type inhibitors), plants 
(squash trypsin inhibitors, Bowman-Birk inhibitors, mustard trypsin inhibitors), and 
microorganisms (saccharopepsin inhibitor, Streptomyces metalloproteinase inhibitor).[108] 
Some of these inhibitors are oligopeptides of less than 100 amino acids. Due to their unique 
fold, these inhibitors are often extremely stable and represent interesting models for 
mechanistic studies.  
The control of proteolytic reactions is usually achieved through a balance of protease 
biosynthesis (expression and zymogen activation), degradation, and its inactivation by the 
interaction with an inhibitor. If one of these three mechanisms is interrupted or missing, an 
onset or progression of several diseases can result. The control of aberrant proteolytic 
activities is challenging for therapeutic research, especially in the case of certain proteases 
which are overexpressed in cancer cells. On the one hand, a highly specific and affine drug-
like agent could directly inhibit the unsolicited reaction and possibly affect tumor growth. On 
the other hand, the conjugation of a protease-selective inhibitor with a label would enable a 
development of a diagnostic method for tumor localization.[109]  
Recently, trypsin has got into focus of biochemical research once again. Pan et al. 
demonstrated the application of an engineered trypsin variant as a tool for sequence-specific 
protein ligation by shifting the equilibrium of the enzyme-catalyzed hydrolysis in direction of 
its reverse reaction.[110] 
 
 
1.5.2 Sunflower Trypsin Inhibitor 1 
Despite their extremely wide diversity, many plant-derived, peptidic inhibitors possess some 
pinpoint similarity in structure and sequence making their categorization possible. Bowman-
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Birk inhibitors (BBI) comprise one of such plant-derived inhibitor classes. The native 
Bowman-Birk inhibitor is a 71 amino acid peptide extracted from soybeans and comprising 
seven intramolecular disulfide bridges.[111] Its natural function is the growth factor regulation 
in several organisms; its inhibitory effect gets lost by heating or by reducing of more than four 
disulfide bonds. A vast number of commonly known plants as rice, wheat, beans, and peas are 
known to synthesize inhibitors of this class.[112] The essential characteristic BBI generally 
share is the constrained shape of the inhibitory loop hold together by intramolecular hydrogen 
bonds and a disulfide bond between two Cys residues interposing the inhibitory loop.[113] A 
Lys or Arg residue at the second position of the inhibitory loop ensures high affinity of 
Bowman-Birk inhibitors towards trypsin-like proteases.  
A distinctive numbering system was introduced for the residues in the inhibitory site of BBIs. 
The numeration starts from the “fictive cleavage site” (scissile bond) of the enzyme-catalyzed 
hydrolysis, a Lys (in some species also Arg). Amino acids disposed N-terminally to the scissile 
bond are numbered with plane numbers growing up with the order of connectivity in chain: 
P1, P2, P3, etc.. Amino acids disposed in direction of C-terminus are numbered with dashed 
numbers: P1’, P2’, P3’, etc. An example for this numbering is shown in Table 3. 
Table 3. Amino acid sequence of the inhibitor loop (blue) and surroundings for BBI (SFTI-1) and the characteristic 
numbering of amino acid positions (lower row). The fictive cleavage site is marked as red line. cis-Proline 
is shown in bold italic. 
 Sequence 
BBI G R C T K S I P P I C F P D 
               
Numbering  P4 P3 P2 P1 P1’ P2’ P3’ P4’ P5’     
The smallest inhibitor from this class is the sunflower trypsin inhibitor-1 (SFTI-1) originally 
extracted from Helianthus annuus. It is a bicyclic 14 amino acid peptide comprising a typical 
seven amino acid inhibitory loop, a disulfide bond connecting the termini of this loop (Figure 
6, left) and a head-to-tail cyclized backbone.  
 
Figure 6. Amino acid sequence and connectivity (left) and 3D computational model (right) of bicyclic SFTI-1 with 
red = oxygen, blue = nitrogen, yellow = sulfur, white = carbon. Model derived from crystal structure of 
SFTI-1 in co-complex with trypsin (PDB 1SFI). Figure reprinted from own publication.[50b] 
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Notwithstanding its simple structure, SFTI-1 exhibits very high affinity towards trypsin with 
an inhibitory constant Ki at subnanomolar range (Ki = 0.1 nM).[114] The monocyclic derivative 
lacking backbone cyclization (open-chain SFTI-1 or SFTI-1[1,14]) is not as potent as the wild 
type, but still has an excellent inhibitor activity against trypsin (Ki = 0.2 nM).[73b]  
The three-dimensional structure of both, SFTI-1 (Figure 6, right) and its monocyclic 
permutant, is featured by the characteristic turn induced by the proline at P3’.[115] This Pro 
residue is known to have a cis-configured peptide bond which is very rare (usual cis/trans 
isomer ratio in chemical equilibrium: 1:1000) in polypeptides and gives the inhibitory loop a 
constrained β-hairpin shape.  The preservation of the cis-Pro at P3’ is sufficient for the 
inhibitory activity of SFTI-1, as Brauer et al. demonstrated by replacement of Pro-P3’ with an 
Ala leading to the drastic loss of inhibitory activity.[116] Contrary, Daly et al. showed that the 
conformation of the neighboring Pro-P4’ peptide bond must be trans to achieve good 
inhibition. Thus, only the combination cis-Pro-P3’, trans-Pro-P4’ gives the characteristic frame 
of the inhibitory loop and results in high inhibitory potency.[117]  
The facts that SFTI-1 comprises, in spite of its small size, several unique architectures and 
important structural elements, that it is simply available and modifiable via SPPS, and that the 
inhibitory activity can be examined by established assays, make the framework an excellent 
model scaffold for structural investigation and a template molecule for development of several 
therapeutics and diagnostics. 
 
 
1.5.3 Heterodimeric Coiled Coils 
Discovered by Crick 1953, the coiled coil is an important structural motif of peptide chains 
composed by two or more homo- or heteromeric α-helices.[118] In nature, it finds a wide range 
of applications giving a protein its superstructure or forming supermolecular protein 
complexes.[119] In the typical coiled-coil motif, two α-helices composed of several copies of 
series-connected repetitive oligopeptide units, are wrapped around each other, forming a 
usually left-handed supercoil (Figure 7).[120] The stability of this non-covalent binding motif is 
determined by the length of the α-helices which can vary from very long (more than 100 of 
repetitive triads), as it is found in collagen, to short (3-4 repetitive heptads), as in the leucine-
zipper transcription factors.[121] Coiled-coil hetero- and homooligomers can be arranged in 
parallel or antiparallel manner depending on the amino acid sequences of the repetitive units 
and affecting the ultimate shape and stability of the superstructure.[122] 
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Figure 7. 3D computational model of an exemplary chosen heterodimeric coiled-coil complex shown in cartoon 
style. Model derived from X-ray crystal structure of Rho-binding domain of Rho-kinase (PDB: 1UXT). 
The driving force of the supermolecular arrangement in coiled coils is the combination of 
hydrophobic and ionic interactions between the amino acid residues of the α-helices.[123] In 
heptad-based coiled coils, often found in short dimerization domains of proteins, an 
alternating order of hydrophobic residues (Ala, Leu, Ile, Val) and hydrophilic or charged 
residues (Ser, Lys or Arg, and Glu or Asp, respectively) are repeated in every eighth position 
(hence, in every second helical turn).[122] The spatial orientation of the residues of α-helices 
involved in a heteromeric coiled-coil can be illustrated by a helical wheel shown in Scheme 
11. The sketch represents the spiral structure of the α-helices from top view, whereby the 
seven amino acid residues of the repetitive unit in heptad-based coils are positioned on the 
surface of the spiral in 100° angle steps and numbered with the letters a, b, c, d, e, f, and g. 
Along with the number of the repetitive units, all of the important structural information of 
consistently repeating heptad coiled-coils are expressed by this simple model. Generally, 
hydrophobic residues as Leu or Ile are placed on positions a and d forming a hydrophobic 
core in a dimer which can be considered as the fundamental interaction holding the helices 
together.[118] At positions e, f, and g, usually charged residues are located, whereby the 
residue in position f has the opposite charge to the residues in e and g. In case of 
heterodimeric coiled coils, the helices have to possess opposite charge to obtain attractive 
ionic interaction, thus the amino acid at these positions depends on the net charge of coil. 
Since the amino acid on position f is not facing the coiled-coil interaction site, its function is 
suggested to be the enhancement of water solubility and the reduction of overall charge of the 
coils. The most typically used ionically interacting amino acid pairs are Glu-Lys or Asp-Lys, 
respectively. Therefore, they are usually placed on complementary positions of each coil. 
Furthermore, uncharged amino acids as Ala or Ser on the remaining positions b and c provide 
the formation of helical structure as well as stabilization of the coils in aqueous environment.  
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Scheme 11. Helical wheel depiction of two complementary interacting α-helices forming a heterodimeric coiled 
coil (E/K coil system). Residue positions contributing to hydrophobic interactions are shown in red, 
positions contributing to ionic interactions are shown in green. Scheme modified from [123]. 
A well-established model system where these 
fundamental structural characteristics for 
heterodimeric coiled coils are represented is the 
E/K coil system where each coil is named after 
its first amino acid in its original heptad 
sequence (Figure 8).[120, 122, 124] 
This artificial coiled-coil system is marked by 
high stability, specificity, modifiability towards 
pinpoint mutations of single amino acids, and 
the well-studied effects of these amino acid 
replacements on the structure of a protein. That 
makes the system appropriate for de novo 
protein design.[124-125] Detailed studies on the 
influence of the primary structure, the variations in the number of repetitive heptads as well 
as the nature of residues within the heptad of the E/K coil system on the stability, specificity, 
and affinity towards the heterodimer were conducted by Litowski et al.[122] It was found that 
the number of repetitive units required for efficient formation of coiled-coil dimer depends on 
the strength of interactions in the hydrophobic core. Therefore the replacement of a Val 
residue by the more hydrophobic Ile resulted in the formation of a three-heptad coiled-coil 
heterodimer whereas the non-modified sequence needed at least four repetitive heptads. 
Furthermore, an interesting observation was made that some of the coils with diverse 
numbers of repetitive heptads tended to form homodimers or oligomers, respectively, instead 
of the desired heterodimers. As preferred formation of homodimers and heterotetramers was 
K coil: H-(K-X-S-A-L-K-E)n-OH
E coil: H-(E-X-S-A-L-E-K)n-OH
Position in helix:
X = V or I
g a b c d e f
Figure 8. Amino acid sequence of K coil and E coil 
with corresponding positions of the residues 
in the helical wheel depiction. The colors of 
the letters corresponds to those shown in 
Scheme 11. 
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mainly found in the four-heptad system of the Ile-bearing coils, the typically used E/K coil 
system is composed of three or five repetitive heptads. 
These sequences characterized by Litowski et al. [122] were adapted by several researchers 
towards the selective conjugation of functional payloads on proteins, thus the coils are acting 
as recognition site for templated chemical conjugation described in chapter 1.4.3. Since the 
E/K coils allows the modification of single amino acid residues while retaining their specific 
affinity towards the complementary coil, several techniques were described for site-selective 
protein or cell labeling as e.g. coiled-coil guided acyl transfer[126] or the dirhodium 
metallopeptide-catalyzed Trp modification.[127] A general notation system for modified coiled-
coil helices is shown in Figure 9. Combined with the sequence of the non-modified heptad, all 
modified positions and the most important structural information are represented in this 
notation. 
 
Figure 9. Amino acid sequences of E/K coils with substituted amino acids (left) and associated abbreviations. 
Sequence taken from modified E/K coil system for Rh2-metallopeptide-catalyzed Trp modification.
[127] 
 
 
1.5.4 Peptide Nucleic Acids 
The double stranded helical structure of DNA is one of the most elegant ways to assemble two 
or more biomacromolecules without formation of covalent linkages, which makes 
oligonucleotides not only attractive for storage, retrieve and translation of genetic 
information, but also for biomolecular engineering.[128] As mentioned in chapter 1.4.3, the 
non-covalent interactions between complementary oligonucleotides possess highly reliable 
sequence selectivity and combinatorial diversity, making them appropriate as recognition tags 
for site-selective conjugation of diverse biomolecules. A major barrier to apply DNA-templated 
chemistry to proteins is the difference in the nature of the biomolecules. Therefore, very often 
highly selective and orthogonal reactions that could be applied to peptides cannot be used in 
presence of oligonucleotides and vice versa. Moreover, the high charge density of the nucleic 
acid backbone can also affect solubility and polarity of the proteins and hamper several 
conventional techniques for protein analysis. 
Peptide nucleic acids (PNAs) are artificial oligo- or polymers combining structural features of 
oligonucleotides and peptides. They consist of a pseudo-peptide backbone and nucleobase-
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bearing side chains (Figure 10A) where all of the four purine and pyrimidine bases found in 
DNA are present (Figure 10B).[129] Although several types of PNA monomers with various 
backbone structures have been to date reported, the most popular one is based on N-(2-
ethyl)glycine (aeg) forming an achiral periodic chain with alternating peptide/peptoid bonds. 
Contrary to conventional amino acids, the side chains of a PNA are not connected to the α-
carbon, but to the amine nitrogen of glycine via a carboxymethylene linker.[130]  
 
 
Figure 10. A: Backbone monomers of DNA, aeg-PNA, and a further PNA additionally bearing an 
amino acid side chain, B: nucleobases. The positions of the substitution within the amino acid side 
chain are shown with Greece letters. 
PNAs were originally designed by Nielsen et al. in 1991 using computational models 
combined with chemical “common sense” to be structurally homomorphous to DNA and 
synthetically accessible.[129, 131] Thus, the resulting oligomers are successful structural mimics 
of DNA, even with the ability to undergo hybridization via Watson-Crick base pairing with 
complementary oligonucleotides and PNA strands in parallel and antiparallel manner 
(Scheme 12). Due to the lack of the charged deoxyribose phosphate backbone with repulsing 
electrostatic interaction, PNA-DNA and PNA-PNA duplexes have an improved thermal stability 
compared to the corresponding DNA-DNA duplex (ΔTm > 30 °C in a 12-mer PNA-DNA duplex 
compared to the corresponding double-stranded DNA at low salt concentration).[132] 
Additionally, the relative rigidity of the pseudo-peptide backbone improves the sequence 
selectivity making PNAs convenient molecules for selective binding to DNAs whereas only a 
small number of residues are required for the recognition of the complementary sequence 
(typically 5-10 residues). Their affinity to the complementary sequence is so strong that PNAs 
possess the ability to invade double-stranded DNAs forming a PNA-DNA-DNA triplex.[133] 
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Scheme 12. A: Hybridization pattern of complementary PNA-PNA, DNA-DNA, and PNA-DNA via Watson-Crick 
base pairing. Hydrogen bonds within the nucleobase pairs are depicted as dashed bonds. B: 3D 
computational models of complementary PNA-PNA, DNA-DNA, and DNA-PNA heptamers. Atoms are 
shown as sticks and the surfaces of the strands are shown in magenta for DNA, and cyan for PNA. Models 
were derived from the NMR solution structures (PDB: 1PUP, 2L8Q, 3PA0). 
Further beneficial features of PNAs are the resistance against proteases and nucleases, the low 
affinity to proteins, and the facilitated introduction of various modifications. The solid-phase 
synthesis of PNA oligomers is well established and relies on both Boc- and Fmoc-SPPS. 
Protected PNA monomers for SPPS are commercially available with an acid-labile 
benzhydryloxycarbonyl (Bhoc) protecting group for the orthogonal protection of the 
nucleobases (despite of T which needs no protection).[134] The standard procedure of Fmoc 
solid-phase PNA assembly is as same as for conventional peptides, but as PNAs are sensitive 
against elevated temperatures and also known to undergo backbiting reaction under strong 
basic condition, microwave-assisted SPPS should not be used. Nevertheless, an iterative 
synthesis of PNA-peptide fusions is possible without changing the strategy. 
PNAs were mainly applied for the recognition of specific sequences in DNA duplexes. It was 
aimed to mimic an oligonucleotide binding to double-stranded DNA via Hoogsteen base 
pairing in the major groove.[128] The fast hybridization rate of PNAs to complementary 
sequences made labeled PNAs interesting as probe for diverse RNA and DNA analysis, e.g. 
southern or northern blotting.[128, 135] Besides target-specific labeling, PNAs are involved in 
assembly and immobilization of various molecules, as e.g. PNA-templated assembly of 
heterogeneous nanoclusters,[136] PNA-mediated immobilization of supercoiled DNAs,[137] PNA-
based mimetic system of transmembrane proteins towards membrane fusion,[138] and vice 
versa, the DNA-templated fragment ligation of PNAs.[102]  
Their antisense action is a further interesting feature of PNAs since they can bind to 
complementary mRNAs with high affinity and specificity resulting in inhibition of the 
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translational process. That was shown in several in vitro antisense experiments.[128] 
Unfortunately, the in vivo application of PNA antisense agents was hampered for quite long 
time as the cellular uptake of PNAs was impended by inefficient membrane penetration. The 
effective knock-out of a growth factor-regulating enzyme in living cells resulting in the total 
inhibition of cell growth was reported by Anubrata et al. They used a PNA-cell-penetrating 
peptide conjugate to deliver the antibacterially acting PNAs through the outer bacterial 
membrane.[139] 
In the presented work, PNA sequences are outlined in small lettered initial of the nucleobases 
to distinguish them from DNA and amino acid sequences depicted in capitals. Left-hand side 
of the sequence corresponds to the N-terminus and right-hand side to the C-terminus of PNA 
oligomers. 
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2 Outline and Scope of Projects 
2.1 Protease Inhibitor with Triazolyl Backbone Mimic 
A vast number of natural enzyme inhibitors are derived from small proteins or peptides as 
BPP5a (chapter 1.2.2) or SFTI (chapter 1.5.2) discussed above. These competitive inhibitors 
possess high affinity to the active site of the enzymes, which is typical for high-affine 
substrates. Thus, a question arises - why do these peptidic molecules act as inhibitors? Like 
other enzymatic processes, the catalytic proteolysis mediated by serine proteases resides at 
equilibrium between substrate hydrolysis and condensation. More particularly, the protease-
catalyzed substrate conversion can be sketched in three equilibrium reactions: 
association/dissociation of substrate to enzyme, hydrolysis of substrate/re-condensation of 
products, and dissociation/re-association of products (Scheme 13A). Since a fast association 
is a prerequisite for both, the difference between a substrate and a peptidic inhibitor is 
stipulated by the position of the equilibrium in the subsequent reaction steps. In general, if the 
reaction rate of product dissociation is higher than the reaction rate of catalytic re-
condensation, the equilibrium is on the side of hydrolysis, and thus the compound is a 
substrate. On the other hand, if the reaction rate of product dissociation is low, the compound 
remains in the active site and becomes an inhibitor (Scheme 13B).  
 
Scheme 13. A: Sketch of the reaction cascade upon proteolytic cleavage of peptidic substrates/inhibitors depicted 
as a series of equilibrium reactions. Peptide chain shown as green balls. B: Simplified chemical equation of 
an enzyme-mediated substrate conversion and competitive inhibition as equilibrium reaction. E = enzyme, 
S = substrate, I = inhibitor, P = product. 
An important aspect in this simplified model is that the enzyme-bound inhibitor is 
permanently in an equilibrium of hydrolysis and condensation, whereby a non-negligible 
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probability of dissociation and release of the active site remains. As this model shows, the 
overall inhibition potency of a competitive inhibitor is not only affected by the association 
rate, but also strongly dependent on the direction of the catalytic equilibrium reaction, thus 
the susceptibility of the scissile bond against proteolytic cleavage became also an essential 
issue in the design of peptide-based inhibitors. 
The inhibitory action of SFTI-1 against trypsin is given by its rigid, constrained framework 
hold together by intramolecular hydrogen bonds and the bicyclic architecture disabling the 
drifting apart of the split ex-peptide bond moieties and finally leading to an enhanced re-
condensation rate. Nonetheless, Marx et al. reported 2003 that even the scissile bond in P1-
P1’ position of monocyclic SFTI-1 goes with a certain share through a proteolytic cleavage by 
trypsin, hence there is still scope for enhancement of inhibitory activity.[140]  
In a previous publication, we have successfully demonstrated the introduction of 1,4- and 1,5-
disubstituted 1,2,3-triazoles into the backbone of a modified open-chain permutant of SFTI-
1.[14a] The triazolyl groups were found viable amide bond surrogates with locked cis or trans 
conformations, respectively, while only slightly affecting the bioactivity (2-10 times less active 
compared to parental inhibitors). In particular, the inhibitory potency of the 1,4-disubstituted 
triazolyl moiety mimicking an Ala residue with trans conformation at P4’ position (Figure 11) 
was non-inferior to the parental [Ala9]SFTI-1[1,14]. This fact demonstrated the usefulness of 
1,4-disubstituted 1,2,3-triazole as an isosteric surrogate of trans amide bonds as Sharpless and 
Kolb have already predicted 2003.[30, 141] Its resistance to proteolytic cleavage made triazolyl 
backbone surrogates highly attractive for the design of proteolysis-stable inhibitors in current 
work.  
 
Figure 11. Structural comparison of the inhibitor loops of SFTI-1 (depicted as yellow, half-transparent sticks) and 
triazole-bearing peptidomimetic inhibitor Ψ8,9 1,4-[1,2,3]triazolyl-SFTI-1[1,14] (depicted as sticks with 
grey: carbon, blue: nitrogen, red: oxygen, green: sulfur) in complex with bovine pancreas trypsin. 3D 
computational structures modeled from corresponding X-ray crystal structures (PDB: 1SFI, 4ABI) by 
energy minimization and aligned at Lys5 of inhibitors.  
Furthermore, Fittler and Empting reported in two consecutive publications the rational design 
of a potent peptidic inhibitor against matriptase, a therapeutically relevant protease, using 
 
DOCTORAL THESIS DAICHI NASU OUTLINE AND SCOPES 
 35 
SFTI-1 as a starting point for molecular design.[142] Matriptase is a trypsin-like serine protease 
with same cleavage selectivity as trypsin (cleavage after basic amino acids at the P1 
positions). Since it is overexpressed in certain type of cancer cells, a selective labeling by the 
peptidic inhibitor was of high therapeutic interest. 
Unfortunately, the option to use matriptase or other trypsin-like serine proteases as target 
enzyme in the presented work was abandoned by the inconvenience in the synthetic strategy. 
The triazole group formed by CuAAC requires a Weinreb amide corresponding to the amino 
acid of the P1 position. As the synthesis of Weinreb amides of basic amino acids needs a 
complicated protection strategy and, furthermore, the successive reactions for generation of 
the alkyne moiety were also not compatible (see chapter 3.1.1), we decided to design the 
peptidomimetic inhibitor towards targeting a serine protease with a scissile bond selectivity 
after hydrophobic amino acids at P1 position. Two appropriate enzymes which came into 
question were chymotrypsin (selective cleavage after large, aromatic residues) and human 
neutrophil elastase (HNE, selective cleavage after small hydrophobic residues). As shown in 
Figure 5 in chapter 1.5.1 both enzymes share remarkable structural and mechanistical 
similarities with trypsin despite its selectivity given by the size, shape, and associated residues 
of the S1 pocket (Figure 12). 
 
Figure 12. Structural comparison of the active sites of A: trypsin, B: chymotrypsin, and C: HNE. 3D computational 
models derived from the crystal structures of corresponding enzymes (PDB: 1SFI, 1T7C, 2Y7F). Shape of 
S1 pockets outlined with red lines. Molecular surfaces of the residues forming the catalytic triad are 
shown in yellow. Molecular surfaces of the residue inside of the S1 pocket contributing to selective 
substrate binding (A: Asp189, B: Val188, C: Val160) are shown in blue. Size and depth of the S1 pockets 
determined from the mean distances between corresponding atoms forming the S1 pocket. 
An alignment of the X-ray crystal structure of bovine trypsin (PDB: 1SFT) and bovine 
chymotrypsin (PDB: 1T7C) resulted in a Root Mean Square Deviation (RMSD) value of 0.871 
Å and a sequence identity of 48.7 %. Same in silico analysis for HNE resulted in a similarly 
good RMSD value of 0.997 Å and 33.7 % sequence identity emphasizing the good structural 
compliance of the two alternatively chosen proteases with trypsin. Furthermore, both enzymes 
are commercially available and (especially HNE) gathered attention as potential therapeutic 
target as it is involved in inflammatory response of immunological diseases and allergic 
symptoms as hyperresponsiveness of the airways.[143] The inhibition of catalytic activity of 
these enzymes by Bowman-Birk type inhibitors is already proven in several reports,[144] thus 
chymotrypsin and HNE are suitable model enzymes for the examination of the desired design 
of proteolysis-resistant BBI derivatives. 
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2.1.1 Aims 
The ultimate goal of this subproject was the design and synthesis of a proteolytically resistant 
peptidomimetic inhibitor of a therapeutically relevant serine protease HNE based on the 
scaffold of BBIs. Bioactivity of the novel inhibitor must be evaluated using enzymatic assays. 
Peptidic and peptidomimetic inhibitors 1-4 depicted in Figure 13 should be chemically 
synthesized using monocyclic SFTI-1 as a lead structure. Design of the compounds 1-4 will be 
discussed in chapter 3.1, and their synthesis and bioactivity – in chapters 3.1.1., 3.1.2, 
respectively. 
 
Figure 13. Chemical structures of synthesized SFTI derivatives/BBI analogs. 
 
 
2.2 PHIP-Active Functional Peptides 
This subproject was conducted in cooperation with the working 
group of Prof. Buntkowsky at the TU-Darmstadt. As described in 
chapter 1.3.3, the development of a viable PHIP label providing 
the signal enhancement upon NMR investigations of bioactive 
peptides and proteins was highly desired. To this end, 
propargylglycine (Pra, Figure 14) bearing a PHIP-active multiple 
bond was found an appropriate residue that can be installed at 
the arbitrary positions of a peptide chain on solid support. In our 
preliminary experiments, the N-terminally Fmoc-protected Pra 
exhibited strong signal amplification with an enhancement factor of more than 200.  
In a previous publication,[145] we have reported a systematic study on PHIP NMR experiments 
using a series of tripeptides comprising an Xaa-Pra-Xaa motif (Xaa = canonical amino acid) 
and two cyclic decapeptides bearing four Pra residues each (chapter 1.4.2).[146] As seen from 
Table 4, the intensity of the amplified signals was influenced by the nature of the adjacent 
amino acids: Indeed, signal amplification varied from an SE of 26 observed for the tripeptide 
Tyr-Pra-Tyr to complete lack of PHIP signals for the sulfur-containing tripeptides H-Cys-Pra-
H
N
O
Pra
Figure 14. L-Propargylglycyl 
building block installed 
in a peptide chain. 
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Cys-OH and H-Cys(Me)-Pra-Cys(Me)-OH. Interestingly, H-Met-Pra-Met-OH and the tetra-Pra 
cysteinyl decapeptide exhibited an adequate enhancement factor of 14 and 5, respectively. 
Table 4. Sequences and simplified structures of the investigated PHIP-labeled peptides and their observed signal 
enhancement factors. Table reprinted from own publication. [145] 
Sequence/Structurea Signal Enhancement 
Fmoc-Pra-OH 206 
Fmoc-AllylGly-OH n.h. 
H-Gly-Pra-Gly-NH2 8 
H-Ala-Pra-Ala-NH2 15 
H-Phe-Pra-Phe-NH2 2 
H-Tyr-Pra-Tyr-NH2 26 
H-Lys-Pra-Lys-NH2 12 
H-Asp-Pra-Asp-NH2 2 
H-Ser-Pra-Ser-NH2 10 
H-Cys-Pra-Cys-NH2 n.h. 
H-Cys(Me)-Pra-Cys(Me)-NH2 n.h. 
H-Met-Pra-Met-NH2 14 
 
5 
 
38 
n.h.: No hydrogenation observed. 
Since the PHIP procedure is based on the polarization transfer during catalytic hydrogenation, 
the resulting signal amplification is supposed to be mainly dependent on the efficacy of 
respective chemical reaction. Indeed, no signal amplification was observed for Cys- and 
(Me)Cys-bearing tripeptides as, according to the lack of expected chemical shifts 
corresponding to the desired product in the 1H-NMR spectra, no catalytic hydrogenation took 
place.  
Furthermore, Trantzschel et al reported that the PHIP-mediated signal enhancement of non-
protected Pra was recorded only at pH ≈ 2.7.[147] Considering that Pra takes a zwitterionic 
form at neutral pH, this result might be explained by the strong donor character of the 
functional groups, especially of the free amines that compete for the coordination site of the 
transition metal catalyst, conclusively leading to its poisoning and inhibition of the 
hydrogenation. This suggests that the effective labeling of peptides and proteins is only 
feasible in absence of strong electron-donors (sulfhydryls or amines) in spatial proximity to 
the multiple bond, thus narrowing the scope of labeling targets. 
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2.2.1 Aims 
The aim of this part is the introduction of PHIP-active moieties in a functional peptide while 
preserving the PHIP-mediated signal amplification of the label, on one hand, and bioactivity 
of the parental peptide, on the other hand. As the 
application of Pra as a PHIP label for functional 
peptides was strongly impeded as outlined above, we 
addresses this issue applying two complementary 
strategies. First, the strong electron-donor groups, 
supposed to mediate poisoning, should be substituted 
by suitable surrogates or disposed. Second, alternative 
SPPS-compatible PHIP building blocks with distinct 
structural and functional features (Figure 15) should 
be considered.  
As a model bioactive peptide, the monocyclic variant of 
sunflower trypsin inhibitor SFTI-1 was chosen (chapter 
1.5.2 and 2.1). Thus, this subproject was divided into 
two parts: design and synthesis of SFTI-derived 
peptides and peptidomimetics bearing PHIP-active 
elements and the evaluation of their bioactivity and 
parahydrogen-mediated NMR signal enhancement. 
 
 
2.3 Affinity-Guided Chemical Ligation towards Multifunctionalization of 
Biomolecular Scaffolds 
This subproject was conducted in cooperation with the working group of Prof. Diederichsen at 
the University of Göttingen.  
Despite the promising bioactivity, a vast number of potent therapeutics remained petty and 
failed to reach preclinical studies due to the lack of drug-like properties (chapter 1.4.2). 
However, the pharmacokinetic properties of small molecules can be easily improved upon 
their conjugation with certain macromolecules. To this end, development of antibody-drug 
conjugates (ADCs) is of particular interest as the in vivo half-life of small-molecular 
counterparts can be extended from few minutes to several days or even weeks upon covalent 
anchoring with IgG-based scaffolds.[92] In conventional ADCs, the target-specific binding is 
provided by the inherent paratope of the parental mAb located at the antigen-binding 
fragment (Fab). Upon engineering of an ADC aimed on delivery of a drug payload to an 
alternative target, an elaborated screening is inevitable. To avoid this procedure, we 
suggested to replace the complete Fab of the parental mAb by a small-molecular binding motif 
that, being used solitarily, possesses restricted drug-like properties. That means, only the Fc 
part of the mAb should be used as multifunctionalization and drug-delivery scaffold.  
This approach allows to develop ADCs comprising synthetic small-molecule ligands, 
oligopeptides (especially those which are hardly recombinantly expressible), and non-peptidic 
biomolecules (i.a. DNA aptamers or oligosaccharides). 
Figure 15. Chemical structures of 
alternative PHIP labels, L-O-
propargyl-tyrosine and Pentynoic 
acid as building blocks installed 
in a peptidic chain. 
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Considering the assembly of a 
multifunctionalized and multivalent drug-
delivery system, a set of orthogonal ligations, 
enabling the selective attachment of various 
ligands, is a prerequisite. For instance, 
synthesis of a tetrafunctionalized, 
heterodimeric Fc conjugate (Figure 16) 
requires four orthogonal biocompatible 
chemical transformations, which is rather 
sophisticated, especially from the view of the 
molecular complexity of the reaction partners. 
Thus, an alternative strategy is required 
where site-selectivity is not compromised by 
the reliability of sequential couplings. In brevi, 
it is desirable to ensure orthogonality and 
efficacy upon simultaneous conjugation of 
different ligands on the desired 
macromolecular scaffold within a single 
reaction step.  
On this account, we decided to apply 
templated bioorthogonal chemistry where the 
selectivity control is determined by the pre-
orientation of the reactive functionalities 
provided upon association of biomolecular 
subunits.  
In this approach referred to as affinity-guided 
ligation (Scheme 14), the reactive moieties for a chemoselective coupling are brought in 
spatial proximity via non-covalently interacting complementary guiding unit pairs. Only upon 
pre-orientation, the triggered bioorthogonal ligation is manually started by exposure to e.g. 
further reactants, catalysts, electromagnetic irradiation, by varying pH, or by applying other 
factors. Consequently, the reaction is controlled by regioselectivity rather than 
chemoselectivity, and the application of orthogonal guiding unit pairs would enable a one-pot 
ligation of multiple ligands and payloads. The installation of a selective cleavage site between 
guiding unit pairs and the respective ligand or scaffold would enable the separation of 
counterparts as soon as the covalent linkage has been formed. 
 
Figure 16. Schematic depiction of a contrived drug-
delivery system based on a heterodimeric Fc 
scaffold with four diverse ligands (or 
payloads). 3D computational model of Fc 
derived from X-ray crystallographic structure 
(PDB: 3AVE). Ligands were exemplary 
chosen without special meaning: ligand 1 
(purple): knottin MCoTI-II (PDB: 4GUX), 
ligand 2 (cyan): Ψ8,9 1,4-[1,2,3]triazolyl-
SFTI-1[1,14] (PDB: 4ABI), ligand 3 (yellow): 
DNA aptamer (PDB: 4DII), ligand 4 
(orange): cytotoxin ispinesib (PDB: 4A5Y). 
Linker unit depicted as grey tubes. 
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Scheme 14. The concept of the affinity-guided ligation with two complementary guiding unit pairs. The SPANC-
reactive moieties are exemplarily depicted. Different colors illustrate diversity of the ligands and the 
guiding units. GU: guiding unit. Lig: functional ligand; white ellipsis: selective cleavage site; black balls: 
linker units. 
 
 
2.3.1 Aims 
The ultimate goal of this part is the development of a multifunctionalized drug-delivery 
system using an antibody Fc scaffold as a platform for modular construction of custom-made 
drug-ligand conjugates via affinity-guided ligation (Scheme 15).  
 
Scheme 15. Attachment of four different ligands to a heterodimeric Fc scaffold via affinity-guided ligation. The 
SPANC-reactive moieties are exemplarily depicted. Different colors illustrate diversity of the ligands and 
the guiding units. GU: guiding unit. Lig: functional ligand; white ellipsis: selective cleavage site; black 
balls: linker units. 
Since this goal requires thorough interdisciplinary investigations, the experiments were 
mainly focused on two sub-projects, the establishment of the affinity-guided ligation 
technique and the attachment of a biomolecular guiding unit to a biocompatible scaffold. 
Affinity-guided ligation was studied using a model system which comprised a complementary 
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guiding unit pair equipped with the reactive moieties for a switchable, bioorthogonal ligation. 
We reduced the complexity of the model system to select an appropriate guiding unit pair and 
the suitable ligation technique in view of synthetic efficiency and feasibility. Considering the 
ultimate goal of the project, the prerequisites for the guiding units comprised: high site- or 
sequence-selectivity, good affinity, combinatorial diversity, and smart installation into the 
scaffold. Moreover, the guiding unit must possess a peptidic or peptide-like structure to keep 
the molecular properties and synthetic setup uniform.  
Two candidate systems sharing the mentioned features were examined: heterodimeric coiled 
coils and complementary PNAs. Both non-covalently interacting architectures have intrinsic 
advantages and disadvantages (Table 5). Thus, PNAs provide combinatorial diversity 
originating from the high sequence-selectivity, and can be preferred for the simultaneous 
multiple ligations, whereas the coiled-coil system is cost-efficient and can be recombinantly 
expressed as fusion protein with the Fc scaffold.  
Table 5. Selected characteristics of non-covalently interacting coiled-coil heteromers and complementary PNAs.  
a: Value determined for three-heptad E/K coil system with sequence XISALXY at pH 7.[122] 
b: Value determined for a fully-complementary PNA-PNA hybrid (12 residues) at pH 7.[135] 
To be suitable for the present study, the chosen ligations require bioorthogonality, switchable 
reactivity, and high efficacy. The application of metal catalysts which can interfere with 
involved biomacromolecules or impede the purification of the resulted conjugate, must be 
avoided. Therefore, metal-catalyzed “click” reactions were excluded from the outset. 
Preliminary experiments with Rh2-metallopeptide-catalyzed Trp modification of a coiled 
coil[127] and site-selective conjugation of polymeric diazonium salts to Tyr residue[148] (data 
not shown) demonstrated the limited operability in our model systems. 
Features Coiled-coil heteromers Complementary PNAs 
Dissociation equilibrium 
constant KD 
9 × 10-6 Ma 4.4 × 10-9 Mb 
Sequence-specificity 
low: pinpoint derivatization 
allowed 
high: recognition of single-
base mismatches 
Oligomerization pattern 
Homo/heterodimers or higher 
oligomers 
Heterodimers only 
Required size of 
monomers 
3-5 repetitive heptads  
= 21-35 residues  
≙ ~ 2000 – 5000 Da 
5-10 residues  
≙ ~ 1500 – 3000 Da 
Synthesis SPPS or recombinant expression SPPS 
Costs for SPPS low high 
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Therefore, we decide to use the 
strain-promoted alkyne-nitrone 
cycloaddition (SPANC). SPANC is a 
[2+3] 1,3-dipolar cycloaddition 
where one of the reagents, the 
nitrone moiety, is in situ generated 
from an aldehyde. Thus, the reaction 
is triggered by addition of an N-
substituted hydroxylamine (Scheme 
16A). As an alternative conjugation 
method for PNA-mediated ligations, 
nucleobase cross-conjugation using a 
psoralen derivative (Scheme 16B) 
should be examined as well.  
The multifunctionalization of an Fc 
scaffold is the second part of the 
project. To this end, the conjugation 
of a guiding unit should be examined 
in an enzyme-catalyzed ligation, 
and the applicability of the resulting 
conjugate as a biocompatible 
delivery module will be evaluated 
by the loading of functional ligands with subsequent bioassays. The concept of this study, 
utilizing a PNA-guided self-assembly with a therapeutically relevant DNA aptamer, is depicted 
in Scheme 17A.  
Ideally, a cytotoxic payload should be attached to the construct via a cleavable linker allowing 
the release of the agent after internalization of the conjugate (Scheme 17B). The main tasks 
in the presented work were the design and synthesis of the PNA guiding units and their 
conjugation to the Fc scaffold. Further modification of the scaffold and the evaluation of the 
bioactivity of the system was the subject of the research of a cooperator and won’t be 
discussed in detail.  
 
Scheme 16. A: SPANC mediated by the in situ generated 
nitrone. B: UVA-mediated addition of psoralen to two 
thymine bases. 
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Scheme 17. A: Synthesis of the aptamer-Fc-payload conjugate equipped with further cargos via PNA-mediated 
self-assembly. B: Mechanism of action of the targeted aptamer-Fc-payload conjugate (structure simplified) 
in living cells: I.) Selective binding to target receptor; II.) Cell internalization by endocytosis; III.) 
Cleavage of the linker unit between toxic payload and scaffold; IV) Release of toxin in lysosome and 
consequential death of target cells. 
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3 Results and Discussion 
3.1 Protease Inhibitor with Triazolyl Backbone Mimic 
3.1.1 Design and Synthesis 
To generate a proteolysis-resistant, peptidomimetic HNE inhibitor comprising a triazolyl 
backbone mimic and based on the scaffold of BBIs, the sequence and structure of the parental 
peptidic inhibitor had to be chosen. Therefore, a structural comparison of the electrostatic 
potentials of the substrate-binding sites of trypsin, chymotrypsin and HNE was performed in 
presence of SFTI using 3D computational modeling and simulation by YASARA software. The 
intention of this in silico study was to evaluate if the rigid scaffold of SFTI could be applied to 
the proteases of interest in view of electrostatic interactions impending the formation of a 
stable inhibitor-protease complex. First, the structures of chymotrypsin and HNE were aligned 
to the co-complex structure of trypsin with SFTI-1 using AMBER 03 force field. After swapping 
the residue within the inhibitor determining the selectivity of proteolysis (Lys5Phe for 
chymotrypsin and Lys5Leu for HNE, respectively), suspension of the backbone cyclization, 
and energy minimization of the associated inhibitor-protein complexes at pH 7.4, the 
electrostatic potentials of the active site surfaces were displayed. A comparison of the surface 
potentials of each protease in attendance of corresponding modeled inhibitors 
[Phe5]SFTI[1,14] 1, [Leu5]SFTI[1,14] 2 and the parental monocyclic SFTI[1,14] (Figure 
17A) resulted in nearly total compliance of the surface patterns of the associated active sites. 
As deriving of 1 and 2 from the parental peptide SFTI[1,14] was limited to the residue at the 
P1 position, the charge patterns of all the other residues were retained, thus highly preserved 
bioactivity towards inhibition of corresponding proteases could be expected. Furthermore, this 
hypothesis was supported by the display of the hydrogen bonds between proteases and 
corresponding inhibitors. As it is apparent from Figure 17B, the numbers of hydrogen bonds 
between 1 and chymotrypsin, and 2 and HNE, respectively, are not different from the 
corresponding SFTI-trypsin complex. These results from in silico examinations led to the 
decision for actual synthesis and investigation of inhibitors 1 and 2.  
Considering the expected selectivity of the synthetic inhibitors 1 and 2 towards binding to the 
corresponding enzymes which can be strongly restricted by significant homology with their 
parental peptide, an alternative BBI-derived scaffold des-Gly1,-Pro13,-
Asp14[Nle2,Leu5,Gln10,Tyr12]SFTI-1[1,14] (3) was designed as an elastase inhibitor. The 
sequence of 3 is based on a BBI found via screening of a library of chemically synthesized and 
randomized peptides by McBride et al. in 1999.[144b] The original cyclic peptide exhibited an 
inhibition constant against HNE of 65 nM. An original Ala at the P1 was substituted by a Leu 
in 3. The 3D computational model of 3 is depicted in Figure 18 (analogously modeled and 
simulated as described for 1 and 2). 
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Figure 17. 3D computational models of SFTI-1[1,14] (left), 1 (center), and 2 (right) as co-complexes with 
corresponding proteases. Structures were produced from crystallographic data of the SFTI-1-trypsin co-
complex (PDB: 1SFI) by modeling and energy minimization at aqueous environment (pH 7.4). A: 
Molecular surfaces of proteases and atoms (styled as sticks) of respective inhibitors are colored according 
to the electrostatic potential and charges in a gradient; red: highest electron density, negatively charged; 
blue: lowest electron density, positively charged. P1 residues of respective inhibitors are marked with 
labels. B: Intermolecular interactions between inhibitors and corresponding proteases are shown. Atoms of 
inhibitor colored by element color with grey: carbon, red: oxygen, blue: nitrogen, green: sulfur; protease 
residues forming intramolecular hydrogen bonds to respective inhibitors are shown in orange, hydrogen 
bonds are depicted as yellow, dashed bonds. Hydrophobic interactions within the S1 pocket are shown as 
purple columns. Molecular surfaces of proteases are shown in semi-transparent style and are colored 
according to their electrostatic potentials. 
 
 
Figure 18. 3D computational models of 3 as a co-complex with HNE. Structures modeled analogously to 
corresponding structures in Figure 17. A: Distribution of electrostatic potentials and charges are shown. 
Same colors and depiction style was applied as described for Figure 17A. B: Intermolecular interactions 
between inhibitors and corresponding proteases are shown. Same colors and depiction style was applied 
as described for Figure 17B. 
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Based on the structure of 3, the triazole-bearing peptidomimetic 4 potentially resistant against 
proteolytic cleavage was designed and modeled analogously to the peptides 1-3. The modeled 
co-complex structure of HNE with 4 (Figure 19) exhibited similar electrostatic potential 
patterns and intramolecular interactions as shown for its parental peptide 3.  
 
Figure 19. 3D computational models of 4 as a co-complex with HNE. Structures modeled analogously to 
corresponding structures in Figure 17. A: Distribution of electrostatic potentials and charges are shown. 
Same colors and depiction style was applied as described for Figure 17A. B: Intermolecular interactions 
between inhibitors and corresponding proteases are shown. Same colors and depiction style was applied 
as described for Figure 17B. 
Moreover, a structural alignment of 4 to 3 
using AMBER 03 force field (Figure 20) 
resulted in an RMSD value of 0.7230 Å which is 
similar to the value calculated for the 
peptidomimetic Ψ8,91,4-[1,2,3]triazolyl-SFTI-
1[1,14], synthesized in previous publication, 
and its parental peptide [Ala9]SFTI-1[1,14] 
(RMSD = 0.5310).[14a] The observed inhibition 
constants Ki of the peptide/peptidomimetic pair 
from the former publication were differed by 
the factor of 2, thus a restriction of bioactivity 
in similar magnitude was expected for the 
peptide/peptidomimetic pair 3/4.  
 
 
 
3.1.1.1 Synthesis of peptides 1 – 3 
Peptidic inhibitors 1, 2, and 3 were synthesized by partially-automated SPPS using standard 
Fmoc strategy. The associated linear precursor peptides 1’, 2’, and 3’ were obtained in very 
good to excellent yield (78.5%, 86.9%, and 83.6%; considering a reaction cascade of more 
than 10 successive coupling cycles, nearly quantitative yield for each cycle). 1’ and 2’ were 
side-chain-cyclized by oxidative folding in 0.1 M (NH4)2CO3 buffer with 0.5 % DMSO while 
monitoring reaction progress by HPLC and ESI-MS, lyophilized and successively isolated by 
semi-preparative RP-HPLC. The chromatographic traces of 1’/1 and 2’/2 before and after 
folding and purification are depicted in Figure 21. Both cyclic peptides 1 and 2 were obtained 
in moderate folding and purification yields of about 35%, presumably due to the limited 
Figure 20. Overlay of computational models of 3 
(yellow, semi-transparent sticks) and 4 
(sticks in element colors with grey: carbon, 
red: oxygen, blue: nitrogen, green: sulfur) 
after energy minimization and structural 
alignment using AMBER03 force field.  
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recovery rate of the used HPLC system. However, the amount of isolated inhibitors was 
sufficient for the examination of their bioactivity and further analysis. 
 
 
Figure 21. Chromatographic profiles of protease inhibitors 1 – 3 (black) and corresponding linear precursors 
(blue). UV detection at λ = 220 nm; eluent left: 18→40.5 % acetonitrile in 0.1 % aq. TFA over 20 minutes 
at flow rate 1 ml/min, eluent center: 18→54 % acetonitrile in 0.1 % aq. TFA over 20 minutes at flow rate 
1 ml/min, eluent right: 9→90 % acetonitrile in 0.1 % aq. TFA over 20 minutes at flow rate 1 ml/min. 
 
First, the oxidative folding of linear precursor 
peptide 3’ was conducted in the same folding 
buffer as 1’ and 2’. Since after more than 10 days 
shaking no product formation was observed, 
neither in HPLC nor in ESI-MS, an alternative 
folding approach using a buffer system comprising 
DMSO/TFE in 1 M guanidium hydrochloride and 
50 mM Na2HPO4 (pH 7) was employed. Associated 
HPLC traces of the monitored folding progress are 
depicted in Figure 22. Formation of a folding 
product could already be observed after a reaction 
time of less than 1 day. After three days folding, 
cyclic peptide 3 was isolated via semi-preparative 
RP-HPLC with 8.2 % folding and purification yield. 
The poor yield is presumably caused by the harsh 
folding conditions and the limited recovery rate of 
the semi-preparative HPLC system. 
  
Figure 22. Chromatographic profiles of oxidative 
folding of 3’ to 3. Colored numbers on 
left-hand side: Reaction time of 
corresponding samples picked from rm. 
UV detection at λ = 220 nm; eluent left: 
9→90 % acetonitrile in 0.1 % aq. TFA 
over 20 minutes at flow rate 1 ml/min. 
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3.1.1.2 Synthesis of peptidomimetic 4 
Towards achieving the triazolyl backbone mimic-bearing peptidomimetic inhibitor 4, an on-
support CuAAC-comprising solid-phase synthesis strategy was applied (Scheme 18).  
 
Scheme 18. General strategy to towards pseudo-peptides with triazolyl backbone mimics via CuAAC on solid 
support. Amino acids and building blocks are depicted as balls, canonical amino acids in green, α-azido 
acid in red, α-acetylenyl amine in blue. Solid support is depicted as grey ball. 
First, an iterative chain elongation was performed by standard Fmoc-SPPS up to the position 
where the amide bond surrogate should be installed. In the present work, this corresponded 
to the scissile bond, thus chain elongation using standard coupling and deprotection 
techniques was accomplished up to Ile at P2’. Regarding the formation of a 1,4-disubstituted 
triazole isosteric to its parental peptide 3 via copper “click” reaction, two precursor building 
blocks were required: an α-azido acid on the P1’ position and an α-acetylenyl amine 
component at the P1 position. Thus, (2S)-2-azido-3-O-tert-butyl-propanoic acid (4a) was 
synthesized according to a published protocol[149] from H-L-Ser(tBu)-OH by Cu(II)-catalyzed 
diazo transfer using triflyl azide prepared from the corresponding anhydride (Scheme 19A). 
4a was obtained in good yield (75 %) and analyzed by 1H and 13C NMR (shown in Scheme 
19B and appendix, respectively). No distinct peaks of contaminations or reactants could be 
observed except small traces of residual solvents and water. 
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Scheme 19. A: Two-step synthesis of 4a. B: 1H NMR spectrum and chemical structure of 4a. Peak integrals are 
shown as blue numbers below the spectrum. As reference for peak integrations duplet signal at 3.90-389 
ppm was chosen. Colored numbers besides structures are predicted chemical shift values in ppm whereby 
estimation quality is indicated with blue: good; pink: medium; red: rough (estimation performed using 
NMR prediction tool of ChemBioDraw®). 
The preparation of its counterpart building block (2S,3S)-N-Boc-1-ethynyl-3-methyl-
butylamine (4b) was performed from Boc-protected Weinreb amide of leucine Boc-L-Leu-
N(OMe)Me by a two-step reaction comprising the reduction of the Weinreb amide to an 
aldehyde and the successive Bestmann modification with the dimethyl-1-diazo-2-oxopropyl 
phosphonate (Ohira-Bestmann reagent).[150] Furthermore, to make alkyne-bearing building 
block compatible with the Fmoc-SPPS strategy, an exchange of the amino protecting group 
from Boc to Fmoc was accomplished yielding sufficient amount of (2S,3S)-N-Fmoc-1-ethynyl-
3-methyl-butylamine (4c) for its application in on-support CuAAC (Scheme 20). The 
corresponding 1H NMR spectra of 4b and 4c (Figure 23) confirmed the high purity of 
synthesized compounds with no contaminations except small traces of residual solvents. 
 
Scheme 20. Three-step synthesis of 4c from the corresponding Weinreb amide.  
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Figure 23. 1H NMR spectra and chemical structure of 4b (A) and 4c (B). Peak integrals are shown as blue 
numbers below the spectrum. As reference for peak integrations multiplet signals at 1.83-1.72 ppm (A) 
and 0.97-0.95 ppm (B) were chosen. Colored numbers besides structures are predicted chemical shift 
values in ppm whereby estimation quality is indicated with blue: good; pink: medium; red: rough 
(estimation performed using NMR prediction tool of ChemBioDraw®). 
For CuAAC on solid support, first 4a was coupled to the free N-terminus of the peptide-resin. 
Cycloaddition was performed as described in previous publication.[14a] Conversion of the azide 
component during CuAAC was verified by ESI-MS and IR spectroscopy of deprotected and 
test-cleaved intermediates. 
After manual, iterative chain elongation up to the N-terminal norleucine (Nle), cleavage from 
solid support and precipitation, the linear precursor peptidomimetic 4’ was obtained with 
nearly quantitative crude yield, whereby a presumably high amount of contamination by 
remaining Cu salts and further side products was expected. As the oxidative folding in 
ammonium acetate buffer failed, 4’ was cystine-cyclized and isolated by same procedure as 
described for 3’. Due to the non-trivial folding condition and high amount of contaminations 
in the crude product, the final purification yield was poor (5.9 %) but 4 could be obtained in 
sufficient amount and purity for further bioactivity assays and proteolysis experiments. Yields 
of synthesized chymotrypsin and elastase inhibitors are summarized in Table 6. 
Table 6. Synthesis of inhibitors 1 – 4. 
Entry Strategy MW 
Crude yield 
precursor [%] 
Folding/purifica-
tion yield [%] 
Overall yield 
[%] 
1 Automated + 85.9 39.5 33.9 
2 Automated + 78.5 34.8 27.3 
3 Automated + 83.6 8.2 6.8 
4 Automated + 97.1 5.9 5.8 
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3.1.2 Characterization and Evaluation of Activity 
3.1.2.1 Bioactivity Assays 
Prior to the examination of the synthesized inhibitors, the proteolytic activities of discussed 
proteases trypsin, chymotrypsin, and HNE were evaluated. Thus, time-dependent degradation 
of corresponding chromogenic substrates was studied at different concentrations. That was 
done to confirm activity of the proteases, establish an assay setup and determine the 
Michaelis-Menten constant KM of the discussed enzyme-substrate systems. Especially the last 
point was of particular importance, since KM was required for the calculation of Ki (chapter 
5.4.1.3). All of the tested enzymes exhibited sufficient proteolytic activity for the application 
in subsequent inhibition assays. The assay setups developed by these preliminary experiments 
are described in chapter 5.4. KM was graphically determined from the Hanes-Woolf plot 
(quotient of substrate concentration and initial reaction rate: [S]i/vi against the substrate 
concentration [S]i).[14a] The Hanes-Woolf plots of three HNE activity measurement series 
against MeO-Suc-AAPV-pNA are exemplary shown in Figure 24. Further Hanes-Woolf plots 
are shown in the appendix.  
 
 
Figure 24. Hanes-Woolf plot of three HNE activity assays against MeO-Suc-AAPV-pNA. Data points, trend lines of 
linear regressions, linear equation of trend lines, and associated regression coefficient of each 
measurement series are marked in individual colors. 
 
KM can be calculated from the slope and point of intersection with the x-axis of the linearly 
regressed trend line of the measured data points using the converted Michaelis-Menten rate 
equation: 
 
     [M]#O# = [M]#OPQR + TUOPQR     (12) 
 
The calculated KM of the discussed enzyme-substrate pairs are shown in Table 7. The 
determination of KM for chymotrypsin against Suc-AAPF-pNA failed because of inconsistent 
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measurement values presumably due to the formation of bubbles on the sample surface. Thus, 
a published value is listed for the KM of chymotrypsin and used for further calculations.[151]  
 
Table 7. Michaelis-Menten constants of discussed proteases. 
Protease Substrate 
KM 
determined [µM] 
KM 
published [µM] 
Trypsin Boc-QAR-pNA 58.9±7.3 41.7±6.2[14a] 
Chymotrypsin Suc-AAPF-pNA - 60±7[151] 
HNE MeO-Suc-AAPV-pNA 42.0±5.2 140[152] 
 
The obtained values of KM for trypsin and HNE were in typical magnitude for proteolytic 
cleavage of affine substrates. The experimentally determined KM of HNE against MeO-Suc-
AAPV-pNA was slightly better than the published one, probably due to the difference in 
experimental setups i. a. used buffer systems and enzyme/substrate concentration range. 
Based on the established setups for proteolytic activity assays, enzyme inhibition assays of the 
synthesized peptidic and peptidomimetic inhibitors 1 – 4 against corresponding serine 
proteases were performed.[14a, 73b, 153] In general, the time-dependent proteolytic degradation 
of chromogenic substrates at defined starting concentrations in presence of a concentration 
series of respective inhibitors was recorded. After preliminary tests to adjust the concentration 
range of the inhibitors, the measurements at optimized concentrations were performed in 
triplicate. Exemplary, a single measurement plot of the photometrically recorded time-
dependent substrate degradation by HNE in presence of 4 is shown in Figure 25A.  
The apparent inhibitory constants Kiapp were graphically determined from the Dixon plot 
(Figure 25B) of the measurement series (quotient of initial reaction rate of inhibited reaction 
and the reaction rate of the non-inhibited reaction = νi/ν0 against the inhibitor concentration 
= [I]i) by a global fitting of the data points to the Morrison equation (see chapter 5.4.1.4). 
Further Dixon plots of inhibition assays with global fittings are given in the appendix. The 
experimentally determined values of Kiapp and respective values for Ki of the inhibitors 1 – 4 
and the linear precursors 3’ and 4’ are listed in Table 8. 
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Figure 25. A: HNE inhibition with 4. Relative absorption at λ = 410 nm (y-axis) is plotted against the reaction 
time (x-axis). B: Dixon plot of HNE inhibition assay using 4 as inhibitor. Experiment was performed as 
triplicate. Relative reaction rate (y-axis) is plotted against the inhibitor concentration (x-axis). 
 
Table 8. Apparent inhibition constants and substrate concentration-independent inhibition constants of examined 
enzyme-inhibitor combinations. 
Inhibitor Protease Kiapp [nM] Ki [nM]a 
1 Chymotrypsin 0.37±0.03 0.07±0.01 
1 Trypsin N/A - 
2 HNE 623.91±45.00 99.98±12.50 
2 Trypsin N/A - 
3 HNE 901.71±161.96 144.48±29.62 
4 HNE 3642.45±687.97 563.63±125.37 
3' HNE 13260.62±1020.49 2124.89±271.70 
4' HNE N/A - 
a: Errors of Ki calculated by propagation of errors of Ki
app and KM (see chapter 5.4.1.5). 
N/A: No activity observed or Ki higher than 100 µM. 
The obtained Ki value for 1 against chymotrypsin was in picomolar range and even better as 
the reported Ki of SFTI-1 against trypsin. As Zablotna et al. reported an association 
equilibrium constant Ka (which reciprocal is corresponding to Ki for reversible inhibitors) of 
2×109 M-1 the obtained value in present work is in same range.[144c] However, due to the 
observation that the applied method for non-linear curve fitting reached to the limit of its 
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validity range and the difficulty to provide the corresponding Weinreb amide, the idea to 
synthesize a mimic of 1 with triazolyl surrogate at the scissile bond was finally abandoned for 
the present work. 
The inhibitory constants of elastase inhibitors 2 and 3 were in triple-digit nanomolar range. 
These results could be compared to published data of similar inhibitors as [Leu5, Trp9]SFTI-
1[1,14] is reported with a Ka of 3×107 M-1 against HNE which is comparable to the Ki of the 
related inhibitor 2, found in the present work.[144c] McBride et al. reported a Ki of 130 nM for 
the inhibitor des-Gly1,-Pro13,-Asp14[Nle2,Val5,Gln10,Tyr12]SFTI-1[1,14].[144b] This value is 
matching to the determined Ki =144 nM of its P1-mutant 3 with a Leu at the scissile bond. 
Peptidomimetic inhibitor 4 exhibited a Kiapp in single-digit micromolar range and a Ki in triple-
digit nanomolar range. The determined inhibitory constant was higher than its parental 
inhibitor 3 by the factor of 3–4 which is in similar range as for previously reported triazolyl 
amide bond surrogates.[14a] The influence of the exchange on the inhibitory potency was 
smaller as in the case of the cis amide surrogate at the P3’ position (decrease by factor 10) but 
greater as for the trans amide mimic at the P4’ position (decrease by factor 2), which 
emphasizes the importance of scissile bond conformation for the inhibitory effect. However, 
from the view of activity preservation, the replacement of the scissile bond by a triazole can 
be considered as successfully realized, since Legowska et al. reported 2011 for SFTI-derived 
trypsin and chymotrypsin inhibitors with scissile bond replacements by Pro or its derivatives a 
decrease in inhibitory activity by 2 – 4 orders of magnitude compared to their parental 
inhibitors.[154]  
An important observation was made during the inhibition assays of the reduced variants of 
HNE inhibitors 3 and 4 (3’ and 4’). Both inhibitors underwent a drastic loss in inhibitory 
potency upon opening the disulfide macrocycle. This outcome can be explained by two 
reasons, the loss in affinity to the active site of the protease by deletion of the rigid framework 
and the lower probability of recondensation after cleavage of the scissile bond. Since the 
decrease in inhibitory activity is also significant for 4’ with a hydrolytically stable surrogate at 
the corresponding position, the loss in affinity is supposed playing a more important role in 
this case. 
Furthermore, the inhibitory activity of 1 and 2 against trypsin was tested to evaluate 
selectivity of synthesized inhibitors. In both cases, no distinct inhibitory effect could be 
observed in the corresponding assays. The inhibitory activity of 3 and 4 against chymotrypsin 
was evaluated only qualitatively in a preliminary experiment without a photometrical assay. 
Comparing the degradation of a chromogenic substrate in presence and absence of an 
inhibitor, no significant difference was observed. Since the target selectivity of synthesized 
inhibitors was not the main issue in present work, no further investigations were done. 
 
 
3.1.2.2 Evaluation of Proteolytic Stability 
Susceptibility of synthesized inhibitors to proteolytic cleavage was examined by incubation of 
the linear precursors 1’ – 4’ (for minimization of the influence of recondensation) in the 
presence of corresponding proteases under reducing conditions. The reaction progress was 
monitored by HPLC and ESI-MS; samples were prepared by precipitation of the proteases 
from the reaction mixture in acidic milieu. Additionally, DTT was added to avoid formation of 
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disulfide bonds and make the characterization by respective analytic methods possible. In 
Table 9, the experimental data for the inhibitor precursors 1’ – 4’ and the cyclic HNE 
inhibitors 3 and 4 are listed. Detailed information on experimental setup is given in chapter 
5.3.1. 
Table 9. Proteolysis of the linear precursors 1’ – 4’ and the cyclic inhibitors 3 and 4. 
Entry Enzyme Setup 
Hydrolyzed 
amount/houra 
Finally 
Hydrolyzed amount (h)b 
1' HNE 1 3.42 % 3.42 % (1 h) 
1' Chymotrypsin 2 27.90 % 69.8 % (2.5 h) 
2' HNE 1 22.68 % 56.7 % (18 h) 
2' Chymotrypsin 2 2.29 % 5.75 % (2.5 h) 
3' HNE 1 52.55 % 93.02 % (24 h) 
3 HNE 3 3.35 % 16.91 % (16 h) 
4' HNE 1 5.23 % 56.24 % (24 h) 
4 HNE 3 0.26 % 4.96 % (24 h) 
a: Mean value of hydrolysis per hour of first 2 - 3 measurements. 
b: Final conversion determined from the last measurements of corresponding reaction mixtures. Numbers in 
brackets are the time after reaction start when the last sample was prepared and measured. 
The progress of proteolytic degradation was assessed upon integration of the HPLC traces for 
the hydrolysis of compounds 1’ – 4’. Due to the low concentration of samples (near to the 
error limit of the applied HPLC system), the obtained conversion should only be considered as 
approximate values and do not possess quantitative accuracy. Nevertheless, a general 
tendency was the enhanced hydrolysis of compounds possessing at the P1 position a residue 
which complied with the substrate selectivity of the enzyme. Thus, linear precursor 1’ 
comprising the P1 Phe underwent chymotrypsin-
mediated degradation but showed certain 
resistance against HNE-promoted hydrolysis. A 
similar effect was observed for 2’.  
In Figure 26 the HPLC monitoring of the 
proteolytic degradation of 3’ by HNE is 
exemplary shown. According to the observed 
tendency, nearly total degradation of the linear 
precursor could be observed after an incubation 
time of 1 d. The cleavage at the scissile bond 
could be confirmed by ESI-MS of the collected 
fraction at Rt = 12.8 min after separation of the 
sample mixture via HPLC. The corresponding 
Figure 26. Chromatographic traces of HPLC-
monitored proteolysis of 3’ by HNE. UV 
detection at λ = 220 nm; eluent: 9→54 % 
acetonitrile in 0.1 % aq. TFA over 20 
minutes at flow rate 1 ml/min. 
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m/z signals of both of the cleaved fragments, H-Nle-CTL-OH and H-SIPPQCY-OH, were found 
either as positively ([M+H]+ and [M+2H]2+) or negatively charged species ([M-H]-). 
Respective MS spectra for 3’ are shown in Figure 27. 
 
Figure 27. ESI mass spectra of prepared reaction mixture after proteolytic cleavage experiment of 3’ after 
chromatographic isolation of fraction at Rt = 12.8 min. A: Spectrum in positive mode. B: Spectrum in 
negative mode. Corresponding m/z signals of calculated and found fragments are listed in the table 
below.  
 
In contrast to 3’, compound 4’ exhibited only slow 
degradation under the same reaction conditions. 
The chromatographic traces of proteolytic 
degradation of peptidomimetic 4’ are depicted in 
Figure 28. 
After incubation over 1 d, about 43% of 
peptidomimetic 4’ still remained in the reaction 
mixture, whereby the MS signals found in the 
fraction at Rt = 13.2 min corresponded to the P2-
P3 cleaved fragment H-T[LtS]IPPQCY-OH and P1-
P2 cleaved fragment H-[LtS]IPPQCY-OH of 4’ 
(Figure 29). This result is in accordance with the 
reported data by McBride et al. concerning the 
affinity of a BBI-based inhibitor comprising a Thr 
at the P1 position with preserved affinity to HNE.[144b] The scissile bond selectivity of HNE 
towards cleavage after Thr is also reported by Dall’Acqua et al.[155] As no corresponding 
signals to the discussed cleavage pattern could be found in case of 3’, the observed proteolysis 
at these positions is assumed to be done alternatively to the more affine Leu, mimicked by a 
hydrolysis-stable surrogate in 4’. Nonetheless, peptidomimetic 4’ seemed to possess also 
higher overall stability against proteolytic degradation than its parental peptide 3’.  
 
Figure 28. Chromatographic traces of HPLC-
monitored proteolysis of 4’ by HNE. UV 
detection at λ = 220 nm; eluent: 
9→54 % acetonitrile in 0.1 % aq. TFA 
over 20 minutes at flow rate 1 ml/min. 
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Figure 29. ESI mass spectra of prepared reaction mixture after proteolytic cleavage experiment of 4’ after 
chromatographic isolation of fraction at Rt = 13.2 min. A: Spectrum in positive mode. B: Spectrum in 
negative mode. Corresponding m/z signals of calculated and found fragments are listed in the table 
below.  
The same tendency was observed for the cystine-bearing inhibitors 3 and 4, whereby the 
overall conversion and reaction rate were significantly suppressed by enhanced re-
condensation of hydrolyzed species. This effect gives to the peptides and peptidomimetics 
their actual activity as protease inhibitors. Especially in case of 4, where the final conversion 
is kept in range of measurements uncertainty of the HPLC system, presented excellent stability 
against proteolytic cleavage (Figure 30). Even by direct injection of the sample after a 
reaction time of 24 h, only m/z signals of the non-cleaved inhibitor could be found. On the 
other hand, a direct MS analysis of the sample mixture of 3 with analogous reaction setup, 
resulted in the detection of same signals observed for 3’, thus the hydrolysis of the scissile 
bond is not completely suppressed.  
 
Figure 30. A: Chromatographic traces of HPLC-monitored proteolysis of 3 by HNE. UV detection at λ = 220 nm; 
eluent: 9→54 % acetonitrile in 0.1 % aq. TFA over 20 minutes at flow rate 1 ml/min. B: Chromatographic 
traces of HPLC-monitored proteolysis of 4 by HNE. UV detection at λ = 220 nm; eluent: 18→40.5 % 
acetonitrile in 0.1 % aq. TFA over 20 minutes at flow rate 1 ml/min. 
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The hydrolytic stability of 4 is higher by a factor of 15 (determined from the hydrolysis of 3 
and 4 per hour), compared to 3. This showed that the approach to improve proteolytic 
stability by replacement of the scissile bond by a triazolyl group was successfully 
accomplished. 
 
 
3.1.3 Digest of Chapter 3.1 
An HNE inhibitor with a triazolyl group as scissile bond mimic was computationally and 
knowledge-based designed from a BBI and successfully synthesized. Its inhibitory activity and 
susceptibility against proteolytic cleavage was examined and compared with the parental 
peptide and further BBI-derived HNE and chymotrypsin inhibitors. All synthesized peptides 
exhibited strong inhibitory potency and selectivity towards their target proteases (pico- to 
nanomolar range). The determined Ki values were all in the range of either published data of 
same/similar compounds, or matching to assumed values derived from in silico modeling. 
Thus, the RMSD of 4 to 3 was 0.723 Å and the loss in activity by the amide bond surrogate is 
marked by the factor 3.9, whereas the SFTI-derived trypsin inhibitor with a triazolyl trans 
amide mimic from previous publication was marked with an RMSD of 0.531 Å and an activity 
loss by the factor of 2, respectively. However, this result demonstrates the applicability of the 
triazole-containing unit [LtS] as a mimic of the associated amino acid residues at P1-P1’, 
which provides the binding selectivity and high affinity of the inhibitors to the active site of 
the corresponding enzyme. At present, this finding cannot be generalized for every inhibitor-
enzyme combination due to the lack of further examples. 
At a first glance, the SFTI-derived chymotrypsin inhibitor 1 demonstrated the best inhibitory 
constant against the associated protease, but the synthesis of its triazolyl-bearing analogue 
was abandoned by practical reasons.  
The most important issue in this project was the improvement of susceptibility against 
proteolytic degradation of 4 compared to its parental BBI-derived inhibitor 3 which was 
examined in hydrolysis experiments. Generally, all non-cyclized inhibitor precursors 1’ – 4’ 
and cystine-cyclized inhibitor 3 showed certain susceptibility in the scissile bond against 
cleavage by their associated proteases. However, 4 exhibited nearly total resistance against 
hydrolysis and underlined the usability of triazole groups as hydrolysis-stable scissile bond 
mimics with only a slight loss of bioactivity compared to the parental peptide. Furthermore, it 
was shown that the side-chain cyclization via disulfide bond formation, which provides the 
rigid framework of BBIs, is not only essential for the inhibitory activity but also a highly 
important requirement for the proteolytic stability of the scissile bond.  
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3.2 PHIP-Active Functional Peptides 
3.2.1 Design and Synthesis 
Regarding the design of a PHIP-labeled SFTI derivative, first, the position for installation of 
the label within the scaffold of SFTI-1[1,14] had to be discussed. Since the label should not 
affect the bioactivity of the inhibitor, positions should be avoided that face the binding side of 
the enzyme and possibly interfere with enzyme-inhibitor interactions. Furthermore, 
modifications within the inhibitory loop (Cys3 – Cys11) were also prevented to keep the rigid 
framework of the scaffold maximally constrained. According to the Ala-scan experiments by 
Daly et al.[117] and an in silico modeling of the SFTI-1[1,14]-trypsin co-complex (derived from 
PDB: 1SFI) the residues Gly1 and Pro13 facing apart from the active site of trypsin were 
found to be favorable for the substitution by a PHIP-active synthetic amino acid (Figure 31A). 
Hence, two SFTI derivatives with substitutions of corresponding residues by Pra, [Pra1]SFTI-
1[1,14] (5) and [Pra13]SFTI-1[1,14] (6) were designed. It was clearly apparent from the 
modeled and energy minimized co-complex structure of 5 and 6 shown in Figure 31B and 
31C that in both cases the substitution does not affect the conformation of the SFTI 
framework and that the side-chain extension is not interfering with the binding sites.  
 
Figure 31. 3D computational models of SFTI-1[1,14], 5 and 6 as co-complexes with trypsin. Structures modeled 
from crystallographic data (PDB: 1SFI) by in silico building and energy minimization. Surface of residues 
forming the active site: green. Atoms of inhibitors are shown as sticks with grey: carbon, red: oxygen, 
blue: nitrogen, green: sulfur. A: Residues for planned substitution by PHIP-active labels are implied by 
depiction of the surface in yellow. B&C: Triple bonds of installed PHIP labels are highlighted in purple. 
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As discussed in chapter 2.2, the NMR signal enhancement by PHIP is extremely affected by 
the presence of strong electron-donating groups presumably poisoning the hydrogenation 
catalyst. Thus, we supposed that the remoteness of the alkyne functionality from those groups 
is an important criteria for the effective PHIP labeling. This presumption was examined by the 
application of two strategies in combination. First, L-Tyr(O-propargyl) was introduced as PHIP 
label with an extended distance between corresponding multiple bond and the peptide 
backbone by the size of a phenyl ring. Second, associated interfering moieties were 
substituted by respective surrogates. [Tyr(O-propargyl)1]SFTI-1[1,14] (7) was designed to 
pursue former strategy (Figure 32A). In view of practicability and efforts in synthesis, the 
installation of PHIP labels in all following SFTI derivatives was restricted to the position of 
Gly1. 
 
 
Figure 32. 3D computational models of 7 and 8 as co-complexes with trypsin. Structures modeled as described for 
Figure 31. Same depiction style and color patterns used as described for Figure 31. 
Considering the data from the previous publication[145] and the findings by Trantzschel et 
al.,[147] sulfhydryle derivatives and primary amines in close proximity to the PHIP label were 
categorized as most drastically hydrogenation-impairing moieties and were decided to be 
substituted. In case of the SFTI-1 scaffold, the cystine-forming residues Cys3 and Cys11, and 
Lys5 as well as the α-amine were concerned. Since Lys5 is essential for the selective binding of 
the inhibitor to trypsin[117] and is not in direct proximity to the PHIP label, the modifications 
were restricted to the replacement of the N-terminal amine group and the disulfide bond. 
Regarding investigation of the influence of the free N-terminus, first an elimination of this 
moiety was undertaken. Thus, SFTI derivative 8 bearing an amine-free isoster of Pra, 4-
pentynoic acid, was designed (Figure 32B). Furthermore, the conversion of the primary to the 
secondary amine by acyl capping was investigated. The modeled structure of resulting SFTI 
derivatives 9 and 10, each bearing Pra and Tyr(O-propargyl) as PHIP labels, are depicted in 
Figure 33. 
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Figure 33. 3D computational models of 9 and 10 as co-complexes with trypsin. Structures modeled as described 
for Figure 31. Same depiction style and color patterns used as described for Figure 31. 
Finally, the remaining issue was the exchange of the sulfur atoms within the cystine pattern. 
Appropriately, Empting et al. published 2011 the successful replacement of a disulfide bond in 
a monocyclic SFTI derivative by a 1,5-disubstituted 1,2,3 triazole with only minimal loss in 
bioactivity.[73b] This strategy was applied to inhibitors 5 and 7 resulting in the peptide analogs 
11 and 12 bearing Pra and Tyr(O-propargyl) as PHIP labels, respectively. From the modeled 
structure of 11 and 12 shown in Figure 34 no dramatic derivation from the original template 
scaffold of SFTI-1 can be observed, thus preserved bioactivities of corresponding peptide 
analogs could be expected. 
 
Figure 34. 3D computational models of 7 and 8 as co-complexes with trypsin. Structures modeled as described for 
Figure 31. Same depiction style and color patterns used as described for Figure 31.. 
An overlay of the modeled SFTI derivatives 5 – 12 is shown in Figure 35. As expected, the 
structural derivations were mainly concentrated within the moieties of respective amino acid 
substitution, while the residues directly contacting with the active site of trypsin (left-hand 
side of Figure 35) are only minimally affected. Even the disulfide bond replacement seemed 
to provide only minor influence on the rigid, constrained SFTI framework. 
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Figure 35. Overlay of computationally modeled inhibitors 5 – 12 (yellow, thin sticks) and SFTI-1[1,14] (sticks in 
element colors with grey: carbon, red: oxygen, blue: nitrogen, green: sulfur) after energy minimization of 
respective trypsin-inhibitor co-complexes and structural alignment using AMBER03 force field. Triple bond 
moieties are shown as purple sticks. 
 
Table 10. Summary of geometric parameters from the in silico models of inhibitors 5 – 12 presumably influencing 
bioactivity and resulting SE during PHIP experiments. Values analyzed from model shown in Figure 35. 
Entry 
RMSD to 
SFTI-1[1,14] [Å] 
Distance to  
N-terminusa [Å] 
Distance to next 
backbone amideb [Å] 
Distance to 
cystine bondc [Å] 
5 0.3700 3.668 5.189 7.407 
6 0.5021 6.767 2.881 9.976 
7 0.6327 9.519 8.825 10.705 
8 0.3750 - 4.656 7.288 
9 0.3830 - 3.453 7.189 
10 0.5449 - 9.170 10.680 
11 0.6959 3.411 5.176 - 
12 0.7856 9.066 8.314 - 
a: Values calculated from mean distances between carbon atoms of triple bonds and nitrogen atom of terminal amine 
b: Values calculated from mean distances between carbon atoms of triple bonds and nitrogen of nearest peptide bond 
c: Values calculated from mean distances between carbon atoms of triple bonds and nearest sulfur atom 
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The in silico-determined geometric parameters of the modeled SFTI derivatives 5 – 12 are 
listed in Table 11. Generally, the RMSD values indicate the degree of structural similarity and 
the usability of 5 – 12 as mimic of the original inhibitor. According to the calculated RMSD 
values, the variants with low RMSD values, 5, 8, and 9, were expected to possess respectively 
high inhibitory potency against trypsin. Analogously to the calculated RMSD values, the 
distances between triple bonds of the installed PHIP labels and potentially catalyst-poisoning 
elements, should give an indication to the efficacy of 
catalytic hydrogenation and, furthermore, to the resulting 
signal enhancement during PHIP experiments.  
Finally, two further SFTI derivatives, 13 and 14, bearing 
Tyr(O-allyl) or 4-pentenoic acid, respectively, at the 
positions for PHIP labeling were designed to study the T1 
relaxation times of the corresponding labels within the 
functional peptides. The corresponding sequences of 13 
and 14 are shown in Figure 36. The modeled 3D structure 
was supposed to be similar to peptides 7 and 8. 
 
 
3.2.1.1 Synthesis of peptides 5 – 10, 13, and 14 
Peptidic inhibitor 5 was synthesized in the lab of Prof. Buntkowsky by manual SPPS; peptidic 
inhibitors 6 – 10, 13 and 14 were synthesized by partially automated SPPS, in both cases 
using standard Fmoc strategy. Peptides 8 – 10 were synthesized from the same starting batch, 
whereby the peptide-resin was splitted after chain elongation up to the last shared amino 
acid. The associated linear precursors were obtained in good to excellent yield (Table 11). All 
precursor peptides were side-chain-cyclized by oxidative folding in 0.1 M (NH4)2CO3 buffer 
with 0.5 % DMSO (in few cases with addition of glutathione, see chapter 5.2.3) while 
monitoring reaction progress by HPLC and ESI-MS. The cyclized inhibitors were lyophilized 
and isolated by semi-preparative RP-HPLC. Chromatographic traces of peptidic inhibitors 5 – 
10, 13, and 14 after folding and purification as well as the corresponding linear precursors 
are shown in Figure 37. In case of SFTI derivatives, the oxidative folding generally led to 
delayed elution of the product fraction compared to the corresponding precursors, indicating 
a decrease in net-polarity or drastic conformational changes within the molecules. Since the 
net-polarity of oxidized oligopeptides should not dramatically differ from the reduced species, 
the observed shift in Rt is assumed to be caused by structural constraint. 
 
RCTKSIPPICFPD-OH
O
H-Tyr(O-allyl)-RCTKSIPPICFPD-OH
13
14
Figure 36. Inhibitors 13 and 14. 
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Figure 37. Chromatographic profiles of purified trypsin inhibitors 5 – 10, 11, 12 (black) and corresponding linear 
precursors (blue). UV detection at λ = 220 nm; eluent 5 – 7, 13, 14: 9→72 % acetonitrile in 0.1 % aq. 
TFA over 20 minutes at flow rate 1 ml/min, eluent 8, 9: 9→90 % acetonitrile in 0.1 % aq. TFA over 20 
minutes at flow rate 1 ml/min. 
The folding and purification yields and overall yields of the corresponding peptides are listed 
in Table 11. All crude yields were typical for SPPS. The variation in folding and purification 
yields resulted from the application of different oxidation conditions and batch sizes which 
influenced the recovery rate of chromatographic purification. The amount and purity of 
isolated inhibitors were sufficient for the examination of their inhibitory potential and PHIP 
activity. 
Table 11. Synthesis of peptidic inhibitors 5 – 14. 
Entry Strategy MW 
Crude yield precursor 
[%] 
Folding/purification 
yield [%] 
Overall 
yield 
 [%] 
5 Manual - 55.6 18.8 10.5 
6 Automateda + 82.5 41.5 34.3 
7 Manual + 71.9 27.8 20.1 
8 Automatedb + 94.6 35.8 30.8 
9 Automatedb + 88.0 36.8 32.4 
10 Automatedb + 81.2 40.3 32.5 
13 Automatedb + 98.8 44.3 43.6 
14 Automatedb + 76.6 41.7 31.7 
a: Synthesized on Liberty® 12-channel peptide synthesizer platform. 
b: Synthesized on Liberty® Blue peptide synthesizer platform. 
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3.2.1.2 Synthesis of peptide analogs 11 and 12 
Peptidomimetic SFTI derivatives 11 and 12 were synthesized according to the published 
technique via manual Fmoc-SPPS and microwave-assisted on-support RuAAC.[73b] The strategy 
of synthesis depicted in Scheme 21 relies on the side-chain macrocyclization by formation of 
the 1,5-disubstituted triazole from Pra and L-azidohomoalanine (Aha). Both surrogates were 
installed during iterative chain elongation using standard coupling protocols (see chapter 
5.2.1) as Fmoc-protected building blocks.  
 
Scheme 21. Synthetic strategy towards peptides analogs with triazolyl disulfide surrogate via RuAAC on solid 
support. Amino acids and building blocks are depicted as colored balls with green: canonical amino acid; 
red: Aha; blue: Pra. Solid support is depicted as grey ball. 
On-support macrocyclizations were accomplished after coupling of Arg2. To avoid undesired 
side reactions and maximize the efficacy of Ru(II) catalyst, RuAAC was performed under 
exclusion of humidity and atmospheric oxygen. The success of backbone macrocyclization was 
examined by treatment of the N-terminally deprotected and test-cleaved peptide analog 11a 
(Scheme 22A) with reducing agent. If the reaction was incomplete, an m/z signal of a species 
with a reduced molecular weight of 26 (formation of an amine from azide by reductive 
cleavage of molecular nitrogen, Scheme 22B) should be observed in mass spectrometric 
analysis. 
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Scheme 22. A: Intermediate 11a. B: Reductive denitrogenation of non-cyclized intermediate towards 11b. 
Since no corresponding mass peak was found in the ESI mass spectrum of the test-cleaved 
intermediate (Figure 38), the PHIP labels Pra or Tyr(O-propargyl), respectively, were 
attached to the deprotected resin-bound peptide.  
 
Figure 38. A: Chromatographic trace of intermediate of 11 after RuAAC, Fmoc deprotection and test cleavage 
from solid support. UV detection at λ = 220 nm; eluent: 9→72 % acetonitrile in 0.1 % aq. TFA over 20 
minutes at flow rate 1 ml/min. Main fraction collected for ESI-MS analysis is marked in red. B: ESI mass 
spectrum of collected fraction. Average ion counts are plotted against m/z. 
After cleavage from support and purification, 11 and 12 were obtained in sufficient purity and 
amount for the examination of inhibitory and PHIP activity. Chromatographic traces of 
purified products can be found in the appendix. Corresponding yields of the peptide 
analogous are summarized in Table 12. The poor crude yield and purification yield resulted 
from the harsh reaction conditions during microwave-assisted RuAAC and the presence of the 
transition metal catalyst responsible for undesired complex formation hampering the 
chromatographic purification. 
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Table 12. Synthesis of peptidomimetic inhibitors 11 and 12. 
Entry Strategy MW 
Crude yield 
[%] 
Purification yield 
[%] 
Overall yield 
[%] 
11 Manual + 39.1 12.0 4.7 
12 Manual + 48.1 11.6 5.6 
 
 
3.2.2 Characterization and Evaluation of Activity 
3.2.2.1 Bioactivity Assays 
The majority of the results presented in this chapter was recently published.[50b] The inhibitory 
potency of the labeled SFTI derivatives 5 – 13 was studied by time-dependent protease 
inhibition assays analogously that described for the HNE and chymotrypsin inhibitors 1 – 4 in 
chapter 3.1.2. The most important issue of this investigation was to examine the influence of 
the installed PHIP labels in combination with certain structural modifications (disulfide 
mimicking motif and N-terminal capping) on the activity of the inhibitors. The general setup 
for bovine pancreas trypsin assays was similar to that described for other proteases in 
previous chapter, and Boc-QAR-pNA was used as a chromogenic substrate. Detailed 
experimental procedure is described in chapter 5.4.1. The Michaelis-Menten constant for the 
used enzyme-substrate system was determined as KM = 58.9±7.8 µM (chapter 3.1.2.1). 
Furthermore, to evaluate if the discussed enzymatic reaction is also feasible under the 
conditions of NMR experiments and to assess how the activity is influenced by the solvent 
system, trypsin activity assays were performed in non-buffered D2O (pD ~7.8) and distilled 
water (pH 6.8). Thereby, a KM of 114.3±27.4 µM in non-buffered water and 51.3±18.3 µM in 
non-buffered D2O were determined. These results did not find direct application in the 
present work, but they are important clues for the future development of PHIP NMR 
experiments with labeled inhibitors in presence of their target enzyme.  
The substrate-independent inhibition constants for 5 – 13 were determined by a modified 
setup of an enzyme inhibition assay in trypsin activity buffer (TA buffer) composed of 50 mM 
Tris/HCl, 150 mM NaCl, 0.01 % Triton X-100, 0.01 % sodium azide, pH 7.6.[14a, 73b, 153] The 
resulted Ki and Kiapp values of all examined labeled SFTI derivatives are listed in Table 13. 
All experimentally determined inhibition constants were at single-digit to subnanomolar 
range. Inhibitory activity of compound 6 was additionally tested in non-buffered D2O (pD 
~7.8) and distilled water (pH 6.8) for the reasons mentioned above. The obtained values for 
Ki were about one order of magnitude higher than those for the measurements in buffered 
system, but strong inhibitory potency around 10 nM was determined confirming the 
applicability of the inhibitory assay to non-buffered solvents. 
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Table 13. Inhibitory activity of inhibitors 5 – 13. 
Entry Label (position) Solvent Kiapp (nM) Ki (nM)b 
5 Pra (1) TA buffer 8.02±0.91 1.53±0.28 
6 Pra (13) TA buffer 8.12±1.46 1.55±0.32 
6 Pra (13) H2O (pH 6.8) 57.25±4.44 10.91±3.27 
6 Pra (13) D2O (pD 7.8) 45.76±10.04 8.73±2.91 
7 Tyr(O-propargyl) (1) TA buffer 7.37±1.18 1.41±0.27 
8 4-Pentynic acid (1) TA buffer 1.02±0.09 0.20±0.03 
9 Pra (1) TA buffer 1.12±0.15 0.21±0.04 
10 Tyr(O-propargyl) (1) TA buffer 1.09±0.10 0.21±0.03 
11 Pra (1) TA buffer 37.81±1.20 7.21±0.90 
12 Tyr(O-propargyl) (1) TA buffer 22.70±2.21 4.33±0.61 
13 Tyr(O-allyl) (1) TA buffer 6.68±0.81 1.27 ± 0.20 
a: Error calculated by propagation of error for Ki
app and KM (see chapter 5.4.1.3).  
Three synthetic inhibitors (8, 9, and 10) displayed an inhibitory potential in the same range 
as their parental peptide (0.28 nM for monocyclic SFTI-1). This result is assumed to be caused 
by the lack of the free N-terminus in 8 – 10. Indeed, their analogues, 5 and 7, bearing an N-
terminal amine, exhibited a Ki of ~ 1.5 nM. Considering the fact that the bicyclic SFTI-1 
lacking an alpha-amine possesses a better Ki as its open-chain variant, the observed result 
corroborates the reported data on the inhibitory potency of SFTI constructs.[156] Since 
compounds 5 – 13 showed Ki in the range of tight-binding inhibitors, it was proven that their 
bioactivity was not affected by the labels, confirming the accuracy of the in silico modeling 
shown in Figures 31 – 34 (chapter 3.2.1). 
 
 
3.2.2.2 PHIP Experiments 
All NMR PHIP experiments and corresponding data analysis were performed by Grit Sauer 
and Dr. Marco Körner from the working group of Prof. Buntkowsky at the Technische 
Universität Darmstadt. Prior to the PHIP experiments with the SFTI derivatives 5 – 13, the 1H 
hyperpolarization ability of individual building blocks Fmoc-L-Tyr(propargyl)-OH, 4-pentynoic 
acid, and the corresponding potential hydrogenation products Fmoc-L-Tyr(All)-OH and 4-
pentenoic acid were examined (Table 14).  
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reported for Fmoc-L-Pra-OH in pervious publication.[159] The hyperpolarized proton signals 
were found at 5.2-5.5 ppm. Hydrogenation of the triple bond of 4-pentynoic acid towards 
respective 4-pentenoic acid exhibited an enhancement factor of 900 which was more than 4 
times higher than the SE of the Fmoc-protected PHIP labels. In an examination of the 
longitudinal relaxation times T1 for the newly formed CH2 (Ha/Hb) group of the double bond 
within the discussed building blocks (see chapter 5.3.2.1 for details), the highest T1 value was 
also observed for 4-pentynoic acid (see Table 14) underlining the high PHIP activity of this 
compound. SE for the second hydrogenation step towards fully saturated products was 
negligibly small or not observable. As the T1 values of these compounds were in same range as 
their triple bond-bearing analogues, the efficacy of hydrogenation (and not the polarization 
transfer efficacy) is assumed to be the main reason for the lack in PHIP activity. 
After these preliminary experiments, PHIP experiments were performed with the labeled SFTI 
derivatives 5 – 13 using the same reaction setup and conditions as described above. The 
obtained SE factors of all PHIP measurements are summarized in Table 15.  
 
Table 15. SE values for SFTI-derivatives 5 - 13, experimentally determined in ALTADENA experiments. 
Entry Label (position) Macrocyclization N-terminus SEa 
5 Pra (1) cystine H- n.h. 
6 Pra (14) cystine H- n.h. 
7 Tyr(O-propargyl) (1) cystine H- 70 
7b Tyr(O-propargyl) (1) cystine H- 74 
7c Tyr(O-propargyl) (1) cystine H- 66 
8 4-Pentynic acid (1) cystine none 5 
9 Pra (1) cystine Ac- n.h. 
9’ Pra (1) - Ac- n.a. 
10 Tyr(O-propargyl) (1) cystine Ac- 68 
10’ Tyr(O-propargyl) (1) - Ac- 65 
11 Pra (1) triazole H- n.a. 
12 Tyr(O-propargyl) (1) triazole H- 35 
13 Tyr(O-allyl) (1) cystine H- n.h. 
a: Values were calculated as described in chapter 5.3.1. 
b: SE was studied in a water-methanol-d4 mixture (1:1, v/v) at 333°K 
c: SE was studied in a water-ethanol-d6 mixture (1:1, v/v) at 333°K 
n.h.: No hydrogenation was observed; n.a.: not analyzable, product signals were negligibly small. 
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applicability of the discussed system for PHIP experiments. We also have evaluated the 
structural integrity and preservation of the inhibitory activity of 7 under these conditions by 
HPLC, ESI-MS and inhibitory assay of the hydrogenated product after incubation at 333 K for 
30 min. The obtained Kiapp was with 7.57±0.88 nM similar to the value determined in the 
experiment without thermal treatment (Kiapp = 6.68±0.81 nM). 
 
 
3.2.3 Digest of Chapter 3.2 
PHIP-labeled trypsin inhibitors 5 - 14 were computationally and knowledge-based designed 
by using SFTI-1 as a starting point and synthesized via SPPS. Their PHIP activity was 
examined by ALTADENA experiments and the bioactivity was evaluated in trypsin inhibition 
assays. The majority of the synthesized peptides and peptide analogs exhibited characteristic 
antiphase signals at 6.5-5.0 ppm, but a distinct enhancement in NMR signals could only be 
observed in case of Tyr(O-propargyl)-labeled variants 7, 10, 12 and the 4-pentynoic acid-
labeled 8. Best values of SE were found for the peptide 7, with free N-terminus and a cystine-
bridged macrocyclization. This suggests that the effect of catalyst poisoning by competitive 
coordination by these moieties has only a minor influence to the SE, compared to the 
remoteness of the unsaturated moiety from the peptide backbone.  
A comparison of the 1H-T1 relaxation time of the individual labels (or the Fmoc-protected 
derivatives) and the observed SE of the synthesized peptides revealed no direct correlation 
between 1H-T1 relaxation time and the enhancement of PHIP signals, thus underlining the 
hypothesis that the PHIP activity strongly depends on the hydrogenation efficacy as described 
in chapter 2.2. On the whole, we suppose that the degree of signal enhancement mainly 
depends on the hydride transfer between unsaturated bond and metal ion center and the 
competition with further coordination sites of the biomolecules while the T1 relaxation 
represents a general prerequisite for the PHIP effect. 
The outcome of PHIP experiments are in good accordance with the geometric parameters 
determined from the in silico models (chapter 3.2.1). Indeed, only the compounds where the 
distance between the triple bond and the nearest electron-donating moiety is larger than 5 Å 
exhibited strong SE. An exception could be seen in case of 8 with a distance to the next 
backbone amide of 4.657 Å. This can be explained by the extremely strong inherent PHIP 
activity of the label.  
Furthermore, the compatibility of the PHIP experiments with aqueous milieu was also 
demonstrated using water-MeOH and water-EtOH mixtures. Under these conditions and 
elevated temperature, peptide 7 exhibited strong SE without loss in the enhancement factor 
while preserving its structural integrity and inhibitor activity. 
The Ki’s of 5 - 13 were all in single-digit nano to picomolar range, thus a distinct decrease in 
inhibitory activity was only found for the triazolyl-cyclized variants 11 and 12 with the 
deterioration in Ki by the factor of 3 – 5 compared to their parental peptides 5 and 7. These 
values are similar to those reported by Empting et al. for the decrease in activity of SFTI-
1[1,14] upon disulfide mimicking by a 1,5-disubstituted triazole (decrease by the factor of 
1.6).  
Interestingly, several novel inhibitors presented an inhibitory potency similar to the original 
SFTI-1[1,14]. These inhibitors (compounds 8 - 10) all lack a free N-terminus and exhibited 
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enhanced inhibitory activity by the factor of ~7 compared to their related peptide 5 and 7 
with an N-terminal amine. 
On the whole, the influence of the PHIP labels on the inhibitory activity is kept within a limit, 
thus all examined inhibitors displayed Ki values in the range of tight-binding inhibitors. The 
obtained Ki‘s were generally in accordance with the tendency of the in silico determined 
RMSD values with the exception of the Tyr(O-propargyl)-labeled variants as they showed 
better activity than expected from the computational models. This outcome confirmed our 
prediction that the labeling at positions P1 and P14 only minimally affects the bioactivity of 
the inhibitors. 
The compatibility of the assays in NMR-related solvents was also confirmed, whereby a slight 
decrease in inhibitor activity by a factor of about 6 – 7 was found compared to the setups in 
the buffered milieu.  
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3.3 Affinity-Guided Chemical Ligation towards Multifunctionalization of 
Biomolecular Scaffolds 
3.3.1 Design and Synthesis 
The model systems for affinity-guided ligation in the presented work comprised only a pair of 
reactive moieties for the bioorthogonal ligation linked to complementary guiding units for 
spatial pre-arrangement of associated functionalities. Fundamental experiments towards 
establishment of a generally applicable reaction setup for the affinity-guided SPANC were 
tested on a heterodimeric coiled-coil system. 
The sequences of a modified synthetic, three-heptad E/K coil pair were derived from the 
coiled-coil heteromer originally designed for Rh-metallopeptide catalyzed Trp modification 
published by Popp et al.[127b] During screening for an appropriate conjugation technique 
applicable for the modification of protein scaffolds, the mentioned methodology was chosen 
as possible candidate (data not shown). However, after preliminary studies, we renounced 
our attempts due to several reasons, among them poor reaction rate and the narrow range of 
applicable diazo-modified ligands. However, the α-helical peptides synthesized during this 
trial, K3g,d2E2 and E3e2W were already tested for heterodimerization in the original 
publication and could be conveniently reused for preliminary experiments of the SPANC-
based model system. All amino acid substitutions (pinpoint derivatization from E/K coil 
system with consistent sequence) in respective coils are orthogonal to the reactive 
functionalities of SPANC, hence no undesired interference to the final conjugation was 
expected. The installation of SPANC-reactive moieties within the Lys-rich K3g,d2E2 coil was 
planned to be realized by N-terminal elongation of the coils by corresponding precursor 
residues.  
Towards incorporation of a strained, cyclic alkyne group, two various strategies depending on 
the pre-installed linker functionalities of two commercially available (1R,8S)-
bicyclo[6,1,0]non-4-yne (BCN) derivatives were proposed. First, the on-support attachment of 
(1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-ylmethyl N-succinimidyl carbonate (BCN-NHS) to the 
free N-terminal amine or to the deprotected side chain of Lys was considered. The second 
strategy was the in-solution conjugation of BCN-(POE)3-NH-C(O)(CH2)3-maleimide (15) to 
the side chain of Cys via maleimide conjugation. Since the on-resin installation of the BCN 
moiety was unsuccessful in a preliminary trial (probably due to the non-compatibility of BCN 
to either Fmoc deprotection or strongly acidic cleavage conditions). Therefore, the in-solution 
strategy was chosen for conjugation of a BCN moiety to the guiding unit. Consequently, the 
precursor K coil peptide 16’ and its derived product 16 were designed (Scheme 23). As C-
terminal functionality, an amide was chosen instead of a carboxylic acid. The chemical and 
physical properties, especially the affinity towards dimerization of the coils should not be 
influenced dramatically by this exchange. 
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Scheme 23. Compounds 15, 16’, and 16 and reaction scheme towards formation of 16 by maleimide-
sulfhydryl conjugation. Guiding unit part is shown as a grey bar. 
As a counterpart for 16, the acidic E3e2W coil should be equipped with a glyoxylyl moiety at 
the side chain. The most popular technique to incorporate aldehydes into proteins is the 
oxidation of terminal vicinal diols and amino alcohols by periodate.[160] For this purpose, the 
modified E coil with an N-terminal Lys residue equipped with Ser at the side chain (17’) was 
designed as precursor peptide of respective aldehyde-bearing guiding unit 17 (Scheme 24).  
 
 
Scheme 24. Peptidomimetics 17’ and 17 and reaction scheme towards formation of 17 by periodate-
mediated oxidation of a corresponding amino alcohol. Guiding unit part is shown as a grey bar. 
Both of the modified coils 16 and 17 were computationally modeled from the crystal structure 
of a three-heptad coiled-coil heterodimer (PDB: 1U01) by residue exchanges and energy 
minimization (Figure 42). The key issue of this in silico study was to ensure that the collision 
of the reactive moieties for SPANC is not influenced by the length or strains within the linker 
units between reactive sites and peptide backbone.  
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Figure 42. 3D computational model of the modified three-heptad coiled-coil system comprising 16 (orange) and 
17 (blue). Structure derived from solution NMR structure of original E/K coil system[161] (PDB: 1U01) by 
residue substitution, in silico building, and energy minimization. Secondary structures of α-helices shown 
in cartoon style. SPANC-reactive moieties are shown as sticks with grey: carbon; red: oxygen; blue: 
nitrogen; green: sulfur. Strained triple bond within the BCN moiety is highlighted in purple. 
A molecular dynamic simulation of the computational model demonstrated that the aliphatic 
hydrocarbon chains and the oligoethylene glycol unit within the linkers comprised high 
degree of freedom, thus ensuring sufficient flexibility for the desired collision of associated 
functionalities. 
Furthermore, a second coiled-coil model system for affinity-guided SPANC comprising a 
coiled-coil heteromer with an expanded number of repetitive heptads was designed. Since the 
strength of coiled-coil interactions depends on the length of the complementary recognition 
sites, stronger affinity and, conclusively, enhanced reaction rate of the cycloaddition was 
expected to the new system. The coiled-coil scaffolds of the second model system are 
composed of five repetitive heptads with the consistent sequence of XISALXY (X = K and Y = 
E for K coil; X = E and Y = K for E coil). Same strategies as described for the three-heptad 
system were planned for the installation of the reactive moieties within the guiding units. 
BCN-functionalized peptide 18 and its aldehyde-bearing reaction counterpart 19 and 
corresponding precursor peptides 18’ and 19’ before in-solution modifications are depicted in 
Figure 43. 
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Figure 43. Peptidomimetics 18, 19 and corresponding precursor peptides. Guiding unit parts are shown as gray 
bars. 
Conclusively, the molecular design and synthesis strategy applied to the coiled-coil model 
system were transferred to a model system using a complementary PNA oligomer pair as 
guiding unit. The sequences of the PNA oligomers (PNA A and PNA B) were taken from a 
publication of Lygina et al.[138] Respective sequences and all further PNA sequences used in 
presented work, are listed along with the corresponding abbreviation in Table 16. 
Table 16. Sequence and corresponding abbreviation of PNAs used in the presented work. 
Sequence Abbreviation Comment 
gtagatcact PNA A Complementary to PNA B (parallel). 
catctagtga PNA B Complementary to PNA A (parallel). 
agtaagctct PNA C No complementarity to PNA A, B, D, E. 
tatagtagatcact PNA D PNA A, N-terminally extended for cross-conjugation 
catctagtgaggag PNA E PNA B, C-terminally extended for aptamer loading 
According to the melting temperature Tm of 46 °C reported in the literature for the similar 
constructs,[138] the hybridization affinity between this parallel interacting PNA pair was 
expected to be sufficiently strong for the proposed application despite its small size. 
Consequently, BCN-equipped PNA oligomer 20 and aldehyde-bearing PNA oligomer 21 were 
designed according to the strategies discussed for the former model systems. The simplified 
structures and sequences of respective compounds 20, 21, and corresponding precursors 20’ 
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and 21’ before in-solution modifications are depicted in Figure 44. As the incorporation of a 
basic amino acid is a common strategy to improve the solubility and cellular uptake of 
PNAs,[162] the C-terminally installed Lys residue had the same purpose and is proposed not to 
affect hybridization of the PNA oligomers.  
 
Figure 44. Conjugate 20, 21 and corresponding precursor PNA-peptide hybrid molecules. Guiding unit parts are 
shown as gray bars. 
However, a 3D computational modeling of 20 and 
21 was not possible since no crystallographic data 
of PNAs with corresponding sequences has been 
published so far and de novo building of the 
molecules was not possible due to the lack of 
structural clues and exact physical properties of 
PNA monomers required for successful simulations. 
Nevertheless, as the installed reactive moieties for 
SPANC, including linker and conjugation units, are 
completely the same as the previously described 
coiled-coil systems, similar chemical properties 
were expected for the PNA-based model system. 
Additionally, a further PNA-peptide hybrid 22 
comprising an alternative PNA sequence (PNA C), 
neither complementary to PNA A nor to PNA B, but 
with the same modifications and SPANC-reactive 
functionalities as in 21 was designed. This hybrid 
molecule was aimed to act as a competitor of 21 to 
check the selectivity provided by the affinity-guided 
approach. Sequences and simplified structures of 
22 and its precursor 22’ are shown in Figure 45A. 
Based on the complementary sequences of PNA A 
A
B
22'
23
H2N
HN
O
R
agtaagctct K-NH2
catctagtga K-NH2
H2N
O
N3
O
NH2
HO
O
O
R =
R =
22
Figure 45. A: PNA-peptide hybrid molecule 22
and corresponding precursor 22’. B: 
PNA-peptide hybrid molecule 23.
Guiding unit parts are shown as gray 
bars. 
 
DOCTORAL THESIS DAICHI NASU RESULTS AND DISCUSSION 
 81 
and PNA B, further model systems using PNAs as guiding units but comprising diverse 
bioorthogonal conjugations as an alternative to SPANC were designed. Aha-bearing PNA 
oligomer 23 (Figure 45B) possessed the same PNA scaffold as 21 and was drafted for the 
application of SPAAC. As this technique required a strained alkyne as a reactive counterpart, 
no further design of the alkyne-bearing PNA was needed. The purpose of this examination 
was to compare the efficacy of SPANC and a non-triggered SPAAC. 
As described in chapter 2.3.1, UVA irradiation-mediated psoralen cross-conjugation was 
chosen as a triggered alternative to SPANC. This two-step cycloaddition (Scheme 25A) 
between psoralen, a DNA-intercalating aromatic photosensitizer, and two thymine bases of 
hybridized, complementary nucleic acid strands has found application for the treatment of 
vitiligo and psoriasis.[163] On the other hand, it is a useful tool for structural studies of nucleic 
acids.[164] The reaction is triggered by electromagnetic irradiation with a wavelength of λ = 
320-380 nm and can also be reversed by high frequency UV irradiation of λ = 220-280 nm. 
The technique utilizes the spatial pre-arrangement of the corresponding reaction sites of 
psoralen and thymine provided by the selective intercalation of psoralen to the major groove 
of DNA typically formed by successively ordered nucleic acid sequences of an A-T and T-A pair 
(Scheme 25B).  
 
Scheme 25. A: General reaction scheme of UVA-mediated two-step cycloaddition of psoralen to two thymine 
bases. B: Schematic depiction of the psoralen-mediated cross-conjugation of complementary DNA strands 
from side view. Structure of DNA strands modeled and modified from NMR structure (PDB: 2V3L). Plain 
nucleobases are depicted as white bars. Psoralen molecule and cycloadducts are depicted as gray shapes. 
However, considering the fact that the sequences of PNA1 and PNA2 contain a number of 
respective sequence pattern, an uncontrollable multiple addition of the psoralen molecule was 
expected making the direct application of 20 and 21 inappropriate as selective conjugation 
technique. An idea to overcome this drawback was found in the publications of Okamoto et al. 
2001[165] and Kim et al. 2007,[166] who reported the synthesis and application of a psoralen 
derivative preinstalled into a PNA oligomer, whereby the cross linker was used for selective 
cross-conjugation of two complementary DNA strands via PNA-mediated sequence specificity. 
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Nevertheless, a psoralen unit covalently linked to one of the PNA oligomers would limit the 
possible cross-conjugation sites and was expected to provide advantage in stoichiometrical 
and site-selective conjugation. To this end, the sequence of PNA B was redesigned with an N-
terminal extension by an SPS-compatible psoralen building block 24 and a Lys side chain-
coupled triple glycine motif representing a conjugation site for loading to a protein scaffolds 
via sortase-mediated ligation, resulting in the psoralen-functionalized PNA 25. Further 
modification within the peptidic part of 25 was based on the re-usage of the PNA-loaded resin 
and should be ignored in presented work. To afford cross-conjugation sites in reachable 
distance from the psoralen unit, a complementary PNA oligomer extended with an N-terminal 
tata PNA (PNA D) motif 26 was appropriately designed. Reaction scheme of planned affinity-
guided conjugation is given in Scheme 26. 
 
Scheme 26. Compounds 24 – 26 and reaction scheme towards formation of 25 by SPS and successive PNA duplex 
formation with 26. Guiding unit parts are shown as grey bars. 
Further PNA oligomers derived from the sequence of PNA B were designed for the 
conjugation of guiding units with an antibody Fc scaffold and towards subsequent application 
of the resulting conjugate to drug delivery (Figure 46). First, the plain PNA-peptide hybrid 27 
comprising the PNA sequence, a C-terminal Lys residue to improve solubility, and an N-
terminal pentaglycine motif as recognition tag for sortase A was constructed along with PNA-
peptide hybrid 28 equipped with an additional TEV protease recognition site (ENLYFQS) and 
a Lys side chain-coupled Ser as an aldehyde precursor to get a further conjugation site for 
carbonyl-reactive payloads. 
 
 
DOCTORAL THESIS DAICHI NASU RESULTS AND DISCUSSION 
 83 
 
Figure 46. Conjugate 27-29. Guiding unit parts are shown as grey bars. 
Both hybrid molecules were applied for preliminary experiments aimed on conjugation of the 
guiding units to the Fc C-terminus as well as hybridization sites for DNA aptamer 
CLN0003[167] equipped with the complementary nucleobase sequence (analogous sequence as 
PNA A). The DNA sequence of the aptamer which specifically binds to the receptor tyrosine 
kinase hepatocyte growth factor receptor (HGF-R or c-Met receptor) was as following: 
 
5’GGAGGGAAAAGTTATCAGGCTGGATGGTAGCTCGGTCGGGGTGGGTGGGTTGGCAAGTCTGATTAGTTTTGGAGTACTCGCTCCTCACTAGATG3’ 
 
Thereby, the complementary sequence to PNA 2 was elongated towards hybridization to the 
Fc-loaded 27 or 28, respectively (red). Therefore, a further PNA guiding unit was designed. 
PNA-peptide hybrid 29 comprised the sequence of PNA B extended on the C-terminus with 
four further PNA residues (PNA E) complementary in anti-parallel manner to the four 
nucleobases on 3’-side of the PNA-hybridization tag within the DNA aptamer.  
Furthermore, the PNA guiding unit was additionally equipped with a cytotoxin. The resulting 
hybrid might function as a hybridization site for the DNA aptamer and as a conjugation site 
for a toxic payload at the same time (Scheme 27).  
 
 
Scheme 27. Synthetic strategy towards a toxin-loaded Fc scaffold for aptamer hybridization by sortase A-mediated 
ligation. 
 
Precursor molecule 30’ comprising the PNA sequence B, an N-terminal pentaglycine motif, a 
C-terminal Aha as conjugation site for the toxin, and a Val-Cit linker was designed (Scheme 
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28). SPAAC was chosen for conjugation of 30’ with cytotoxin ispinesib, a highly efficient and 
selective small molecule kinesin spindle protein inhibitor.[168] Therefore, ispinesib was 
functionalized with the complementary conjugation site for the bioorthogonal ligation 
resulting in building block 31 The Val-Cit linker between PNA part and conjugation site of the 
toxin represents a selective cleavage site for the endogenous protease cathepsin B.  
 
Scheme 28. Compounds 30, 31 and respective precursor 30’ and reaction scheme towards formation of 30 via 
SPAAC. Guiding unit parts are shown as gray bars. 
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3.3.1.1 Synthesis of BCN-Comprising Guiding Units 16, 18, and 20 
The general strategy to obtain BCN-
comprising guiding units is depicted in 
Scheme 29. Maleimide-sulfhydryl 
conjugation was used for the covalent 
loading of the BCN group to the plain 
precursor peptides or PNAs, synthesized on 
solid phase.  
SPPS of N-terminally derivatized α-helical K 
coils 16’ and 18’, and PNA-peptide hybrid 20’ 
were performed by standard Fmoc-SPPS (see 
chapter 5) on a Rink amide MBHA (RAM) 
resin providing the formation of a C-terminal 
amide after cleavage. Microwave assistance 
was only applied for coupling of canonical 
amino acids when no PNA component was 
present within the resin-bound peptides. 
First batches of PNA-loaded resins (without 
N-terminal modifications) were synthesized 
by Stephen Middel and Dr. Cornelia Panse 
from Diederichsen group (Universität 
Göttingen) using the PNA chain elongation 
protocol I (see chapter 5.2.2). The crude 
yield of the cleaved and precipitated 
precursor peptides 16’ and 18’ (50.0 % and 
84.0 %) depended on the conditions of the 
automated peptide synthesis. The crude yield 
of PNA-peptide hybrid 20’ was poorer than 
that for the peptidic precursors (44.1 %), demonstrating the general difficulty of solid-phase 
PNA synthesis.  
Considering the next synthetic step, the maleimide-sulfhydryl conjugation, the precursor 
compounds had to be separated from dithiothreitol (DTT) which was supplemented to the 
loaded resin during cleavage of the precursors.  
Prior to the next synthetic step, the maleimide-functionalized BCN building block 15 had to 
be prepared. As 15 was not suitable for long-term storage, precursor of the commercially 
available building block was supplied as a ready-to-mix three-component system. The reaction 
scheme for preparation of 15 from corresponding BCN-POE3-NH2 and NHS-pre-activated 
maleimido acid is shown in Scheme 30.  
 
guiding unitH
RAM
resin
1. Coupling: Fmoc-Cys(Trt)-OH
2. Piperidin
3. Cleavage from resin
guiding unitH-Cys NH2
N
O
O
linker
guiding unitH-Cys NH2
S
N
O
O
linker
Maleimide-
sulfhydryl
ligation
Scheme 29. Synthetic strategy towards BCN-loaded 
guiding units via maleimide-sulfhydryl 
conjugation. 
 
DOCTORAL THESIS DAICHI NASU RESULTS AND DISCUSSION 
 86
 
Scheme 30. Formation of 15 by in-solution coupling of NHS-pre-activated maleimide building block to BCN-POE3-
NH2. 
The reaction progress was monitored via ESI-MS. Full conversion of the BCN-bearing 
component was observed after a reaction time of about 60 min (Figure 47). Initial 
experiments to isolate 15 via preparative HPLC or by extraction and freeze-drying failed. 
Hence, the reaction mixture was stored at -80°C in small aliquots without further purification 
and was directly applied for maleimide conjugation after defrosting. 
 
Figure 47. ESI mass spectra of monitored reaction mixtures towards preparation of 15 A: pre-reaction; B: 10 min; 
C: 30 min after beginning of reaction. Average ion counts of Rt = 6.9 – 9.5 min in pre-switched LC with a 
gradient of 2→100 % acetonitrile in 0.1 % formic acid over 10 minutes at flow rate 0.2 ml/min are 
plotted against m/z. 
The maleimide conjugation of precursors 16’, 18’, and 20’ was performed in degassed Tris-
HCl or ammonium acetate buffer (pH 6.5 or 6.8, respectively). It was important to keep a 
slightly acidic condition to avoid side reaction by coupling of the maleimide to the amine 
function of Lys (nucleophilic at basic conditions) as well as to keep reaction mixture free from 
atmospheric oxygen to prevent spontaneous formation of disulfide bonds. The conversion of 
the precursors in the respective final products 16, 18, or 20 monitored by analytical HPLC 
stopped after a reaction time of about 5 h presumably by reaching the equilibrium. In case of 
16’ and 18’, a precipitation of the formed conjugates was observed. The precipitates were re-
dissolved by addition of a small amount of acetonitrile before chromatographic isolation. The 
chromatographic traces of the isolated final products are shown in the appendix. The 
conversions of 18’ and 20’ were calculated from the peak integrals of corresponding 
chromatograms resulting in conversion values of 64.8 % and 71.5 %, respectively (Figure 
48A). A second-order reaction kinetics (k2 = 0.21 M-1s-1) was estimated for the bioorthogonal 
conjugation regarding the conversion of 18’ (Figure 48B). The value is at same range as 
reported for other maleimide conjugations.[169]  
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Figure 48. Chromatographic profiles of the reaction mixtures of monitored maleimide-sulfhydryl conjugations of 
16’ (A), 18’(C), and 20’(D). UV detection at λ = 220 nm (A, C) or 260 nm (D); eluent: 18→54 % (A),  
18→90 % (C), or 0→54 % (D) acetonitrile in 0.1 % aq. TFA over 20 minutes at flow rate 1 ml/min. A: 
Zoom-in of the corresponding peak of 18’; diverse traces of samples analyzed after distinct reaction times 
are marked with corresponding colors. B: kinetic data plotting regarding conversion of 18’ for 
determination of reaction rate constant k2 by linear regression. C, D: Profiles of respective reaction 
mixtures before (blue) and after 5-8 h reaction time (black). 
Yields are summarized in Table 17. The poor overall yields resulted from the necessity of 
multiple chromatographic purification steps, each with restricted recovery rate (in case of 
compound 16, a third chromatographic purification step had to be applied since the manual 
separation of the components in fractions failed at the first trial). However, the amount and 
purity of isolated products was sufficient for their application in subsequent affinity-guided 
approaches. 
Table 17. Synthesis of BCN-decorated guiding units 16, 18, and-20. 
Entry Strategy MW 
Crude 
yield 
[%] 
Purification 
yielda  
[%] 
MS-couplingb/ 
purification yieldc 
[%] 
Overall yield 
[%] 
16 Automated + 50.0 30.0 12.7 1.9 
18 Automated + 84.1 58.3 38.6 18.9 
20 Manual -d 44.1 43.3 22.1 4.2 
a: First chromatographic purification of precursor compounds. 
b: MS: maleimide-sulfhydryl. 
c: Second chromatographic purification after in-solution modification. 
d: First amino acid (Fmoc-L-Lys(Boc)-OH) was loaded with microwave assistance to resin. 
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3.3.1.2 Synthesis of Aldehyde-Bearing Guiding Units 17, 19, 21, and 22 
The general strategy towards aldehyde-
bearing guiding units is depicted in 
Scheme 31. Periodate-mediated oxidation 
of an amino alcohol yielded glyoxylyl from 
a Ser residue coupled to the side chain of 
Lys. 
SPPS of N-terminally derivatized α-helical 
E coil peptides 17’ and 19’, and PNA-
peptide hybrids 21’ and 22’ was performed 
as described for 16’, 18’, and 20’ in 
chapter 3.1.3.1. First batches of PNA-
loaded resins (without N-terminal 
modifications) were synthesized by 
Stephen Middel and Dr. Cornelia Panse 
from Diederichsen group (Universität 
Göttingen) using the PNA chain elongation 
protocol I (see chapter 5.2.2). Towards 
side chain modification of Lys, Fmoc-L-
Lys(Mtt)-OH was coupled to the N-termini 
of corresponding resin-bound 
peptides/PNAs. Selective deprotection of 
the Mtt was achieved upon treatment of 
the loaded resins with 1 % TFA and triethyl 
silane (TES). Subsequently, Boc-L-Ser(tBu)-
OH was coupled to the free amine moiety.  
Oxidation of serine was performed with ten 
equivalents of sodium periodate at neutral 
pH. To minimize the risk of over-oxidation 
or further unfavorable side reactions, 
oxidation was terminated by quenching of 
the oxidative species with ethylene glycol 
or 4-methoxythiophenol. However, it was found that the most efficient method was the direct 
injection into preparative HPLC. The net polarity of the final products were similar to the 
precursor compounds resulting in a similar retention time Rt during HPLC analysis. Therefore, 
the conversion upon periodate-mediated oxidation was assured by disappearance of the 
corresponding reactant signals in ESI mass spectrum. The chromatographic profiles of 
respective substances before and after periodate-mediated oxidation are shown in Figure 49. 
guiding unitFmoc
RAM
resin
1. Coupling: Fmoc-Lys(Mtt)-OH
2. Mtt deprotection
guiding unit NH2
guiding unitFmoc-Lys
RAM
resin
1. Coupling: Boc-Ser(tBu)-OH
2. Fmoc deprotection
3. Cleavage from resinNH2
H-Lys
HN
O
NH2
OH
NaIO4
guiding unit NH2H-Lys
HN
O
O
H
Scheme 31. Synthetic strategy towards guiding units 
with aldehyde functions in the side chain via
periodate-mediated oxidation of terminal and 
vicinal amino alcohols. 
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Figure 49. Chromatographic profiles of the reaction mixtures of crude precursor molecules of 17’ (A), 19’(B), 21’ 
(C), and 22’ (D) and corresponding purified products after periodate-mediated oxidation. UV detection at 
λ = 220 nm (A, B) or 260 nm (C, D); eluent: 9→90 % (A), 9→72 % (B), 0→90 % (C), and 0→54 % 
(D)acetonitrile in 0.1 % aq. TFA over 20 minutes at flow rate 1 ml/min. 
The cleaved and precipitated crude precursor peptides 17’ and 19’ were used in successive 
oxidation step without chromatographic purification, whereas the crude PNA-peptide hybrids 
21’ and 22’ were purified prior to oxidation. Corresponding yields regarding SPPS of 
precursors and in-solution modification towards final products are summarized in Table 18.  
 
Table 18. Synthesis of aldehyde-bearing guiding units 17, 19, 21 and 22. 
Entry Strategy MW 
Crude 
yield 
[%] 
Purification 
yielda  
[%] 
Oxidation / 
purification yieldb 
[%] 
Overall yield 
[%] 
17 Automated + 27.9 - 6.4 1.8 
19 Automated + 35.9 - 12.0 4.3 
21 Manual -c 44.1 61.0 63.7 17.3 
22 Manual -c 22.5 63.7 52.3 7.5 
a: First chromatographic purification of precursor compounds.  
b: Second chromatographic purification after in-solution modification. 
c: First amino acid (Fmoc-L-Lys(Boc)-OH) was loaded with microwave assistance to resin. 
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3.3.1.3 Synthesis of Psoralen-Decorated PNA Guiding Unit 25 
Synthesis of hybrid molecule 25 was accomplished on solid phase according to Scheme 32 
shown in chapter 3.3.1. PNA chain elongation was performed according to the protocol II 
(chapter 5.2.2.3). After manual chain elongation up to Lys1 (side chain-protected by Mtt 
protecting group), SPPS-compatible psoralen derivative 24 was attached to the N-terminus. 
24 was prepared from 8-hydroxy psoralen (xanthotoxol) via a two-step synthesis comprising 
the attachment of a protected acetic acid derivative by a Williamson ether synthesis towards 
intermediate 24’ and subsequent deprotection of the carboxylate moiety (Scheme 32).[166] A 
good overall yield (67.8 %) of 24 was obtained, though the main loss was caused by the 
chromatographic purification of 24’. However, a sufficient amount of 24 was gained. 
Corresponding NMR spectra of 24’ and 24 demonstrating the purity of respective compounds 
are shown in the appendix. 
 
Scheme 32. The two-step synthesis of 24 from xanthotoxol. 
After the aminoterminal capping of the resin-bound peptide-PNA hybrid with 24, Boc-Gly3-OH 
was coupled to the side chain of Lys1 by the on-resin side chain modification described in 
chapter 3.3.1.2. Final product 25 was gained in sufficient amount and purity for the 
successive studies towards affinity-guided PNA-DNA and PNA-PNA cross-conjugations. The 
overall yield of 25 (10.0 %) was similar to other PNA-based guiding units. 
 
 
3.3.1.4 Synthesis of PNA guiding units 23, 26, 27, 28 and 29 
PNA-peptide hybrid molecules 23 and 26 – 29 were synthesized by iterative chain elongation 
on solid support, cleavage from resin and chromatographic purification. Generally, two 
various protocols were applied for PNA chain elongation (chapter 5.2.2.2 and 5.2.2.3), 
whereby protocol I is featured by a larger excess of Fmoc-protected PNA monomers and 
coupling reagents with numerous washing steps between coupling, capping, and deprotection 
cycles. Chain elongation protocol II is a cost- and time-saving variant of protocol I with a 
smaller excess of coupling reagents, less washing steps and with application of DMF instead of 
NMP in some cases. The corresponding yields of respective compounds are listed in Table 19.  
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Table 19. Synthesis of PNA-peptide hybrids 23 and 26 – 29. 
Entry 
Number of 
PNA 
residues 
Number of 
overall 
residues 
PNA chain-
elongation 
protocol 
Crude 
yield 
[%] 
Purification 
yield  
[%] 
Overall 
yield 
[%] 
23 10 12 I 69.8 44.0 30.7 
26 14 15 I+II
a 37.6 26.6 10.0 
27 10 16 II 30.9 50.4 15.6 
28 10 23 I 27.0 51.5 13.9 
29 14 20 II 44.2 12.6 5.6 
a: Coupling up to c5 with protocol I; coupling of last four PNAs with protocol II.  
Generally, the application of protocol I resulted in slightly better yields, but a direct 
comparison of the batches is not possible due to different numbers of incorporated PNAs and 
considering the impact of further peptidic residues. However, the variance between crude 
yield and overall yield demonstrated that the purity of the crude product was much higher 
when using protocol I. In conclusion, it was found that the protocol II provides sufficient 
coupling efficacy for shorter PNA sequences of up to 10 residues, but for longer PNA 
sequences it resulted in drastic loss of purity. A generic protocol for PNA SPS could not be 
established during the presented work, thus the combination of the two protocols was found 
to be optimal as it was demonstrated for PNA-peptide hybrid 26 (compared to 29). 
 
 
3.3.1.5 Synthesis of Toxin-Loaded PNA Guiding unit 30 
Synthesis of the toxin-loaded hybrid molecule 30 was realized using the strategy depicted in 
Scheme 27 (chapter 3.3.1). First, precursor molecule 30’ was prepared on solid phase using 
the PNA chain elongation protocol I. After cleavage from solid support and precipitation, 30’ 
was yielded in sufficient purity (chromatographic profile shown in appendix) for successive 
conjugation to the toxin.  
Since SPAAC was chosen as conjugation technique, a strained triple bond moiety had to be 
installed into the payload toxin as reaction counterpart. Therefore, the toxin ispinesib was 
decorated with a BCN group by in-solution coupling of a commercially available NHS-pre-
activated BCN leading to molecule 31 (Scheme 33).  
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Scheme 33. Reaction scheme towards formation of 31 from ispinesib. 
In preliminary experiments it was found that, although the reaction was quantitative 
regarding the consumption of BCN-NHS, the chromatographic isolation of 31 was not efficient 
due to low recovery rate and purity. Hence, a decision was made to treat 30’ directly with the 
respective reaction mixture after consumption of the BCN-NHS. Formation of 31 and SPAAC 
with 30’, were monitored via HPLC and ESI-MS. The progress of cycloaddition was assessed 
from the integrals of respective peaks of the chromatographic traces (Figure 50). Thus, 79.6 
and 89.1 % conversion was calculated for two different batches with the same reaction setup. 
The slightly greasy profile of the product peak at Rt = 19.3 min was supposed to be caused by 
the formation of a mixture of steroisomers (regarding to the relative configuration of C1 and 
C8 within the BCN moiety). A mean second-order kinetic constant of k2 = 0.55 M-1s-1 was 
calculated for the two corresponding SPAAC batches which is similar to published values (0.2-
0.3 M-1s-1).[170] The slightly higher values obtained in the presented work were presumably 
caused by the excess of the BCN component 31 (2 eq. related to 30’). 
 
Figure 50. Chromatographic profiles of the reaction mixture of SPAAC of 30’ and 31 towards formation of 30. UV 
detection at λ = 260 nm; eluent: 0→ 54% acetonitrile in 0.1 % aq. TFA over 20 minutes at flow rate 1 
ml/min. Divers traces of samples analyzed after distinct reaction times are marked with corresponding 
colors. 
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Chromatographic isolation yielded 30 (66.7 %) in sufficient purity for subsequent sortase A-
mediated conjugation to the Fc scaffold. 
 
 
3.3.1.6 Recombinant Production of Fc scaffold 
The production of homodimeric Fc scaffold, C-terminally decorated with the recognition site 
for sortase A-mediated ligation (LPETG), was performed by Stephan Dickgießer from Kolmar 
group. Recombinant expression was realized in suspension-adapted human embryonic kidney 
(HEK293-6E) cells transiently transfected with Fc fragment-encoding plasmid pEXPR-IBA42 
and the produced protein was purified using protein A chromatography. Since this part of 
project was not a subject of presented work, further experimental data and protocols are 
presented in a respective publication.[171] 
 
 
3.3.2 Characterization and Evaluation of Activity 
3.3.2.1 SPANC of Guiding Unit Pairs 
Alkyne-nitrone cycloaddition of synthetic guiding unit pairs 16 and 17, 18 and 19, and 20 
and 21 were examined in a series of test-reactions comprising respective model compounds, 
an N-hydroxylamine component and a catalyst for the nitrone-formation. The reaction setup 
was based on the protocol reported by Temming et al. in 2013,[172] whereby the 
stoichiometry, temperature, or incubation time were varied. In Scheme 34 the alkyne-nitrone 
cycloaddition between the five-heptad E/K coiled coil 18 and 19 is shown as an example of 
the affinity-guided SPANC. 
 
Scheme 34. Reaction scheme of the affinity-guided SPANC of 18 and 19 towards a covalently linked heterodimer. 
Coils are depicted as green (Kcoil) and blue (Ecoil) cartoon, whereby the shapes were chosen only for 
graphic representation and do not reflect the real geometric data of the molecules. An enlarged image of 
the scheme is given in the appendix. 
In a general approach, an aldehyde-bearing molecule and its alkyne counterpart were 
incubated in neutral to slightly acidic buffered solution for 1 h. Subsequently, p-anisidine and 
an N-hydroxylamine derivative of choice were added and the reaction mixture was shaken at 
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ambient temperature or under cooling on ice. The reaction progress was monitored by HPLC 
and ESI-MS; in few experiments the samples were diluted afterwards with acetonitrile since 
precipitation was observed. The isolation of the cycloaddition product was not possible due to 
the small batch sizes of the test reactions and formation of a side-product with similar Rt 
(explained in the next chapter). Hence, the efficacy of the reaction was assessed from the 
consumption of the aldehyde components along with reaction progress using HPLC analysis. 
In view of its application to the site-selective one-pot ligation of multiple components the 
affinity-guided coupling had to be optimized regarding conversion, reaction rate and 
specificity. An important issue was to minimize excess of the alkyne component to enhance 
selectivity. Indeed, in the majority of the reported protocols concerning SPANC of 
biomolecules, the alkyne component was used in 5-10 eq. excess to accelerate the 
reaction.[172-173] As we assume that pre-orientation of the reactive moieties boosts their local 
concentration per se, the guiding unit pairs were applied in the present work almost 
equimolarly.  
Therefore, the next parameters were varied: batch size (200-1500 µl), final concentration of 
reactants (max. 200 µM, concentration adjusted to minimally required for analysis), 
stoichiometry of guiding units, concentration of hydroxylamine derivatives (1 – 20 eq.) and p-
anisidine (5 – 50 eq.), coupling and incubation conditions (prior to reaction initiation and 
during SPANC, respectively), buffer solutions, and order and timing of reactant/catalyst 
addition. Moreover, few approaches employing in situ generated aldehydes were also tested. 
Detailed information on the setup for SPANC test reactions are given in chapter 5.3.2 (coiled-
coil) and 5.3.3 (PNA), respectively.  
Coiled-Coil Guiding Units 
Initial affinity-guided SPANC experiments were conducted with the three-heptad and five-
heptad coiled-coil peptides; respective data are given in Table 20. In these experiments, the 
formation of a covalently conjugated product was confirmed by ESI-MS. Detailed information 
is given in chapter 5.3.2.  
Table 20. Setups and conversion of preliminary affinity-guided SPANC experiments using three-heptad and five-
heptad coiled coils.  
Setup A
a Bb 
Eq. 
A:B 
[A] 
(µM) 
[MeNOH] 
(µM) Analysis 
Conversionc 
(%) 
1 16 17 1:1 125 150 HPLC, ESI-MS 74.1±5.2e 
2 18 19 1:1 50 60 ESI-MS n. c. 
3 18 19 1:1 50 240 ESI-MS n. c. 
4 18 19 1:1 50 240 HPLC, ESI-MS 69.8 
5d 18 19 1:1 50 240 HPLC, ESI-MS 61.2 
a: BCN-decorated guiding unit. 
b: Aldehyde-bearing guiding unit. 
c: Conversion calculated from decrease in HPLC traces of aldehyde-bearing guiding unit. 
d: Reaction performed in water pH 7.0. 
e: Mean value of conversions of two reaction batches using same setup. 
n.c.: Conversion not calculated. 
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In all setups, guiding units were used equimolarly and their conversion into the conjugations 
products cp1 and cp2 (list of conjugation products given in appendix) was determined as 60 
– 75 %. In case of setup 1 using the three-heptad coiled coils 16 and 17, precipitation of the 
ligation product cp1 was observed after 1 h. This precipitate was dissolved by addition of 
acetonitrile and analyzed by HPLC. The chromatographic profiles of the monitored reaction 
are shown in Figure 51A. 
 
Figure 51. Chromatographic profiles of the reaction mixture of A: SPANC between 16 and 17 (setup 1) and B: 
SPANC between 18 and 19 (setup 4) towards formation of the heterodimeric conjugation product. UV 
detection at λ = 220 nm; eluent: 9→90 % acetonitrile in 0.1 % aq. TFA over 20 minutes at flow rate 1 
ml/min. Divers traces of samples analyzed after distinct reaction times are marked with corresponding 
colors. 
A conversion of 74.1% regarding 17 was calculated, while the absorption profile of 16 
showed its consume during the reaction. The reaction with the five-heptad guiding units 18 
and 19 (setup 4) had similar conversion rate (chromatographic profile shown in Figure 51B). 
A mean second-order kinetic constant of k2 = 1.88 M-1s-1 was calculated for setup 1 while a 
higher k2 of 4.61 M-1s-1 was determined for setup 4 indicating a faster reaction for the five-
heptad coiled-coil system. This outcome is presumably caused by the fact that the used three-
heptad coiled coils can form homo- and hetero oligomers, as shown by size exclusion 
chromatographic analysis (SEC, see appendix) in a preliminary study. Thus, the five-heptad 
coiled-coil system appeared more advantageous for affinity-guided conjugation and for 
successive HPLC analysis, thus, further SPANC experiments were performed using this model 
system. 
The formation of cp2 was confirmed by ESI-MS and HPLC analysis. The mass spectrum of the 
conjugation product (setup 4, after HPLC isolation) is exemplarily shown in Figure 52A. 
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Figure 52. ESI mass spectra of the main product fraction of test reactions A: using setup 4 and B: using setup 8 
upon chromatographic purification of the reaction mixture after a reaction time of 150 min (Rt = 16.1 
min). Spectra are in positive mode. Corresponding m/z signals of calculated and found species are listed 
in the table below.  
The reaction was performed in ammonium acetate buffer to assure its direct analysis by LC-
MS. Indeed, under these conditions the E/K coils could easily become multiply charged upon 
ionization. Thus, a number of positively charged species with a complex ionization pattern 
was observed due to the formation of ammonium, sodium, or potassium (traces found in dist. 
water used for preparation of buffers and HPLC eluent) salts. This leads to the strong 
background signals and made the evaluation of the spectrum difficult. Nevertheless, the m/z 
of the desired conjugation product were found as 7 – 13 times charged cations.  
Furthermore, a SPANC experiment employing the five-heptad coiled coils was performed in 
non-buffered aqueous milieu at pH 7.0 (setup 5). A conversion of 61.2 % (regarding 19) was 
determined and a second-order kinetic constant of k2 = 3.55 M-1s-1was calculated. Both values 
were slightly worse than those for setup 4, which indicated that the non-buffered reaction was 
less efficient for SPANC, presumably due to the change in pH by addition of MeNOH·HCl as 
reaction initiator. 
To check the selectivity provided by the affinity-guided approach, further SPANC setups were 
developed in the presence of benzaldehyde as competitor of 19 (setup 6 – 9). The reaction 
efficacy and selectivity was evaluated by alteration in conversion of 19 and by investigation of 
all relevant HPLC fractions by ESI-MS towards corresponding signals of the benzaldehyde-
conjugation product cp3. Information and data of the setups are summarized in Table 21. 
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Table 21. Setups and conversion of affinity-guided SPANC using five-heptad coiled coils in presence of 
benzaldehyde as a competitive reactant. 
Setup A
a Bb Cc 
Eq. 
A:B:C 
[A] 
[µM] Analysis 
Conversiond 
[%] 
6 18 19 benzaldehyde 1:1:1 50 HPLC, ESI-MS 80.0 
7 18 19 benzaldehyde 2:3:2 100 HPLC, ESI-MS 71.5 
8 18 19 benzaldehyde 1:1:1 150 HPLC, ESI-MS 79.3 
9e 18 - benzaldehyde 1:0:10 100 HPLC, ESI-MS 50.1 
a: BCN-decorated guiding unit. 
b: Aldehyde-bearing guiding unit. 
c: Competitive aldehyde component. 
d: Conversion calculated from decrease in HPLC trace of aldehyde-bearing guiding unit after termination of 
reaction (when no further consumption of B was observed). 
e: Control experiment using 18 and benzaldehyde. Conversion calculated from consumption of 18. 
 
All conversions regarding 19 were in similar range (70 – 80%) as found for setup 4 without 
competitive aldehyde component. All reactions were performed in ammonium acetate buffer 
pH 6.5 with an excess of MeNOH (2.5-5 eq.). The slightly poorer conversion found for setup 7 
was caused by the small excess of 19 (1.3 eq.) for this setup. During reaction monitoring 
(Figure 53A), all relevant HPLC fractions were collected and analyzed by ESI-MS, but in none 
of the fractions the corresponding signals of cp3 were found (Figure 52B).  
 
 
Figure 53. Chromatographic profiles of the reaction mixture of A: SPANC between 18 and 19 (setup 8) and B: 
SPANC between 18 and benzaldehyde (setup 9) towards formation of conjugation products. UV detection 
at λ = 220 nm; eluent: 9→90 % acetonitrile in 0.1 % aq. TFA over 20 minutes at flow rate 1 ml/min. 
Diverse traces of samples analyzed after distinct reaction times are marked with corresponding colors. 
 
To evaluate the SPANC reactivity of 18 against benzaldehyde, a control reaction was 
performed (setup 9). The HPLC profile of the monitored reaction (Figure 53B) indicated the 
consumption of 18 along with reaction progress, but in the MS spectrum of the newly formed 
fraction (Rt = 16.1 min) the signals corresponding to the cp3 were found only in traces 
(spectrum given in appendix).  
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At this point, we recognized that in none of the test reactions the aldehyde-bearing guiding 
units were fully consumed, whereas the signals of their reaction counterparts disappeared 
after a certain reaction time. Hence, we 
hypothesized that the BCN-comprising 
component underwent a competitive 
side reaction. To evaluate this 
assumption, a control experiment 
employing only guiding unit 18 and 
MeNOH was performed (setup 10). 
The reaction was conducted in 
ammonium acetate buffer at pH 6.5 
and a 20-fold excess of MeNOH was 
applied. No distinct changes were 
found in the HPLC traces during 
reaction progress. However, ESI-MS 
analysis showed the signals of the 
conjugation product between MeNOH 
and 18 (cp4, Scheme 35) along with 
those corresponding to unmodified 18 
(Figure 54).  
 
 
 
 
 
Figure 54. ESI mass spectra of the reaction mixture of the control reaction with only 18 and MeNOH (setup 10) 
after a reaction time of 24 h. A: averaged ionization signals at 9.0 – 9.5 min. B: averaged ionization 
signals at 9.5 – 9.8 min. Spectra are in positive mode. Corresponding m/z signals of calculated and found 
species are listed in the table below.  
Scheme 35. General SPANC with BCN and a nitrone, in situ
formed from an aldehyde (black) and suspected side 
reaction towards formation of a conjugation product 
between BCN and MeNOH (red). 
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This product cp4 exhibited a similar retention time as the 
unmodified 18, thus the HPLC traces were 
indistinguishable. Therefore the determination of 
conversion and reaction rate for this side reaction was not 
possible. But as the MS signals corresponding to 18 still 
remained after a reaction time of 1 day despite the excess 
of MeNOH, this undesired side-reaction was supposed to 
be generally slower than SPANC. Interestingly, this 
observation has not been reported in previous publications 
dealing with alkyne-nitrone cycloaddition of 
biomolecules,[77, 172-173] presumably due to the fact that in 
all cases the BCN component was employed in excess (5 – 
10 eq., equimolar to MeNOH). Nevertheless, the stoichiometry of the reactants was further 
kept nearly equimolar in the present work. 
Further test reactions with an alternative aldehyde-bearing competitive peptide 32 (Figure 
55) were performed (setup 11 and 12). Peptide 32 is an SFTI-derived matriptase inhibitor 
with an aldehyde installed via the Lys side-chain as a conjugation site. It was synthesized by 
Heiko Fittler[142b] using a similar procedure as described for the aldehyde-bearing peptides 17 
and 19. The advantage of 32 over benzaldehyde was that the consumption of the peptide can 
be monitored by RP-HPLC, whereas benzaldehyde was eluted without interaction with the 
column material. Information and data of the setups are summarized in Table 22. 
Table 22. Setups and conversion of affinity-guided SPANC using five-heptad coiled coils in presence of peptide 32 
as a competitive reactant. 
Setup A
a Bb Cc 
Eq. 
A:B:C 
[A] 
[µM] Analysis 
Conversiond 
[%] 
11 18 19 32 1:1:1 100 HPLC, ESI-MS 89.2 
12e 18 - 32 1:0:1 100 HPLC, ESI-MS 60.2 
a: BCN-decorated guiding unit. 
b: Aldehyde-bearing guiding unit. 
c: Competitive aldehyde component. 
d: Conversion calculated from decrease in HPLC trace of aldehyde-bearing guiding unit after termination of 
reaction (when no further consumption of B was observed). 
e: Control experiment using 18 and 32. Conversion calculated from consumption of 32. 
 
The test reaction employing setup 11 exhibited an excellent conversion of about 90 % 
regarding 19 after a reaction time of 5 h. The HPLC profiles of the reaction progress are 
shown in Figure 56A.  
 
RCTKSIPPRCHPD-OHH2N
HN
O
O
O
32
Figure 55. Competitive aldehyde-
bearing peptide 32. 
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Figure 56. Chromatographic profiles of the reaction mixture of A: SPANC between 18 and 19 in presence of 32 
(setup 11) and B: SPANC between 18 and 32 (setup 12) towards formation of conjugation products. UV 
detection at λ = 220 nm; eluent: 9→90 % acetonitrile in 0.1 % aq. TFA over 20 minutes at flow rate 1 
ml/min. Divers traces of samples analyzed after distinct reaction times are marked with corresponding 
colors. 
 
In none of the relevant HPLC fractions the corresponding signals of conjugation product 
between 32 and 18 (cp5) were found. A fraction with Rt = 12.0 min was also collected and 
analyzed by ESI-MS but only the m/z corresponding to 32 were observed. In all SPANC 
experiments the nitrone intermediate could not be detected by MS analysis, presumably due 
to the reverse reaction to the corresponding aldehydes during ionization or by the acidic 
HPLC and LC-MS eluent.[173b] The analyzed fraction is presumed to belong to the nitrone 
intermediate of 32. Analogously to the setups using benzaldehyde, the general SPANC 
reactivity of 32 was evaluated in a test reaction lacking guiding unit 19 (setup 12, Figure 
56B). The formation of cp5 was confirmed by MS analysis and 60.2% conversion of 32 was 
determined. A second-order kinetic constant of k2 = 0.39 M-1s-1 was calculated for this non-
templated reaction, whereas the affinity-guided reaction (setup 11) exhibited a significantly 
enhanced reaction rate with k2 = 3.57 M-1s-1, hence the benefits of the affinity guided 
approach towards reaction rate and selectivity was proven by these experiments. 
Furthermore, an additional reaction setup where the aldehyde component was formed in situ 
(without chromatographic purification) prior to SPANC was developed and tested (setup 13). 
The oxidation of 19’ was quenched by addition of 4-methoxythiophenol (MeOPhSH) and 
further procedure was similar to those described for the SPANC setups 2 – 5. The completion 
of oxidation was confirmed by MS analysis of the reaction mixture as no signals of the 
precursor 19’ were found in the spectrum. A conversion of 72.2 % was calculated for 19 from 
the HPLC traces of the monitored reaction (figure given in appendix), which was similar to 
the values of all other test reactions using this guiding unit pair. But in contrast to the 
reaction using the solitaire aldehyde, the reaction rate was significantly lower (k2 = 
0.66 M-1s-1) and only traces of cp2 were found in MS analysis. Possible reasons for this 
outcome were, for instance, the interruption of the conjugation process by quenching agents 
or the decrease in complexation efficacy of the guiding units by the application of a more 
complicated solvent system with several additional compounds. However, it was shown that 
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the approach comprising an in situ oxidation of the amino alcohol component is also 
applicable for the affinity-guided SPANC, whereby further optimization must be done. 
All conversions and kinetic data of the test reactions of coiled coil-guided SPANC and control 
reactions are summarized in Table 23.  
 
Table 23. Conversion and kinetic data of affinity-guided SPANC experiments using coiled-coil guiding units. 
Setup A
a Bb Cc 
Eq. 
A:B:C 
Conversiond 
[%] 
k2 
[M-1s-1] R2 e 
Data 
pointsf 
1 16 17 - 1:1 74.1 1.88 0.931 6 
4 18 19 - 1:1 69.8 4.16 0.981 3 
5 18 19 - 1:1 61.2 3.56 0.991 3 
6 18 19 benzaldh. 1:1:1 80.0 7.24 0.825 5 
7 18 19 benzaldh. 2:3:2 71.5 2.34 0.596 3 
8 18 19 benzaldh. 1:1:1 79.3 7.82 0.783 4 
9 18 - benzaldh. 1:0:10 50.1 1.42 0.476 3 
11 18 19 32 1:1:1 89.2 3.57 0.707 5 
12 18 - 32 1:0:1 60.2 0.39 0.681 3 
13 18 19' - 1:1 72.2 0.66 0.757 3 
a: BCN-decorated guiding unit. 
b: Aldehyde-bearing guiding unit. 
c: Competitive aldehyde component. 
d: Conversion calculated from decrease in HPLC trace of aldehyde-bearing guiding unit after termination of 
reaction (when no further consumption of B was observed). 
e: Regression coefficient of trend line determined for calculation of k2. 
f: Number of data points used for the liner regression. 
As an excess of MeNOH was used in each reaction, a simplified kinetic model of a two-
component system could be applied (plots for determination of k2 given in appendix). Due to 
the low number of recorded data points few trend lines of the linear regressions were of low 
quality (R2 < 0.8). Hence, these values should only be considered as approximate values. But 
on the whole, it became obvious that a significantly higher reaction rate was found for 
affinity-guided SPANC approaches. A summary of all affinity-guided SPANC setups with coiled 
coil guiding units is given in the appendix. 
 
PNA Guiding Units 
The basic setup for the test reactions of PNA-guided SPANC experiments was similar to those 
for coiled coil-mediated test reactions, whereby two analytical approaches were examined to 
confirm product formation. In preliminary experiments, a limited applicability of PNAs to ESI-
MS analysis was observed, presumably caused by the high charge density and the ability to 
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form a vast number of multiply charged species, leading to a complex ionization pattern. 
Therefore, two denaturing polyacrylamide gel electrophoresis (PAGE) techniques were used 
as an alternative method to detect conjugate formation. First, an SDS-PAGE with a highly 
concentrated polyacrylamide gel was performed (details given in chapter 5.3.4). As the 
resulted bands were not distinct and sharp, only tendency to form dimers was seen. An SDS-
PAGE gel of the PNA guiding units 20, 21 and the reaction mixtures of SPANC, SPAAC, and 
psoralen cross-linkage, stained with coomassie brilliant blue, is shown in Figure 57.  
 
 
Figure 57. SDS-PAGE gel to monitor diverse PNA-guided conjugation reactions and solitary guiding units 20 and 
21. PM = protein molecular mass marker (low range). Since the electrophoresis behavior of PM and PNAs 
was not comparable, the protein sizes of the marker bands are not given.  
As the protein marker (PM) loaded along with the samples exhibited a different 
electrophoresis behavior as the PNA probes, the marker bands could not be used as references 
and size determination and quantification of the product was not possible. As a second 
electrophoresis technique an urea-PAGE with a highly concentrated and highly cross-linked 
urea-polyacrylamide gel (26% w/v in polyacrylamide and 8 M urea at pH 3) modified from a 
reported protocol for PNA analysis was tested.[174] The experiment was performed more than 
10 times under slightly altered conditions (e.g. voltage of electrophoresis, electrophoresis 
time, and sample preparation) but in none a distinct separation of the bands could be 
observed (gel pictures not shown). As both PAGE techniques were found to be inappropriate 
for reaction monitoring and an optimization was expected to be too cost- and time-
consuming, finally, the conventional strategy using chromatographic isolation and successive 
MS analysis of the collected fractions was chosen. UV detection of HPLC probes was 
performed at 260 nm to minimize the background signals and for facilitated tracking of the 
PNA-containing fractions. 
After preliminary experiments to adjust the concentration range and the gradient of HPLC 
eluents, three standard setups employing BCN-decorated guiding unit 20 and aldehyde-
bearing guiding unit 21 with small variation in reactant stoichiometry were developed (Table 
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24). All reactions were performed in ammonium acetate buffer at pH 6.5 and ambient 
temperature. 
Table 24. Setups and conversion of affinity-guided SPANC using PNA guiding units. 
Setup A
a Bb 
Eq.  
A:B 
[Aa] 
(µM) 
[MeNOH] 
(µM) 
[p-anisidine] 
(µM) 
tcomp 
(min) 
Conversionc 
(%) 
1 20 21 1:1 200 333 333 60 51.0 
2 20 21 4:3 130 667 0 60 52.0 
3 20 21 4:3 130 667 333 60 57.1 
a: BCN-decorated guiding unit. 
b: Aldehyde-bearing guiding unit. 
c: Conversion calculated from decrease in HPLC trace of aldehyde-bearing guiding unit after termination of 
reaction (when no further consumption of B was observed). 
Similarly as observed for the coiled coil-based test reactions, the BCN component was 
consumed within 6 – 7 h, whereby the conversion of the aldehyde-component 21 was about 
50-60 % and generally worse than found for the coiled-coil setups. A further important result 
from these reactions was that the final conversion of the reactant was not distinctly influenced 
by the presence of p-anisidine as the reaction lacking this additive (setup 2) exhibited a 
similar conversion of 21 as the other setups. Chromatographic profiles and the MS spectrum 
of the collected product fraction of the test reaction using setup 3 is shown in Figure 58 and 
Table 25. As expected, the product cp6 was poorly ionizable and possessed the high diversity 
in ionization patterns resulting in a complex spectrum with strong background signals. But the 
m/z corresponding to cp6 were actually found. 
 
 
Figure 58. A: Chromatographic profiles of the reaction mixture of SPANC between 20 and 21 (setup 3) after 120 
min towards formation of a covalently bond heterodimer. UV detection at λ = 260 nm; eluent: 0→72 % 
acetonitrile in 0.1 % aq. TFA over 20 minutes at flow rate 1 ml/min. B: ESI mass spectrum of the main 
product fraction of the test reaction using setup 3 after chromatographic purification of the reaction 
mixture (Rt = 16.3 min). Spectra are in positive mode.  
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Table 25. List of m/z signals corresponding to cp6 found in the ms spectrum given in Figure 58B. 
Species Ions m/z calc. m/z obs. 
cp6 
(M = 6515.60 g/mol) 
[M+4H]4+ 1628.9 1629.9 
[M+5H]5+ 1303.3 1304.2 
[M+6H]6+ 1086.3 1086.9 
[M+7H]7+ 931.3 931.8 
[M+8H]8+ 815.0 815.5 
[M+11H]11+ 591.1 590.3 
 
Addressing the optimization of reaction conditions, test-reactions were performed using the 
general conditions of setups 1-3 and varying buffer system, reaction temperature, and 
complexation time (setup 4-10, 13; Table 26). 
 
Table 26. Setups and conversion of affinity-guided SPANC experiments using PNA guiding units. 
Setup A
a Bb 
Eq.  
A:B 
[Aa] 
(µM) 
Main solvent 
(pH) 
tcomp 
(min) Trct 
Conversionc 
(%) 
4 20 21 4:3 130 HEPESaq (6.0) 60 rt 66.1 
5 20 21 1:1 67 NH4OAcaq (6.0) 60 rt 75.1 
6 20 21 1:1 67 NH4OAcaq (6.0) 60 4°C 75.9 
7 20 21 1:1 67 NaOAcaq (5.0) 60 4°C 55.6 
8 20 21 1:1 67 PBSaq (7.4) 60 4°C 39.3 
9 20 21 6:5 80 HEPESaq (6.0) 60 4°C 73.2 
10 20 21 1:1 220 HEPESaq (6.0) 0 4°C 61.3 
13 20 21 1:1 200 NH4OAcaq (6.0) 60 rt 73.1 
a: BCN-decorated guiding unit. 
b: Aldehyde-bearing guiding unit. 
c: Conversion calculated from decrease in HPLC trace of aldehyde-bearing guiding unit after termination of 
reaction (when no further consumption of B was observed). 
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An improvement in conversion was realized by changing the buffer system, whereby the best 
results were observed in ammonium acetate and HEPES buffer systems at pH 6.0 (10-15 % 
improvement in conversion of 21). Chromatographic profiles and the MS spectrum of the 
collected product fraction in setup 4 is shown exemplary in Figure 59. 
 
 
Figure 59. A: Chromatographic profiles of the reaction mixture of SPANC between 20 and 21 (setup 4) towards 
formation of a covalently bond heterodimer. UV detection at λ = 260 nm; eluent: 0→72 % acetonitrile in 
0.1 % aq. TFA over 20 minutes at flow rate 1 ml/min. B: ESI mass spectrum of the main product fraction 
of the test reaction using setup 4 upon chromatographic purification of the reaction mixture after a 
reaction time of 140 min (Rt = 15.8 min). Spectra are in positive mode. Corresponding m/z signals of 
calculated and found species are listed in the table below.  
As a reaction in sodium acetate buffer (pH 5.0, setup 7) exhibited similar conversion as in 
ammonium acetate buffer pH 6.5 (setup 3) and, contrary, a drastic loss in conversion was 
observed in PBS at pH 7.4, the optimal pH for PNA-guided SPANC was assumed to be slightly 
acidic (pH 6.0). The reactions in HEPES buffer resulted in formation of complex PNA-HEPES 
salts found in MS-spectrum and making the signal mapping extremely complicated. Hence, 
ammonium acetate (pH 6.0) was chosen as the most appropriate buffer for SPANC 
experiments in the present work. Chromatographic profiles and the MS spectrum of the 
collected product fraction of the test reaction using setup 13 is shown exemplary in Figure 
60. 
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Figure 60. A: Chromatographic profiles of the reaction mixture of SPANC between 20 and 21 (setup 13) towards 
formation of a covalently bond heterodimer. UV detection at λ = 260 nm; eluent: 9→63 % acetonitrile in 
0.1 % aq. TFA over 20 minutes at flow rate 1 ml/min. B: ESI mass spectrum of the main product fraction 
of the test reaction using setup 13 upon chromatographic purification of the reaction mixture after a 
reaction time of 280 min (Rt = 14.6 min). Spectra are in positive mode. Corresponding m/z signals of 
calculated and found species are as same as given in Table 26.  
A variation of reaction temperature (ambient temperature or on-ice) resulted in no 
remarkable differences in reaction efficacy, contrary to our expectations that the decrease in 
temperature could eventually suppress the previously discussed side reaction (direct addition 
of MeNOH to BCN group). 
However, in setup 10, the order of reactant addition was altered. Thus, p-anisidine and 
MeNOH was added first to the aldehyde component 21 and the reaction counterpart 20 was 
given later to the mixture (complexation time = 0 min). This experiment resulted in decrease 
of conversion of about 10 %. Further experiments with no pre-complexation of guiding units 
are described later for the SPAAC of PNA guiding units. 
Furthermore, reaction setups using phenyl hydroxylamine (PhNOH) instead of MeNOH as 
nitrone-forming agent were also tested (Table 27) as McKay et al. reported an enhanced 
reaction efficacy for nitrones formed by this alternative hydroxylamine.[77] 
Table 27. Setups and conversion of affinity-guided SPANC using PNA guiding units in combination with phenyl 
hydroxylamine as nitrone-forming agent. 
Setup A
a Bb 
Eq.  
A:B 
[Aa] 
(µM) 
Main solvent 
(pH) 
tcomp 
(min) Trct 
Conversionc 
(%) 
11 20 21 6:5 240 NH4OAcaq (6.5) 60 4°C 50.9 
12 20 21 4:1 320 NH4OAcaq (6.5) 60 4°C 68.5 
a: BCN-decorated guiding unit. 
b: Aldehyde-bearing guiding unit. 
c: Conversion calculated from decrease in HPLC trace of aldehyde-bearing guiding unit after termination of 
reaction (when no further consumption of B was observed). 
 
Contrary to our expectations, no obvious enhancement in conversion of 21 was observed. As 
the signals of the conjugation product between PhNOH and 20 (cp9) were found in MS 
analysis, the presence of the undesired side reaction was confirmed also for these setups. 
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Thus, it was shown that the strongest rate- and efficacy-limiting issue in SPANC was this 
unavoidable side reaction. This fact was also confirmed by the improvement of conversion of 
21 by about 20 % using a four-fold excess of the BCN compound (setup 12) whereby full 
conversion of an aldehyde was still not possible. 
Selectivity of the PNA-guided SPANC was examined in a test reaction comprising 20 and 21 
in the presence of the competitive aldehyde-bearing PNA-peptide hybrid 22 bearing a non-
complementary PNA sequence. All of the three components were mixed equimolarly in 
ammonium acetate buffer pH 6.0 and incubated for 1 h (setup 14). The reaction was initiated 
by addition of MeNOH (5 eq.). The HPLC profiles of the monitored reaction progress are 
given in Figure 61. 
 
Figure 61. Chromatographic profiles of the reaction mixture of SPANC between 20 and 21 in presence of 22 
(setup 14) towards formation of a covalently bond heterodimer. UV detection at λ = 260 nm; eluent: 
9→63 % acetonitrile in 0.1 % aq. TFA over 20 minutes at flow rate 1 ml/min. 
The retention times of both aldehyde-bearing guiding units, 21 and 22, were completely the 
same (Rt = 11.3 min), thus a distinction in HPLC was not possible. Hence, the selectivity was 
evaluated by the presence of the MS signals corresponding to the conjugation product 
between 22 and 20 (cp7) in the spectrum of all relevant fractions. As no traces of a SPANC 
conjugate cp7 was detected, the selectivity of the PNA-guided SPANC was confirmed. This 
outcome was additionally supported by Matrix Assisted Laser Desorption/Ionization mass 
spectrometry (MALDI-MS) of the collected main fractions (Figure 62).  
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Figure 62. MALDI mass spectra of the collected fractions of test reactions using setup 3 after chromatographic 
purification of the reaction mixture (A: Rt = 14.3 – 14.8 min, B: Rt = 13.3 – 14.3 min, C: Rt = 14.8 – 15.8 
min). Spectra are in positive mode. Corresponding m/z signals of calculated and found species are listed 
in the table below. Spectra recorded by Dr. Alesia Tietze (Prof. Thiele group, TU Darmstadt). 
The found m/z of 6929.9 was in good agreement with that calculated for cp6 (m/z = 6515.6) 
whereby two sinapic acid molecules from the matrix surface were added upon measurement 
(additional m/z of + 412.05), which is a frequently reported observation for MALDI-MS.[175] 
The same effect was also found in the doubly charged species with m/z = 3466.3 - 3468.1 
(calculated m/z = 3258.8). In none of the fractions the signals of the side products, neither of 
cp7, nor of cp8, were found. As the retention time in HPLC of the aldehyde-bearing 
compounds 21 and 22 was indistinguishable, only the sum of conversion of these compounds 
could be determined (50.4 %). Since no formation of the cp7 was confirmed, it was supposed 
that after 220 min the remaining signals (Rt = 11.8 min) mainly corresponded to 22. That 
means, 21 was converted into cp6 nearly quantitatively. This assumption was confirmed by 
ESI-MS of the respective fraction where only corresponding m/z signals of 22 were found 
(Figure 63).  
 
Figure 63. ESI mass spectrum of the HPLC-separated reaction mixture of SPANC using setup 14. Fraction at Rt = 
11.8 min (Figure 61) Spectrum in positive mode. Corresponding m/z signals of calculated and found 
species are as same as given in the table on right. a: Found mass mainly corresponded to monohydrate of 
22 (hemiacetale) with M = 3016.95 g/mol. 
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The SPANC reactivity of 22 was evaluated by a test reaction with 20 using a similar setup as 
for the coiled-coil modes system (setup 5, SPANC between 18 and 32). As the m/z 
corresponding to cp8 was found in the ESI-MS spectrum of the reaction mixture after 4 h, the 
general reactivity of 22 was confirmed (MS-spectrum given in appendix). 
Finally, four reaction setups based on the in situ generation of the aldehyde were tested 
(Table 28). All test reactions were performed at ambient temperature after one hour 
incubation of equimolar ratio of the PNA guiding units. 
Table 28. Summary of reaction setups and conversion of affinity-guided SPANC experiments using PNA guiding 
units with in situ oxidation of 21’. 
Setup A
a Bb 
[Aa] 
(µM) 
Main solvent 
(pH) Quenching agent 
Conversionc 
(%) 
15 20 21' 100 NH4OAcaq (6.5) 4-MeOPhSH 51.0 
16 20 21' 200 NH4OAcaq (6.5) 4-MeOPhSH 51.9 
17 20 21' 200 NH4OAc/THFd 4-MeOPhSH 49.5 
18e 20 21' 200 NH4OAc/THFd Ethylene glycol 76.6 
a: BCN-decorated guiding unit. 
b: Aldehyde-bearing guiding unit. 
c: Conversion calculated from decrease in HPLC trace of aldehyde-bearing guiding unit after termination of 
reaction (when no further consumption of B was observed). 
d: 7:5, v/v mixture of NH4OAc buffer pH 6.0 and THF. 
e: PhNOH used instead of MeNOH as nitrone-forming agent. 
The test reactions showed similar conversion as determined for the setups comprising the 
isolated compound 21. In setup 18, employing PhNOH as nitrone-forming agent and ethylene 
glycol as a quenching additive, a good conversion of more than 75 % was found. As described 
for the coiled-coil system, only traces of the corresponding m/z signals of cp6 were found. 
In general, all determined conversions of the aldehyde components in the PNA-guided 
approach were slightly worse compared to those obtained for the coiled coil-guided approach 
(10 – 15 % lower conversion). Similar tendency was observed for the reaction rate in each 
model systems, with the second order kinetic constant k2 being generally smaller by the factor 
of 2-5 in the PNA-guided setups (Table 29). 
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Table 29. Conversion and kinetic data of affinity-guided SPANC experiments using PNA guiding units. 
Setup A
a Bb Cc 
Eq. 
A:B:C 
Conversiond 
[%] 
k2 
[M-1s-1] R2 e 
Data 
pointsf 
4 20 21 - 4:3 66.1 3.03 0.924 5 
6 20 21 - 1:1 75.9 0.97 0.412 4 
7 20 21 - 1:1 55.6 0.61 0.991 6 
8 20 21 - 1:1 39.3 0.12 0.789 5 
9 20 21 - 6:5 73.2 1.86 0.946 5 
10 20 21 - 1:1 61.3 0.74 0.529 3 
11 20 21 - 6:5 50.9 0.34 0.516 4 
12 20 21 - 4:1 68.5 1.40 0.965 5 
13 20 21 - 1:1 73.1 0.80 0.963 3 
14 20 21 22 1:1:1 50.4g 0.90 0.971 3 
16h 20 21 - 1:1 51.9 0.71 0.566 4 
17h 20 21 - 1:1 49.5 0.14 0.339 5 
18h 20 21 - 1:1 76.6 0.69 0.686 6 
a: BCN-decorated guiding unit. 
b: Aldehyde-bearing guiding unit. 
c: Competitive aldehyde component. 
d: Conversion calculated from decrease in HPLC trace of aldehyde-bearing guiding unit after termination of 
reaction (when no further consumption of B was observed). 
e: Regression coefficient of trend line determined for calculation of k2. 
f: Number of data points used for the liner regression. 
g: Sum of decreased ratio of the HPLC signals of 21 and 22. 
h: In situ formation of aldehyde without isolation of 21. 
 
As the number of used data points to determine the kinetic constants were limited, the 
calculated values should only be given as approximate values, especially for those with low R2 
for the linear regression (plots given in appendix). However, the obtained k2 values were still 
in distinctly higher range than the reported ones. Indeed, MacKenzy et al. reported a second 
order kinetic constant k2 of 0.05 M-1s-1 for a non-guided SPANC of BCN with a cyclic nitrone 
and McKay et al. a k2 of 0.09 M-1s-1 for the reaction between dibenzo cyclooctyne (DIBO) and 
benzaldehyde.[77, 173b] A linear relation between the overall conversion of the aldehyde 
component and the kinetic constant was not observed, presumably, due to the fact that the 
reaction progress and efficacy were mainly limited by the unexpected consumption of the BCN 
component by the side-reaction discussed above. Since the direct addition of hydroxylamine 
seemed not to be dramatically fast, the simple incensement in reaction rate would be the best 
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way to suppress this reaction. To this end, the application of biarylazacyclooctynone (BARAC) 
as strained alkyne component with a up to 800 fold higher reported kinetic constant 
compared to BCN could become a viable alternative.[173b]  
A general problem in the isolation of the conjugation product by HPLC was its broad elution 
profile, presumably caused by the formation of stereoisomeric SPANC product, and the fact 
that by-products have similar HPLC retention. Thus, for future approaches a more appropriate 
separation method should be used as e.g. SEC. 
 
SPAAC of PNA Guiding Units 
To underline the benefits of the affinity-guided SPANC approaches, SPAAC test reactions 
employing the BCN-decorated PNA guiding unit 20 and the azide-functionalized PNA guiding 
unit 23 were performed. The general setup of the test reaction (Table 30) was similar to the 
SPANC approaches but since the reaction was non-triggered, the guiding unit pair was not 
pre-incubated.  
Table 30. Setups, conversion, and kinetic data of SPAAC  using PNA guiding units 20 and 23. 
Setup A
a Bb 
Eq.  
(A:B) 
[Aa] 
(µM) 
Main solvent 
(pH) 
Conversionc 
(%) 
k2 
[M-1s-1] 
1 20 23 3:4 130 NH4OAcaq (6.5) 54.4 0.54 
2 20 23 1:1 330 NH4OAcaq (6.5) 33.7d 0.82 
a: BCN-decorated guiding unit. 
b: Aldehyde-bearing guiding unit. 
c: Conversion calculated from decrease in HPLC trace of aldehyde-bearing guiding unit after termination of 
reaction (when no further consumption of B was observed). 
d: Reaction monitored only for 5 h. Reaction progress presumably not terminated. 
Compared to the SPANC approaches, the conversions regarding the azide component 23 
within same reaction time were slightly worse. The calculated k2 values were in similar range 
as found for the affinity-guided SPANC approaches but also slightly worse. As a second-order 
constant of k2 = 0.55 M-1s-1 was calculated for a non-templated SPAAC approach (see chapter 
3.3.1.5) no significant improvement in reaction rate could be observed by application of the 
guiding units. This outcome emphasized the importance of the complexation step before 
initiation of the reaction. The HPLC profiles of the monitored test reaction are given in Figure 
64. The formation of a conjugation product (cp10) was confirmed by ESI-MS.  
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Figure 64. A: Chromatographic profiles of the reaction mixture of SPAAC between 20 and 23 (setup 1) towards 
formation of a covalently bond heterodimer. UV detection at λ = 220 nm; eluent: 0→72 % acetonitrile in 
0.1 % aq. TFA over 20 minutes at flow rate 1 ml/min. B: ESI mass spectrum of the main product fraction 
of the SPAAC using setup 1 after chromatographic purification of the reaction mixture (Rt = 15.8 min). 
Spectra are in positive mode. Corresponding m/z signals of calculated and found species are listed in the 
table below.  
 
 
3.3.2.2 Psoralen Cross-Linkage of PNA Guiding Units 
As an alternative conjugation technique, the UVA-mediated nucleobase cross-linkage by 
psoralen was chosen. Preliminary experiments using solitaire psoralen and the precursor PNA 
guiding units 20’ and 21’ (lacking SPANC-reactive groups) were performed. After incubation 
of the guiding units in PBS at pH 7.0 for hybridization, an excess of psoralen was given to the 
mixture. The mixture was exposed to UVA irradiation with λ = 366 nm. Detailed reaction 
setup is given in chapter 5.3.4.1.  
In full agreement with our expectation (see chapter 3.3.1), a non-controllable addition of 
multiple psoralen molecules to the PNA guiding units occurred, which was indicated by 
precipitation during UVA irradiation and the emerge of multiple peaks in the HPLC traces at 
Rt > 20 min (strongly nonpolar area, Figure 65).  
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Figure 65. Chromatographic profiles of the reaction mixture of UVA-mediated cross-linking between 20’ and 21’ 
with free psoralen molecules. UV detection at λ = 260 nm; eluent: 9→54 % acetonitrile in 0.1 % aq. TFA 
over 20 minutes at flow rate 1 ml/min. 
ESI-MS analysis of the collected fractions showed a vast number of non-assignable signals 
emphasizing the formation of a non-defined mixture of conjugates. Also in SDS-PAGE of the 
test reaction (chapter 3.3.2.1, Figure 57) no distinct bands of conjugation products or traces 
of covalently linked dimers were observed. 
Therefore, a cross-linking strategy using the PNA guiding unit 25 with N-terminally pre-
installed psoralen moiety was pursued. The complementary guiding unit 26 with an 
N-terminal extension by a tata motif (for PNA-PNA cross-linkage) and its DNA analogue 33 
with the sequence 5’TATAGTAGATCACT3’ (for PNA-DNA cross-linkage) were applied.  
Preliminary experiments were performed in Tris-HCl buffer at pH 7.5, ammonium acetate 
buffer at pH 6.5, and sodium acetate buffer at pH 5.0, whereby only in Tris-HCl buffer a 
distinct reaction progress was observed by HPLC analysis. The general reaction setup was 
similar to the reaction with psoralen itself (see chapter 5.3.4.2). The chromatographic profiles 
of the HPLC-monitored reactions of PNA-DNA cross-conjugation and PNA-PNA cross 
conjugations are shown in Figure 66. 
 
Figure 66. Chromatographic profiles of the reaction mixture of UVA-mediated cross-linking using PNA-bound 
psoralen 25 and A: complementary DNA 33; B: complementary PNA 26. UV detection at λ = 260 nm; 
eluent: 0→36 % acetonitrile in 0.1 % aq. TFA over 20 minutes at flow rate 1 ml/min.  
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In general, a distinct reaction progress was only observed after a prolong UVA irradiation 
(about 90 min). In both approaches, the emerging of a novel HPLC peak could be observed, 
whereby no further progress was found after an irradiation time of about 2 h in case of the 
PNA-PNA conjugation, despite both of the reactants remained in reaction mixture. A distinct 
calculation of reactant consumption was not possible as the retention of the reactants and the 
newly formed compound was similar. A proof for formation of the desired heterodimeric 
conjugate (cp12) was also not given as in MS analysis only traces of signals contingently 
matching to the calculated m/z of products were found (MS spectra given in appendix).  
Contrary, the test reaction of PNA-DNA cross-conjugation resulted in nearly full consumption 
(99 % for 25) of both the guiding units while emerging of a novel product peak at 17.8 min. 
But since only traces of highly charged and complexly ionized signals of the potential product 
were found in MS, a proof for formation of desired product conjugate cp13 was not given for 
this approach, too. Thus, the results of the preliminary studies given in this subchapter should 
be interpreted with wariness and further detailed investigation is needed. Especially, a more 
effective method for qualification of the PNA-DNA conjugate must be developed as the DNA 
molecule 33 was not detected in ESI-MS, even as pure compound (data not shown).  
Furthermore, it was observed that a too long and intensive irradiation caused precipitation 
and formation of strongly nonpolar compounds, similar to the reaction using free psoralen. 
This indicated that uncontrolled addition of psoralen was not suppressed as this molecule 
possesses two cycloaddition sites. 
 
 
3.3.2.3 Functionalization of Protein Scaffolds with PNA Guiding Units  
The synthesis of a multivalent ADC by affinity-guided simultaneous conjugation of several 
ligands on a protein scaffold is an ultimate goal of this project. Therefore, the attachment of 
PNA guiding units 27 – 30 to an antibody Fc fragment was examined. Enzymatic ligation by 
Sortase A from Staphylococcus aureus (eSrtA) was chosen for coupling of the peptide-PNA-
hybrids to the Fc scaffold.[176] Both counterparts were functionalized with the specific 
recognition sequence required for the Sortase A catalysis. This transpeptidase specifically 
cleaves a peptide bond between Thr and Gly of the sequence LPXTG forming a thioacyl 
intermediate with further attachment of an activated carbonyl to an N-terminal oligo-Gly 
motif.[177]  
In initial sortase-catalyzed condensations, the Fc fragment reacted with compound 28 
comprising a TEV protease cleavage sequence and a Lys(ε-Ser) unit between the N-terminal 
pentaglycine and the PNA guiding unit. Conjugation took place in sortase reaction buffer 
(50 mM Tris, 150 mM NaCl, 5 mM CaCl2, pH 7.5). The success of ligation was examined by 
reducing SDS-PAGE (Figure 67) of the reaction mixture after 30 min incubation at 22 °C. 
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Figure 67. Reducing SDS-PAGE gel to monitor eSrtA-catalyzed ligation between Fc and 28 towards 34. Expected 
molecular masses of reduced Fc and 34 are 29 kDa and 33 kDa, respectively. PM: protein molecular mass 
marker. 
28 was used at different concentrations (10 – 80 eq. to the Fc fragment). The protein bands 
between 17 kDa and 25 kDa corresponded to eSrtA with a molecular mass of about 18 kDa. A 
distinct shift of the band corresponding to the Fc fragment (~ 29 kDa) towards increased 
molecular mass was observed in all reaction mixtures comprising the PNA ligand, compared 
to the control reaction lacking 28. This small shift was in good agreement with our 
expectations, as the molecular mass of the desired Fc-PNA conjugate 34 was calculated as 
33043 g/mol. Interestingly, a frequently reported side reaction of sortase A-mediated ligation, 
the recognition of ε-amino groups of Lys as substrate for sortase leading to an unproductive 
polypeptide cross-linking,[178] was not observed for the discussed setup. In contrast, a faint 
band was recognizable in lane VI in the range of 50 – 60 kDa, which matches the dimeric Fc 
fragment despite the application of a reducing PAGE. However, the full conversion of the Fc 
fragment to the PNA conjugate within a short reaction time was demonstrated verifying the 
applicability of the method to the decoration of proteins with PNA ligands. 
Further, the resulted construct 34 was used in cargo delivery and cell internalization studies 
(by Stephan Dickgießer). The outline and aims of this study using a cMet receptor-addressing 
DNA aptamer was already explained in Scheme 17 (chapter 2.3.1) and chapter 3.3.1. 
Thereby, the attachment of a toxic payload to the protein scaffold was abandoned due to low 
solubility of resulting conjugates. Instead, the Fc fragment was N-terminally labeled with a 
fluorescent TAMRA derivative via formylglycine-generating enzyme (FGE)-mediated oxime 
ligation (Fc’). However, Dickgießer succeeded in the functionalization of the respective Fc 
scaffold with the DNA aptamer by self-assembly of complementary PNA/DNA pair: between 
the Fc-conjugated PNA sequence and the extended sequence on 3’ end of the aptamer. The 
hybridization of the aptamer to 34’ was monitored by SEC and the stability of the DNA-PNA 
complex was evaluated by SEC upon incubation of the Fc-PNA/DNA complex 35 for several 
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days. Both experiments confirmed the high stability and hybridization efficacy of the resulted 
aptamer/PNA-Fc construct. Furthermore, a melting curve analysis of the respective DNA/PNA 
duplex was performed. Thereby, a melting temperature (Tm) of 51.2±0.2 °C was determined 
which is slightly higher as the value reported for the PNA A/PNA B duplex (Tm = 46 °C) 
demonstrating the high stability of the resulted hybridized complex. More detailed 
information and resulted data are given in respective publication.[171] 
The applicability of the complex molecule 35 as drug delivery scaffold and for cell 
internalization was evaluated in a set of receptor-binding assays and experiments employing 
cMet-overexpressing cancer cells, i. a. biolayer interferometry (BLI) experiments of the Fc’-28 
conjugate 35b with recombinantly expressed cMet receptors, affinity titration and several flow 
cytometry studies of binding of 35b to cMet-positive cells and cMet-negative cells.  
An equilibrium dissociation constant KD of 12.9 nM was determined for 35b with cMet 
receptor by BLI experiments, whereas the aptamer solely exhibited a value in the same range 
(KD = 7.8 nM). The dissociation constant of 35b (cMet-positive cells) were determined to 
24.5 nM from the titration experiments. Binding specificity and selective internalization of the 
construct by target cells was evaluated by flow cytometry and, conclusively, by fluorescence 
microscopy.  
On the whole, the investigation towards synthesis and characterization (including evaluation 
of bioactivity) of an Fc-based delivery scaffold with a high flexibility for target receptors was 
accomplished within this follow-up study mainly elaborated by Stephan Dickgießer. As this 
part of the project was not essential for the present work, more detailed information is not 
given; it can be found in the respective publication.[171]  
Moreover, the eSrtA-mediated conjugation of PNA guiding unit 27 to Fc was also 
demonstrated. Corresponding SDS-PAGE of the ligation is given in Figure 70, lanes V, VIII, 
XV, and XVIII. 
The ligation was characterized by a similar band pattern as shown for the conjugation of 28 
(see Figure 68), but the reaction efficacy seemed to be slightly worse than the former 
experiment as full conversion of the labeled Fc was not achieved. Moreover, the Fc fragment 
seemed to undergo the side reaction discussed above, which was considerable from the 
formation of a third band corresponding to a covalently linked dimeric Fc.  
Conclusively, the eSrtA-mediated ligation comprising 29 bearing a pentaglycine-elongated 
PNA sequence, the toxin-loaded PNA 30 and the LPETG-modified Fc fragment was performed. 
The same experimental setup was employed as described for the ligation of 28. The stained 
gels after SDS-PAGE of the test reactions are depicted in Figure 70, lanes VII, X, XVII, and XX. 
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Figure 68. Reducing SDS-PAGE gel of monitored conjugation of 27, 29, and 30 to Fc via eSrtA-mediated ligation 
and control experiments with various incubation times. PM: protein molecular mass marker. PNA: PNA 
guiding unit 27, 29, and 30. tinc: incubation time. Lane VIII – X: Supernatant of reaction mixture after 
centrifugation of precipitate. Lane XVIII – XX: Pellet after centrifugation, resolved in SDS-PAGE loading 
buffer (250 mM Tris/HCl pH 8.0, 7.5 % SDS, 25 % glycerol, 0.25 mg/mL bromophenol blue, 12.5 % 2-
mercaptoethanol) and heated at 90 °C.  Gels were stained with coomassie-brilliant blue. PAGE 
experiments performed and evaluated by Stephan Dickgießer. 
The conjugation of 29 was characterized by a similar separation pattern in SDS-PAGE as seen 
for the analogous reaction of 27. No full conversion of the Fc scaffold was observed and the 
side reaction towards Fc dimerization occurred. Furthermore, small precipitation of the 
conjugation product was found. 
eSrtA-mediated ligation of 30 using the strategy shown in Scheme 17B (chapter 2.3.1) and 
Scheme 27 (chapter 3.3.1) with the Fc scaffold failed due to low solubility of the resulting 
conjugate. The shift between the protein band in the supernatant and in the centrifuged and 
redissolved pellet (Figure 70, lane IX and XIX) showed that the ligation was successful. But 
due to the poor solubility of the conjugation product in water, further investigation of this 
construct was not possible. As the observed precipitation was assumed to be caused by a 
hydrophobic toxin ispinesib loaded on the guiding unit, an alternative toxin should be 
considered. 
It was demonstrated that the eSrtA-mediated ligation is an appropriate technique to load 
tagged PNA guiding units onto protein scaffolds. All ligation experiments, with the exception 
of the preliminary study using PNA guiding unit 28, were performed by Stephan Dickgießer. 
 
 
3.3.3 Digest of Chapter 3.3 
A number of peptidic and peptidomimetic guiding unit molecules and corresponding building 
blocks comprising conjugation sites for bioorthogonal ligation (compounds 15 - 31) were 
synthesized on solid support and by conventional solution-phase chemistry. Their general 
applicability for affinity-guided ligation was studied. All compounds were obtained in 
appropriate yield and purity depending on the strategy.  
The efficacy of the bioorthogonal conjugations was evaluated by the conversion of the 
reactants and by determination of the kinetic constants of test reactions. SPANC was chosen 
as a ligation technique, and a series of test reactions with varied parameters were conducted. 
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Generally, the reactions comprising the coiled-coil guiding units demonstrated a slightly 
better conversion (50-90 %) compared to those comprising PNA guiding units (40-80 %). 
Interestingly, the reported KD values for coiled-coil interactions are significantly higher than 
the values for PNA-PNA interactions.[122, 135] An explanation for this outcome was not found. 
However, it was found that the major conversion-limiting factor was the undesired addition of 
the hydroxylamine to the BCN moiety. Thus, the affinity between the guiding units was 
assumed to be not of prime importance for the discussed approach. Nevertheless, the affinity-
guided ligation needs further investigation (e.g. application of more reactive strained alkynes 
as BARAC or cyclic nitrones) to suppress the discussed side reaction and reach full conversion 
of the reactants.  
Nonetheless, the advantage of the affinity-guided approach over the non-guided ones was 
demonstrated by comparison of the second-order kinetic constants. Thus, all k2 values 
determined for the affinity-guided SPANC with appropriate reaction conditions (0.8 - 3 M-1s-1 
for PNA-guided reactions, 2 – 7 M-1s-1 for coiled coil-guided reactions) were significantly 
higher than those determined for the non-guided approach (0.39 M-1s-1) or the reported 
reactions under similar conditions (k2 < 0.1 M-1s-1). Table 32 shows a summary of reported or 
experimentally determined k2 values of bioorthogonal conjugations used in the present work. 
 
Table 31. Summary of experimentally determined reactant conversions and k2 of all bioorthogonal ligations used 
in the present work with few reported k2 values of similar reactions as reference.  
Reaction Templated Trigger 
Conversion 
[%] 
k2 (determ.) 
[M-1s-1] 
k2 (ref.)a 
[M-1s-1] 
SPANC + (coils) hydroxylamine 50 – 90 2 – 7 - 
SPANC + (PNAs) hydroxylamine 40 – 80 0.8 –3 - 
SPANC - hydroxylamine 60 0.39 0.05[173b] 
SPAAC + (PNAs) none 54 0.54 - 
SPAAC - none 90 0.55 0.2 – 0.3[170] 
MS-couplingb - none 72 0.21 0.15[169] 
Psoralen CLc + (PNAs) UVA 99d - - 
a: Reported k2 values of reactions with similar reactants or conditions. 
b: Maleimide-sulfhydryl conjugation. 
c: UVA-mediated cross-linkage of PNA-bound psoralen to complementary DNA. 
d: Formation of desired product not confirmed. 
The experimentally determined data shown in this table should be considered as 
approximated values due to the analytical inaccuracy and insufficient number of data points 
used for the calculations. However, it is obvious that the affinity-guided approach provided a 
significant improvement of reaction rate, especially when the reaction start was triggered, 
ensuring pre-orientation of the guiding units.  
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Furthermore, the selectivity of the affinity-guided approach was demonstrated with the coiled 
coil-guided SPANC, whereby no cycloaddition of a non-guided nitrone component to the BCN 
compounds was observed in a competitive assay. The selectivity of the PNA-guided approach 
was also investigated and yielded the same outcome. However, for the application in 
simultaneous protein multiple labeling, this model system needs further investigation in view 
of sequence selectivity.  
According to the expectations, the UVA-mediated psoralen cross-linkage of PNAs employing 
solitaire psoralen resulted in its uncontrollable addition and non-selective intra- and 
intermolecular cross-linking. Cross-conjugation experiments using PNA-bound psoralen were 
attempted but the formation of the desired product was not confirmed due to the lack of 
appropriate analytical methods.  
Conclusively, the eSrtA-mediated ligation of PNA guiding units with a protein scaffold was 
studied. Conjugation of PNA-peptide hybrids 27 and 28 to an antibody Fc fragment was 
efficient and fast. The binding properties and bioactivity of the resulted construct 34 and its 
derivative 35 loaded with a cMet receptor-binding aptamer were evaluated in a follow-up 
study by Stephan Dickgießer. 
The synthesis of a toxin-loaded ADC using the ispinesib-preloaded PNA construct 30 by eSrtA-
mediated ligation failed due to poor solubility.  
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4 Conclusion and Outlook 
4.1 Protease Inhibitor with Triazolyl Backbone Mimic 
Application of a triazole structural motif to engineering of peptide-based protease inhibitors 
was studied. Using sunflower trypsin inhibitor (SFTI-1) as a scaffold, an inhibitor of human 
neutrophil elastase comprising a trans-amide surrogate at the P1-P1’ position was rationally 
designed. For the first time a 1,4-disubstituted triazole was used as a non-cleavable 
replacement for the scissile bond in a BBI-derived protease inhibitor. It was demonstrated that 
the triazole-bearing peptide possessed enhanced proteolytic stability in vitro. Indeed, upon 
incubation of synthetic inhibitor 4 with its target enzyme no cleavage at the P1-P1’ position 
was observed within 24 h, while 17 % of the parent peptide 3 was degraded under this 
conditions. Interestingly, introduction of a triazolyl moiety enhanced the general resistance of 
4 against proteolysis. However, with the Ki of 563.63 nM, its inhibitory potency was 
decreased compared to 3 (Ki of 144.48 nM). Nevertheless, 4 appeared significantly more 
potent than similar SFTI derivatives comprising prolyl-based backbone mimics at the 
respective position.[154] Therefore, triazole surrogates can become a valuable tool for the 
engineering of intrinsically potent but proteolysis-prone inhibitors. 
 
Comparing different SFTI-derived peptides and peptide mimetics, we found that enhancement 
of proteolytic stability was more pronounced for the linear precursors, presumably due to the 
fact that the cyclic backbone supports substrate re-condensation at the active site of an 
enzyme (Scheme 14). Therefore, we assume that mimicking a scissile bond by triazolyl motif 
can appear beneficial for peptidic inhibitors comprising linear backbone and possessing poor 
intrinsic stability against proteolysis, or can be used to convert highly affine substrates to 
potential inhibitors. However, this issue requires further investigation. 
 
4.2 PHIP-Active Functional Peptides 
For the first time para-hydrogen induced polarization (PHIP), a promising method to enhance 
NMR signals while analyzing biological macromolecules, was studied in a series of specifically 
labeled protease inhibitors in the working group of Prof. Gerd Buntkowsky. The results of this 
systematic study have been recently reported.[50b] 
 
A triple bond as a target for catalytic hydrogenation with para-enriched hydrogen was 
installed at the desired position within the backbone of an SFTI-based trypsin inhibitor 
yielding constructs 5 – 12. Propargylglycine (Pra), pentynoic acid and O-propargyltyrosine 
(Tyr(O-propargyl)) were examined as labels in PHIP experiments. The aminoterminus was 
designated as the optimal labeling site. 
 
We hypothesized that electron-donating groups in spatial proximity to the unsaturated bond 
affect hydrogenation efficacy, hence, PHIP effect. Indeed, none of the peptides 5, 6, 9, and 11 
labeled with Pra and comprising a single carbon atom between the triple bond and the 
peptide backbone, exhibited significant signal enhancement. Similarly, high intrinsic PHIP 
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activity of 4-pentynoic acid was also attenuated by this effect when installed within peptide 8. 
However, strong signal enhancement of about 70 was detected upon PHIP experiments in 
aqueous media using Tyr(O-propargyl)-labeled constructs 7, 10, and 12 possessing the 
spatially isolated label. In general, the remoteness of hydrogenation target from a peptide 
backbone was found to be the crucial requirement for efficient PHIP. 
 
Poisoning of a hydrogenation catalyst was another factor found to influence the PHIP activity. 
However, the substitution of catalyst-poisoning groups (disulfide, terminal amine) did not 
result in significant signal enhancement. Therefore, we assumed that the poisoning of a 
catalyst is caused by a complex of factors rather than by a distinct functional group. 
 
Generally, the investigated PHIP labels possessed short relaxation time T1 despite their SE was 
sufficiently high. Therefore, further studies aimed on extension of T1 are required. To this end, 
polarization transfer to neighboring 13C or NMR-active heteroatoms[179] as well as transfer of 
the hyperpolarized nuclear spin order to long-lived nuclear singlet state[180] should be 
considered. 
 
Additionally, we showed that PHIP-labeled compounds preserved their bioactivity. Indeed, 
constructs 5 – 13 inhibited trypsin in the range of tight-binding inhibitors. This issue is of 
profound importance for further investigations regarding PHIP studies of enzyme-inhibitor 
systems. Indeed, as trypsin-like proteases retain their activity in water-methanol mixtures[181] 
used in our NMR experiments, PHIP-based investigations can be extended to enzyme-ligand 
interactions and to the proteases of therapeutic relevance. 
 
4.3 Affinity-Guided Chemical Ligation towards Multifunctionalization of 
Biomolecular Scaffolds 
Application of affinity-guided ligation strategy to the synthesis of biomolecular conjugates was 
studied on oligopeptides and on a multifunctional protein scaffold derived from the Fc 
fragment of an antibody. As guiding counterparts, coiled coil systems and complementary 
PNA strands were used.  
 
For SPANC-based ligations, reactive BCN with in situ generated nitrone were installed at the 
aminotermini of, respectively, 3 and 5 heptad coiled coils and complementary PNA oligomers. 
In our hands, affinity-guided SPANC on these constructs provided advantages over non-
guided/non-triggered reactions of oligopeptides/PNAs in view of reaction kinetics and 
selectivity. Interestingly, compared to the PNA guiding pair, coiled coil-guided SPANC was 
characterized by better conversion and faster reaction rate, suggesting that strength of 
interaction between guiding units plays a minor role.  
 
An unexpected side-reaction was observed during SPANC in the case of equimolar ratio of 
reaction counterparts; this transformation which disabled the full consumption of starting 
reagents has not been reported in the literature so far. Further investigations should be 
focused on the suppression of this reaction as application of SPANC for simultaneous multi-
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labeling of proteins is not possible until full conversion of reactants is ensured. An alternative 
purification method should be considered as well. Additionally, further investigations aimed 
on enhanced selectivity of PNA guiding units are required. 
 
Applicability of sortase-mediated ligation for the attachment of PNA-comprising ligands to an 
Fc scaffold was studied. The resulted Fc-PNA conjugate was used as a modular platform for 
the generation of multifunctionalized cellular delivery module comprising non-peptidic 
binders of therapeutically relevant targets, a fluorescent label, and vehicles for cellular 
delivery (Stephan Dickgießer). Further studies should be aimed on improvement of stability 
of the conjugate upon covalent linkage between Fc-PNA and aptamer ligand. Affinity-guided 
approach should be applied to this system and a toxic payload should be covalently attached 
resulting in an antibody-drug conjugate. 
 
 
4.4 Closing Remarks 
The present thesis summarizes three research projects addressing fundamental studies aimed 
on application of non-natural elements to design and synthesis of bioactive peptide mimetics, 
bioconjugates, and hybrid macromolecules. The study comprised computational and 
knowledge-based design, total synthesis, and evaluation of biologic activity as well as 
application to NMR-based structural analysis. 
Results summarized in the present work were reported in two scientific publications[50b, 171] 
and should be considered as milestones for further investigations aimed on application of the 
discussed concepts to biomedical studies. 
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5 Experimental Part 
5.1 General 
5.1.1 Reagents and Solvents 
All reagents were from highest or semi-highest grade and used without further purification. 
Commonly available chemicals and solvents were purchased from Iris Biotech (Marktredwitz, 
Germany), Acros Organics (Geel, Belgium), Novabiochem (Bad Solden, Germany), Merck 
(Darmstadt, Germany), Sigma-Aldrich (St. Louis, USA), Rapp Polymere (Tübingen, Germany), 
Karl Roth (Karlsruhe, Germany), Carbolution Chemicals (Saarbrücken, Germany), Fischer 
Scientific (Schwerte, Germany), or Bachem (Bubendor, Swiss). Azide- and alkyne-bearing 
building blocks Fmoc-L-propargylglycine (Fmoc-L-Pra-OH) and Fmoc-L-azidohomoalanine 
(Fmoc-L-Aha-OH) were obtained from Iris Biotech. Fmoc-PNA monomers were purchased from 
PNA Bio (Thousand Oaks, USA). BCN-bearing building blocks BCN-NHS and BCN-(POE)3-NH-
C(O)-(CH2)3-maleimide precursor mixture were acquired from Synaffix (Molenstraat, 
Netherlands). The building blocks Fmoc-L-propargyltyrosine (Fmoc-L-Tyr(O-propargyl)-OH) 
and Fmoc-L-Tyr(All)-OH were purchased from PolyPetide Laboratory (Wolfenbüttel, 
Germany), 4-Pentynoic acid, the Bestmann-Ohira reagent and 
chloro(pentamethylcyclopentadienyl)(cyclooctadiene)-ruthenium(II) (Cp*RuCl(COD)) from 
Sigma-Aldrich. Xanthotoxol were purchased by Carbosynth (Compton, UK). Human neutrophil 
elastase was purchased from Serva Electrophoresis (Heidelberg, Germany). Ispinesib was 
purchased from ShangHai Biochempartner (Shang-Hai, China). Boc-Leu-N(OMe)Me was 
purchased from Chem-Implex International Inc. (Illinois, USA). The catalyst 
Rh(dppb)(COD)BF4 was purchased from Strem Chemicals Inc. (Boston, USA). 
For special purposes dry and degassed solvents were prepared. DMF was heated along with 
molecular sieve 3 Å under reduced pressure and finally flushed with dry argon. DCM was pre-
dried over calcium hydride, then distilled over calcium hydride and finally flushed with dry 
argon. Diethyl ether was pre-dried over molecular sieve 3 Å, then distilled from sodium 
benzophenone ketyl and flushed with dry argon. 
 
 
5.1.2 Analytical and Preparative Instruments 
Chromatographic analysis of purchased or synthesized compounds using HPLC was conducted 
with a Varian 920-LC® system equipped with a Phenomenex Hypersil® 5u BDS C18 LC 
column (150×4.6 mm, 5 µm, 130 Å) or Agilent 1260 Infinity® HPLC system equipped with 
the same column. Semi-preparative RP-HPLC was performed on a Varian modular system 
comprising a PrepStar® 218 Solvent Delivery Module, a ProStar® 410 HPLC autosampler 
and a ProStar® 325 Dual Wavelength UV-Vis HPLC Detector using a YMC J'sphere® ODS-
H80 C-18 LC column (250×20 mm, 4 µm, 8 nm)). The eluent system for all HPLC systems 
comprised eluent A (0.1 % aq. TFA) and eluent B (90 % aq. MeCN containing 0.1 % TFA). For 
both of the eluents, deionized and degassed water with Milli-Q®-grade water was used. The 
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recorded data was processed and analyzed using the Varian Galaxy© software or Agilent 
HPLC Chemstation© software. 
ESI mass spectra were recorded with a Shimadzu LCMS-2020 equipped with a Phenomenex 
Jupiter® 5u C4 LC column (50×1 mm, 5 µm, 300 Å) or Phenomenex Hypersil® 5u BDS C18 
LC column (150×4.6 mm, 5 µm, 130 Å) and a Bruker-Franzen Esquire® LC mass 
spectrometer. The eluent system consisted of eluent A (0.1 % aq. formic acid, LC-MS grade) 
and eluent B (100 % MeCN containing 0.1 % formic acid, LC-MS grade). The recorded data 
was processed and analyzed using the Shimadzu Labsolution© software. 
MALDI mass spectra were recorded with Shimadzu AXIMATM TOF2 by Dr. Alesia Tietze (Prof. 
Thiele group) at the Frauenhofer LBF (Darmstadt). 
IR spectra were measured on PerkinElmer FT IR spectrometer 1000PC. Freeze-dried samples 
were homogeneously mixed and pressed to potassium bromide pellets.  
Loading determination of SPPS resins was performed via UV/VIS absorption spectrometry 
using an UV/VIS spectrometer Shimadzu UV-1650PC. 
Enzyme kinetics assays were measured with a Tecan GENios® microplate reader using the 
Xfluor 4TM system for recording the measured absorption kinetics.  
Standard NMR studies were conducted on a Bruker Advance® II 300 instrument (300 MHz). 
All samples were dissolved in chloroform-d1, methanol-d4, DMSO-d6, or D2O and measured 
using a symmetrical NMR microtube. Resulting spectra were processed and analyzed using 
the Mestrelab Research MestReNova© software. 
Libration of dry substances was realized by evaporation of volatile organic solvents using a 
rotary evaporator Buchi Rotavapor® R-ZZZ. H2O/MeCN mixtures and residues of other 
organic solvents were removed by freeze-drying with a Martin Christ Gefriertrockungsanalgen 
Alpha-2-4-LSC® at -85 °C combined with an Ilmvac GmbH high vacuum pump type 109012. 
 
 
5.1.3 Storage 
All Fmoc-protected amino acids, PNA monomers, resins, purified and dry peptides and 
peptidomimetics, heat-sensitive building blocks, coupling reagents, enzymes, and catalysts 
were stored at -20 °C. BCN-bearing building blocks, purified PNA-containing peptides and 
stock solution of inhibitors and enzymes were kept at -80 °C. During solid-phase synthesis, the 
loaded resins were dried by multiple rinsing with DCM and diethyl ether and preserved in a 
desiccator under reduced pressure at ambient temperature. For short-time storage the 
peptide-loaded resin were stored in DMF or NMP at 4 °C. 
 
 
5.2 Synthesis 
5.2.1 General Procedure of Solid-Phase Peptide Synthesis 
All peptides and peptidomimetics were synthesized by manual or partially-automated Fmoc-
SPPS. For microwave-assisted synthesis, a CEM Discover® SPS microwave peptide synthesizer 
platform was used.  
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5.2.1.1 Loading of First Fmoc-Amino Acid on Solid Support 
Loading onto AmphiSpheres® 40 RAM resin 
 
The resin was pre-swollen in DCM (60 min) and DMF (30 min) and thoroughly washed with 
DMF. To remove the Fmoc protecting group on the linker, the resin was treated with 2×2 – 
5 ml 20 % piperidine in DMF for 5 min at ambient temperature. (30 W over 3 min at 50 °C 
when using microwave irradiation). After thorough washing with 3×DMF and 2×DCM, the 
pre-activated amino acid (4 eq. Fmoc-amino acid, 3.9 eq. 2-(1H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluronoium hexafluorophosphate (HBTU), 8 eq. N,N-diisopropylethylamine (DIEA)) 
was added and the reaction mixture was shaken for 30 min at ambient temperature (30 W 
over 15 min at 50 °C when using microwave irradiation).  
 
Loading onto 2-Cl-Trt resin 
 
The resin was pre-swollen in DCM for 60 min. 1 eq. of the first Fmoc-Amino acid and 4 eq. of 
DIEA were dissolved in 2 – 5 ml DCM and added to the resin. The coupling mixture was 
shaken for 2.5 h continuously at ambient temperature. After removal of the coupling solution 
via filtration, the loaded resin was treated with 3×6 mL DCM/MeOH/DIEA (17:2:1, v:v:v) for 
3 min and finally washed with 3×5 mL DCM and 2×5 mL DMF. 
 
Preloaded Rapp Polymere TentaGel® resins 
 
TentaGel® resins were already preloaded with the corresponding Fmoc- and side chain 
protected amino acids. The preloaded resins were swollen in DCM (60 min) and DMF 
(30 min). 
 
 
5.2.1.2 Manual Chain Elongation 
Canonical amino acids were attached by double coupling employing 4 eq. of the 
corresponding Fmoc-protected amino acid, 3.9 eq. of HBTU and 8 eq. of DIEA or, in case of 
cysteine, 6 eq. of 2,4,6-trimethylpyridine (collidine). For coupling of Fmoc-Arg, Fmoc-Cys, 
and Fmoc-His, triple coupling was applied. Attachment of non-canonical amino acids and 
amino acids with non-common side chain protecting groups were performed as triple coupling 
employing 3 eq. of Fmoc-Pra, 2.9 eq. of 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl 
uronium hexafluorophosphate (HATU) and 6 eq. of DIEA for the first coupling and 2 eq. 
Fmoc-Pra, 1.9 eq. HATU and 4 eq. DIEA for the further two coupling steps. For Cys, Arg and 
non-canonical amino acids, a microwave irradiation of 30 W was used over 30 min at 50 °C, 
and for other canonical amino acids - 30 W over 15 min at 50 °C. Fmoc deprotection was 
accomplished in two steps using 20 % piperidine in DMF: initial deprotection at 50 °C, 30 W 
over 0.5 min followed by a second deprotection at 50 °C, 30 W over 5 min. In case of non-
microwave-assisted synthesis, each reaction time, for coupling and deprotection, were 
elongated by twice and the reaction vessel was shaken at ambient temperature. 
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After each double/triple coupling/deprotection step, the peptide-resin were washed with DMF 
3×5 ml and 2×5 ml DCM. Among each single coupling and deprotection steps, the peptide-
resin was washed with 3×5 ml DMF. 
 
 
5.2.1.3 Automated Chain Elongation 
Automated chain elongation was performed in a CEM Liberty® 12-channel peptide 
synthesizer or Liberty Blue® peptide synthesizer on a Discover SPS microwave peptide 
synthesizer platform. The pre-swollen (peptide-) resin was set into a 30 ml PTFE reaction 
chamber.  
Upon using the Liberty® system, all canonical amino acids were attached by double or triple 
coupling employing 4 eq. of the corresponding Fmoc-amino acid, 4. eq. HBTU and 8 eq. of 
DIEA, or in case of Cys 4 eq. of collidine. Arg and Cys were coupled using a two-step 
microwave program: 1.) RT, 0 W, 25 min; 2.) 75 °C, 25 W, 0.5 min (Arg) and 1. RT, 0 W, 2 
min; 2.) 50 °C, 25 W, 4 min (Cys), respectively. All other canonical amino acids were coupled 
using a standard microwave program: 75 °C, 21 W, 5 min. Fmoc deprotection was realized in 
two steps by treating with 20 % piperidine in DMF at 75 °C, 42 W for 0.5 min (initial 
deprotection) followed by a second deprotection step with 20% piperidine in DMF at 75 °C, 
42 W for 3 min. 
Upon usage of the Liberty Blue® system, all canonical amino acids despite Arg and Cys were 
attached using a single coupling method. Each coupling was performed with 5 eq. 
corresponding Fmoc-amino acid, 5 eq. DIC, and 5 eq. cyano(hydroxyimino)acetic acid ethyl 
ester (Oxyma). Each single coupling cycle comprises a two-step microwave method: 1.) 75°C, 
170 W, 15 s; 2.) 90 °C, 30 W, 110 s. For Arg and Cys a double coupling method was applied.  
The two-step coupling method for Arg and Cys comprises: 1.) 25 °C, 0 W, 25 min; 2.) 75 °C, 
30 W, 2 min (Arg) and 1.) 25°C, 0 W, 2 min; 2.) 50°C, 35 W, 4 min, respectively. Fmoc 
deprotection was performed with 20 % piperidine v/v 0.1 M Oxyma in DMF using a two-step 
microwave method at 75 °C, 155 W for 15 s, followed by 90 °C, 30 W for 50 s. 
 
 
5.2.1.4 Cleavage and Isolation 
Cleavage of peptides from the solid support and removal of side chain protecting groups were 
achieved via acidolysis of the dry peptide-resin using a cleavage cocktail consisting of 
TFA/H2O/anisole/triethylsilane (TES) (47:1:1:1, v:v:v:v). In case of Cys-containing peptides 
an amount of 1,4-dithiothreitol (DTT) was added. The cleavage mixture was shaken for 3 h at 
ambient temperature followed by precipitation and subsequent washing (3×) using diethyl 
ether or methyl tert-butyl ether (MTBE) to yield crude unprotected peptides. 
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5.2.2 General Procedure of Solid-Phase Synthesis of PNA-Peptide Hybrids 
All PNA-peptide hybrids were synthesized completely manually. Microwave-assisted coupling 
and deprotection was only performed before coupling of the first Fmoc-PNA to the peptide-
resin. 
 
 
5.2.2.1 Loading of First Fmoc-Amino Acid on Solid Support 
Loading onto AmphiSpheres® 40 RAM resin 
Loading of the first amino acid onto RAM resin was performed as described in chapter 5.2.1.1. 
 
 
5.2.2.2 PNA Chain Elongation Protocol I 
One coupling cycle for the chain elongation of PNAs comprised a double coupling, a double 
capping, and a double deprotection step separated by several washing steps. For coupling 
5 eq. of the corresponding Fmoc-PNA monomer, 4.9 eq. HATU, 5 eq. 1-hydroxybenzotriazole 
(HOBt), 10 eq. DIEA, and 10 eq. 2,6-lutidine were dissolved in NMP. The final concentration 
of the Fmoc-PNA monomer in the coupling mixture was set to 0.25 M. After pre-activation of 
the coupling mixture for 10 min, the solution was given to an N-terminally deprotected 
peptide-resin. The reaction mixture was continuously shaken for 60 min at ambient 
temperature. After removal of the coupling mixture by filtration, the resin was thoroughly 
washed with 5×2 ml NMP, 5×2 ml DCM, and 5×2 ml NMP and the coupling step was 
repeated. After second coupling the peptide-loaded resin was washed thoroughly with 5×2 ml 
5 % DIEA in NMP, 5×2 ml DCM, and 5×2 ml NMP. Quenching of the non-reacted free 
N-termini was carried out by treating of the peptide-resin with a capping mixture consisting of 
Ac2O, 2,6-lutidine, NMP (1:2:7, v:v:v) for 5 min at ambient temperature. After second 
capping step, the peptide-resin was washed with 5×2 ml 5 % DIEA in NMP, 5×2 ml DCM, 
and 5×2 ml NMP. For N-terminal Fmoc deprotection, the peptide-resin was shaken in 2 ml of 
20 % piperidine in NMP for 4 min at ambient temperature. After second deprotection step, 
the peptide-resin was thoroughly washed with 5×2 ml NMP, 5×2 ml DCM, and 5×2 ml NMP. 
Coupling cycles of canonical amino acids after the PNA sequence were performed as described 
in 5.2.1.2, but in all steps, NMP was used as solvent instead of DMF. 
 
 
5.2.2.3 PNA Chain Elongation Protocol II 
One coupling cycle for the chain elongation of PNAs comprised a double coupling, a double 
capping, and a double deprotection step. 2 eq. of the corresponding Fmoc-PNA monomer, 1.9 
eq. HATU, and 4 eq. DIEA were dissolved in 0.5 ml NMP. The coupling solution was pre-
activated for 10 min and the solution was given to the N-terminally deprotected peptide-resin. 
The reaction mixture was continuously shaken for 60 min at ambient temperature. After 
removal of the coupling mixture by filtration, the resin was thoroughly washed with 3×2 ml 
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DMF, 2×2 ml DCM, 1×2 ml DMF, and 2×2 ml NMP and the coupling step was repeated. 
After second coupling, the peptide-loaded resin was washed thoroughly with 5×2 ml 5 % 
DIEA in DMF, 5×2 ml DCM, 3×2 ml DMF, and 2×2 ml NMP. Capping was performed by 
shaking of the peptide-resin in a capping mixture (same composition as in 5.2.2.2) for 5 min 
at ambient temperature. After second capping step, the peptide-resin was washed with 
5×2 ml 5 % DIEA in DMF, 5×2 ml DCM, 3×2 ml DMF, and 2×2 ml NMP. Fmoc deprotection 
was achieved by shaking of the peptide-resin in 2 ml of 20 % piperidine in NMP for 4 min at 
ambient temperature. Subsequently, the peptide-resin was thoroughly washed with 5×2 ml 
DMF, 5×2 ml DCM, 3×2 ml DMF, and 2×2 ml NMP. 
Coupling cycles of canonical amino acids after the PNA sequence were performed as described 
in 5.2.1.2, but in all reaction steps, NMP was used as solvent instead of DMF. Additionally, a 
capping step was introduced between the coupling and deprotection steps using a capping 
mixture consisting of Ac2O, DIEA, NMP (1:1:18, v:v:v) for 5 min. 
 
 
5.2.2.4 Cleavage and Isolation 
Cleavage and isolation of the PNA-peptide hybrids was achieved as same as described in 
chapter 5.2.1.4. 
 
 
5.2.3 Synthesis of Protease Inhibitors 
5.2.3.1 [Phe5]SFTI-1[1,14] (1) 
 
 
1 was synthesized partially automated on the Liberty® 12-channel peptide synthesizer 
system. As a solid support, 500 mg of Fmoc-Asp(tBu)-preloaded TentaGel® S AC resin with 
0.22 mmol/g loading capacity was chosen (batch size: 0.1 mmol). Iterative chain elongation 
was achieved following the mentioned general protocol described in 5.2.1.3.   
Cleavage of the linear peptide precursor 1’ from solid support and removal of the side chain 
protecting groups was achieved by acidolysis using 5 ml of the standard cleavage cocktail as 
described in 5.2.1.4. After precipitation and washing with diethyl ether, 133.3 mg of dried 
crude unprotected precursor peptide 1’ (0.086 mmol, 85.9 %) was yielded. RP-HPLC: Rt = 
21.7 min, 18 % MeCN over 2 min followed by 18 %→40.5 % MeCN over 20 min in 0.1 % aq. 
TFA at flow rate 1 ml/min. ESI-MS: m/z: [M+H]+ obsd. = 1552.9 (calc = 1553.1), 
[M+2H]2+ obsd. = 777.3 (calc = 777.0), [M-H]- obsd. = 1550.8 (calc = 1551.1). 
20 mg (0.013 mmol) precursor 1’ was dissolved in 10 ml folding buffer (0.1 M (NH4)2CO3 aq. 
with 0.5 % DMSO) and the reaction mixture was stirred for three days while monitoring with 
RP-HPLC and ESI-MS of the collected fractions. The solvent was removed by lyophilization 
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followed by purification via semi-preparative RP-HPLC to yield 7.9 mg of oxidatively folded 
peptide 1 (0.005 mmol, 39.5 % purification yield, 33.9 % overall yield). RP-HPLC: Rt = 24.5 
min, 18 % MeCN over 2 min followed by 18 %→40.5 % MeCN over 20 min in 0.1 % aq. TFA 
at flow rate 1 ml/min. ESI-MS: m/z: [M+H]+ obsd. = 1550.9 (calc = 1551.1), [M+2H]2+ 
obsd. = 776.3 (calc = 776.0), [M-H]- obsd. = 1548.8 (calc = 1549.1). 
 
5.2.3.2 [Leu5]SFTI-1[1,14] (2) 
 
 
2 was synthesized partially automated on the Liberty® 12-channel peptide synthesizer 
system. The choice of solid support, the iterative chain elongation, cleavage from solid 
support, and isolation of the linear precursor peptide was performed completely as same as 
described for 1 in 5.2.3.1. 119.2 mg of dried crude precursor peptide 2’ (0.079 mmol, 78.5 %) 
was yielded. RP-HPLC: Rt = 18.9 min, 18 % MeCN over 2 min followed by 18 %→40.5 % 
MeCN over 20 min in 0.1 % aq. TFA at flow rate 1 ml/min. ESI-MS: m/z: [M+H]+ obsd. = 
1519.0 (calc = 1519.8), [M+2H]2+ obsd. = 760.4 (calc = 760.4), [M-H]- obsd. = 1517.5 (calc 
= 1517.8), [M-2H]2- obsd. = 758.8 (calc = 758.4). 
20 mg (0.013 mmol) precursor 2’ was oxidatively folded and purified via semipreparative 
HPLC as described for 1. 7.1 mg of oxidatively folded peptide 2 (0.005 mmol, 34.8 % 
purification yield, 27.3 % overall yield) was obtained. RP-HPLC: Rt = 20.4 min, 18 % MeCN 
over 2 min followed by 18 %→40.5 % MeCN over 20 min in 0.1 % aq. TFA at flow rate 1 
ml/min. ESI-MS: m/z: [M+H]+ obsd. = 1518.0 (calc = 1517.8), [M+2H]2+ obsd. = 759.4 
(calc = 759.4), [M-H]- obsd. = 1514.9 (calc = 1515.8). 
 
 
5.2.3.3 des-Gly1,-Pro13,-Asp14[Nle2,Leu5,Gln10,Tyr12]SFTI-1[1,14] (3) 
 
 
3 was synthesized manually with microwave assistance. As a solid support, 500 mg of Fmoc-
Tyr(tBu)-preloaded TentaGel® S AC resin with 0.22 mmol/g loading capacity  was chosen 
(batch size: 0.1 mmol). Iterative chain elongation was achieved following the mentioned 
general protocol described in 5.2.1.2. Cleavage and isolation of the crude linear precursor 
peptide was as same as described for 1 (5.2.3.1). 103.5 mg of dried crude precursor peptide 
3’ (0.083 mmol, 83.6 %) was yielded. RP-HPLC: Rt = 11.6 min, 9 % MeCN over 2 min 
followed by 9 %→90 % MeCN over 20 min in 0.1 % aq. TFA at flow rate 1 ml/min. ESI-MS: 
m/z: [M+H]+ obsd. = 1237.8 (calc = 1238.5), [M+2H]2+ obsd. = 619.6 (calc = 619.7), [M-
H]- obsd. = 1235.5 (calc = 1236.5), [M-2H]2- obsd. = 617.6 (calc = 617.7). 
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10 mg (0.008 mmol) linear precursor peptide 3’ was eluted in 400 µl acetonitrile, followed by 
3 ml redox-buffer (1 M guanidiumhydrochlorid, 50 mM Na2HPO4, pH 7 with 400 µl DMSO, 
and 400 µl trifluoroethanol (TFE)). The folding mixture was shaken at ambient temperature 
for 3 days while monitoring via RP-HPLC and ESI-MS. The reaction mixture was directly 
injected into the semipreparative RP-HPLC and after lyophilization of the collected product 
fractions, 0.8 mg of oxidatively folded peptide 3 (0.65 µmol, 8.2 % purification yield, 6.8 % 
overall yield) was obtained. RP-HPLC: Rt = 13.6 min, 9 % MeCN over 2 min followed by 9 
%→90 % MeCN over 20 min in 0.1 % aq. TFA at flow rate 1 ml/min. ESI-MS: m/z: [M+H]+ 
obsd. = 1235.8 (calc = 1236.5), [M+2H]2+ obsd. = 618.8 (calc = 618.7), [M-H]- obsd. = 
1233.5 (calc = 1234.5). 
 
 
5.2.3.4 (2S)-2-Azido-3-O-tert-butyl-propanoic acid (4a)  
 
 
The synthesis of 4a was performed according to a reported protocol.[149] A solution of sodium 
azide (5 g, 76.9 mmol) was dissolved in distilled H2O (13 ml) with DCM (22 ml) and cooled 
on an ice bath. Triflyl anhydride (2.5 ml, 14.9 mmol) was added slowly over 5 min with a 
syringe and stirred continuously for 2 h while cooling. The organic phase of the reaction 
mixture was separated using a separatory funnel. The aqueous layer was extracted with 
2×20 ml DCM and the organic fractions containing the triflyl azide were collected and 
washed once with saturated Na2CO3 and used without further purification for the next 
reaction step.  
1.29 g H-L-Ser(tBu)-OH (8.0 mmol), 1.63 g K2CO3 (11.8 mmol), 26 mg Cu(II)SO4·5H2O 
(0.104 mmol) were dissolved in a mixture of 25 ml H2O and 50 ml MeOH. The solution of 
triflyl azide in DCM previously prepared was added to the mixture and stirred over night at 
ambient temperature. After removal of the organic solvents under reduced pressure the 
remained suspension was dissolved in 150 ml H2O. The pH of the aqueous solution was 
adjusted to 6 with conc. HCl and 150 ml of PBS (0.25 M, pH 6.2) was added. The aqueous 
layer was washed with 4×100 ml EtOAc to remove sulfonamide by product, acidified with 
conc. HCl to pH 2, and finally the product was isolated by extraction with 3×100 ml EtOAc. 
The combined EtOAc fractions were dried over anhydrous MgSO4 and the organic solvent was 
removed under reduced pressure yielding 1.12 g of 4a as pale oil (6.0 mmol, 75 %). No 
further purification was needed. 1H NMR (300 MHz, CD2Cl2) δ = 9.94 (OH, 1 H), 3.90 (t, 1 H, 
J= 3 Hz), 3.77 (dd, J= 3 Hz, 2 H), 1.16 (s, 9 H). 13C NMR (75 MHz, CD2Cl2) δ = 174.1, 74.4, 
62.7, 61.4, 27.2. 
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5.2.3.5 (2S,3S)-N-(tert-butyloxycarbonyl)-1-ethynyl-3-methyl-butylamine (4b) 
 
 
2.56 g of Boc-protected Weinreb amide Boc-L-Leu-N(OMe)Me (9.3 mmol) were weighted in a 
two-necked flask and flushed with dry argon. 75 ml of dry DCM was added while argon back 
flush from bottom and the resulting solution was cooled to -78 °C in an acetone/dry ice bath. 
12 ml of Diisobutylaluminum hydride (DIBAH, 1 M in DCM, 12 mmol) was added drop-wise 
with an argon-flushed syringe to the solution and the reaction mixture was stirred for 40 min 
at -78 °C. The reaction was quenched by addition of 20 ml anhydrous MeOH.  
The quenched mixture was allowed to warm to 0 °C with an ice/water bath and 2.76 g K2CO3 
(20 mmol) was carefully added. Subsequently, 2.15 mg of dimethyl-(1-diazo-2-
oxopropyl)phosphonate (Ohira-Bestmann reagent, 2.15 g, 11.2 mmol) was added drop-wise 
to the suspension. The resulted reaction mixture was stirred for 18 h at ambient temperature. 
The organic solvents were removed under reduced pressure and the resulted solid was eluted 
in 200 ml EtOAc/H2O (1:1, v/v). After separation of the layers, the organic phase was washed 
with 3×50 ml H2O and dried over anhydrous MgSO4 and finally, the organic solvent was 
removed under reduced pressure. The resulted pale oil was purified by column 
chromatography (silica gel 600,040-0,063 mm, 230 – 300 mesh, eluent CHCl3 /CH3OH, 100:1, 
v/v) and after removal of the solvents 623.6 mg of 4b (3.0 mmol, 32.3 %) was obtained. 1H 
NMR (300 MHz, CDCl3) δ = 4.80 (s, 1 H), 4.41 (dd, J= 6 Hz, 1 H), 2.32 (d, J = 3 Hz, 1 H), 
1.86 – 1.71 (m, J = 6 Hz, 1 H), 1.54 (t, J= 6 Hz, 2 H), 1.45 (s, 9 H), 0.95 (dd, J = 6 Hz, 6 H). 
13C NMR (75 MHz, CDCl3) δ = 155.1, 84.6, 79.8, 70.7, 45.5, 41.5, 28.6, 25.3, 22.7, 22.1. 
 
 
5.2.3.6 (2S,3S)-N-(9-Fluorenylmethyloxycarbony)-1-ethynyl-3-methyl-butylamine (4c) 
 
 
623.6 mg of 4b (3.0 mmol) was dissolved in 6 ml TFA/DCM (1:1, v/v) and the resulting 
mixture was stirred for 1 h at ambient temperature. After removal of the solvents under 
reduced pressure, the resulted pale oil was dissolved in 10 ml acetone/H2O (1:1, v/v). 322 mg 
of Na2CO3 (3.0 mmol) was added and the pH was adjusted to 9 – 10 by addition of Na2CO3 
(aq., 1 M). 1.03 g Fmoc-OSu (3.0 mmol) was carefully added while the pH was kept at 9-10 
by addition of further Na2CO3 (aq., 1 M). After stirring overnight, 12 ml EtOAc was added to 
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the suspension and the mixture was acidified by treatment with HCl (6 M) to pH 2 – 3. The 
organic layer was separated, washed with 4×5 ml H2O, and dried over anhydrous MgSO4. 
The organic solvent was removed under reduced pressure and the oily crude residue was 
cooled to 4 °C. Finally, the resulting crystalline product was washed with hexane yielding 
836.1 mg of 4c (2.5 mmol, 85.0 %). 1H NMR (300 MHz, CDCl3) δ = 7.81 (d, J = 8 Hz, 2H), 
7.64 (d, J = 8 Hz, 2 H), 7.44 (t, J = 6 Hz, 2 H), 7.35 (t, J = 6 Hz, 2 H),5.04 (s, 1 H), 4.54- 
4.39 (m, 3 H), 4.26 (t, J = 7 Hz, 1 H), 1.81 (m, J = 6 Hz, 1 H), 1.58 (t, 8 Hz, 2 H), 0.96 (d, J 
= 6 Hz, 6 H). 13C NMR (75 MHz, CDCl3) δ = 155.8, 144.5, 141.9, 128.1, 127.4, 125.4, 120.3, 
83.9, 71.2, 67.2, 47.7, 45.4, 42.2, 25.3, 22.7, 22.1. 
 
 
5.2.3.7 des-Gly1,-Pro13,-Asp14,Ψ5,6 1,4-[1,2,3]triazolyl-[Nle2, Gln10,Tyr12]SFTI-1[1,14] (4) 
 
 
4 was synthesized manually with microwave assistance. As a solid support, 500 mg of Fmoc-
Tyr(tBu)-preloaded TentaGel® S AC resin with 0.22 mmol/g loading capacity was chosen 
(batch size: 0.1 mmol). Iterative chain elongation was achieved following the mentioned 
general protocol described in 5.2.1.2. After coupling of azido acid 4a (procedure following the 
protocol described in 5.2.1.2), amino alkyne 4c was attached via CuAAC: 67.2 mg of 4c (0.2 
mmol), 5.0 mg Cu(II)SO4·5H2O (0.02 mmol, 20 % of batch size), 7.0 mg NaAsc (0.04 mmol), 
and 121 µl DIEA (0.08 mmol) was eluted in 2 ml dry and degassed DMF. After 2 min pre-
activation, the suspension was added to the well-rinsed peptide-resin. The reaction mixture 
was shaken at ambient temperature over night. After removal of the solution via filtration, the 
peptide-resin was washed with 3×10 ml MeOH, 3×10 ml 0.5 % sodium 
diethyldithiocarbamate in DMF (w/v), 3×10 ml DMF, and 3×10 ml DCM. The iterative chain 
elongation was continued up to the coupling and Fmoc deprotection of the final amino acid 
Nle2. Cleavage and isolation of the crude, linear precursor peptide was as same as described 
for 1 (5.2.3.1). 122.4 mg of dried crude precursor peptidomimetic 4’ (0.097 mmol, 97.1 %) 
was yielded. RP-HPLC: Rt = 10.8 min, 9 % MeCN over 2 min followed by 9 %→90 % MeCN 
over 20 min in 0.1 % aq. TFA at flow rate 1 ml/min. ESI-MS: m/z: [M+H]+ obsd. = 1262.8 
(calc = 1262.5), [M+2H]2+ obsd. = 631.8 (calc = 631.8), [M-H]- obsd. = 1262.8 (calc = 
1260.5). 
10 mg (0.008 mmol) linear precursor 4’ was oxidatively folded and purified as described for 3 
(5.2.3.3). 0.6 mg of purified, oxidatively folded pseudo-peptide 4 (0.48 µmol, 5.9 % 
purification yield, 5.8 % overall yield) was obtained. RP-HPLC: Rt = 14.2 min, 9 % MeCN 
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over 2 min followed by 9 %→90 % MeCN over 20 min in 0.1 % aq. TFA at flow rate 
1 ml/min. ESI-MS: m/z: [M+H]+ obsd. = 1259.8 (calc = 1260.5), [M+2H]2+ obsd. = 630.7 
(calc = 630.8), [M-H]- obsd. = 1257.5 (calc = 1258.5). 
 
 
5.2.3.8 [Pra1]SFTI-1[1,14] (5)  
 
 
5 was synthesized by manual Fmoc-SPPS without microwave assistance. As a solid support, 
0.5 g of 2-chlorotrityl chloride resin was chosen. The resin was loaded as described in 5.2.1.1 
with 0.1 mmol Fmoc-L-Asp using a loading mixture consisting of 1 eq Fmoc-L-Asp-OH, 4 eq 
DIEA dissolved in 5 ml DCM. Iterative chain elongation was achieved following the mentioned 
general protocol described in 5.2.1.2.  
Cleavage of the linear peptide precursor 5’ from solid support and removal of the side chain 
protecting groups was achieved by acidolysis using 5 ml of the standard cleavage cocktail as 
described in 5.2.1.4. The resulting reaction mixture was shaken for 3 h at ambient 
temperature and the product was isolated by precipitation in 45 ml methyl tert.-butyl ether 
(MTBE) followed by washing with 3×15 ml MTBE. 218.5 mg of dried crude precursor peptide 
5’ (0.139 mmol, 55.6 %) was yielded. RP-HPLC: Rt = 12.6 min, 18 % MeCN over 2 min 
followed by 9 %→90 % MeCN over 20 min in 0.1 % aq. TFA at flow rate 1 ml/min.  
50 mg (0.032 mmol) precursor 5’ was dissolved in 10 ml folding buffer (100 mM (NH4)2CO3 
aq. with 0.5% DMSO) and the reaction mixture was stirred for three days with RP-HPLC 
monitoring and ESI-MS of the collected fractions. The solvent was removed by freeze-drying 
followed by purification via semi-preparative HPLC to yield 9.0 mg of oxidatively folded 
peptide 6 (0.006 mmol, 18.8 % folding yield, 10.5 % overall yield). RP-HPLC: Rt = 14.4 min, 
18 % MeCN over 2 min followed by 9 %→90 % MeCN over 20 min in 0.1 % aq. TFA at flow 
rate 1 ml/min. ESI-MS: m/z: [M+H]+ obsd. = 1570.8 (calc = 1570.9), [M+2H]2+ obsd. = 
786.0 (calc = 785.9), [M+3H]3+  obsd. = 524.3 (calc = 524.3), [M-H]- obsd. = 1568.8 (calc 
= 1568.8). 
 
 
5.2.3.9 [Pra13]SFTI-1[1,14] (6) 
 
 
6 was synthesized partially automated on the Liberty® peptide synthesizer system. As a solid 
support 1.05 g of Fmoc-Asp(tBu)-preloaded TentaGel® S AC resin with 0.22 mmol/g loading 
capacity was chosen (batch size 0.23 mmol). After manual, MW-assisted coupling of Fmoc-L-
Pra-OH, all following amino acid were coupled by automated coupling cycles.  
 
DOCTORAL THESIS DAICHI NASU EXPERIMENTAL PART 
 136
Cleavage of the linear peptide precursor 6’ from solid support and removal of the side chain 
protecting groups was achieved by acidolysis using 5 ml of the standard cleavage cocktail as 
described in 5.2.1.4. After a reaction time of 4 h and precipitation and washing with diethyl 
ether, 290.1 mg of dried crude precursor peptide 6’ (0.190 mmol, 82.5 %) was yielded. RP-
HPLC: Rt = 12.6 min, 9 % MeCN over 2 min followed by 9 %→90 % MeCN over 20 min in 
0.1 % aq. TFA at flow rate 1 ml/min. ESI-MS: m/z: [M+H]+ obsd. = 1533.2 (calc = 1532.8), 
[M+2H]2+ obsd. = 767.2 (calc = 766.4), [M-2H]2- obsd. = 765.1 (calc = 764.4). 
20 mg (0.013 mmol) precursor 6’ was oxidatively folded and purified analogously to 5 
yielding 8.3 mg of final product 6 (0.005 mmol, 41.5 % folding yield, 34.3 % overall yield). 
RP-HPLC: Rt = 14.1 min, 9 % MeCN over 2 min followed by 9 %→90 % MeCN over 20 min in 
0.1 % aq. TFA at flow rate 1 ml/min. ESI-MS: m/z: [M+H]+ obsd. = 1530.1 (calc = 1530.8), 
[M+2H]2+ obsd. = 765.5 (calc = 765.9). 
 
 
5.2.3.10 [Tyr(O-propargyl)1]SFTI-1[1,14] (7)  
 
 
7 was synthesized manually with microwave assistance. As a solid support, 1.14 g of Fmoc-
Asp(tBu)-preloaded TentaGel® S AC resin with 0.22 mmol/g loading capacity was chosen 
(batch size 0.25 mmol). Further chain elongation was achieved following the mentioned 
general protocol described in 5.2.1.2.  
Cleavage of the linear peptide precursor 7’ from solid support and removal of the side chain 
protecting groups was achieved by acidolysis using 5 ml of the standard cleavage cocktail as 
described in 5.2.1.4. After a reaction time of 4 h and precipitation and washing, 120.5 mg of 
dried crude precursor peptide 7’ (0.072 mmol, 71.9 %) was yielded. RP-HPLC: Rt = 14.6 min, 
9 % MeCN over 2 min followed by 9 %→90 % MeCN over 20 min in 0.1 % aq. TFA at flow 
rate 1 ml/min. ESI-MS: m/z: [M+H]+ obsd. = 1677.9 (calc = 1679.0), [M+2H]2+ obsd. = 
839.9 (calc = 840.0), [M+3H]3+  obsd. = 560.2 (calc = 560.3), [M-H]- obsd. = 1676.8 (calc 
= 1677.0). 
30 mg (0.018 mmol) precursor 7’ was oxidatively folded and purified analogously to 5 
yielding 8.6 mg of peptide 7 (0.005 mmol, 27.8 % folding yield, 20.1 % overall yield). RP-
HPLC: Rt = 15.9 min, 9 % MeCN over 2 min followed by 9 %→90 % MeCN over 20 min in 
0.1 % aq. TFA at flow rate 1 ml/min. ESI-MS: m/z: [M+H]+ obsd. = 1676.8 (calc = 1676.9), 
[M+2H]2+ obsd. = 838.9 (calc = 839), [M-H]- obsd. = 1674,8 (calc = 1675.0). 
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5.2.3.11 [4-Pentynoic acid1]SFTI-1[1,14] (8)  
 
 
8 was synthesized partially automated on the Liberty Blue® peptide synthesizer system. As a 
solid support, 1.36 g of Fmoc-Asp(tBu)-preloaded TentaGel® S AC resin with 0.22 mmol/g 
loading capacity was chosen (batch size 0.3 mmol). Iterative chain elongation up to Arg2 was 
achieved following the protocol for automated Fmoc-SPPS described in 5.2.1.3. After coupling 
of Fmoc-Arg, the peptide-resin was removed from the reaction chamber of the synthesizer and 
washed and dried. 500 mg of the split peptide-resin (25 wt%, 0.075 mmol) was used for 
attachment of N-terminal 4-pentynoic acid. Coupling was performed as manual double 
coupling with same conditions as the canonical amino acids.  
Cleavage of the linear peptide precursor 8’ from solid support and removal of the side chain 
protecting groups was achieved by acidolysis using 5 ml of the standard cleavage cocktail as 
described in 5.2.1.4. After a reaction time of 4 h and precipitation and washing with diethyl 
ether 110.5 mg of dried crude precursor peptide 8’ (0.071 mmol, 94.6 %) was yielded. RP-
HPLC: Rt = 15.2 min, 9 % MeCN over 2 min followed by 9 %→72 % MeCN over 20 min in 
0.1 % aq. TFA at flow rate 1 ml/min. ESI-MS: m/z: [M+H]+ obsd. = 1558.2 (calc = 1557.8), 
[M+2H]2+ obsd. = 779.4 (calc = 779.4), [M-H]- obsd. = 1554.87 (calc = 1558.5). 
30 mg (0.019 mmol) precursor 8’ was dissolved in 30 ml folding buffer (100 mM (NH4)2CO3 
aq. with 0.5% DMSO and ox. glutathione) and the reaction mixture was stirred for three days 
with RP-HPLC monitoring (9 % MeCN over 2 min followed by 9 %→90 % MeCN over 20 min 
in 0.1 % aq. TFA at flow rate 1 ml/min) and ESI-MS of the collected fractions. The solvent 
was removed by freeze-drying followed by semi-preparative purification via RP-HPLC and 
after freeze-drying of the product fraction 11.6 mg of final product peptide 8 was yielded 
(0.007 mmol, 35.8 % folding yield, 30.8 % overall yield). RP-HPLC: Rt = 16.3 min, 9 % 
MeCN over 2 min followed by 9 %→72 % MeCN over 20 min in 0.1 % aq. TFA at flow rate 1 
ml/min. ESI-MS: m/z: [M+H]+ obsd. = 1555.8 (calc = 1555.8), [M+2H]2+ obsd. = 778.4 
(calc = 778.4), [M-H]- obsd. = 1552.9 (calc = 1553.8), [M-H]- obsd. = 776.2 (calc = 776.4). 
 
 
5.2.3.12 [Ac-Pra1]SFTI-1[1,14] (9) 
 
 
9 was synthesized partially automated on the Liberty Blue® peptide synthesizer system. 
500 mg of the peptide-loaded resin (25 wt%, 0.075 mmol) synthesized and split previously 
for 8 was used. After coupling of Fmoc-L-Pra-OH and Fmoc deprotection, N-terminal acylation 
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was performed as double capping using acetic anhydride (Ac2O) and DIEA (1:1, v/v) in 9 ml 
DMF within 60 min each.  
Cleavage of the linear peptide precursor 9’ from solid support and removal of the side chain 
protecting groups was achieved by acidolysis using 5 ml of the standard cleavage cocktail as 
described in 5.2.1.4. 105.9 mg of dried crude unprotected precursor peptide 9’ (0.066 mmol, 
88.0 %) was yielded. RP-HPLC: Rt = 15.5 min, 9 % MeCN over 2 min followed by 9 %→72 % 
MeCN over 20 min in 0.1 % aq. TFA at flow rate 1 ml/min. ESI-MS: m/z: [M+H]+ obsd. = 
1615.2 (calc = 1614.9), [M+2H]2+ obsd. = 807.9 (calc = 808.0), [M-H]- obsd. = 1611.88 
(calc = 1612.9). 
30 mg (0.017 mmol) precursor 9’ was oxidatively folded and purified analogously to 5 
yielding 11.8 mg of final product 9 (0.007 mmol, 36.8 % folding yield, 32.9 % overall yield). 
RP-HPLC: Rt = 16.4 min, 9 % MeCN over 2 min followed by 9 %→72 % MeCN over 20 min in 
0.1 % aq. TFA at flow rate 1 ml/min. ESI-MS: m/z: [M+H]+ obsd. = 1612.8 (calc = 1612.8), 
[M+2H]2+ obsd. = 806.9 (calc = 806.9), [M-H]- obsd. = 1610.9 (calc = 1610.9), [M-2H]2- 
obsd. = 804.9 (calc =804.9 ). 
 
 
5.2.3.13 [Ac-Tyr(propargyl)1]SFTI-1[1,14] (10) 
 
 
10 was synthesized partially automated on the Liberty Blue® peptide synthesizer system. 500 
mg of the peptide-loaded resin (25 wt%, 0.075 mmol) synthesized and split previously for 8 
was used. After coupling of Fmoc-L-Tyr(O-propargyl)-OH and Fmoc deprotection, N-terminal 
acylation was performed as double capping using a acetic anhydride (Ac2O) and DIEA (1:1, 
v:v) in 9 ml DMF within 60 min each.  
Cleavage of the linear peptide precursor 10’ from solid support and removal of the side chain 
protecting groups was achieved by acidolysis using 5 ml of the standard cleavage cocktail as 
described in 5.2.1.4. 104.6 mg of dried crude unprotected precursor peptide 10’ (0.061 mmol, 
81.2 %) was yielded. RP-HPLC: Rt = 16.7 min, 9 % MeCN over 2 min followed by 9 %→72 % 
MeCN over 20 min in 0.1 % aq. TFA at flow rate 1 ml/min. ESI-MS: m/z: [M+H]+ obsd. = 
1720.6 (calc = 1721.0), [M+2H]2+ obsd. = 861.0 (calc = 861.0), [M-H]- obsd. = 1718.0 
(calc = 1719.0). 
30 mg (0.017 mmol) precursor 10’ was oxidatively folded and purified analogously to 8 
yielding 11.8 mg of final product 10 (0.007 mmol, 40.3 % folding yield, 32.5 % overall yield). 
RP-HPLC: Rt = 18.5 min, 9 % MeCN over 2 min followed by 9 %→72 % MeCN over 20 min in 
0.1 % aq. TFA at flow rate 1 ml/min. ESI-MS: m/z: [M+H]+ obsd. = 1718.9 (calc = 1719.0), 
[M+2H]2+ obsd. = 859.9 (calc = 860.0), [M-H]- obsd. = 1716.9 (calc = 1717.0). 
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5.2.3.14 [Pra1,Ala3(&1),Ala11(&2)]SFTI-1[1,14][(&1-CH2-1,5-[1,2,3]triazolyl-&2)] (11) 
 
 
11 was synthesized manually on a Discover® SPS microwave synthesis platform using the 
Fmoc strategy. As a solid support, 0.43 g of Fmoc-L-Asp(tBu) preloaded TentaGel® S AC resin 
with 0.22 mmol/g loading capacity was chosen (batch size 0.1 mmol). Chain elongation up to 
Arg2 was achieved following the protocol for microwave assisted SPPS (5.2.1.2).  
After attachment of Fmoc-Arg(Pbf)-OH to the N-terminus of the resin-bound precursor 
peptide, the ruthenium(II)-catalyzed macrocyclization on solid support was performed as 
previously described.[182] The well-rinsed and dried peptide-resin was put into a 20 ml open-
end polypropylene syringe equipped with a frit and connected to the argon line. After 
addition of 5 ml dry and degassed DMF from the top, argon was bubbled through the mixture 
over 20 min. Subsequently, 7.6 mg (20 mol% of the initial loading of resin) Cp*RuCl(COD) 
was added from top while argon flush from the outlet nozzle. The mixture was flushed with 
argon for further 10 min. Then, the syringe was carefully sealed and placed into the 
microwave chamber of the Discover system. For temperature control, a second, open 
reference tube filled with DMF was placed into the chamber, thus the fiber-optic of the 
Discover SPS was able to measure the temperature inside. A microwave program with 60 °C, 
30 W was used, whereby in the first heating period, the microwave irradiation was applied 
gradually in 10 °C steps until reaching the appointed temperature. After a reaction time of 5 h 
the peptide-resin was washed with 3×10 ml MeOH , 3×15 ml 0.5 % sodium 
diethyldithiocarbamate in DMF and 3×10 ml DMF. The success of macrocyclization was 
proven by a test cleavage in the presence of DTT as reducing agent.[183] 30 mg of the peptide- 
resin was treated with 1 ml solution of 1 M DTT and 2 M DIEA in DMF for 2 h at rt. Following 
the cleavage of the peptidomimetics with 1 ml of the standard cleavage cocktail and 
subsequent isolation by the described method (5.2.1.4) an MS analysis was performed. In 
case of a failed macrocyclization, the remaining azide residue of the peptide would be 
reduced by the DTT and a loss of 26 u would be detectable in the resulting spectrum. Since 
this was not the case, Pra1 was coupled and the final Fmoc deprotection was performed 
according to the manual, microwave-assisted chain elongation protocol described in 5.2.1.2.  
Cleavage of the macrocyclic peptidomimetic 11 from solid support and removal of the side 
chain protecting groups was achieved by the mentioned procedure using 5 ml of the standard 
cleavage cocktail as described in 5.2.1.4. Isolation of the peptide was achieved in 45 ml MTBE 
and washing by 4×15 ml MTBE. 62.1 mg of dried crude 11 (0.039 mmol, 39.1 %) was 
obtained. The crude peptidomimetic was purified via semipreparative RP-HPLC and after 
freeze-drying of the collected product fractions 7.4 mg of purified 11 (0.005 mmol, 4.7 % 
overall yield) was yielded. RP-HPLC: Rt = 14.4 min, 9 % MeCN over 2 min followed by 
9 %→90 % MeCN over 20 min in 0.1 % aq. TFA at flow rate 1 ml/min. ESI-MS: m/z: 
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[M+H]+ obsd. = 1587.6 (calc = 1587.8), [M+2H]2+ obsd. = 794.4 (calc = 794.4), 
[M+3H]3+  obsd. = 529.9 (calc = 529.9), [M-H]- obsd. = 1584.9 (calc = 1585.8). 
 
 
5.2.3.15 [Tyr(propargyl)1,Ala3(&1),Ala11(&2)]SFTI-1[1,14][(&1-CH2-1,5-[1,2,3]triazolyl-&2)] (12) 
 
 
SPPS of peptidomimetics 12 was performed by manual Fmoc-SPPS on a Discover® SPS 
microwave synthesis platform. As a solid support, 0.43 g of Fmoc-L-Asp(tBu) preloaded 
TentaGel® S AC resin with 0.22 mmol/g loading capacity was chosen (batch size 0.1 mmol). 
Chain elongation up to Arg2, on-resin cyclization via RuAAC and the reduction test after 
macrocyclization was performed analogously as described for 11. After evidence of successful 
macrocyclization, Fmoc-L-Tyr(O-propargyl) was coupled to the peptidomimetic and finally the 
N-terminal Fmoc was removed following the described procedure. 
12 was cleaved and isolated as described for 11 yielding 81.5 mg of the crude peptidomimetic 
(0.048 mmol, 48.1 %). The crude 12 was purified via semipreparative RP-HPLC and after 
freeze-drying of the collected product fractions 9.5 mg of purified 12 (0.006 mmol, 5.6 % 
overall yield) was achieved. RP-HPLC: Rt = 15.3 min, 9 % MeCN over 2 min followed by 
9 %→90 % MeCN over 20 min in 0.1 % aq. TFA at flow rate 1 ml/min. ESI-MS: m/z: 
[M+H]+ obsd. = 1693.8 (calc = 1693.9), [M+2H]2+ obsd. = 847.4 (calc = 847.5), 
[M+3H]3+  obsd. = 565.3 (calc = 563.5), [M-H]- obsd. = 1692.0 (calc = 1691.9). 
 
 
5.2.3.16 [Tyr(allyl)1]SFTI-1[1,14] (13)  
 
 
13 was synthesized partially automated on the Liberty Blue® peptide synthesizer system. As a 
solid support, 0.46 g of Fmoc-L-Asp(tBu) preloaded TentaGel® S AC resin with 0.22 mmol/g 
loading capacity was chosen (batch size 0.1 mmol). Chain elongation was achieved following 
protocol described in 5.2.1.3. 
Cleavage of the linear peptide precursor 13’ from solid support and removal of the side chain 
protecting groups was achieved by acidolysis using 5 ml of the standard cleavage as described 
in 5.2.1.4. 159.2 mg of dried crude precursor peptide 13’ (0.098 mmol, 98.8 %) was yielded. 
RP-HPLC: Rt = 14.6 min, 9 % MeCN over 2 min followed by 9 %→90 % MeCN over 20 min in 
0.1 % aq. TFA at flow rate 1 ml/min. ESI-MS: m/z: [M+H]+ obsd. = 1677.9 (calc = 1679.0), 
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[M+2H]2+ obsd. = 839.9 (calc = 840.0), [M+3H]3+  obsd. = 560.2 (calc = 560.3), [M-H]- 
obsd. = 1676.8 (calc = 1677.0). 
40 mg (0.024 mmol) precursor 13’ was oxidatively folded and purified analogously to 7 
yielding 17.9 mg of peptide 13 (0.011 mmol, 44.3 % folding yield, 43.6 % overall yield). RP-
HPLC: Rt = 15.7 min, 9 % MeCN over 2 min followed by 9 %→90 % MeCN over 20 min in 
0.1 % aq. TFA at flow rate 1 ml/min. ESI-MS: m/z: [M+H]+ obsd. = 1676.8 (calc = 1676.9), 
[M+2H]2+ obsd. = 838.9 (calc = 839), [M-H]- obsd. = 1674,8 (calc = 1675.0). 
 
 
5.2.3.17 [4-Pentenoic acid1]SFTI-1[1,14] (14) 
 
 
14 was synthesized partially automated on the Liberty Blue® peptide synthesizer system. As a 
solid support, 0.23 g of Fmoc-L-Asp(tBu)-preloaded TentaGel® S AC resin with 0.22 mmol/g 
loading capacity was chosen (batch size 0.05 mmol). Chain elongation was achieved 
following protocol described in 5.2.1.3. 
Cleavage of the linear peptide precursor 14’ from solid support and removal of the side chain 
protecting groups was achieved by acidolysis using 5 ml of the standard cleavage cocktail as 
described in 5.2.1.4. 60.4 mg of dried crude unprotected precursor peptide 14’ (0.038 mmol, 
76.6 %) was yielded. RP-HPLC: Rt = 14.4 min, 9 % MeCN over 2 min followed by 9 %→90 % 
MeCN over 20 min in 0.1 % aq. TFA at flow rate 1 ml/min. ESI-MS: m/z: [M+H]+ obsd. = 
1558.9 (calc = 1559.9), [M+2H]2+ obsd. = 780.4 (calc = 780.4), [M+3H]3+  obsd. = 520.6 
(calc = 520.6), [M-H]- obsd. = 1556.9 (calc = 1557.9). 
50 mg (0.024 mmol) precursor 14’ was oxidatively folded and purified analogously to 8 
yielding 15.4 mg of peptide 14 (0.010 mmol, 41.7 % folding yield, 31.7 % overall yield). RP-
HPLC: Rt = 15.3 min, 9 % MeCN over 2 min followed by 9 %→90 % MeCN over 20 min in 
0.1 % aq. TFA at flow rate 1 ml/min. ESI-MS: m/z: [M+H]+ obsd. = 1558.1 (calc = 1557.9), 
[M+2H]2+ obsd. = 779.4 (calc = 779.4), [M-H]- obsd. = 1555,8 (calc = 1555.8). 
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5.2.4 Synthesis of Modified Coiled Coil Guiding Units 
5.2.4.1 BCN-(POE)3-NH-C(O)(CH2)3-maleimide (15) 
 
 
Preparation of 15 was performed following the instruction included in commercially available 
three-component kit (Synaffix). 250 µl of BCN-POE3-NH2 solution in DMSO (0.35 M, 
87.5 µmol) was given to 33.5 mg of solid mixture of N-[γ-maleimidobutyryloxy]succinimide 
ester and K2CO2 (45:22, w/w). The resulted mixture was stirred at ambient temperature 
while the reaction progress was monitored by ESI-MS. After complete conversion of BCN-
POE3-NH2 was verified, the solid phase was decanted and the solution was separated in 30 µl 
aliquots and stored at -80 °C. 15 was applied as mixture for further synthetic steps. RP-HPLC: 
Rt = 14.0 min, 9 % MeCN over 2 min followed by 9 %→90 % MeCN over 20 min in 0.1 % aq. 
TFA at flow rate 1 ml/min. ESI-MS: m/z: [M+Na]+ obsd. = 512.2 (calc = 512.6), [M+H]+ 
obsd. = 490.2 (calc = 490.6). 
 
 
5.2.4.2 Cys-K3g,d2E2 Coil (16‘) 
 
 
16 was synthesized partially automated with the Liberty® 12-channel peptide synthesizer 
system using the protocol described in 5.2.1.3. 480 mg AmphiSpheres® 40 RAM resin with 
0.27 mmol/g loading capacity (total batch size: 0.130 mmol) were chosen as solid support 
and prepared as described in 5.2.1.1. After automated chain elongation up to Lys2, the 
peptide-resin was dried and 200 mg (25 wt%, 0.033 mmol) was split for further microwave-
assisted attachment with Fmoc-Cys(Trt)-OH according to the protocol described in 5.2.1.2. 
After final deprotection, cleavage, and precipitation (5.2.1.4), 44.1 mg of crude 16’ was 
obtained (0.017 mmol, 50.0 %). 20.0 mg of the crude peptide was purified via 
semipreparative RP-HPLC and after freeze-drying of the collected product fractions 6.0 mg of 
purified 16’ was achieved (0.002 mmol, 30.0 % purification yield, 15.0 % overall yield). RP-
HPLC: Rt = 16.7 min, 9 % MeCN over 2 min followed by 9 %→72 % MeCN over 20 min in 
0.1 % aq. TFA at flow rate 1 ml/min. ESI-MS: m/z: [M+2H]2+ obsd. = 1223.5 
(calc = 1223.46), [M+3H]3+ obsd. = 816.0 (calc = 816.0), [M+4H]4+ obsd. = 612.7 
(calc = 612.2), [M-H]- obsd. = 1221.4 (calc = 1221.5). 
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5.2.4.3 [S β1-(3-succinimido-(CH2)3-C(O)-NH-(POE)3-BCN)]Cys-K3g,d2E2 Coil (16) 
 
 
Maleimide coupling of helical peptide 16’ with the maleimido-BCN building block 15 was 
performed according to a modified protocol.[184] 6.0 mg of 16’ (2.5 µmol) was dissolved in 
2 ml Tris-HCl buffer (100 mM, pH 6.8) and 14 µl of 15 in DMSO prepared in 5.2.4.2 (0.35 M, 
5 µmol) was added. The resulted mixture was stirred at ambient temperature. The reaction 
progress was monitored by analytical RP-HPLC. After the equilibrium of the reaction was 
reached, the mixture was diluted with 2 ml H2O and purified via two semipreparative RP-
HPLC runs. 1.0 mg of the purified BCN-loaded coil 16 (0.32 µmol, 12.7 %) was yielded. RP-
HPLC: Rt = 20.3 min, 9 % MeCN over 2 min followed by 9 %→90 % MeCN over 20 min in 
0.1 % aq. TFA at flow rate 1 ml/min. ESI-MS: m/z: [M+2H]2+ obsd. = 1468.2 (calc = 
1468.3), [M+3H]3+ obsd. = 979.1 (calc = 979.2), [M+4H]4+ obsd. = 734.4 (calc = 734.6), 
[M-H]- obsd. = 1466.2 (calc = 1466.3). 
 
5.2.4.4 [N ε1-Ser]Lys-E3e2W Coil (17‘) 
 
 
17’ was synthesized partially automated with the Liberty® 12-channel peptide synthesizer 
system using the protocol described in 5.2.1.3. 479 mg AmphiSpheres® 40 RAM resin with 
0.27 mmol/g loading capacity (total batch size: 0.130 mmol) was used as solid support and 
prepared as described in 5.2.1.1. After automated chain elongation up to Glu2, the peptide-
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resin was dried and 200 mg (25 wt%, 0.033 mmol) was split for further microwave-assisted 
attachment with Fmoc-Lys(Mtt)-OH according to the protocol described in 5.2.1.2. The on-
resin cleavage of the Mtt protecting group was carried out via acidolysis under mild condition. 
Therefore, the peptide-resin was rinsed with 5×5 ml DCM and treated with 3 ml 1 % TFA in 
DCM. The cleavage mixture was shaken for 10 min at ambient temperature. Subsequently, 
20 µl of TES was added and the mixture was shaken for another 5 min. After rinsing the 
peptide-resin with DCM, further 1 % TFA was given and the cycle was repeated as far as no 
yellow coloring of the liquid phase could be observed before TES was given to the mixture (5 
– 10 times).  Subsequently, Boc-Ser(tBu)-OH was coupled to the Lys side chain using the 
standard amino acid coupling protocol. After deprotection of the N-terminus, cleavage, and 
precipitation (see 5.2.1.4), 24.1 mg of crude 17’ was obtained (0.009 mmol, 27.3 %). The 
crude peptide was used without further purification for the next synthetic step. RP-HPLC: Rt = 
22.4 min, 9 % MeCN over 2 min followed by 9 %→72 % MeCN over 20 min in 0.1 % aq. TFA 
at flow rate 1 ml/min. ESI-MS: m/z: [M+2H]2+ obsd. = 1301.9 (calc = 1302.0), [M+3H]3+ 
obsd. = 867.9 (calc = 868.3), [M+4H]4+ obsd. = 651.0 (calc = 651.5), [M-H]- obsd. = 
1299.9 (calc = 1300.0). 
 
 
 
5.2.4.5 [N ε1-glyoxylyl]Lys-E3e2W Coil (17) 
 
 
15.5 mg of crude 17’ (5.95 µmol) was dissolved in 3 ml PBS (1×, pH 7.4)-MeCN mixture 
(2:1, v/v). 12.9 mg sodium (meta)periodate (59.52 µmol) was dissolved in 1 ml PBS and 
added to the peptide solution. Following shaking for 10 min at ambient temperature, the 
reaction mixture was injected directly into the semipreparative RP-HPLC. After freeze-drying 
of the collected product fractions, 0.9 mg of purified 17 was achieved (0.35 µmol, 6.4 %). RP-
HPLC: Rt = 22.4 min, 18 % MeCN over 2 min followed by 18 %→90 % MeCN over 20 min in 
0.1 % aq. TFA at flow rate 1 ml/min. ESI-MS: m/z: [M+H2O+2H]2+ obsd. = 1295.4 (calc = 
1295.5), [M+H2O-H]- obsd. = 1293.4 (calc = 1293.5). 
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5.2.4.6 Cys-K5 Coil (18’) 
 
 
18’ was synthesized partially automated with the Liberty® 12-channel peptide synthesizer 
system using the protocol described in 5.2.1.3. 380 mg AmphiSpheres® 40 RAM resin with 
0.27 mmol/g loading capacity (total batch size: 0.100 mmol) was used as solid support and 
prepared as described in 5.2.1.1. After automated chain elongation up to Lys2, the peptide-
resin was dried and 220 mg (25 wt%, 0.025 mmol) was split for further microwave-assisted 
attachment with Fmoc-Cys(Trt)-OH according to the protocol described in 5.2.1.2. After final 
deprotection, cleavage, and precipitation (see 5.2.1.4), 84.0 mg of crude 18’ was obtained 
(0.021 mmol, 84.0 %). 30.0 mg of the crude peptide was purified via semipreparative RP-
HPLC and after freeze-drying of the collected product fractions 17.5 mg of purified 18’ was 
achieved (0.004 mmol, 58.3 % purification yield, 49.0 % overall yield). RP-HPLC: Rt = 
19.2 min, 9 % MeCN over 2 min followed by 9 %→54 % MeCN over 20 min in 0.1 % aq. TFA 
at flow rate 1 ml/min. ESI-MS: m/z: [M+4H]4+ obsd. = 993.4 (calc = 993.0), [M+5H]5+ 
obsd. = 795.0 (calc = 794.6), [M+6H]6+ obsd. = 662.7 (calc = 662.3), [M+7H]7+ obsd. = 
568.1 (calc = 567.8), [M+8H]8+ obsd. = 497.2 (calc = 497.0). 
 
5.2.4.7 [S β1-(3-succinimido-(CH2)3-C(O)-NH-(POE)3-BCN)]Cys-K5 Coil (18) 
 
 
4.0 mg of 18’ (1.0 µmol) was dissolved in 4 ml degassed Tris-HCl buffer (100 mM, pH 6.8) 
and 4.2 µl of 15 in DMSO prepared in 5.2.5.1 (0.35 M, 1.5 µmol) was added. The resulted 
mixture was stirred at ambient temperature. The reaction progress was monitored by 
analytical RP-HPLC. After the equilibrium of the reaction was reached, the mixture was 
purified via semipreparative RP-HPLC. 1.7 mg of the purified 18 (0.39 µmol, 38.6 %) was 
yielded. RP-HPLC: Rt = 18.8 min, 18 % MeCN over 2 min followed by 18 %→54 % MeCN 
over 20 min in 0.1 % aq. TFA at flow rate 1 ml/min. ESI-MS: m/z: [M+4H]4+ obsd. = 1115.8 
(calc = 1115.6), [M+5H]5+ obsd. = 892.8 (calc = 892.7), [M+6H]6+ obsd. = 744.2 
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(calc = 744.1), [M+7H]7+ obsd. = 638.0 (calc = 637.9), [M+9H]8+ obsd. = 558.4 
(calc = 558.3). 
 
 
5.2.4.8 [N ε1-Ser]Lys-E5 Coil (19’) 
 
 
19’ was synthesized manually using the protocol for microwave-assisted Fmoc-SPPS (5.2.1.3). 
380 mg AmphiSpheres® 40 RAM resin with 0.27 mmol/g loading capacity (total batch size: 
0.100 mmol) was used as solid support and prepared as described in 5.2.1.1. After manual 
chain elongation up to Glu2, the peptide-resin was dried and 200 mg (25 wt%, 0.025 mmol) 
was split for further microwave-assisted attachment with Fmoc-Lys(Mtt)-OH according to the 
protocol described in 5.2.1.2. The on-resin cleavage of the Mtt protecting group and side 
chain modification was carried out as described in 5.2.5.4. After final deprotection of the N-
terminus, cleavage, and precipitation (see 5.2.1.4), 36.7 mg of crude 19’ was obtained (0.009 
mmol, 35.9 %). The crude peptide was used without further purification for the next synthetic 
step. RP-HPLC: Rt = 19.6 min, 9 % MeCN over 2 min followed by 9 %→72 % MeCN over 
20 min in 0.1 % aq. TFA at flow rate 1 ml/min. ESI-MS: m/z: [M+3H]3+ obsd. = 1363.2 
(calc = 1326.2), [M+4H]4+ obsd. = 1022.7 (calc = 1022.7), [M+5H]5+ obsd. = 818.3 
(calc = 818.3), [M+6H]6+ obsd. = 682.1 (calc = 682.1), [M+2Na+5H]7+ obsd. = 590.0 
(calc = 591.1). 
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5.2.4.9 [N ε1-glyoxylyl]Lys-E5 Coil (19) 
 
 
16.0 mg of crude 19’ (3.92 µmol) was dissolved in 2.5 ml PBS (1×, pH 7.4)-MeCN mixture 
(4:3, v/v). 8.4 mg sodium (meta)periodate (39.16 µmol) was dissolved in 1 ml PBS and 
added to the peptide solution. Following shaking for 10 min at ambient temperature, the 
reaction mixture was injected directly into the semipreparative RP-HPLC. After freeze-drying 
of the collected product fractions, 1.9 mg of purified 19 was achieved (0.47 µmol, 12.0 %). 
RP-HPLC: Rt = 19.1 min, 9 % MeCN over 2 min followed by 9 %→90 % MeCN over 20 min in 
0.1 % aq. TFA at flow rate 1 ml/min ESI-MS: m/z: [M+H2O+3H]3+ obsd. = 1359.2 
(calc = 1058.9), [M+H2O+4H]4+ obsd. = 1019.6 (calc = 1019.5), [M+H2O+5H]5+ obsd. = 
815.8 (calc = 815.8), [M+H2O+6H]6+ obsd. = 679.9 (calc = 680.0). 
 
 
5.2.5 Synthesis of Modified PNA Guiding Units 
5.2.5.1 Cys-PNA A-Lys (20’) 
 
 
20’ was synthesized by manual Fmoc-SPPS. 185.0 mg of AmphiSpheres® 40 RAM resin with 
0.27 mmol/g loading capacity (total batch size: 0.050 mmol) was used as solid support and 
prepared as described in 5.2.1.1. Loading of first amino acid Fmoc-Lys(Boc)-OH was 
performed with microwave-assistance. For the chain elongation of the PNA sequence, the 
protocol described in 5.2.2.2 was used. After chain elongation up to g2, the PNA-resin was 
dried and 127.6 mg (50 wt%, 0.025 mmol) was spilt for further synthesis. After manual 
coupling of Fmoc-Cys(Trt)-OH, N-terminal deprotection, cleavage, and isolation 32.1 mg of 
the crude PNA-peptide hybrid 20’ was obtained (0.011 mmol, 44.1 %). 22 mg crude 20’ (7.57 
µmol) was purified via semipreparative RP-HPLC and after isolation and freeze-drying of the 
collected product fractions, 9.7 mg of purified 20’ was achieved (3.28 µmol, 43.3 % 
purification yield, 19.1 % overall yield). RP-HPLC: Rt = 18.1 min, 0 % MeCN over 2 min 
followed by 0 %→27 % MeCN over 20 min in 0.1 % aq. TFA at flow rate 1 ml/min ESI-MS: 
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m/z: [M+3H]3+ obsd. = 987.2 (calc = 986.9), [M+4H]4+ obsd. = 740.5 (calc = 740.5), 
[M+5H]5+ obsd. = 593.1 (calc = 592.6), [M+6H]6+ obsd. = 494.2 (calc = 494.0). 
 
 
5.2.5.2 [S β1-(3-succinimido-(CH2)3-C(O)-NH-(POE)3-BCN)]Cys-PNA A-Lys (20) 
 
 
4.7 mg of purified 20’ (1.59 µmol) was dissolved in 4 ml degassed NH4OAc buffer (0.1 M, pH 
6.5). 7 µl of 15 in DMSO prepared in 5.2.5.1 (0.35 M, 2.45 µmol) was added. The resulted 
mixture was stirred at ambient temperature. The reaction progress was monitored by 
analytical RP-HPLC. After the equilibrium of the reaction was reached, 500 µl MeCN was 
added to the mixture. The solid compounds in the mixture were separated by centrifugation 
and the liquid phase was purified via semipreparative RP-HPLC. 1.2 mg of the purified 20 
(0.35 µmol, 22.1 %) was yielded. RP-HPLC: Rt = 17.3 min, 0 % MeCN over 2 min followed by 
0 %→72 % MeCN over 20 min in 0.1 % aq. TFA at flow rate 1 ml/min. ESI-MS: m/z: 
[M+2H]2+ obsd. = 1724.7 (calc = 1724.8), [M+3H]3+ obsd. = 1150.2 (calc = 1150.2), 
[M+4H]4+ obsd. = 862.7 (calc = 862.8), [M+5H]5+ obsd. = 690.5 (calc = 690.4), 
[M+6H]6+ obsd. = 575.6 (calc = 575.6). 
 
 
5.2.5.3 [N ε1-Ser]Lys-PNA B-Lys (21’) 
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21’ was synthesized by manual Fmoc-SPPS. 185.0 mg of AmphiSpheres® 40 RAM resin with 
0.27 mmol/g loading capacity (total batch size: 0.050 mmol) was used as solid support and 
prepared as described in 5.2.1.1. Loading and chain elongation was performed as described 
for 20’ (5.2.6.1). After chain elongation up to c2, the peptide-resin was dried and 150.1 mg 
(50 wt%, 0.025 mmol) was spilt for further synthesis. After manual coupling of Fmoc-
Lys(Mtt)-OH, the Mtt protecting group was cleaved and Boc-Ser(tBu)-OH was coupled to the 
Lys side chain as described for 17’ (5.2.5.4). After N-terminal deprotection, cleavage, and 
isolation, 35.3 mg of the crude PNA-peptide hybrid 21’ was obtained (0.011 mmol, 44.1 %). 
10 mg crude 21’ (3.26 µmol) was purified via semipreparative RP-HPLC and after isolation 
and freeze-drying of the collected product fractions, 6.1 mg of purified 21’ was achieved 
(1.99 µmol, 61.0 % purification yield, 26.9 % overall yield). RP-HPLC: Rt = 18.1 min, 0 % 
MeCN over 2 min followed by 0 %→27 % MeCN over 20 min in 0.1 % aq. TFA at flow rate 
1 ml/min. ESI-MS: m/z: [M+3H]3+ obsd. = 1024.4 (calc = 1024.3), [M+4H]4+ obsd. = 
768.2 (calc = 768.5), [M+5H]5+ obsd. = 615.1 (calc = 615.0). 
 
 
5.2.5.4 [N ε1-glyoxylyl]Lys-PNA B-Lys (21) 
 
 
6.1 mg of crude 21’ (1.99 µmol) was dissolved in 3 ml PBS (1×, pH 7.4). 4.2 mg sodium 
(meta)periodate (19.8 µmol) was dissolved in 1 ml PBS and added to the PNA solution. 
Following shaking for 10 min at ambient temperature, the reaction mixture was injected 
directly into the semipreparative RP-HPLC. After freeze-drying of the collected product 
fractions, 2.2 mg of purified 21 was achieved (0.72 µmol, 36.2 %). RP-HPLC: Rt = 13.4 min, 
0 % MeCN over 2 min followed by 0 %→72 % MeCN over 20 min in 0.1 % aq. TFA at flow 
rate 1 ml/min. ESI-MS: m/z: [M+H2O+2H]2+ obsd. = 1529.4 (calc = 1529.5), [M+3H]3+ 
obsd. = 1014.0 (calc = 1014.0), [M+4H]4+ obsd. = 760.7 (calc = 760.7), [M+H2O+5H]5+ 
obsd. = 612.4 (calc = 612.4), [M+H2O+6H]6+ obsd. = 510.5 (calc = 510.5). 
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5.2.5.5 [N ε1-Ser]Lys-PNA C-Lys (22’) 
 
 
22’ was synthesized by manual Fmoc-SPPS. 185.0 mg of AmphiSpheres® 40 RAM resin with 
0.27 mmol/g loading capacity (total batch size: 0.050 mmol) was used as solid support and 
prepared as described in 5.2.1.1. Loading and chain elongation was performed as described 
for 20’ (5.2.6.1). After chain elongation up to a2, the peptide-resin was dried and 113.3 mg 
(50 wt%, 0.025 mmol) was spilt for further synthesis. After coupling of Fmoc-Lys(Mtt)-OH, 
the Mtt protecting group was cleaved and Boc-Ser(tBu)-OH was coupled to the side chain as 
described for 17’ (5.2.5.4). Following the cleavage and isolation protocol discussed in 5.2.1.4, 
17.4 mg of the PNA-peptide hybrid 22’ was obtained (0.006 mmol, 22.5 %). 42 mg crude 22’ 
(9.79 µmol) was purified via semipreparative RP-HPLC and after isolation and freeze-drying 
of the collected product fractions, 10.8 mg of purified 22’ was achieved (0.004 mmol, 63.7 % 
purification yield, 14.3 % overall yield). RP-HPLC: Rt = 14.2 min, 0 % MeCN over 2 min 
followed by 0 %→54 % MeCN over 20 min in 0.1 % aq. TFA at flow rate 1 ml/min ESI-MS: 
m/z: [M+2H]2+ obsd. = 1515.9 (calc = 1516.0), [M+3H]3+ obsd. = 1011.1 (calc = 1011.0), 
[M+4H]4+ obsd. = 758.6 (calc = 758.5), [M+5H]5+ obsd. = 607.1 (calc = 607.0), 
[M+6H]6+ obsd. = 506.1 (calc = 506.0). 
 
 
5.2.5.6 [N ε1-glyoxylyl]Lys-PNA C-Lys (22) 
 
 
5.0 mg of crude 22 (1.65 µmol) was dissolved in 3 ml PBS (1×, pH 7.4). 3.5 mg sodium 
(meta)periodate (16.5 µmol) was dissolved in 1 ml PBS and added to the PNA solution. The 
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reaction mixture was handled as described for 21 (5.2.6.4) and after isolation via 
semipreparative RP-HPLC and freeze-drying of the collected product fractions, 2.6 mg of 
purified 22 was achieved (0.86 µmol, 52.3 %). RP-HPLC: Rt = 14.9 min, 0 % MeCN over 
2 min followed by 0 %→54 % MeCN over 20 min in 0.1 % aq. TFA at flow rate 1 ml/min. ESI-
MS: m/z: [M+H2O+3H]3+ obsd. = 1006.6 (calc = 10067.7), [M+H2O+4H]4+ obsd. = 755.1 
(calc = 755.2), [M+H2O+5H]5+ obsd. = 604.3 (calc = 604.4), [M+H2O+6H]6+ obsd. = 
503.1 (calc = 503.8). 
 
 
5.2.5.7 Aha-PNA B-Lys (23) 
 
 
For the synthesis of 23, 59.0 mg of the dried and split PNA-resin prepared in 5.2.6.3 was used 
(20 wt%: 0.01 mmol). After swelling of the PNA-resin and N-terminal deprotection, Fmoc-
Aha-OH was coupled according the protocol mentioned in 5.2.1. After N-terminal 
deprotection, cleavage, and isolation, 52.0 mg of the crude PNA-peptide hybrid 23 was 
obtained (0.017 mmol, 69.8 %). 20 mg of the crude PNA/peptide (0.007 mmol) was purified 
by semipreparative HPLC yielding 8.8 mg of purified 23 (0.003 mmol, 44.0 % purification 
yield, 30.7 % overall yield). RP-HPLC: Rt = 14.0 min, 16.0 min, 0 % MeCN over 2 min 
followed by 0 %→54 % MeCN over 20 min in 0.1 % aq. TFA at flow rate 1 ml/min. ESI-MS: 
m/z: [M+2H]2+ obsd. = 1491.5 (calc = 1491.5), [M+3H]3+ obsd. = 994.6 (calc = 994.6), 
[M+4H]4+ obsd. = 746.2 (calc = 746.2), [M+5H]5+ obsd. = 597.2 (calc = 597.2). 
 
5.2.5.8 8-(tert-butoxycarbonylmethyleneoxy)psoralen (24’) 
 
 
333 mg 8-hydroxypsoralen (1.64 mmol), 1.28 g tert-butyl bromoacetate (6.59 mmol) and 
1.67 g potassium carbonate (12.08 mmol) were dissolved in 50 ml acetone. The mixture was 
stirred under reflux for 2 h. The solid residue was removed by filtration and centrifugation. 
The supernatant was purified by flash column chromatography (silica gel 600, 0.040-0.063 
mm, 230 – 300 mesh, eluent DCM, followed by MeOH). After removal of the solvent, 
350.1 mg (1.11 mmol, 67,8 %) of purified 24’ was obtained. 1H-NMR (300 MHz, CDCl3): 7.77 
(d, J=9.6 Hz, 1H), 7.67 (d, J=2.3 Hz, 1H), 7.36 (s, 1H), 6,82 (d, J=2.3 Hz, 1H), 6.38 (d, 
J=9.6 Hz, 1H), 5.07 (s, 2H), 1.43 (s, 9H). 
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5.2.5.9 8-(Carboxymethyleneoxy)psoralen (24) 
 
 
350.1 mg 24’ (1.11 mmol) was given in 20 ml TFA and stirred under reflux for 2 h. TFA was 
removed by rotary evaporation to afford 290.2 mg 24 as a pale-brown solid (1.11 mmol, 
100 %). 1H-NMR (300 MHz, DMSO-d6):  8.15 (d, J=9.7 Hz, 1H), 8.11 (d, J=2.2 Hz, 1H), 
7.65 (s, 1H), 7.09 (d, J=2.2 Hz, 1H), 6.45 (d, J=9.6 Hz, 1H), 5.13 (s, 2H). 
 
5.2.5.10 [N ε2- Gly3]8-(Carboxymethyleneoxy)psoralen-Lys-PNA2-Lys-Val-Cit-Glu (25) 
 
 
For the synthesis of 25, 59.0 mg of the dried and split PNA-resin analogously prepared as 
described in 5.2.5.3 was used (20 wt%, 0.01 mmol). After swelling of the PNA-resin and N-
terminal deprotection, Fmoc-Lys(Mtt)-OH and 24 was coupled according to the protocol 
described in 5.2.1.2 (24 was handled as same as non-canonical amino acids: 4 eq. 24, 
activation with 3.9 eq. HATU and 8 eq. DIEA). Mtt deprotection was carried out as described 
for 5.2.5.3. Coupling of Boc-Gly3-OH to the free amine of the lysine side chain was achieved 
following the protocol mentioned in 5.2.1.2 (Boc-Gly3-OH was handled as same as non-
canonical amino acids: 4 eq. Boc-Gly3-OH, activation with 3.9 eq. HATU and 8 eq. DIEA). The 
entire crude PNA-peptide hybrid after cleavage and isolation (5.2.1.4; 9.7 mg, 2.565 mmol, 
25.6 %) was purified by semipreparative HPLC yielding 3.8 mg of purified 25 (0.001 mmol, 
10.0 % overall yield). RP-HPLC: Rt = 15.7 min, 0 % MeCN over 2 min followed by 0 %→54 % 
MeCN over 20 min in 0.1 % aq. TFA at flow rate 1 ml/min. ESI-MS: m/z: [M+3H]3+ obsd. = 
1261.6 (calc = 1261.5), [M+4H]4+ obsd. = 946.4 (calc = 946.4), [M+5H]5+ obsd. = 757.3 
(calc = 757.3), [M+6H]6+ obsd. = 631.3 (calc = 631.2), [M+7H]7+ obsd. = 541.3 
(calc = 541.2). 
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5.2.5.11 PNA D-Lys (26) 
 
 
For the synthesis of 26, 50.8 mg of the dried and split PNA-resin prepared in 5.2.5.1 was used 
(20 wt%, 0.01 mmol). N-terminal extension with the tata PNA motif was performed following 
the PNA extension protocol II (5.2.2.3). The entire crude PNA-peptide hybrid after cleavage 
and isolation (5.2.1.4; 14.8 mg, 3.758 mmol, 37.6 %) was purified by semipreparative HPLC 
yielding 4.0 mg of purified 26 (0.001 mmol, 10.0 % overall yield). RP-HPLC: Rt = 14.9 min, 
0 % MeCN over 2 min followed by 0 %→54 % MeCN over 20 min in 0.1 % aq. TFA at flow 
rate 1 ml/min. ESI-MS: m/z: [M+3H]3+ obsd. = 1313.6 (calc = 1313.6), [M+4H]4+ obsd. = 
985.5 (calc = 985.5), [M+5H]5+ obsd. = 788.6 (calc = 788.5), [M+6H]6+ obsd. = 657.4 
(calc = 657.3), [M+7H]7+ obsd. = 563.6 (calc = 563.5), [M+8H]8+ obsd. = 493.4 (calc = 
493.4). 
 
 
5.2.5.12 Gly5-PNA B-Lys (27) 
 
 
SPPS of 27 was performed on 37.0 mg AmphiSpheres® 40 RAM resin with loading capacity 
of 0.27 mmol/g (batch size: 0.010 mmol). For chain elongation of the PNA part and the N-
terminal Gly5-tag, the PNA protocol II (5.2.2.2) was applied. After cleavage of the PNA-
peptide hybrid from solid support, 9.7 mg of crude 27 was isolated (0.003 mmol, 30.9 %). A 
purification via semipreparative RP-HPLC resulted in 4.9 mg of 27 (1.56 µmol, 50.4% 
purification yield, 15.6 % overall yield). RP-HPLC: Rt = 13.5 min, 0 % MeCN over 2 min 
followed by 0 %→54 % MeCN over 20 min in 0.1 % aq. TFA at flow rate 1 ml/min ESI-MS: 
m/z: [M+3H]3+ obsd. = 1047.7 (calc = 1047.7), [M+4H]4+ obsd. = 786.1 (calc = 786.0), 
[M+5H]5+ obsd. = 629.1 (calc = 629.0), [M+6H]6+ obsd. = 524.4 (calc = 524.3). 
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5.2.5.13 [N ε6-Ser]Gly5-Lys-TEV-PNA B-Lys (28) 
ENLYFQScatctagtgaK-NH2
H
N
HN
O
O
NH2
HO
H-G5
 
 
For the synthesis of 28, 150.4 mg of the dried and split PNA-resin prepared in 5.2.5.3 was 
used (50 wt%, 0.025 mmol). N-terminal extension with the TEV protease cleavage site, 
Lys(Mtt), and Gly5 tag was performed following the protocol for manual peptide chain 
elongation without microwave assistance (5.2.1.2). After coupling of Fmoc-Lys(Mtt)-OH, the 
Mtt protecting group was cleaved and Boc-Ser(tBu)-OH was coupled to the side chain as 
described for 17 (5.2.5.4). Finally, 28.6 mg of the crude PNA-peptide hybrid 28 could be 
isolated by cleavage and precipitation (0.007 mmol, 27.0 %). After purification via 
semipreparative RP-HPLC, isolation and freeze-drying of the collected product fractions, 
15.3 mg of purified 28 was achieved (3.61 µmol, 51.5 % purification yield, 13.9 % overall 
yield). RP-HPLC: Rt = 15.3 min, 0 % MeCN over 2 min followed by 0 %→90 % MeCN over 
20 min in 0.1 % aq. TFA at flow rate 1 ml/min. ESI-MS: m/z: [M+3H]3+ obsd. = 1413.4 
(calc = 1414.1), [M+4H]4+ obsd. = 1060.3 (calc = 1060.8), [M+5H]5+ obsd. = 848.5 
(calc = 848.8), [M+6H]6+ obsd. = 707.2 (calc = 707.5). 
 
 
5.2.5.14 Gly5-PNA E-Lys (29) 
 
 
29 was synthesized by manual Fmoc-SPPS. 185.0 mg of AmphiSpheres® 40 RAM resin with 
0.27 mmol/g loading capacity (total batch size: 0.050 mmol) was chosen as solid support and 
prepared as described in 5.2.1.1. Loading and chain elongation was performed according to 
the PNA chain elongation protocol II (5.2.2.3). After chain elongation up to c2, the peptide-
resin was dried and 130.6 mg (1/2 of total batch, 0.025 mmol) was spilt for further synthesis. 
After cleavage and isolation (5.2.1.4), 47.4 mg of the strongly contaminated crude PNA-
peptide hybrid 29 was obtained (0.011 mmol, 44.2 %). 42.0 mg crude 29 (9.79 µmol) was 
purified via semipreparative RP-HPLC and after isolation and freeze-drying of the collected 
product fractions, 5.3 mg of purified 29 was achieved (1.23 µmol, 12.6 % purification yield, 
5.6 % overall yield). RP-HPLC: Rt = 11.0 min, 12.3 min, 9 % MeCN over 2 min followed by 
9 %→54 % MeCN over 20 min in 0.1 % aq. TFA at flow rate 1 ml/min. ESI-MS: m/z: 
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[M+4H]4+ obsd. = 1073.2 (calc = 1073.3), [M+5H]5+ obsd. = 858.9 (calc = 858.8), 
[M+6H]6+ obsd. = 715.9 (calc = 715.9), [M+7H]7+ obsd. = 613.6 (calc = 613.7). 
 
 
5.2.5.15 Gly5-PNA2-Lys-Val-Cit-Aha (30’) 
 
 
SPPS of 30’ was performed on 75.0 mg AmphiSpheres® 40 RAM resin with loading capacity 
of 0.27 mmol/g (batch size: 0.020 mmol). Chain elongation of the C-terminal, peptidic part 
was performed according the protocol for manual microwave-assisted SPPS (5.2.1.2). For 
chain elongation of the PNA part and the N-terminal Gly5-tag the PNA protocol I (5.2.2.2) was 
applied. After cleavage of the PNA-peptide hybrid from solid support, crude 30’ could be 
isolated in high purity, thus no further purification was required. 23.4 mg of 30’ was obtained 
(0.007 mmol, 33.2 %). RP-HPLC: Rt = 14.0 min, 0 % MeCN over 2 min followed by 
0 %→72 % MeCN over 20 min in 0.1 % aq. TFA at flow rate 1 ml/min. ESI-MS: m/z: 
[M+4H]4+ obsd. = 881.7 (calc = 881.6), [M+5H]5+ obsd. = 705.6 (calc = 705.5), 
[M+6H]6+ obsd. = 588.1 (calc = 588.1). 
 
5.2.5.16 BCN-9-methoxycarbonyl-N-Ispinesib (31) 
 
 
2.8 mg of Ispinesib (5.4 µmol) was dissolved in 1 ml DMSO. 80 µl of BCN-NHS (34 mM in 
DMSO, 2.7 µmol) was added and the resulting mixture was shaken at ambient temperature 
until conversion of Ispinesib was terminated, while monitoring the reaction progress by RP-
HPLC and ESI-MS. The mixture was applied without further purification for the successive 
SPAAC. RP-HPLC: Rt = 19.5 min, 0 % MeCN over 2 min followed by54 %→90 % MeCN over 
20 min in 0.1 % aq. TFA at flow rate 1 ml/min. ESI-MS: m/z: [M+Na]+ obsd. =715.3 
(calc = 716.3), [M+H]+ obsd. = 693.3 (calc = 694.3). 
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5.2.5.17 [C γ19- ((7R,8s,9S)-5,6,7,9,10,11-hexahydro-bicyclo[6.1.0]nona[1,2,3]triazolyl)-8-
methoxy)carbonyl-N-Ispinesib)]Gly5-PNA B-Lys-Val-Cit-hAla (30)  
 
 
The loading of ispinesib to the PNA-peptide hybrid 30 was achieved via SPAAC. 5 mg of 30’ 
(1.35 µmol) was dissolved in 500 µl H2O and 1 ml of the 31 containing mixture prepared in 
5.2.6.11 was added. The resulting mixture was diluted with DMSO to 3 ml and shaken at 
ambient temperature for 5 h. Finally, the toxin-loaded PNA-peptide hybrid 30 was purified via 
semipreparative RP-HPLC yielding 3.8 mg of pure 30 (0.9 µmol, 66.7 %). RP-HPLC: Rt = 
19.6 min, 0 % MeCN over 2 min followed by 0 %→90 % MeCN over 20 min in 0.1 % aq. TFA 
at flow rate 1 ml/min. ESI-MS: m/z: [M+3H]3+ obsd. =1406.2 (calc = 1405.3), [M+4H]4+ 
obsd. = 1055.0 (calc = 1054.2), [M+5H]5+ obsd. = 844.2 (calc = 843.6), [M+6H]6+ obsd. 
= 703.7 (calc = 703.1), [M+7H]7+ obsd. = 603.3 (calc = 602.8). 
 
 
5.3 Test Reactions 
5.3.1 Proteolysis Experiments of Protease Inhibitors 
Proteolysis experiments of the linear precursor of the inhibitors 1’-4’ and cyclic HNE inhibitors 
3 and 4 were performed by incubation in presence of the HNE or chymotrypsin and analysis 
of the supernatant of the reaction mixture after protein precipitation via analytical RP-HPLC 
and ESI-MS of the collected fraction.  
Setup 1. 20 µl of precursors 1’ – 4’ (1 mM in H2O, 20 nmol) was treated with 200 µl DTT 
(50 mM in elastase activity buffer: 100 mM Tris/HCl, 20 mM CaCl2, 500 mM NaCl, 0.005 % 
Triton X-100, pH 7.8; 10 µmol). 100 µl of HNE (1 µM in PBS pH 7.5, 100 pmol) was added. 
The reaction mixture was shaken at ambient temperature while taking 20 µl of the mixture in 
10 – 60 min steps for HPLC analysis. HNE was removed by precipitation in acidic milieu: the 
sample solution was given in 80 µl HCl (aq. 100 mM).  
Setup 2. 20 µl of precursors 1’ – 4’ (1 mM in H2O, 20 nmol) was treated with 200 µl DTT 
(50 mM in chymotrypsin activity buffer: 100 mM Tris/HCl, 20 mM CaCl2, 0.05 % Triton X-
100, pH 7.8; 10 µmol). 100 µl of bovine chymotrypsin (1 µM in PBS pH 7.5, 100 pmol) was 
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added and the reaction mixture was shaken at ambient temperature. Further procedure was 
same as described for setup 1.  
Setup 3. 100 µl of cyclic inhibitors 3 or 4 (1 mM in H2O, 100 nmol) was diluted with 200 µl 
elastase activity buffer (10 µmol). 100 µl of HNE (1 µM in PBS pH 7.5, 100 pmol) was added 
and the reaction mixture was shaken at ambient temperature while taking 20 µl of the 
mixture in 10 – 60 min steps for HPLC analysis. HNE was removed by precipitation in acidic 
milieu: the sample solution was given in 80 µl HCl (aq. 100 mM). An excess amount of DTT 
(solid) was added and the samples were heated at 90 °C for 1-2 min.  
 
 
5.3.2 PHIP Experiments of SFTI Derivatives 
NMR PHIP experiments were performed either on a 7 T Bruker AVANCE® ІІІ (300 MHz) or on 
an 11 T Bruker AVANCE® HD (OXFORD, 500 MHz) spectrometer. All probes were dissolved 
in the NMR solvents: Methanol-d4, Ethanol-d6 and D2O (Euriso-Top). Para-hydrogen was 
enriched at liquid nitrogen temperature in a home-build apparatus which was described 
previously.[185]  
All ALTADENA experiments were performed in the terrestrial magnetic field at ambient 
temperature in 5 mm “screw cap” NMR tubes equipped with a silicon rubber septum. 2.5 µmol 
of the catalyst and 50 µmol of the Fmoc-L-Pra-OH, Fmoc-L-Tyr(O-propargyl)-OH and 4-
pentynoic acid or 2.5 µmol of SFTI derivative 5 - 13 (respective to the amount of C-C triple 
bonds in the sample) were dissolved in 600 µL NMR solvent. The NMR tube was sealed and 
para-enriched H2 gas was filled into the sample tube through the septum with a pressure of 
2 bar. Subsequently, the sample was vigorously shaken for a short time, placed into the 
measuring chamber of the spectrometer, and a standard PHIP sequence (i.e. signal acquisition 
after a 45° pulse) was applied for irradiation. All PHIP spectra have been recorded as “single-
shot experiments”, performing one scan. Full relaxation of the polarized protons products was 
observed at least 2 minutes after the hydrogenation normally recorded with 256 scans. 
Additional PHIP experiments employing peptide 7 were performed at 333K in D2O-methanol-
d4 and D2O-ethanol-d6 mixture (both 1:1, v/v).  
Signal enhancements (SE) were calculated from the normalized integrals of the respective 
signal after deconvolution using the implemented line fitting function in MestReNova 8. SE 
was estimated as the quotient of the integral for the polarized signals during PHIP 
experiments (Int (PHIP)) and the integral for the hydrogenation product at thermal 
equilibrium (Int (therm.)) using following equation: 
 
    & ≈ 	 WEX	YZWYWEX	X[\]^.     (13) 
 
Int (PHIP) was determined as the sum of the absolute values each of the emission and 
absorption area of the antiphase signals since the integral sum of the antiphase signals is 
equal to zero., Further information about determination and calculation of SE can be found in 
the recently published protocol.[50b] All PHIP experiments were performed by Grit Sauer and 
Dr. Marco Körner (Prof. Buntkowsky group). 
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5.3.2.1 Determination of T1 Relaxation Times 
Determination of T1 times of the hydrogenation products were performed by the inversion 
recovery method at 500 MHz. T1 of Fmoc-L-allyglycine, Fmoc-L-Tyr(All)-OH and 4-Pentenoic 
acid, were determined using commercially available substances purchased from PolyPeptide 
and Sigma Aldrich. T1 time of the hydrogenation product of peptide 7 was calculated from 
measurement of peptide [Tyr(O-allyl)1]SFTI-1[1,14] (13). T1 time of the hydrogenation 
product of peptide 8 was calculated from measurement of peptide [4-Pentenoic acid1]SFTI-
1[1,14] (14). T1 (Ha/Hb) represents the average relaxation time of the Ha-Hb spin system. As 
previously mentioned, a distinction of respective proton signals was not possible. All T1 
determination experiments were performed by Grit Sauer and Dr. Marco Körner (Prof. 
Buntkowsky group). 
 
 
5.3.3 Strain-Promoted Cycloaddition and Nucleobase Cross-Conjugation 
All strain-promoted cycloadditions were referred to modifications of reported protocols.[172-173] 
In general, the test reactions were performed in degassed NH4OAc buffer (0.1 M, pH 6.5 or 
pH 6.0). In special cases, HEPES buffer (0.1 M, pH 6.0), NaOAc buffer (0.1 M, pH 5.0), and 
PBS (1×, pH 7.5) were also applied as solvent. All coiled coil and PNA-peptide hybrids were 
applied as 1 mM or 0.5 mM stock solutions in H2O. All reactions were monitored via direct 
injection of the reaction mixture in LC-MS equipped with a C18 RP column or RP-HPLC and 
the collected fraction were analyzed by ESI-MS. For SPANC, in situ oxidation of side chain-
coupled Ser and the application of pre-oxidized and isolated aldehyde-bearing guiding units 
were tried, both. The amount and equivalents of reactants, the timing and order of their 
addition, reaction temperature, hybridization time of the guiding units and batch size were 
varied 
 
 
5.3.3.1 SPANC: Coiled-Coil Guiding Units 
Setup 1: 150 µl of 16 (0.5 mM in H2O, 75 nmol) and 150 µl of 17 (0.5 mM in H2O/DMSO, 
2:3, v/v, 75 nmol) were mixed and diluted with NH4OAc buffer (0.1 M, pH 6.5) and DMSO 
(3:5, v/v) to a total volume of 580 µl. The mixture was shaken for 1 h at ambient 
temperature. 10 µl of p-anisidine (37.5 mM in MeCN, 375 nmol) was added and the resulting 
mixture was shaken for another 10 min. After addition of 10 µl of MeNOH·HCl (9 mM in 
NH4OAc buffer, 90 nmol), the reaction mixture was shaken at ambient temperature, while 
monitoring the reaction progress via analytical HPLC. After a reaction time of 4 h, 74.1 % 
conversion regarding 17 was obtained. 
Setup 2: 10 µl of 18 (1 mM in H2O, 10 nmol) and 10 µl of 19 (1 mM in H2O, 10 nmol) were 
mixed and diluted with NH4OAc buffer (0.1 M, pH 6.5) to a total volume of 180 µl. The 
mixture was shaken for 1 h at ambient temperature. 10 µl of p-anisidine (5 mM in MeCN, 
50 nmol) was added and the resulting mixture was shaken for another 10 min. After addition 
of 10 µl of MeNOH·HCl (1.2 mM in NH4OAc buffer, 12 nmol), the reaction mixture was 
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shaken at ambient temperature, while monitoring the reaction progress via LC-MS equipped 
with a C18-RP column. Reactant conversion was not able to calculate for this setup. 
Setup 3: 10 µl of 18 (1 mM in H2O, 10 nmol) and 20 µl of 19 (0.5 mM in H2O, 10 nmol) 
were mixed and diluted with NH4OAc buffer (0.1 M, pH 6.5) to a total volume of 180 µl. The 
mixture was shaken for 1 h at ambient temperature. 10 µl of p-anisidine (5 mM in MeCN, 
50 nmol) was added and the resulting mixture was shaken for another 10 min. After addition 
of 10 µl of MeNOH·HCl (4.8 mM in NH4OAc buffer, 48 nmol), the reaction mixture was 
shaken at ambient temperature, while monitoring the reaction progress via LC-MS equipped 
with a C18-RP column. Reactant conversion was not able to calculate for this setup. 
Setup 4: 10 µl of 18 (1 mM in H2O, 10 nmol) and 20 µl of 19 (0.5 mM in H2O, 10 nmol) 
were mixed and diluted with NH4OAc buffer (0.1 M, pH 6.5) to a total volume of 180 µl. The 
mixture was shaken for 1 h at ambient temperature. 10 µl of p-anisidine (5 mM in MeCN, 
50 nmol) was added and the resulting mixture was shaken for another 10 min. After addition 
of 10 µl of MeNOH·HCl (4.8 mM in NH4OAc buffer, 48 nmol), the reaction mixture was 
shaken at ambient temperature, while monitoring the reaction progress via RP-HPLC and ESI-
MS of the collected fractions. 69.8 % conversion regarding 19 was obtained within a reaction 
time of 3 h. 
Setup 5: 10 µl of 18 (1 mM in H2O, 10 nmol) and 20 µl of 19 (0.5 mM in H2O, 10 nmol) 
were mixed and diluted with H2O to a total volume of 180 µl. Further procedure was as same 
as described for setup 4. 61.2 % conversion regarding 19 was obtained within a reaction time 
of 2.5 h. 
Setup 6: 10 µl of 18 (1 mM in H2O, 10 nmol), 20 µl of 19 (0.5 mM in H2O, 10 nmol), and 
10 µl of benzaldehyde (purified via distillation, 1 mM in DMSO, 10 nmol) were mixed and 
diluted with NH4OAc buffer (0.1 M, pH 6.5) to a total volume of 180 µl. Further procedure 
was as same as described for Setup 4. 80.0 % conversion regarding 19 was obtained within a 
reaction time of 4 h. 
Setup 7: 20 µl of 18 (1 mM in H2O, 20 nmol), 40 µl of 19 (0.5 mM in H2O, 30 nmol), and 
10 µl of benzaldehyde (purified via distillation, 2 mM in MeCN, 20 nmol) were mixed and 
diluted with NH4OAc buffer (0.1 M, pH 6.5) to a total volume of 180 µl. The mixture was 
shaken for 1 h at ambient temperature. 10 µl of p-anisidine (8 mM in MeCN, 80 nmol) was 
added and the resulting mixture was shaken for another 10 min. After addition of 10 µl of 
MeNOH·HCl (9.6 mM in NH4OAc buffer, 96 nmol), the reaction mixture was shaken at 
ambient temperature, while monitoring the reaction progress via RP-HPLC and ESI-MS of the 
collected fractions. 71.5 % conversion regarding 19 was obtained within a reaction time of 
3 h. 
Setup 8: 30 µl of 18 (1 mM in H2O, 30 nmol), 60 µl of 19 (0.5 mM in H2O, 30 nmol), and 
10 µl of benzaldehyde (purified via distillation, 3 mM in MeCN, 30 nmol) were mixed and 
diluted with NH4OAc buffer (0.1 M, pH 6.5) to a total volume of 180 µl. The mixture was 
shaken for 1 h at ambient temperature. 10 µl of p-anisidine (6 mM in MeCN, 60 nmol) was 
added and the resulting mixture was shaken for another 10 min. After addition of 10 µl of 
MeNOH·HCl (7.2 mM in NH4OAc buffer, 72 nmol), the reaction mixture was shaken at 
ambient temperature, while monitoring the reaction progress via RP-HPLC and ESI-MS of the 
collected fractions. 81.5 % overall conversion regarding 19 was obtained. 
Setup 9: 20 µl of 18 (1 mM in H2O, 20 nmol) and 10 µl of benzaldehyde (purified via 
distillation, 20 mM in DMSO, 200 nmol) were mixed and diluted with NH4OAc buffer (0.1 M, 
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pH 6.5) to a total volume of 170 µl. The mixture was shaken for 1 h at ambient temperature. 
20 µl of p-anisidine (50 mM in MeCN, 1000 nmol) was added and the resulting mixture was 
shaken for another 10 min. After addition of 10 µl of MeNOH·HCl (20 mM in NH4OAc buffer, 
200 nmol), the reaction mixture was shaken at ambient temperature, while monitoring the 
reaction progress via RP-HPLC and ESI-MS of the collected fractions. 50.1 % conversion 
regarding 18 was obtained within a reaction time of 2 h. 
Setup 10: 10 µl of 18 (1 mM in H2O, 10 nmol) was mixed with 10 µl of p-anisidine (50 mM 
in MeCN, 500 nmol) and diluted with NH4OAc buffer (0.1 M, pH 6.5) to a total volume of 
90 µl. The mixture was shaken for 1 h at ambient temperature. After addition of 10 µl of 
MeNOH·HCl (20 mM in NH4OAc buffer, 200 nmol), the reaction mixture was shaken at 
ambient temperature, while monitoring the reaction progress via RP-HPLC and ESI-MS of the 
collected fractions.  
Setup 11: 20 µl of 18 (1 mM in H2O, 20 nmol), 40 µl of 19 (0.5 mM in H2O, 20 nmol), and 
20 µl of 32 (1 mM in H2O, 20 nmol) were mixed and diluted with NH4OAc buffer (0.1 M, pH 
6.5) to a total volume of 180 µl. The mixture was shaken for 1 h at ambient temperature. 10 
µl of p-anisidine (4 mM in MeCN, 40 nmol) was added and the resulting mixture was shaken 
for another 10 min. After addition of 10 µl of MeNOH·HCl (8 mM in NH4OAc buffer, 
80 nmol), the reaction mixture was shaken at ambient temperature, while monitoring the 
reaction progress via RP-HPLC and ESI-MS of the collected fractions. 89.2 % conversion 
regarding 19 was obtained within a reaction time of 6 h. 
Setup 12: 20 µl of 18 (1 mM in H2O, 20 nmol) and 20 µl of 32 (1 mM in H2O, 20 nmol) were 
mixed and diluted with NH4OAc buffer (0.1 M, pH 6.5) to a total volume of 180 µl. The 
mixture was shaken for 1 h at ambient temperature. 10 µl of p-anisidine (4 mM in MeCN, 
40 nmol) was added and the resulting mixture was shaken for another 10 min. After addition 
of 10 µl of MeNOH·HCl (8 mM in NH4OAc buffer, 80 nmol), the reaction mixture was shaken 
at ambient temperature, while monitoring the reaction progress via RP-HPLC and ESI-MS of 
the collected fractions. 60.2 % overall conversion regarding 32 was obtained. 
Setup 13: 40 µl of 19’ (0.5 mM in H2O, 20 nmol) were diluted with 90 µl NH4OAc buffer 
(0.1 M, pH 6.5). 11 µl NaIO4 (2 mM in NH4OAc buffer, 22 nmol) was added to the solution at 
4 °C and the resulting mixture was shaken for 30 min at 4 °C. 10 µl of 4-methoxythiophenol 
(40 mM in MeCN, 400 nmol) was carefully added while shaking at ambient temperature. 
After 15 min shaking, 20 µl of 18 (1 mM in H2O, 20 nmol) was added and the mixture was 
shaken for another 1 h. After addition of 10 µl p-anisidine (4 mM in MeCN, 40 nmol) and 10 
µl MeNOH·HCl (4 mM in NH4OAc buffer, 40 nmol), the reaction mixture was shaken at 
ambient temperature, while monitoring the reaction progress via RP-HPLC and ESI-MS of the 
collected fractions. 72.2 % overall conversion related to 19 was obtained. 
 
 
5.3.3.2 SPANC: PNA Guiding Units 
Setup 1: 30 µl of 20 (1 mM in H2O, 30 nmol) and 30 µl of 21 (1 mM in H2O, 30 nmol) were 
mixed and diluted with NH4OAc buffer (0.1 M, pH 6.5 or pH 6.0) to a total volume of 135 µl. 
The mixture was shaken for 1 h at ambient temperature. 10 µl of p-anisidine (2 mM in MeCN, 
50 nmol) was added and the resulting mixture was shaken for another 10 min. After addition 
of 5 µl of MeNOH·HCl (10 mM in NH4OAc buffer, 50 nmol), the reaction mixture was shaken 
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at ambient temperature, while monitoring the reaction progress via analytical HPLC. After a 
reaction time of 6 h, the mixture was lyophilized over night, dissolved in 60 µl H2O and 
analyzed via HPLC and ESI-MS. 70.5 % conversion regarding 21 was obtained. 
Setup 2: 20 µl of 20 (1 mM in H2O, 20 nmol) and 15 µl of 21 (1 mM in H2O, 15 nmol) were 
mixed and diluted with NH4OAc buffer (0.1 M, pH 6.5) to a total volume of 140 µl. The 
mixture was shaken for 1 h at ambient temperature. 10 µl of MeNOH·HCl (10 mM in NH4OAc 
buffer, 100 nmol) was added and the reaction mixture was shaken at ambient temperature, 
while monitoring the reaction progress via analytical HPLC. After a reaction time of 5 h, the 
mixture was lyophilized over night, dissolved in 60 µl H2O and analyzed via HPLC and ESI-
MS. 52.0 % conversion regarding 21 was obtained. 
Setup 3: 20 µl of 20 (1 mM in H2O, 20 nmol) and 15 µl of 21 (1 mM in H2O, 15 nmol) were 
mixed and diluted with NH4OAc buffer (0.1 M, pH 6.5) to a total volume of 135 µl. The 
mixture was shaken for 1 h at ambient temperature. 10 µl of p-anisidine (2 mM in MeCN, 
50 nmol) was added and the resulting mixture was shaken for another 10 min. After addition 
of 5 µl of MeNOH·HCl (10 mM in NH4OAc buffer, 50 nmol), the reaction mixture was shaken 
at ambient temperature, while monitoring the reaction progress via analytical HPLC. After a 
reaction time of 2 h, the mixture was lyophilized over night, dissolved in 60 µl H2O and 
analyzed via HPLC and ESI-MS. 57.1 % conversion regarding 21 was obtained. 
Setup 4: 20 µl of 20 (1 mM in H2O, 20 nmol) and 15 µl of 21 (1 mM in H2O, 15 nmol) were 
mixed and diluted with HEPES buffer (0.1 M, pH 6.0) to a total volume of 135 µl. The 
mixture was shaken for 1 h at ambient temperature. 10 µl of p-anisidine (5 mM in MeCN, 50 
nmol) was added and the resulting mixture was shaken for another 10 min. After addition of 
5 µl of MeNOH·HCl (10 mM in HEPES buffer, 50 nmol), the reaction mixture was shaken at 
ambient temperature, while monitoring the reaction progress via analytical HPLC. After a 
reaction time of 2.5 h, the mixture was lyophilized over night, dissolved in 60 µl H2O and 
analyzed via HPLC and ESI-MS. 66.1 % conversion regarding 21 was obtained. 
Setup 5: 100 µl of 20 (1 mM in H2O, 100 nmol) and 100 µl of 21 (1 mM in H2O, 100 nmol) 
were mixed and diluted with NH4OAc buffer (0.1 M, pH 6.0) to a total volume of 1440 µl. The 
mixture was shaken for 1 h at ambient temperature. 10 µl of p-anisidine (50 mM in MeCN, 
500 nmol) was added and the resulting mixture was shaken for another 10 min. 10×5 µl of 
MeNOH·HCl (10 mM in NH4OAc buffer, 10×50 nmol) was added to the mixture in 20 min 
steps while shaking at ambient temperature. The reaction progress was monitored via 
analytical HPLC and ESI-MS. 75.1 % overall conversion related to 21 was obtained. 
Setup 6: 100 µl of 20 (1 mM in H2O, 100 nmol) and 100 µl of 21 (1 mM in H2O, 100 nmol) 
were mixed and diluted with NH4OAc buffer (0.1 M, pH 6.0) to a total volume of 1475 µl. The 
mixture was shaken for 1 h at 4 °C. 10 µl of p-anisidine (50 mM in MeCN, 500 nmol) was 
added and the resulting mixture was shaken for another 10 min. 3×5 µl of MeNOH·HCl 
(10 mM in NH4OAc buffer, 3×50 nmol) was added to the mixture in 20 min steps while 
shaking at 4 °C. The reaction progress was monitored via analytical HPLC and ESI-MS. After a 
reaction time of 6 h, the mixture was lyophilized over night, dissolved in 60 µl H2O and 
analyzed via HPLC and ESI-MS. 75.9 % conversion regarding 21 was obtained. 
Setup 7: 100 µl of 20 (1 mM in H2O, 100 nmol) and 100 µl of 21 (1 mM in H2O, 100 nmol) 
were diluted with 1275 µl NaOAc buffer (0.1 M, pH 5.0). 10 µl of p-anisidine (50 mM in 
MeCN, 500 nmol) was added and the resulting mixture was shaken for 60 min. 15 µl of 
MeNOH·HCl (10 mM in NaOAc buffer, 150 nmol) was added and the resulting reaction 
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mixture was shaken at 4 °C. The reaction progress was monitored via analytical HPLC and 
ESI-MS. The reaction progress was monitored via analytical HPLC and ESI-MS. After a 
reaction time of 7 h, the mixture was lyophilized over night, dissolved in 60 µl H2O and 
analyzed via HPLC and ESI-MS. 55.6 % conversion regarding 21 was obtained. 
Setup 8: 100 µl of 20 (1 mM in H2O, 100 nmol) and 100 µl of 21 (1 mM in H2O, 100 nmol) 
was diluted with 1275 µl PBS (137 mM NaCl, 2.7 mM KCl, 10.0 mM Na2HPO4, 1.76 mM 
KH2PO4, pH 7.4). 10 µl of p-anisidine (50 mM in MeCN, 500 nmol) was added and the 
resulting mixture was shaken for 60 min. 15 µl of MeNOH·HCl (10 mM in PBS, 150 nmol) 
was added and the mixture was shaken was shaken at 4 °C. The reaction progress was 
monitored via analytical HPLC and ESI-MS. 39.3 % overall conversion regarding 21 was 
obtained. 
Setup 9: 120 µl of 20 (1 mM in H2O, 120 nmol) and 100 µl of 21 (1 mM in H2O, 100 nmol) 
were mixed and diluted with HEPES buffer (0.1 M, pH 6.0) to a total volume of 1440 µl. The 
mixture was shaken for 1 h at 4 °C. 10 µl of p-anisidine (50 mM in MeCN, 500 nmol) was 
added and the resulting mixture was shaken for another 10 min. 5×10 µl of MeNOH·HCl 
(10 mM in HEPES buffer, 5×100 nmol) was added to the mixture in 20 min steps while 
shaking at 4 °C. The reaction progress was monitored via analytical HPLC and ESI-MS. After a 
reaction time of 6 h, the mixture was lyophilized over night, dissolved in 60 µl H2O and 
analyzed via HPLC and ESI-MS. 73.2 % conversion regarding 21 was obtained. 
Setup 10: 100 µl of 20 (1 mM in H2O, 100 nmol) was diluted with 240 µl HEPES buffer 
(0.1 M, pH 6.0). 20 µl of p-anisidine (50 mM in MeCN, 1 µmol) was added and the resulting 
mixture was shaken for 30 min. 10 µl of MeNOH·HCl (100 mM in HEPES buffer, 1 µmol) was 
added and the mixture was shaken for another 30 min. Subsequently, 100 µl of 21 (1 mM in 
H2O, 100 nmol) was added and the resulting reaction mixture was shaken at 4 °C. The 
reaction progress was monitored via analytical HPLC and ESI-MS. 61.3 % conversion 
regarding 21 was obtained within a reaction time of 3 h. 
Setup 11: 120 µl of 20 (1 mM in H2O, 120 nmol) and 100 µl of 21 (1 mM in H2O, 100 nmol) 
were mixed and diluted with NH4OAc buffer (0.1 M, pH 6.5) to a total volume of 480 µl. The 
mixture was shaken for 1 h at 4 °C. 10 µl of p-anisidine (50 mM in THF, 500 nmol) was added 
and the resulting mixture was shaken for another 10 min. 10 µl of PhNOH (10 mM in NH4OAc 
buffer, 100 nmol) was added to the mixture while shaking at 4 °C. The reaction progress was 
monitored via analytical HPLC and ESI-MS. After a reaction time of 3.5 h, the mixture was 
lyophilized over night, dissolved in 60 µl H2O and analyzed via HPLC and ESI-MS. 50.9 % 
conversion regarding 21 was obtained. 
Setup 12: 160 µl of 20 (1 mM in H2O, 160 nmol) and 40 µl of 21 (1 mM in H2O, 40 nmol) 
were mixed and diluted with NH4OAc buffer (0.1 M, pH 6.5) and THF (5:4, v/v) to a total 
volume of 480 µl. The mixture was shaken for 1 h at 4 °C. 10 µl of p-anisidine (16 mM in 
THF, 160 nmol) was added and the resulting mixture was shaken for another 10 min. 10 µl of 
PhNOH·HCl (16 mM in NH4OAc buffer, 100 nmol) was added to the mixture while shaking at 
4 °C. The reaction progress was monitored via analytical HPLC and ESI-MS. 68.5 % overall 
conversion regarding 21 was obtained. 
Setup 13: 20 µl of 20 (1 mM in H2O, 20 nmol) and 20 µl of 21 (1 mM in H2O, 20 nmol) were 
mixed and diluted with NH4OAc buffer (0.1 M, pH 6.0) to a total volume of 93 µl. The 
mixture was shaken for 1 h at ambient temperature. 6 µl of p-anisidine (17 mM in THF, 100 
nmol) was added and the resulting mixture was shaken for another 10 min. 1 µl of 
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MeNOH·HCl (100 mM in NH4OAc buffer, 100 nmol) was added to the mixture while shaking 
at ambient temperature. The reaction progress was monitored via analytical HPLC and ESI-
MS. 73.1 % conversion regarding 21 was obtained within a reaction time of 4.5 h. 
Setup 14: 20 µl of 20 (1 mM in H2O, 20 nmol), 20 µl of 21 (1 mM in H2O, 20 nmol), and 20 
µl of 22 (1 mM in H2O, 20 nmol) were mixed and diluted with NH4OAc buffer (0.1 M, pH 
6.0) to a total volume of 193 µl. The mixture was shaken for 1 h at ambient temperature. 
12 µl of p-anisidine (17 mM in THF, 200 nmol) was added and the resulting mixture was 
shaken for another 10 min. 2 µl of MeNOH·HCl (100 mM in NH4OAc buffer, 200 nmol) was 
added to the mixture while shaking at ambient temperature. The reaction progress was 
monitored via analytical HPLC and ESI-MS. 54.0 % conversion regarding 21+22 was 
obtained within a reaction time of 3.5 h.  
Setup 15: 20 µl of 21 (1 mM in H2O, 20 nmol) were diluted with 130 µl NH4OAc buffer (0.1 
M, pH 6.5). 11 µl NaIO4 (2 mM in NH4OAc buffer, 22 nmol) was added to the solution at 4 °C 
and the resulting mixture was shaken for 30 min at 4 °C. 10 µl of 4-methoxythiophenol 
(40 mM in MeCN, 400 nmol) was carefully added while shaking at ambient temperature. 
After 15 min shaking, 20 µl of 21 (1 mM in H2O, 20 nmol) was added and the mixture was 
shaken for another 1 h. After addition of 10 µl p-anisidine (4 mM in MeCN, 40 nmol) and 10 
µl MeNOH·HCl (4 mM in NH4OAc buffer, 40 nmol), the reaction mixture was shaken at 
ambient temperature while monitoring the reaction progress via RP-HPLC and ESI-MS of the 
collected fractions. 51.0 % conversion regarding 21 was obtained within a reaction time of 
5 h. 
Setup 16: 100 µl of 21 (1 mM in H2O, 100 nmol) were diluted with 140 µl NH4OAc buffer 
(0.1 M, pH 6.5). 50 µl NaIO4 (2.2 mM in NH4OAc buffer, 110 nmol) was added to the 
solution at 4 °C and the resulting mixture was shaken for 30 min at 4 °C. 50 µl of 4-
methoxythiophenol (40 mM in MeCN, 2 µmol) was carefully added while shaking at ambient 
temperature. After 15 min shaking, 100 µl of 20 (1 mM in H2O, 100 nmol) was added and the 
mixture was shaken for another 1 h. After addition of 10 µl p-anisidine (20 mM in MeCN, 200 
nmol) and 50 µl MeNOH·HCl (2 mM in NH4OAc buffer, 100 nmol), the reaction mixture was 
shaken at ambient temperature while monitoring the reaction progress via RP-HPLC and ESI-
MS of the collected fractions. 51.9 % conversion regarding 21 was obtained within a reaction 
time of 7 h. 
Setup 17: 100 µl of 21 (1 mM in H2O, 100 nmol) were diluted with 240 µl 0.1 M NH4OAc 
buffer/THF (7:5, v/v). 50 µl NaIO4 (2.2 mM in NH4OAc buffer, 110 nmol) was added to the 
solution at 4 °C and the resulting mixture was shaken for 30 min at 4 °C. 50 µl of 4-
methoxythiophenol (40 mM in THF, 2 µmol) was carefully added while shaking at ambient 
temperature. After 15 min shaking, 100 µl of 20 (1 mM in H2O, 100 nmol) was added and the 
mixture was shaken for another 1 h. After addition of 10 µl p-anisidine (20 mM in THF, 
200 nmol) and 50 µl MeNOH·HCl (2 mM in NH4OAc buffer, 100 nmol), the reaction mixture 
was shaken at ambient temperature while monitoring the reaction progress via RP-HPLC and 
ESI-MS of the collected fractions. 49.5 % overall conversion regarding 21 was obtained. 
Setup 18: 100 µl of 21 (1 mM in H2O, 100 nmol) were diluted with 240 µl 0.1 M NH4OAc 
buffer/THF (7:5, v/v). 50 µl NaIO4 (2.2 mM in NH4OAc buffer, 110 nmol) was added to the 
solution at 4 °C and the resulting mixture was shaken for 30 min at 4 °C. 50 µl of ethylene 
glycol solution (20 mM in THF, 1 µmol) was carefully added while shaking at ambient 
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temperature. Further procedure is as same as described for setup x. 76.6 % overall conversion 
regarding 21 was obtained. 
 
 
5.3.3.3 SPAAC: PNA Guiding Units 
Setup 1: 30 µl of 20 (1 mM in H2O, 30 nmol) and 40 µl of 23 (1 mM in H2O, 40 nmol) were 
mixed and diluted with NH4OAc buffer (0.1 M, pH 6.5) to a total volume of 500 µl. The 
mixture was shaken at ambient temperature and the reaction progress was monitored via 
analytical HPLC and ESI-MS. 54.4 % conversion regarding 23 was obtained within a reaction 
time of 6 h. 
Setup 2: 100 µl of 20 (1 mM in H2O, 100 nmol) and 100 µl of 23 (1 mM in H2O, 100 nmol) 
were mixed and diluted with NH4OAc buffer (0.1 M, pH 6.5) to a total volume of 300 µl. The 
mixture was shaken at ambient temperature and the reaction progress was monitored via 
analytical HPLC and ESI-MS. 28.1 % conversion regarding 23 was obtained within a reaction 
time of 3 h. 
 
 
5.3.4 Psoralen Cross-Linkage 
The psoralen cross-linking test reaction of PNA/DNA oligomers were referred to a 
modification of a reported protocol.[186] For UVA irradiation, an 8 W UV hand lamp with λ = 
366 nm in distance of 5 – 10 cm to reaction tube surface was used. The irradiation was 
performed while cooling on ice without stirring. All reactions were monitored via direct 
injection of the reaction mixture in LC-MS equipped with a C18 RP column or RP-HPLC and 
the collected fraction were analyzed by ESI-MS. 
 
 
5.3.4.1 PNA-PNA Cross-Linkage with Free Psoralen 
50 µl of 20’ (1 mM in H2O, 50 nmol) and 50 µl of 21’ (1 mM in H2O, 50 nmol) were mixed 
and diluted with NH4OAc buffer (0.1 M, pH 6.5) to a total volume of 450 µl. The mixture was 
shaken on ice for 1 h. After addition of 50 µl of psoralen (10 mM in DMSO, 500 nmol), the 
resulting mixture was shaken for another 10 min on ice and subsequently exposed to UVA 
irradiation in a darkened room. For monitoring the reaction progress, HPLC probes were 
taken from the reaction mixture in 15 or 30 min steps, respectively.  
 
 
5.3.4.2 PNA-DNA Cross-Linkage with Psoralen-loaded PNA Guiding Unit 
40 µl of 25 (1 mM in H2O, 40 nmol) and 30 µl of 33 (1 mM in H2O, 30 nmol) were mixed and 
diluted with Tris-HCl buffer (0.05 M, pH 7.5), NH4OAc buffer (0.1 M, pH 6.5), or NaOAc 
buffer (0.1 M, pH 5.0) to a total volume of 300 µl. The resulting mixture was shaken for 1 h 
on ice and subsequently exposed to UVA irradiation in a darkened room. For monitoring the 
reaction progress, HPLC probes were taken from the reaction mixture in 15 or 30 min steps, 
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respectively. 99.1 % conversion regarding 25 was obtained within an irradiation time of 
90 min. 
 
 
5.3.4.3 PNA-PNA Cross-Linkage with Psoralen-loaded PNA Guiding Unit 
40 µl of 25 (1 mM in H2O, 40 nmol) and 30 µl of 26 (1 mM in H2O, 30 nmol) were mixed and 
diluted with Tris-HCl buffer (0.05 M, pH 7.5), NH4OAc buffer (0.1 M, pH 6.5), or NaOAc 
buffer (0.1 M, pH 5.0) to a total volume of 300 µl. The resulting mixture was shaken for 1 h 
on ice and subsequently exposed to UVA irradiation in a darkened room. For monitoring the 
reaction progress, HPLC probes were taken from the reaction mixture in 15 or 30 min steps, 
respectively. 
 
 
5.3.5 Sortase-Mediated Ligation 
PNA-Fc conjugates 34 and its derivatives were synthesized upon sortase A-mediated 
transpeptidation. An evolved permutant of sortase A (eSrtA) with improved catalytic activity 
was produced and purified as described by Chen et al.[176] 10 µM Fc fragment produced 
according a published protocol[171] were supplemented with 10 – 100 eq. (25 eq. for 
preparative batch) of PNA-peptide hybrids 27 - 30 in sortase reaction buffer (50 mM Tris, 
150 mM NaCl, 5 mM CaCl2, pH 7.5 adjusted with HCl). Reaction was initiated by addition of 
10 µM eSrtA and incubated for 30 min at 22 °C. Controls included reactions without either Fc 
fragment, eSrtA, or counterparts 27 - 30. 
 
 
5.3.5.1 PAGE 
Protein samples and Fc-PNA conjugate were analyzed by SDS-PAGE (15 %, w/v) under 
reducing conditions as described elsewhere.[187] Prior to electrophoresis, samples were 
supplemented with 5×sample buffer (250 mM Tris/HCl pH 8.0, 7.5 % SDS, 25 % glycerol, 
0.25 mg/mL bromophenol blue, 12.5 % 2-mercaptoethanol) and heated to 95 °C for 10 min. 
For non-reducing gels sample buffer without 2-mercaptoethanol was used. Proteins 
conjugated with fluorescent dyes were visualized under UV-light. Protein bands were stained 
with Coomassie brilliant blue R-250 solution. 
Reaction monitoring of PNA-guided ligation approaches (SPANC, SPAAC, psoralen cross-
linkage) were tested by a SDS-PAGE with highly concentrated polyacrylamide gel (20 %, 
w/v). Same sample loading buffer was used as described for standard SDS-PAGE and sample 
preparation as well as experimental procedure were same as described above. 
Further PNA-guided ligation approaches were tested in urea-PAGE using a modified version of 
a reported protocol.[174] Urea gels were prepared with 26 % (w/v) polyacrylamide and 1.6 % 
(w/v) bisacrylamide. In a typical experiment 7.4 g urea were dissolved in 10.3 ml of 
polyacrylamide (40 %, w/v) and 39 mg bisacrylamide was added. 925 µl glacial acetic acid 
and 50 µl concentrated aqueous ammonia were added and the volume was adjusted to 15 ml. 
After degassing under reduced pressure, the polymerization was initiated by the addition of 
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300 µl ammonium persulfate (aqueous, 10 %, w/v) and 90 µl tetramethylethylendiamine 
(TEMED). Resulting gels were pre-electrophoresed at a constant voltage of 10 V/cm for 4 – 
5 h at ambient temperature. Electrophoresis running buffer consisted of 1 M acetic acid with 
0.1 M glycine. Gel overlay buffer consisted of 8M urea, 10 % (w/v) PEG-8000, 1 M acetic 
acid, and 50 mM ammonium hydroxide. Samples were mixed prior to electrophoresis with an 
equivalent volume (~ 10 µl) of loading solution consisting of 1 % methylene blue, 5 % acetic 
acid and 8 M urea and heated at 90 °C for 1 – 2 min. 
 
 
5.4 Enzyme Kinetic Assays 
Kinetic curves were recorded by photometrical monitoring of protease-catalyzed hydrolysis of 
the corresponding chromogenic substrates in 96-well-plates (NUNC, round bottom, clear) at 
405 nm in defined intervals at ambient temperature. All experiments were performed in 
triplicate.  
 
 
5.4.1 Trypsin 
Trypsin from bovine pancreas (Sigma-Aldrich) was standardized by active-site titration with 
p-nitrophenyl-p'-guanidinobenzoate (NPGB) in phosphate buffered saline (PBS: 137 mM 
NaCl, 2.7 mM KCl, 10.0 mM Na2HPO4, 1.76 mM KH2PO4, pH 7.4). The kinetic assays were 
performed in trypsin activity buffer (50 mM Tris/HCl, 150 mM NaCl, 0.01 % Triton X-100, 
0.01 % sodium azide, pH 7.6), in non-buffered water (pH 6.9), or D2O (pH/pD 7.4). 
 
 
5.4.1.1 Determination of Michaelis-Menten Constant (KM) for Boc-QAR-pNA 
The initial reaction rate (vi) of the proteolytic degradation of Boc-QAR-pNA (Bachem) by 
bovine trypsin (100 nM) was determined for a series of concentrations ([S]i) of the 
chromogenic substrate. The Michaelis-Menten constant (KM) was calculated via Hanes-Woolf 
plot (quotient of substrate concentration and initial reaction rate: [S]i/vi against the substrate 
concentration [S]i) and linear regression of the resulting data. KM was determined as 
58.89±7.34 µM for this system in trypsin activity buffer, 114.27±27.36 µM for non-buffered 
water and 51.27±18.32 µM for non-buffered D2O (arithmetic mean, standard deviation given 
as error). 
 
 
5.4.1.2 Determination of Apparent Inhibition Constant (Ki
app) of Trypsin Inhibitors 5 – 13 
The normalized residual trypsin reaction ratio (v/v0) towards the chromogenic substrate 
Boc-QAR-pNA at different concentrations of the synthesized trypsin inhibitors was determined 
at a constant concentration of trypsin (E0 = 0.9 nM) and substrate (S0 = 0.25 mM). The 
apparent inhibition constants (Kiapp) were calculated by fitting the Morrison equation for tight-
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binding inhibitors (14) onto the resulting kinetic data with the Marquardt-Levenberg 
algorithm of SigmaPlot 11®.   
 OO2	 = 1 − a2W2T#Qbbcda2W2T#Qbbce2W22     (14) 
 
 
5.4.1.3 Calculation of Substrate-Independent Inhibition Constant (Ki) of Trypsin Inhibitors 
5 – 13 
Substrate-independent inhibition constant Ki was calculated from Kiapp and KM using the 
equation 15 (with S0 ≡ concentration of chromogenic substrate Boc-QAR-pNA used for Kiapp 
determination). 
      @f = T#Qbbg h2ijk      (15) 
The error of Ki (∆Ki) was calculated by propagation of errors of Kiapp and KM using the 
following approach: 
→ ∆@f = m n@fn@foppm
 ∙ a∆@foppc + r n@fn@sr ∙ ∆@s 
 
→ ∆@f = tm n@fn@foppm
 ∙ a∆@foppc + r n@fn@sr ∙ ∆@s 
Differentiation of Ki with respect to Kiapp yields: 
→ n@fn@fopp = 1/1 + @s4 
Differentiation of Ki with respect to KM: 
using    @f = @fopp /1 + M2Tj4   and chain rule for differentiation yields: 
uT#uTj = v− T#Qbbg [h]ijkwx ∙ /− M2Tjw4     and thus: 
     → n@fn@s = @fopp ∙ g1 + []@sk ∙ @s 
Combination of respective equations gives the final formula for calculating the error of Ki: 
 
 → ∆@f = yz g h2ijk{
 ∙ a∆@foppc + v T#Qbb∙[M]g h2ijkw∙Tjwx
 ∙ ∆@s   (16) 
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5.4.2 Chymotrypsin 
Chymotrypsin from bovine pancreas (Sigma-Aldrich) was standardized by active-site titration 
with p-nitrophenylacetate (NPA) and dissolved in NaOAc (100 mM, pH 5.0) and diluted with 
2.5 mM HCl with 0.05 % triton X-100. The kinetic assays were performed in chymotrypsin 
activity buffer (100 mM Tris/HCl, 20 mM CaCl2, 0.05 % Triton X-100, pH 7.8). As 
chromogenic substrate Suc-AAPF-pNA (Sigma-Aldrich) with a reported KM of 60.0±7.0 µM for 
this system was used.[151] 
 
 
5.4.2.1 Determination of Ki
app and the Ki of the Chymotrypsin Inhibitor 1 
The normalized residual chymotrypsin reaction ratio (v/v0) towards the chromogenic 
substrate Suc-AAPF-pNA at different concentrations of 1 was determined at a constant 
concentration of chymotrypsin (E0 = 0.8 nM) and substrate (S0 = 0.25 mM, in 70 % DMF). 
Ki
app and Ki were calculated as described for the trypsin inhibitors (5.4.1.2 and 5.4.1.3). 
 
 
5.4.3 Elastase 
Human neutrophil elastase (HNE, Serva Electrophoresis) was standardized by active-site 
titration with p-nitrophenylacetate (NPA) and dissolved in PBS (137 mM NaCl, 2.7 mM KCl, 
10.0 mM Na2HPO4, 1.76 mM KH2PO4, pH 7.4). The kinetic assays were performed in elastase 
activity buffer (100 mM Tris/HCl, 20 mM CaCl2, 500 mM NaCl, 0.005 % Triton X-100, pH 
7.8).  
 
 
5.4.3.1 Determination of KM for MeO-Suc-AAPV-pNA 
vi of the proteolytic degradation of MeO-Suc-AAPV-pNA (Sigma-Aldrich) by HNE (100 nM) 
was determined for a series of concentrations ([S]i) of the chromogenic substrate. The 
experimental procedure and data processing was performed as described for trypsin (5.4.1.1). 
KM was determined as 47.7±5.8 µM for this system. 
 
 
5.4.3.2 Determination of Ki
app and the Substrate Ki of the Elastase Inhibitor 2-4 
The normalized residual HNE reaction ratio (v/v0) towards the chromogenic substrate Suc-
AAPV-pNA at different concentrations of the synthesized elastase inhibitors 2 – 4 were 
determined at a constant concentration of HNE (E0 = 10 nM) and substrate (S0 = 0.25 mM, in 
70 % DMF). Kiapp and Ki were calculated as described for the trypsin inhibitors (chapters 
5.4.1.2 and 5.4.1.3). 
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5.5 In Silico Modeling 
All 3D computational models of synthesized or only designed compounds were derived from 
the crystal structure or NMR structure of the parental peptides, proteins, or protein-ligand co-
complexes. PDB numbers of parental structures are given in the main text or in figure 
descriptions. 3D modeling and all in silico experiments were realized with the YASARA® 
structure package applying the YASARA 2 force field.[188] After modeling of the designed 
structure using the “build” function of respective software, each structure was energy 
minimized individually or as co-complex with its target enzyme, first in vacuo, then in 0.9 M 
NaCl (aq.) at pH 7.4 and 298.16 K. Generally, the simulation cell was set with the distance of 
5 Å around all atoms of the inhibitor structure, thus only the binding region of enzymes was 
included to the simulation when simulating an enzyme-inhibitor co-complex.  
For alignment and superposition of the energy minimized structures, the multiple structural 
alignment algorithm MUSTANG were applied, normally on the backbone structure of modeled 
peptides and proteins. Thereby, the flipping of side chains was allowed to minimize RMSD 
values. Alternations from this general protocol are mentioned in the main text or in the figure 
descriptions. All graphics were rendered with POVRayTM. In few cased, the resulted image was 
post-processed with a graphical tools as Adobe® Photoshop® for better presentation 
(schemes, concept sketches, etc). 
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7 Appendix 
List of Abbreviations 
2-Cl-Trt 2-Chlorotrityl 
Å Ångström 
aa Amino acid 
AAC Alkyne-azide cycloaddition 
Ab Antibody 
Ac Acetate 
ADC Antibody-drug conjugate 
ADMET Absorption, distribution, metabolism, excretion, toxicity 
aeg N-(2-ethyl)glycine 
Aha Azidohomoalanine 
Ala Alanine 
All Allyl 
AgAAC Silver(I)-catalyzed alkyne-azide cycloaddition 
AGD Affinity-guided DMAP 
ALTADENA Adiabatic longitudinal transport after dissociation engenders nuclear alignment 
Arg Arginine 
Asp Aspartic acid 
B Magnetic field 
BARAC Biarylazacyclooctynone 
BBI Bowman-Birk inhibitor 
BCN (1R,8S,9s)-bicyclo[6.1.0]non-4-yn 
Bhoc Benzhydryloxycarbonyl 
BLI Biolayer interferometry 
Boc tert-butoxycarbonyl 
BPP5a bradykinin potentiating peptide 
°C Degrees Celsius 
CIDNP Chemically induced dynamic nuclear polarization 
Cit Citrulline 
CL Cross-linkage 
cm Centimeter 
COD Cyclooctadiene 
COSS Cube-octametric silsequioxane 
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cp Cyclopentadiene 
CuAAC Copper(I)-catalyzed alkyne-azide cycloaddition 
Cys Cysteine 
d Day 
DA Diels-Alder 
Da Dalton 
DAR Drug-to-antibody ratio 
DCM Dichloromethane 
DIBAH Dibuthylaluminium hydride 
DIEA N,N-diisopropylethylamine 
DMAP N,N-dimethyl-4-aminopyridine 
DMF N,N’-dimethyl formamide 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DNP Dynamic nuclear polarization 
DOTA 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
DTS DNA-templated synthesis 
DTT Dithiothreitol 
E Magnetic quantum energy 
[E] Enzyme concentration 
EF Enhancement factor 
ESI Electrospray ionization 
eSrtA Evolved sortase A 
EtOH Ethanol 
Fab Antigen-binding fragment 
Fc Fragment crystallizable 
FGE Formylglycine-generating enzyme 
Fmoc 9-Fluorenylmethyloxycarbonyl 
FRET Fluorescence polarization energy transfer 
G Free Energy 
g Gram 
Glu Glutamic acid 
Gly Glycine 
GRAB Group replacement assisted binding 
h Hour 
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HATU 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium 
hexafluorophosphate 
HBTU 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronoium hexafluorophosphate 
His Histidine 
HNE Human neutrophil elastase 
HOBt 1-hydroxybenzotriazole 
HP/Xe Hyperpolarized Xenon biosensor 
HPLC High-performance liquid chromatography 
HTS High-throughput screening 
I Nuclear spin quantum number 
[I] Inhibitor concentration 
IgG Immunoglobulin G 
IgM Immunoglobulin M 
Ile Isoleucine 
Int Intensity 
IR Infrared 
J NMR J-coupling 
K Kelvin 
kB Boltzmann constant 
kcal Kilocalories 
kDa Kilodalton 
K Binding/affinity/equilibrium constant 
k2 Second-order kinetic constant 
Ka Association constant 
Kavid Affinity constant wit avidity effect 
KD Dissociation constant 
Ki Inhibition constant 
Ki
app Apparent inhibition constant 
KM Michaelis-Menten constant 
LDT Ligand-directed tosyl 
Leu Leucine 
Lys Lysine 
λ Wavelength 
M Mol per liter 
M Magnetization 
mAB Monoclonal antibody 
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MALDI Matrix-assisted laser desorption/ionization 
MBHA 4-Methyl benzhydrylamine 
Me Methyl 
MeCN Acetonitrile 
MeOH Methanol 
Met Methionine 
min Minute 
mm Millimeter 
MRI Magnetic resonance imaging 
mRNA Messenger ribonucleic acid 
MS Mass spectrometry 
MTBE Methyl tert-butyl ether 
MW Microwave  
m/z Mass to charge signal 
µ Magnetic moment 
µl Microliter 
µM Micromol per liter 
µmol Micoromol 
N Number of nuclei 
NCL Native chemical ligation 
NHS N-succinimidyl carbonate  
Nle Norleucine 
nM Nanomol per liter 
nm Nanometer 
nmol Nanomol 
NMP N-methyl pyrrolidone 
NMR Nuclear magnetic resonance 
NPA p-nitrophenylacetate 
ν Wave number 
P Polarization 
Ψ Wave function 
PASADENA Parahydrogen and synthesis allow dramatically enhanced nuclear alignment 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate-buffered saline 
PET Positron emission tomography 
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Phe Phenylalanine 
PHIP Parahydrogen induced polarization 
pmol Picomol 
PNA Peptide nucleic acid 
pNA para-nitro aniline 
POE, PEG Polyethylene glycol 
ppm Parts per million 
Pra Propargylglycine 
Pro Proline 
Pso Psoralen 
R Ideal gas constant 
R2 Regression coefficient of trend line 
RAFT Regioselectively addressable functionalized templates 
RAM Rink amide MBHA 
RMSD Root mean square derivation 
RP-HPLC Reversed-phase HPLC 
Rt Retention time 
RuAAC Ruthenium(II)-catalyzed alkyne-azide cycloaddition 
S Signal 
s Second 
[S] Substrate concentration 
S1 pocket Specificity-site pocket 
SABRE Signal amplification by reversible exchange 
SDS Sodium dodecyl sulfonate 
SE Signal enhancement 
SEC Size exclusion chromatography 
Sem Selenomethionine 
Ser Serine 
SFTI Sunflower trypsin inhibitor 
SNR Signal-to-noise-ratio 
SPAAC Strain-promoted alkyne-azide cycloaddition 
SPANC Strain-promoted alkyne-nitrone cycloaddition 
SPECT Single-photon emission computed tomography 
SPPS Solid-phase peptide synthesis 
SPS Solid-phase synthesis 
ssNMR Solid-state nuclear magnetic resonance 
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Su, Suc Succinimide 
T Tesla 
T Temperature 
t trans 
T1 Spin relaxation time 
TAMRA Carboxytetramethylrhodamine 
TASP Template assembled synthetic proteins 
t Time 
TES Triethyl silane 
TFA Trifluoroacetic acid 
TFE 2,2,2,-Trifluoroehtanol 
Thr Threonine 
Tm Melting temperature 
TPCK Tosyl phenylalanyl chloromethyl ketone 
tRNA Transfer ribonucleic acid 
Trp Tryptophan 
ts Transition state 
Tyr Tyrosine 
Tyr(O-propargyl) O-Propargyltyrosine 
Val Valine 
v Reaction rate 
Xaa Any canonical amino acid 
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Enlarged version of Figure 34 
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Summary of test reaction setups of coiled coil-guided SPANC  
Setup A
a Bb Cc 
Eq. 
A:B:C 
[A] 
[µM] Analysis 
Conversiond 
[%] 
1 16 17 - 1:1 125 HPLC, ESI-MS 74.1f 
2 18 19 - 1:1 50 ESI-MS n. c. 
3 18 19 - 1:1 50 ESI-MS n. c. 
4 18 19 - 1:1 50 HPLC, ESI-MS 69.8 
5f 18 19 - 1:1 50 HPLC, ESI-MS 61.2 
6 18 19 benzaldehyde 1:1:1 50 HPLC, ESI-MS 80.0 
7 18 19 benzaldehyde 2:3:2 100 HPLC, ESI-MS 71.5 
8 18 19 benzaldehyde 1:1:1 150 HPLC, ESI-MS 79.3 
9g 18 - benzaldehyde 1:0:10 100 HPLC, ESI-MS 50.1 
10h 18 - - - 50 HPLC, ESI-MS - 
11 18 19 32 1:1:1 100 HPLC, ESI-MS 89.2 
12i 18 - 32 1:0:1 100 HPLC, ESI-MS 60.2 
13j 18 19' - 1:1 100 HPLC, ESI-MS 72.2 
a: BCN-decorated guiding unit. 
b: Aldehyde-bearing guiding unit. 
c: Competitive aldehyde component. 
d: Conversion calculated from decrease in HPLC traces of aldehyde-bearing guiding unit. 
e: Reaction performed in water pH 7.0. 
f: Mean value of conversions of two reaction batches using same setup. 
g: Control experiment using 18 and benzaldehyde. Conversion calculated from consumption of 18. 
h: Control experiment with only 18 and MeNOH. 
i: Control experiment using 18 and 32. Conversion calculated from consumption of 32. 
j: In situ aldehyde-formation strategy was applied. 
n.c.: conversion not calculated. 
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Summary of test reaction setups of coiled coil-guided SPANC  
Setup A
a Bb, Cc 
Eq.  
A:B:C 
[Aa] 
[µM] 
Main solvent 
(pH) 
tcomp 
[min] Trct 
Conversiond 
[%] 
1 20 21 1:1 200 NH4OAcaq (6.5) 60 rt 51.0 
2 20 21 4:3 130 NH4OAcaq (6.5) 60 rt 52.0 
3 20 21 4:3 130 NH4OAcaq (6.5) 60 rt 57.1 
4 20 21 4:3 130 HEPESaq (6.0) 60 rt 66.1 
5 20 21 1:1 67 NH4OAcaq (6.0) 60 rt 75.1 
6 20 21 1:1 67 NH4OAcaq (6.0) 60 4°C 75.9 
7 20 21 1:1 67 NaOAcaq (5.0) 0 4°C 55.6 
8 20 21 1:1 67 PBSaq (7.4) 0 4°C 39.3 
9 20 21 6:5 80 HEPESaq (6.0) 60 4°C 73.2 
10 20 21 1:1 220 HEPESaq (6.0) 0 4°C 61.3 
11e 20 21 6:5 240 NH4OAcaq (6.5) 60 4°C 50.9 
12e 20 21 4:1 320 NH4OAcaq (6.5) 60 4°C 68.5 
13 20 21 1:1 200 NH4OAcaq (6.0) 60 rt 73.1 
14 20 21, 22 1:1:1 100 NH4OAcaq (6.0) 60 rt 54.0f 
15f 20 21' 1:1 100 NH4OAcaq (6.5) 60 rt 51.0 
16f 20 21' 1:1 200 NH4OAcaq (6.5) 60 rt 51.9 
17e,f 20 21' 1:1 200 NH4OAc/THF 60 rt 49.5 
18e,i 20 21' 1:1 200 NH4OAc/THF 60 rt 76.6 
a: BCN-decorated guiding unit. 
b: Aldehyde-bearing guiding unit. 
c: Competitive aldehyde component. 
d: Conversion calculated from decrease in HPLC traces of aldehyde-bearing guiding unit. 
e: PhNOH was applied as nitrone-forming agent. 
f: In situ aldehyde-formation strategy was applied. Reaction quenched with MeOPhSH. 
i: In situ aldehyde-formation strategy was applied. Reaction quenched with ethylene glycol. 
 
 
 
 
 
DOCTORAL THESIS DAICHI NASU APPENDIX 
 188
List of conjugation products of cycloaddition experiments  
Conjugation 
product 
Reaction 
type Reaction equation 
M 
[g/mol] 
cp1 SPANC  5979.2 
cp2 SPANC  8543.0 
cp3 SPANC  4593.5 
cp4 -  4506.0 
cp5 SPANC  6181.4 
cp6 SPANC  6515.6 
cp7 SPANC  6475.6 
cp8 -  3494.5 
cp9 -  3556.6 
cp10 SPAAC  6428.4 
cp11 Pso-CL  6183.1 
cp12 Pso-CL  7717.7 
cp13 Pso-CL  8047.0 
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Hanes-Woolf Plots of Protease Activity Assays 
 
 
Hanes-Woolf plot of trypsin activity assays against Boc-QAR-pNA in trypsin activity buffer in triplicate. Data points, 
trend lines of linear regressions, linear equation of trend lines, and associated regression coefficient of each 
measurement series are marked in individual colors. 
 
 
Hanes-Woolf plot of trypsin activity assays against Boc-QAR-pNA in non-buffered water in triplicate. Data points, 
trend lines of linear regressions, linear equation of trend lines, and associated regression coefficient of each 
measurement series are marked in individual colors. 
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Hanes-Woolf plot of trypsin activity assays against Boc-QAR-pNA in non-buffered D2O in triplicate. Data points, 
trend lines of linear regressions, linear equation of trend lines, and associated regression coefficient of each 
measurement series are marked in individual colors. 
 
 
Dixon Plots of Enzyme Inhibition Assays 
 
Dixon plots of inhibition assays of 1 against chymotrypsin (left) and 2 against HNE (right) with trend curves of 
global fittings of triplicate measurements. 
 
 
Dixon plots of inhibition assays of 2 against trypsin (left) and 3 against HNE (right) with trend curves of global 
fittings of triplicate measurements. 
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Dixon plot of inhibition assays of 3’ against HNE after 2 h incubation of the inhibitor with enzyme (left) and 4 
against HNE (right) with trend curves of global fittings of triplicate measurements. 
 
 
Dixon plot of inhibition assays of 4’ against HNE upon 2 h incubation of the inhibitor with enzyme with trend 
curves of global fittings of the triplicate measurement. 
 
 
Dixon plots of inhibition assays of 5 against trypsin (left) and 6 against trypsin (right) in trypsin activity buffer 
with trend curves of global fittings of triplicate measurements. 
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Dixon plots of inhibition assays of 6 against trypsin in non-buffered water (left) and 6 against trypsin in non-
buffered D2O (right) with trend curves of global fittings of triplicate measurements. 
 
 
 
Dixon plots of inhibition assays of 7 against trypsin (left) and 8 against trypsin (right) in trypsin activity buffer 
with trend curves of global fittings of triplicate measurements. 
 
 
 
Dixon plots of inhibition assays of 9 against trypsin (left) and 10 against trypsin (right) in trypsin activity buffer 
with trend curves of global fitting of triplicate measurements. 
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Kinetic Plots of Bioorthogonal Conjugation
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HPLC Traces
 
Chromatographic profiles of 
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Chromatographic profiles of 3 (left) and 4 (right). UV detection at λ = 220 nm; eluent: 18→72 % acetonitrile in 
0.1 % aq. TFA over 20 minutes at flow rate 1 ml/min. 
 
 
Chromatographic profiles of 5 (left) and 6 (right). UV detection at λ = 220 nm; eluent (left): 9→90 % acetonitrile 
in 0.1 % aq. TFA over 20 minutes at flow rate 1 ml/min; eluent (right):  18→40.5 % acetonitrile in 0.1 % aq. TFA 
over 20 minutes at flow rate 1 ml/min. 
 
 
Chromatographic profiles of 7 (left) and 8 (right). UV detection at λ = 220 nm; eluent (left): 9→90 % acetonitrile 
in 0.1 % aq. TFA over 20 minutes at flow rate 1 ml/min; eluent (right):  9→72 % acetonitrile in 0.1 % aq. TFA over 
20 minutes at flow rate 1 ml/min. 
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Chromatographic profiles of 9 (left) and 10 (right). UV detection at λ = 220 nm; eluent : 9→72 % acetonitrile in 
0.1 % aq. TFA over 20 minutes at flow rate 1 ml/min. 
 
 
Chromatographic profiles of 11 (left) and 12 (right). UV detection at λ = 220 nm; eluent: 9→90 % acetonitrile in 
0.1 % aq. TFA over 20 minutes at flow rate 1 ml/min. 
 
 
Chromatographic profiles of 13 (left) and 14 (right). UV detection at λ = 220 nm; eluent: 9→90 % acetonitrile in 
0.1 % aq. TFA over 20 minutes at flow rate 1 ml/min. 
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Chromatographic profiles of 16 (left) and 17 (right). UV detection at λ = 220 nm; eluent (left): 27→72 % 
acetonitrile in 0.1 % aq. TFA over 20 minutes at flow rate 1 ml/min; eluent (right):  9→90 % acetonitrile in 0.1 % 
aq. TFA over 20 minutes at flow rate 1 ml/min. 
 
 
Chromatographic profiles of 18 (left) and 19 (right). UV detection at λ = 220 nm; eluent: 9→90 % acetonitrile in 
0.1 % aq. TFA over 20 minutes at flow rate 1 ml/min. 
 
 
Chromatographic profiles of 20 (left) and 21 (right). UV detection at λ = 260 nm; eluent: 0→72 % acetonitrile in 
0.1 % aq. TFA over 20 minutes at flow rate 1 ml/min. 
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Chromatographic profiles of 22 (left) and 23 (right). UV detection at λ = 260 nm; eluent: 0→54 % acetonitrile in 
0.1 % aq. TFA over 20 minutes at flow rate 1 ml/min. 
 
 
Chromatographic profiles of 25 (left) and 26 (right). UV detection at λ = 260 nm; eluent (left): 0→72 % 
acetonitrile in 0.1 % aq. TFA over 20 minutes at flow rate 1 ml/min; eluent (right): 0→36 % acetonitrile in 0.1 % 
aq. TFA over 20 minutes at flow rate 1 ml/min. 
 
 
Chromatographic profiles of 27 (left) and 28 (right). UV detection at λ = 260 nm; eluent: 0→72 % acetonitrile in 
0.1 % aq. TFA over 20 minutes at flow rate 1 ml/min. 
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Chromatographic profiles of 29 (left) and 30 (right). UV detection at λ = 260 nm; eluent (left): 9→54 % 
acetonitrile in 0.1 % aq. TFA over 20 minutes at flow rate 1 ml/min, eluent (right): 0→90 % acetonitrile in 0.1 % 
aq. TFA over 20 minutes at flow rate 1 ml/min. 
 
 
 
Chromatographic profiles of reaction mixtures of coiled coil-guided SPANC (left, setup 13) and PNA-guided SPANC 
(right, setup 19), both applying the in situ aldehyde formation strategies. UV detection at λ = 220 nm (left) or 
260 nm (right); eluent (left): 0→90 % acetonitrile in 0.1 % aq. TFA over 20 minutes at flow rate 1 ml/min, eluent 
(right): 0→72 % acetonitrile in 0.1 % aq. TFA over 20 minutes at flow rate 1 ml/min. 
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SEC Traces 
 
 
SEC profiles of three-heptad coiled coils E3e2W/K3g,d2E2 (A) and five-heptad coiled coils E5e3Y/K5g3C (B) as 1:1 
mixture and individual peptides. Recorded with Varian 920-LC system equipped with a Phenomenex BioSep-SEC-
S2000TM column (300×7.8 mm, 5 µm, 145 Å). Absorption detected at 220 nm and 280 nm, eluent: degassed 1× 
PBS at pH 7, flow rate 1 ml/min. 
 
 
Summary of dimerization experiments of three-heptad coiled coils E3e2W/K3g,d2E2 and five-heptad coiled coils 
E5e3Y/K5g3C via SEC with molecular mass and retention time of reference proteins/peptides using same analytical 
setup. 
Reference/Sample 
Molecular mass 
[kDa] 
Rt 
[min] 
Lysozyme 14.3 10.8 
Ribonuclease A 13.7 10.0 
Aprotinin 6.5 10.8 
MCoTI-II 3.5 12.5 
E3e2W 2.4 11.2 
K3g,d2E2 2.3 10.6 
E3e2W + K3g,d2E2 4.7 10.6 & 11.2 
E5e3Y 3.9 9.7 
K5g3C 3.8 10.3 
E5e3Y + K5g3C 7.7 10.0 
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MS Spectra 
 
 
ESI mass spectrum of collected HPLC fraction (Rt = 16.8 min) of a control SPANC reaction between 18 and 32 
(setup 12) towards cp5 after 2 h. Spectrum is in positive mode. 
 
 
 
ESI mass spectrum of collected HPLC fraction (Rt = 14.8 min) of SPANC between 20 and 21 using PhNOH as 
nitrone-forming agent (setup 11) towards cp6 after 2 h. m/z corresponding to cp9 are also observed. Spectrum is 
in positive mode. 
 
 
 
ESI mass spectrum of collected HPLC fraction (Rt = 16.1 min) of a control SPANC reaction between 20 and 22 
(applied in equimolar ratio) towards cp7 after 24 h. Spectrum is in positive mode. 
 
 
 
ESI mass spectrum of reaction mixture of UVA-mediated cross-linkage between 25 and 26 (applied in equimolar 
ratio) towards cp12 after 2 h irradiation. Spectrum is in positive mode. 
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ESI mass spectrum of reaction mixture of UVA-mediated cross-linkage between 25 and 33 (applied in equimolar 
ratio) towards cp13 after 2 h irradiation. Spectrum is in positive mode. 
 
 
NMR Spectra 
 
 
 
13C NMR spectrum of isolated compound 4a with structure and predicted chemical shifts. Sample was dissolved in 
CDCl3. 
 
 
13C NMR spectrum of isolated compound 4b and predicted chemical shifts. Sample was dissolved in CDCl3. 
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13C NMR spectrum of isolated compound 
 
 
1H NMR spectrum of isolated compound 
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1H NMR spectrum of isolated compound 
 
 
 
1H NMR spectrum of
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1H NMR spectrum of
1H NMR spectrum of
 
Further PHIP NMR spectra (compounds 
 
6 upon hydrogenation. (PHIP spectrum) Sample was dissolved in MeOH
6 after relaxation. Sample was dissolved in MeOH
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